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 Abstract 
 Background 1.1
 
Smoking in pregnancy is a major cause of morbidity and mortality [1-3], with a significant 
cost burden to the NHS. [4] An estimated 26% of women still report smoking at the 
beginning of or just before pregnancy, with 12% reporting smoking throughout. [5]While 
economic evaluations of cessation interventions in the non-pregnant population are well 
developed, similar evaluations of within-pregnancy interventions are not. [6] Because of 
the special circumstances associated with pregnancy, general smoking evaluations cannot 
be applied in these settings. [4, 5] This thesis outlines the development of an improved 
economic model designed to capture the healthcare costs and benefits associated with 
smoking and cessation within pregnancy. 
 
 Methods 1.2
 
A series of scoping reviews of the electronic resource Medline were conducted to identify 
either within-pregnancy or childhood morbidities which had potentially causal associations 
with smoking during or after pregnancy, as well as the incidences of morbidities and health 
related quality of life (HRQoL) scores attributable to those identified. A systematic review 
appraised the previous economic literature on cessation during pregnancy, to determine 
where improvements were needed. To ensure that relapse to smoking could be accounted 
for, a second systematic review generated pooled estimates of abstinence from smoking in 
the postpartum period. This information was used to develop and construct the improved 
economic model. 
  
viii 
 
 Results 1.3
 
11 conditions were identified as having a causal association with smoking during 
pregnancy. The systematic review of previous evaluations identified 17 studies; however, 
only three were considered high quality, suggesting the need for an improved model. The 
pooled estimates of abstinence suggested that by two years postpartum, most women had 
restarted smoking, with most relapsing after three, but before 12, months postpartum. The 
Economic impacts of Smoking In Pregnancy (ESIP) model consists of two linked decision 
trees which capture the within-pregnancy aspects, while two linked Markov chains capture 
the post-pregnancy smoking behaviour for both the mother and her child. ESIP was also 
extended to control for uncertainty. 
 
 Conclusion 1.4
 
ESIP improves on the previous literature since it directly captures the impact of the 
ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ŽŶ ƚŚĞ ŚĞĂůƚŚ ŽĨ ŚĞƌ ŽĨĨƐƉƌŝŶŐ ? ďŽƚŚ ǁŝƚŚŝŶ-pregnancy and 
childhood, using the most accurate data currently available. Future extensions to ESIP 
include an adult component for the infant to capture their smoking behaviour. 
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 Chapter 1: Introduction. 
 Smoking in non-pregnant populations 1.1
 
Smoking is a major and preventable cause of morbidity and mortality, killing an estimated 
six million people globally each year. [7] Smoking was attributable to an estimated 81,700 
deaths in 2010 in the United Kingdom (UK), around 35% of all deaths of adults aged 35 
years or older. [8] Smoking has been linked with lung cancer, respiratory diseases, 
cardiovascular disease, and other serious health conditions, all of which are important 
causes of mortality. [9] Around 22,300 (36%) of all respiratory disease related deaths and 
37,500 (29%) of all cancer deaths among adults aged 25 or over were attributable to 
smoking in 2010. [8] Smoking not only has direct effects on the smoker, but can lead to 
increased mortality in the non-smoking population. Passive smoking at home in the UK 
potentially accounts for 2,700 deaths per year in persons aged between 20 and 64 years 
and 617 deaths a year from workplace passive smoking. [10] Despite high profile public 
health campaigns, the prevalence of smoking in the UK has remained relatively static in 
recent years, with 21% of the UK population reporting smoking in 2009, the same as in 
2007 and 2008. [8] Internationally, this is slightly more than the 19.3% in the United States 
(US) [11] and 16.4% in Australia [12], but slightly less than in other countries in Europe such 
as France (27%) and Germany (25%) [7]. In the UK, smoking tends to be more prevalent in 
men than in women, with 22% and 20% smoking respectively. [8]. Smoking is cited as one 
of the principal causes of health inequality between rich and poor. [13] In the UK in 2009, 
the prevalence was lowest in the highest income quartile households (14% for men, 11% 
for women), and highest in the lowest quintile households (40% for men and 34% for 
women). [8]  
 
 UK economic burden of smoking outside of-pregnancy  1.2
 
The prevalence of smoking puts a large economic burden on the National Health Service 
(NHS). In 2009/10 approximately 5% (461,700) of all people admitted to hospital aged over 
34 years were attributable to smoking [8], and in 2005/6 smoking was estimated to cost 
2 
 
the NHS £5 billion, or 5.5% of ƚŚĂƚǇĞĂƌ ?Ɛtotal NHS expenditure.  [14] However, it has been 
suggested that this is an underestimation and the true value could be around 15% of total 
healthcare costs. [15] It is also estimated to cost a further £12.8 million (at 2002 prices) 
through the effects of passive smoking in non-smoking adults. [15] With such a large 
economic and disease burden, it is understandable why smoking remains such an 
important public health issue.  
 
 Smoking during pregnancy 1.3
 
Smoking during pregnancy has severe health consequences for both the mother and infant. 
Not only is the mother increasing her risks of developing smoking-related diseases (e.g. 
lung cancer), but she is exposing herself to greater risks of pregnancy-related conditions 
that can severely jeopardise her health and that of her infant, potentially proving fatal for 
either, or both. Strong evidence has demonstrated that smoking during pregnancy can lead 
to increased risks of the following conditions [2]: 
x ectopic pregnancy: where the foetus develops outside the uterus; potentially fatal 
for the mother, always fatal for the foetus 
x placenta previa: where the placenta covers the cervix and can lead to vaginal 
bleeding 
x placental abruption: the placental lining separates from the wall of the uterus, 
leading to vaginal bleeding, common contributor to maternal mortality 
x preterm premature rupture of the membranes (PPROM): rupture of the 
membranes before 37 weeks gestation, leading to labour 
Smoking during pregnancy is also the potential cause of up to 4,000 deaths per year from 
miscarriage and stillbirth. [16] Furthermore, there is strong evidence that it is a 
determinant in increasing the risks of premature birth (infants born before 37 weeks 
gestation) and low birth weight (LBW) (infants born weighing less than 2500 grams), which 
often require support in paediatric intensive care units. [17]  There is growing evidence that 
links smoking during pregnancy with longer term health issues for the infant. Chronic 
conditions such as asthma and other respiratory illnesses have been widely established as 
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being associated with smoking during pregnancy. [1, 4] These can severely impact on the 
ĐŚŝůĚ ?Ɛ ůŝĨĞ ? ƌĞĚƵĐŝŶŐ ƚŚĞŝƌ ƋƵĂůŝƚǇ ŽĨ ůŝĨĞ ĂŶĚ ƉŽƚĞŶƚŝĂůůǇ ŚĂŵƉĞƌŝŶŐ ƚŚĞŝƌ ŝŶƚĞŐƌĂƚŝŽŶ ŝŶƚŽ
society. [18] 
 
Despite evidence of the adverse effects of smoking, smoking during pregnancy remains a 
significant international problem. In the UK, in 2010, 12% of mothers smoked throughout 
their pregnancy and 26% smoked either during or in the 12 months before pregnancy. [5] 
In Spain, the rate is reported to be as high as 39.4% [19], while in other countries such as 
Australia, the US, and Germany rates are 14.5%, 14.1%, and 13% respectively. [20-22] 
Other countries report lower rates; ĨŽƌĞǆĂŵƉůĞ ?ĂŶĂĚĂ ?ƐƉƌĞǀĂůĞŶĐĞŝƐ ? ? ? ?A?[23], but this 
is still a substantial proportion of the population. However, pregnancy provides an 
incentive for mothers to quit, and in the UK, 54% of smokers stop smoking before child 
birth. [5] Mothers in routine and manual work occupations report higher smoking 
prevalence than those in professional and managerial occupations (40% versus 14% 
respectively). [5] Those classified in the more deprived socio-economic groups also report 
the lowest quit rate, with 50% reporting quitting by birth, compared with 72% in the 
highest socio-economic group. [5]  
 
Unfortunately, the Infant Feeding Survey (IFS) does not report rates of relapse to smoking 
after birth, although this has been estimated to be quite high, at between 67% and 80% 
during the first year after pregnancy. [4] Not only does this have direct health 
consequences for the mother, but it also exposes the infant to the risks of passive smoking, 
such as doubling the risk of sudden infant death syndrome (SIDS) and increasing the risks of 
wheezing and other respiratory problems by 20% to 40%. [24] More recently, evidence has 
demonstrated that if the mother smokes, the infant is over twice as likely to become an 
adult smoker [25], exposing their life to the excess health effects of smoking and 
potentially producing a cycle that could carry on for generations.  
 
The economic burden of smoking during pregnancy is substantial, costing the NHS up to 
£64 million annually. [4]  A substantial proportion is attributable to infant outcomes, with 
conservative estimated costs of £23.5 million for the first year of life. [4] It is possible that 
by including the potential effects of passive smoking and chronic diseases such as asthma 
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on the child, the cost could be substantially greater. In the US, it is estimated that smoking 
during pregnancy increases neonatal costs by over USD 700 per child (£416.081), and is 
attributable for almost USD 367 million (1996 prices) (£218,144,8002)in neonatal costs for 
the US as a whole. [26] Since smoking during pregnancy is preventable, it is understandable 
why this topic remains a serious public health concern. 
 
 Effectiveness of cessation interventions during pregnancy 1.4
 
Systematic reviews have investigated smoking cessation interventions in pregnancy. 
Coleman et al conducted a meta-analysis of six trials of 1,745 women to investigate the 
effectiveness of nicotine replacement therapy (NRT). [27] The review looked at four trials 
where the control group were placebo randomised control trials (RCTs) and two studies 
which involved an intervention arm with both NRT and behavioural support, with the 
control group only receiving behavioural support. Combining all studies, the pooled relative 
risk (RR) for NRT was 1.33 (95% confidence interval (CI) 0.93 to 1.91). In the sensitivity 
analysis, when using only biochemically validated data, the RR was 1.40 (95% CI 0.97 to 
2.04). For placebo controlled trials, there was no evidence of a benefit in quitting with NRT, 
whereas in non-placebo trials there was a significant effect estimate with an RR of 7.81 
(95% CI 1.51 to 40.35). The authors concluded that there was insufficient evidence to 
demonstrate that NRT used by pregnant women for smoking cessation was effective or 
safe. Since no other pharmacological interventions are licensed to be used within 
pregnancy, this suggests that these interventions would appear ineffective, but this may be 
due to the lack of currently available data. 
 
A recent Cochrane review investigated psychosocial interventions designed to support 
women stopping smoking in pregnancy. [28] The review identified six types of intervention: 
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1. Counselling; includes motivational interviewing (MVI), cognitive behaviour therapy 
(CBT), providing motivation to quit and improved problem-solving and coping skills. 
Interventions may be delivered face-to-face, by telephone or by computer 
programmes. Counselling may be provided by a range of personnel, both 
healthcare professionals and others, and duration varied between less than five 
minutes to up to an hour per session. 
2. Health education; includes providing women with information about the risks of 
smoking and advice to quit; no further support given. Usually delivered by self-help 
manuals or automated text messaging. 
3. Feedback; informing the mother of the foetal health status or measuring the by-
products of smoking to encourage the mother to quit. 
4. Incentives; a financial or other form of reward contingent on smoking cessation 
5. Social support; either peer or partner 
6. Other; includes exercise and intensive dissemination interventions. 
The review included 77 RCTs with a total of over 24,000 women included in the meta-
analysis. At the primary outcome of late pregnancy, the most effective intervention 
appeared to be feedback, with an RR of 4.39 (95% CI 1.89 to 10.21), based on seven trials. 
Incentives were second, with an RR of 3.59 (95% CI 0.10 to 130.49), however this was only 
based on four trials and the authors suggested interpreting this with caution. When 
comparing counselling with usual care, the RR was 1.44 (95% CI 1.19 to 1.75) suggesting a 
significant effect. However, for health education and social support versus usual care there 
seemed to be no significant effect on quit rates with RRs of 1.51 (95% CI 0.64 to 3.59) and 
1.29 (95% CI 0.94 to 1.78) respectively.  
 
The authors concluded that psychosocial interventions were effective at supporting women 
in stopping smoking during pregnancy. However, all the interventions appeared to have 
varying degrees of effectiveness and certain interventions seemed better in some 
situations than others. These should be considered when delivering an intervention to 
smoking women. The review also highlighted that using these interventions appeared to 
give a significant reduction in both premature births (18%) and in the proportion of babies 
born with LBW (18%). Therefore it would appear that from a population level, these 
interventions could be seen as particularly effective. 
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 Why economic evaluation is important 1.5
 
Regardless of the country or the healthcare system used, demand for healthcare usually 
exceeds supply, and hence the amount of care given can be equalised either by the use of 
monetary criteria or by some definition of need. [29] This means healthcare has to be 
rationed, which occurs when an individual is deprived of care which is of benefit to them, 
and this takes place both in private healthcare systems, where the care delivered is a result 
of insurance cover, and in a state-funded healthcare system where non-price rationing 
determines access.[29] In a country like the UK, the state-funded healthcare system has a 
fixed budget; for example, for 2013/14 the NHS England budget was £95.6 billion to deliver 
healthcare within England. [30] The population of England in mid-2013 was 53.9 million, all 
of whom in theory could demand some form of healthcare, which is theoretically feasible if 
the healthcare cost associated with each individual is less than £1,773.66. [31] This budget 
has to cover all healthcare, including the overheads for running the NHS, staffing, current 
available treatments, as well as covering the expenditure of any new technologies 
introduced. Maynard stated that there were six fundamental assumptions associated with 
rationing healthcare: the role of health care is to improve health and reduce inequalities in 
health; access to care is determined based on need and not ability to pay; need can be 
either a demand (patients want care) or supply (doctors supply care to meet a need) 
concept; how the need principle achieves efficiency within equity goals; the role of judging 
needs of competing patients should be given to independent and neutral experts; and that 
doctors have their performance managed and monitored to ensure they do not undermine 
this process. [29] Maynard concluded that if one or more of these assumptions were to be 
ignored, then resource allocation would be wasteful, and allocative efficiency (the optimal 
allocation of goods and services, where marginal benefit to consumers equals marginal cost 
of producing [32]) would not be achieved. [29] 
 
When introducing a new health technology, it has to compete with existing healthcare 
processes; however because we practise non-price rationing, it is necessary to determine 
whether the new technology is an appropriate use of resources. [33] As part of this 
decision process, the policy maker needs to be able to determine whether the new 
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technology offers value for money; is the increased healthcare cost warranted by the 
increased benefits. It is important to demonstrate this, as the introduction of an 
intervention which is wasteful of resources could lead to a reallocation of NHS resources 
which could make society worse off. For example, Claxton et al suggested that had the drug 
ranibizumab been introduced in 2011, it is estimated that it would have cost the NHS an 
extra £80 million per annum to treat the eligible population, but resulted in 411 additional 
deaths because of the reallocation of resources.[34] One approach to determine value for 
money is to use economic evaluation, which has been defined as the comparative analysis 
of alternative courses of action in terms of both their costs and consequences. [33] 
Economic evaluation demonstrates to the policy maker whether the intervention offers 
value for money, or whether it is cost-effective, allowing a policy maker to decide whether 
a new intervention/drug should be made available by the state funded healthcare service.   
In the UK, since 2004, cost-effectiveness has been an important criterion in decisions about 
use of healthcare interventions in the NHS. [35] It is also an integral part of the (National 
Institute of Health and Care Excellence) NICE reference case, which is the gold standard for 
the decision-making process in the UK. [36] Furthermore, economic evaluation is used 
widely across the globe, informing the decision process in Australia, Canada, and many 
others.[37, 38]  
 
 Process of economic evaluation 1.6
 
1.6.1 Initial considerations for economic evaluations 
 
When first developing an economic evaluation, the initial stage is the setting of the 
research question the evaluation is aiming to answer. [33, 39] A simple example would be 
that a different evaluation would be required to answer a question of technical efficiency 
(how to deliver a new service/intervention) compared to a question of allocative efficiency 
(should we use the new service/intervention); the required outcomes and costs to be 
collected are likely to be very different (e.g. intervention effectiveness for allocative 
efficiency versus intervention reach for technical efficiency). The research question may be 
specified by the policy/decision maker; either way the question should be clear and may 
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state some explicit requirements for the evaluation (e.g. a particular population or 
healthcare setting).  
 
The second consideration for designing evaluations, which is closely linked with the 
research question, is the setting for the evaluation: either within-trial, or as a separate 
hypothetical decision analytical modelling exercise.  A within-trial analysis is an economic 
evaluation which is conducted alongside a clinical trial, usually with the trial directly 
collecting data required to inform the effectiveness and costs associated with the new 
intervention and its comparator. [40] Decision analytical modelling (DAM) is an alternative 
to within-trial analysis when either conducting a clinical trial is impractical or multiple 
interventions require evaluating, which would not be possible in a single trial. [39, 41] DAM 
compares expected outcomes and costs of new interventions or decision options by 
synthesising multiple sources of data (e.g. literature based estimates, national statistics, 
expert opinion) using mathematical techniques to produce estimates. This provides 
decision makers with the best available evidence on which they can base their decision. 
This chapter and thesis will primarily focus on methods associated with DAM and not 
within-trial analyses, although some methods associated with within-trial analyses will be 
alluded to where relevant. This is because this thesis is not being conducted alongside a 
clinical trial and will be utilising DAM methods. For a more detailed summary on economic 
evaluation alongside within-trial analyses, see Petrou et al and Glick et al. [40, 42] 
 
1.6.2 Perspective of analysis and time horizon 
 
Once the research question has been specified, the next critical consideration is the 
perspective and time horizon to be utilised in the evaluation. [33, 39] Time horizon refers 
to the length of follow-up to be included in the evaluation. This could be relatively short, 
for example one year if part of within-trial analysis, or could be considerably longer, such as 
40 or 50 years if modelling the remaining life expectancy of a patient as part of a DAM. [39] 
Although the time horizon can be specified by the research team, it should reflect not only 
the requirements of and conditions/impacts of interest to the decision maker, but also 
capture all the differences in costs and outcomes that are associated with both the 
intervention and its comparator. [36, 43]  
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The study perspective refers to the viewpoint from which the intervention and 
ĐŽŵƉĂƌĂƚŽƌ ?Ɛ ĐŽƐƚƐ ĂŶĚ ŽƵƚĐŽŵĞƐ ĂƌĞ ďĞŝŶŐ ĐŽŶƐŝĚĞƌĞĚ ĂŶĚĞǀĂůƵĂƚĞĚ ?[33, 43] An 
evaluation conducted with a narrow perspective, for example institutional (e.g. hospital), 
may only include costs and associated outcomes directly related to the intervention and 
the hospital, such as the cost of the intervention and the number of bed days saved within 
the hospital. A broader perspective, for example societal, would not only include these 
direct healthcare costs, but may also include productivity loss due to sickness, family out-
of-pocket expenses, and costs to the criminal justice system. Like the time horizon, the 
perspective may be set by the research team; however, it is common for the decision 
maker to pre-specify the perspective of the analysis. For example, in the UK, NICE specifies 
that all evaluations include a NHS and Personal Social Services perspective [36], which 
covers all direct health benefits associated with the patient, all direct costs to the NHS, and 
indirect health care costs from community-based care, but not productivity costs 
associated with the patient. Other countries, such as Austria and Australia, adopt the 
broader societal perspective [37, 44], while in the US it is common to adopt the narrower 
payer/insurer perspective which only covers the direct healthcare costs  and benefits. [45]   
 
1.6.3 Types of analysis 
 
There are several types of economic analysis used in healthcare evaluations; however all 
consider costs in monetary units. The difference occurs in how the effectiveness of new 
interventions is evaluated. All types of analysis are ways of estimating which 
interventions/services offer value for money to the decision maker. What follows is a brief 
summary of the most common types of analysis; 
 
1.6.3.1 Cost-minimisation (CMA) 
 
In CMA, all interventions are assumed to have equal effectiveness, and hence interventions 
can be ranked cheapest to most expensive, with the cheapest option being chosen as the 
intervention of choice. [33]  One of the advantages of CMAs is that they are inherently easy 
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to conduct and interpret, and are particularly useful where the treatments have been 
demonstrated to have clinical equivalence. [46] For example, CMAs are often used for non-
inferiority trials, where the intervention is demonstrated to be not clinically worse than its 
comparator to a specified end-point. [46, 47] However, it is often found that interventions 
are not equivalent, for example either in effectiveness or safety, which means that CMA 
cannot be utilised. [48] An example where CMA may lead to a wrong decision is the 
Scottish Unexplained Infertility Trial. [49, 50] This trial found that intrauterine insemination 
was significantly more expensive than expectant management, but did lead to an 
insignificant increase in additional live births; therefore the CMA concluded that expectant 
management was the treatment of choice. However, using CEA, Dakin et al suggested that 
the incremental cost per additional live birth was £5,604, and concluded that intrauterine 
insemination was ultimately cost-effective. [51]Furthermore, Dakin et al demonstrated that 
CMA was still being used and that it was biasing the measurement of uncertainty and the 
estimates of the probability of the treatment being cost-effective, suggesting that incorrect 
decisions were being made on the basis of evaluations producing incorrect results. [51] This 
could lead to society not gaining allocative efficiency in that it is losing resources by 
investing in inefficient interventions. 
 
1.6.3.2 Cost-effectiveness (CEA) 
 
In CEA, costs are compared to the effectiveness of the intervention as measured in a 
natural scale, e.g. years of life gained, number of cases detected, number of disease-free 
days. [33] The output for a CEA can be seen as a directly relevant statement of the value for 
money of the new intervention, which could be considered clinically relevant to both 
clinicians and patients. [52] However, CEA makes it difficult to compare the value for 
money of multiple interventions for different diseases across a healthcare service since 
they may use different outcomes, making comparison between the evaluations 
inappropriate. [33] 
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1.6.3.3 Cost-utility (CUA) 
 
CUA is a sub-group of CEA, utilising the same approach, except the outcome is measured as 
ĂŐĞŶĞƌŝĐŵĞĂƐƵƌĞŽĨŚĞĂůƚŚƌĞůĂƚĞĚƋƵĂůŝƚǇŽĨůŝĨĞ ?ƚĂŬŝŶŐŝŶƚŽĂĐĐŽƵŶƚƉĂƚŝĞŶƚƐ ?preferences 
(utility). [33] Common outcomes used (which will be described in more detail later in this 
chapter) are Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years (DALYs), 
ǁŚŝĐŚĂƌĞŐĞŶĞƌŝĐĂŶĚ ƌĞƉƌĞƐĞŶƚĂƉĂƚŝĞŶƚƐ ?ƉƌĞĨĞƌĞŶĐĞŽĨďĞŝŶŐ ŝŶĂĐĞƌƚĂŝŶŚĞĂůƚŚƐƚĂƚĞ
(e.g. limited mobility, bedridden, persistent vegetative state) for a given period of time (e.g. 
one year). Because of the generic nature of the outcome utilised in a CUA, this allows 
comparison of multiple interventions for different diseases across a healthcare service due 
ƚŽƚŚĞƵƐĞŽĨƚŚŝƐƐŝŶŐůĞ ? “ƵƚŝůŝƚǇ ?ďĂƐĞĚŵĞĂƐƵƌĞ ?[53] Because of this comparability across 
all disease categories and the healthcare system, CUA rather than CEA tends to be favoured 
by governing bodies such as NICE. [36] However, CUA can be limited in that utility can be 
sufficiently insensitive to changes in milder conditions which may be important to the 
patient, and that the utility that society attaches to health are not unrelated to the 
characteristics of the individual experiencing the health, with health gains associated with 
severe health states potentially more highly valued than those in milder health states. [54] 
Furthermore, there is evidence that QALYs are unreliable, since the method used to elicit 
ƚŚĞƉĂƚŝĞŶƚ ?ƐƉƌĞĨĞƌĞŶĐĞƌĂƚĞĐan highly influence the reported weight. [55]   
 
1.6.3.4 Cost-benefit (CBA) 
 
CBA is a broader approach than CEA and CUA, with the effectiveness and outcomes of the 
intervention valued in monetary units. [33] Because CBA values everything in money, this 
allows the inclusion of wider concerns associated with the intervention, such as 
investments in other sectors of the economy other than healthcare. [56] Early approaches 
to cost-ďĞŶĞĨŝƚ ĂŶĂůǇƐĞƐ ŝŶǀŽůǀĞĚ ƚŚĞ ƵƐĞ ŽĨ 'ƌŽƐƐŵĂŶ ?Ɛ ,ƵŵĂŶ ĂƉŝƚĂů ƉƉƌŽĂĐŚ  ?, ?
[57], whereby it was assumed that human beings could be treated as capital equipment, 
and that their future productivity can be assumed to be equal to their future rate of pay, 
and hence any gains from healthcare can be measured as the future flow of income that 
ǁŽƵůĚ ŚĂǀĞ ŽƚŚĞƌǁŝƐĞ ďĞĞŶ ĨŽƌŐŽŶĞ ŝĨ ƚŚĞ ƉĞƌƐŽŶ ŚĂĚ ďĞĞŶ ƐŝĐŬ ? &ƌŽŵ ĂŶ ĞĐŽŶŽŵŝƐƚ ?Ɛ
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perspective, when a decision maker is making a decision regarding healthcare, they are 
implicitly applying a value on a human life, therefore using the HCA within CBA is explicitly 
stating this value. [56] However, the use of the HCA has been described ĂƐ  “ƵŶĞƚŚŝĐĂů ?
because it is putting a price on a life, and that people who are unemployed (e.g. retired 
individuals) appear to have no benefits from healthcare as calculated by the HCA. [56] An 
ĂůƚĞƌŶĂƚŝǀĞ ƚŽ ƚŚĞ ŚƵŵĂŶ ĐĂƉŝƚĂů ĂƉƉƌŽĂĐŚ ŝƐ ƚŚĞ  “ǁŝůůŝŶŐŶĞƐƐƚŽ ƉĂǇ ? ĂƉƉƌŽĂĐŚ  ?tdW ? ?
whereby an individual is directly asked how much they are willing to pay to improve their 
quality of life or reduce their risk of death. [58] The advantage of the WTP approach is that 
ŝŶ ƚŚĞŽƌǇ ŝƚ ĚŝƌĞĐƚůǇ ƌĞƉƌĞƐĞŶƚƐ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ ƉƌĞĨĞƌĞŶĐĞ ĨŽƌ Ă ƉĂƌƚŝĐƵůĂƌ ŚĞĂůƚŚ ƐƚĂƚĞ ?
taking into consideration all other concerns of the individual [56], yet there is evidence that 
individuals adjust their responses to take into account ability to pay, hence not revealing 
their true preference. [59] Additionally, it has also been suggested that WTP is insensitive 
to the magnitude of health benefit, with individuals reporting similar values for both 
interventions that give small benefits compared to those which generate large benefits, 
hence over-inflating the benefits associated with the small interventions. [60] Another 
common criticism of CBA is that because of its broad scope, necessitating both health and 
non-health benefits, it requires all costs and benefits associated with the intervention, 
which may not be possible as it needs levels of data that are not available, or beyond the 
capabilities of researchers to estimate. [33]  For example, Schoenbaum et al evaluated a 
rubella vaccination using a CBA with an HCA approach. [61] The analysis included 
consequences not only associated with medical cost savings, but also the productivity gains 
from reduced disability and premature death. However, the analysis failed to take into 
account the additional gains to be had from the positive externality from people being 
unable to catch rubella from one another because they were vaccinated, which would have 
further increased the benefits associated with vaccination, suggesting that the estimates 
generated by Schoenbaum et al were conservative. However, calculating the productivity 
gains from the externality would have been intensely complicated, and it may not be 
possible to assign an accurate value to capture these gains. 
 
1.6.3.5 Cost-consequence (CCA) 
 
A CCA is where the outcomes of an intervention are reported separately to the costs 
associated. [62] It has been suggested that the common outcomes generated by the other 
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evaluation approaches are not particularly useful for decision makers, and that presenting 
disconnected outcomes (e.g. life years gained, QALYs gained, number of premature deaths 
averted) in a tabulated form alongside estimated costs is more useful for the decision 
maker, and more transparent. [62] Conversely, it has been argued that CCA can complicate 
the decision making process, since the decision maker may not be able to determine what 
is a meaningful increase in outcome for the patient, and that it reduces the comparability 
across the healthcare sector. [33, 63] 
 
1.6.3.6 Cost-offset (COA) 
 
COA involves the comparison of the intervention cost with the healthcare savings it 
generates, i.e. does the intervention generate medical cost-savings which can outweigh the 
benefits? [64] COA is a form of limited CBA, since COA does not take into account any 
benefits of treatment to the patients, focusing purely on the medical cost-savings 
generated by the treatment; however the outcome is expressed in monetary values. [64]   
 
1.6.3.7 Which method? 
 
The choice of method is purely down to the perspective of the analysis and requirements of 
the decision maker. Since the ultimate aim of this thesis is to develop an economic model 
which will inform the UK governing body, NICE, the thesis will focus on the use of CEA and 
CUA rather than the other methods. This is because NICE require the use of CUA and CEA 
as part of their reference case. [36] 
 
1.6.4 Measuring effectiveness 
 
This section discusses the sort of outcomes that may be relevant to smoking in pregnancy, 
which could be used as the measure of effectiveness in an economic evaluation with a 
particular focus on those in a CEA and CUA. 
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1.6.4.1 Measures for effectiveness in CEA 
 
As has already been defined, the effectiveness of an intervention is measured in a natural 
scale under a CEA. There are several possible outcomes which could be utilised to measure 
the effectiveness of cessation during pregnancy. For the mother, smoking has been linked 
to several within-pregnancy conditions, such as placenta abruption, placenta previa, and 
ectopic pregnancy. [2] The comparison with costs could be made using number of placenta 
abruptions avoided, number of ectopic pregnancies prevented, or, if wishing to combine all 
the within-pregnancy conditions, number of adverse pregnancy outcomes avoided. These 
would be seen as relevant to the decision maker, clinician, and patient should the decision-
making process be interested in a within-pregnancy time horizon. Conversely, although 
previous evaluations of cessation within-pregnancy have included these complications, 
they have not been used as the measure of effectiveness in the evaluation. [65] However, if 
a longer term time horizon is required, then a likely measure of effectiveness is life years 
gained (LYG), which is the difference between the intervention and usual care groups 
measured in terms of the number of individuals who are still alive at later time points or at 
the end of the simulation. LYG take into account the premature mortality of 
disease/health-risk behaviour.  Other possible alternatives for the mother could be to use 
number of Coronary Heart Disease (CHD) events avoided, or number of Chronic Obstructive 
Pulmonary Disorder (COPD) events avoided, as smoking has been linked to increased risk of 
CHD and COPD. [66] However, it should be noted that although these outcomes for the 
mother appear relevant, if a comparison was to be made between either other cessation or 
other healthcare interventions, the CEAs would not be comparable unless the measures of 
effectiveness were the same (e.g. LYG). 
 
For the infant, there are within-pregnancy conditions which could be used as the measure 
of effectiveness within an evaluation. Smoking during pregnancy has been associated with 
low birth weight (LBW), premature birth, and miscarriage. [3, 67] Suitable measures could 
be: number of LBW infants prevented, number of premature births prevented, number of 
infants lost avoided, and the all-encompassing number of adverse pregnancy outcomes for 
the infant avoided. Previous evaluations of cessation within-pregnancy have utilised similar 
measures of effectiveness, including LBW avoided [68, 69], so there is a precedent for using 
these outcomes. When considering post-pregnancy for the infant, LYG could be used, but 
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smoking within-pregnancy has been linked with childhood asthma [70], so a possible 
alternative could be number of childhood asthma cases prevented. Some previous 
evaluations have focused on the use of SIDS averted [71], but this is an only short-term 
outcome, limited to one year post pregnancy. 
 
1.6.4.2 Measures of effectiveness in CUA 
 
There are two common measures used for measuring effectiveness in CUA: Quality 
Adjusted Life Years (QALYs), and Disability Adjusted Life Years (DALYs). A QALY is a measure 
of a length of time spent in a particular health state weighted by its quality of life; hence it 
represents the burden of disease. [72] A QALY is calculated by weighting a life year by a 
preference value which represents the patient ?s preference/utility of being in that health 
state [73], where utility refers to the economic definition of satisfaction experienced from 
consuming a particular good. [32] dŚĞ ƉƌĞĨĞƌĞŶĐĞ ǁĞŝŐŚƚŝŶŐ ŚĂƐ Ă ǀĂůƵĞ A? ? ? ǁŚĞƌĞ ŽŶĞ
represents perfect health and zero represents death; however, negative values can exist if 
patients perceive a health state to be worse than death. Furthermore, Weinstein et al 
summarised the underlying assumptions of the conventional QALY approach as [74]: 
x Resources are limited  and each intervention/alternative has resource implication 
x A resource-allocation must be made, hence we are rationing healthcare 
x The decision maker is interested in maximising the health stock of the population 
subject to resource constraints 
x Health is expressed as preference (desirability)-weighted time across the relevant 
time horizon 
x Individuals are risk-neutral (neither averse to risk or seeking risk) with respect to 
longevity 
x Preference scores can be additive across time and can be aggregated for the group 
x QALYs can be aggregated across individuals (i.e. a QALY is a QALY regardless who 
gains it) 
There are several methods of determining preference rates, however the most common 
method, as recommended by NICE in the UK, is use to the generic health related quality of 
life questionnaire, EuroQols EQ-5D. [36, 75] The advantages of the QALY approach is that it 
provides a common currency to assess the extent of the benefits gained from healthcare 
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interventions, and that it reflects the value judgement that just survival is an insufficient 
measure of health benefit. [76] However, the QALY approach is not without its limitations. 
One assumption is that a QALY is a QALY, i.e. that a QALY gained/lost is blind to health 
conditions and personal characteristics; however, if society is interested in targeting 
specific population groups, e.g. the socioeconomically disadvantaged, this would suggest 
that a QALY for one group of people is not the same as for another group. [77] 
Furthermore, it has been argued that the QALY does not capture all the benefits generated 
by a healthcare intervention, particularly if the generic instruments are utilised on 
conditions which only lead to small changes in the health of the individual. [77] A particular 
example of this is the EQ- ? ?Ɛ ĂƉƉĂƌĞŶƚ ŝŶĂďŝůŝƚǇ ƚŽ ƉŝĐŬ ƵƉ ĐŚĂŶŐĞƐ ŝŶ ŚĞĂƌŝŶŐ ǁŚĞŶ
persons with hearing complaints receive hearing aids. [78] 
 
An alternative to the QALY is the DALY, which can be considered as one lost year of healthy 
life. [79] The formula for calculating a DALY is, as defined by the World Health Organisation 
(WHO) [79]: 
 ܦܣܮܻ ൌ ܻ݁ܽݎݏ݋݂ܮ݂݅݁ܮ݋ݏݐሺܻܮܮሻ ൅ ܻ݁ܽݎݏ݈݋ݏݐ݀ݑ݁ݐ݋ܦ݅ݏܾ݈ܽ݅݅ݐݕሺܻܮܦሻ (1.1) 
Where: 
 ܻܮܮ ൌ ܰݑܾ݉݁ݎ݋݂݀݁ܽݐ݄ݏൈ ݏݐܽ݊݀ܽݎ݀݈݂݅݁݁ݔ݌݁ܿݐܽ݊ܿݕܽݐܽ݃݁݋݂݀݁ܽݐ݄݅݊ݕ݁ܽݎݏ (1.2)  
And: 
 ܻܮܦൌ ܰݑܾ݉݁ݎ݋݂݅݊ܿ݅݀݁݊ܿ݁݊ݐܿܽݏ݁ݏ ൈ ݀݅ݏܾ݈ܽ݅݅ݐݕݓ݄݁݅݃ݐൈ ܽݒ݁ݎܽ݃݁݀ݑݎܽݐ݅݋݊݋݂ݐ݄݁ܿܽݏ݁ݑ݊ݐ݈݅ݎ݁݉݅ݏݏ݅݋݊݋ݎ݀݁ܽݐ݄ሺݕ݁ܽݎݏሻ 
(1.3) 
Or: 
 ܻܮܦ ൌ ݊ݑܾ݉݁ݎ݋݂݌ݎ݁ݒ݈ܽ݁݊ݐܿܽݏ݁ݏ ൈ ݀݅ݏܾ݈ܽ݅݅ݐݕݓ݄݁݅݃ݐ (1.4) 
 
The YLL corresponds to the number of years lost due to premature mortality associated 
with the disease, while the YLD represents the years of healthy life lost due to people 
having to suffer the consequences of the condition. By summing the DALYs across the 
population, the disease burden can be calculated. In comparison to the QALY, while the 
QALY represents the preferences of individual health states, the DALY reflects the degree 
to which health is reduced by a disease condition. However, unlike the QALY, the DALY 
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applies an age-weighting function which values differently depending on the age of disease 
onset, giving a greater weight to a year lived as young adult compared to a child or elderly 
person. [73] DALYs are recommended for use in CEAs used to inform the World Health 
Organisation (WHO). [80]  However, the DALY has been criticised for including this age-
weighting function when there is no evidence that supports the assumption, that DALYs do 
not cover multiple causes, and that the minimisation of DALYs as the criterion for decision 
making could lead to perverse outcomes such as allocating fewer resources to a disabled 
person than an able-bodied person.  [81, 82] 
 
For this thesis, the measure of effectiveness will be QALYs and not DALYs, as recommended 
by NICE guidance. [36] 
 
1.6.5 Measuring costs 
 
As important as measuring the effectiveness of any intervention is the measurement of 
costs associated with it. However, unlike measuring effectiveness, costs are measured in 
the same way across all types of evaluations, in monetary units. The costs included within 
the evaluation are determined by the perspective of the analysis, with broader 
perspectives requiring more cost data. [33] For ĞǆĂŵƉůĞ ? ĨƌŽŵ Ă ƉƌŽǀŝĚĞƌ ?Ɛ ƉĞƌƐƉĞĐƚŝǀĞ, 
ƉĂƚŝĞŶƚƐ ?ƚƌĂǀĞůĐŽƐƚƐǁŽƵůĚŶŽƚďĞƐĞĞŶĂƐŝŵƉŽƌƚĂŶƚ ?ďƵƚƚŚĞƐĞĂƌĞĐŽŶƐŝĚĞƌĞĚŝŵƉŽƌƚĂŶƚ
ĨƌŽŵĂƉĂƚŝĞŶƚ ?ƐǀŝĞǁƉŽŝŶƚĂŶĚĂƐŽĐŝĞƚǇǀŝĞǁƉŽŝŶƚ ?dŚĞĂůůŽĐĂƚŝŽŶŽĨĐŽƐƚƐĐĂŶďĞƐƉůŝƚŝŶƚŽ
three categories: 
x Direct costs: costs immediately associated with the intervention, for example 
consumables, staff time, medical supplies   
x Indirect costs: costs to society incurred as a result of participating in the 
ŝŶƚĞƌǀĞŶƚŝŽŶ ?ĚŝƐĞĂƐĞ ?ĨŽƌĞǆĂŵƉůĞƉĂƚŝĞŶƚ ?ƐǁŽƌŬůŽƐƐĚƵĞƚŽŝůůŚĞĂůth/treatment, 
reduced social and leisure activities 
x Intangible costs: cost of anxieties or cost of quality of life that result from the 
intervention 
While it is common for economic evaluations to include both direct and indirect costs, 
intangible costs are very difficult to measure and value, and hence are generally omitted. 
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[83] However, there is a distinction between the types of cost used in an evaluation. 
Drummond et al defined the different types of cost as [33]:  
x Total cost (TC): all costs associated with the production of a output of health (q), 
defined as 
 ܶܥሺݍሻ ൌ ܨܥ ൅ ܸܥሺݍሻ (1.5) 
x Fixed cost (FC): costs which are not dependent on output in the short term (usually 
one year), e.g. building, equipment, rent, but may vary with time 
x Variable cost (VC): costs that vary with the level of output of health, such as 
supplies, food, personnel, defined as a function of output  ܸܥሺݍሻ 
x Average cost (AC): cost per unit produced, defined as 
 ܣܥሺݍሻ ൌ ܶܥሺݍሻ ൊ ݍ (1.6) 
x Marginal cost (MC): the extra cost of producing one extra unit of output, defined as 
 ܯܥሺݍሻ ൌ   ?ܶ ܥሺݍሻ ൊ  ?ݍ (1.7) 
x Incremental cost (IC): the difference in costs between two or more interventions in 
an evaluation, defined as 
 ܫܥ஺஻ ൌ  ܶܥ஺ െ ܶܥ஻ (1.8) 
 
In cost estimation, an initial consideration is whether to use average or marginal costs; 
however an important difference is that fixed costs are included in average costs, but not in 
marginal costs. [83] Therefore, the inclusion of average costs or marginal costs is often 
down to the research question, but economic evaluation of healthcare technologies are 
often interested in evaluating interventions which may have long term costs and effects, 
and therefore tend to favour average costs. With the incremental approach, the evaluation 
estimates both the total costs associated with the intervention and its comparator, and 
hence an incremental cost is calculated, although these costs are often shown as an 
average cost per patient.  
 
In economic evaluation, there are currently two common approaches to measuring and 
calculating total costs for an intervention and its comparator; bottom-up micro-costing and 
top-down macro-costing. [84] The top-down macro- (gross) costing approach can be seen 
as the least precise [33], as it uses the average per diem across all categories of patient, 
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with a slightly more precise version involving disease-specific per diem across the 
treatments in each disease category. The advantage of macro-costing is that it is relatively 
easy to undertake and can often be calculated using routinely available data, but it can lack 
sensitivity. [84] Bottom-up micro-costing refers to the detailed analysis of changes in 
resource used due to the intervention. [33] This can involve multiplying each component of 
resource use by its associated price (if it exists) or reimbursement cost, which can be 
difficult to undertake, computationally demanding and complex, and possibly only 
generalizable to specific contexts. [84] However, if prices do not exist or are not considered 
ƚŽƌĞĨůĞĐƚƐŽĐŝĞƚǇ ?ƐǀĂůƵĞƐŽĨƌĞƐŽƵƌĐĞƐ ?ƚŚŝƐŵĂǇƌĞƋƵŝƌĞĐƵƐƚŽŵŝƐĞĚǁŽƌŬ ?ĨƵƌƚŚĞƌĂĨĨĞĐƚŝŶŐ
the generalisability of the cost estimates. [85] In practice, researchers often use a 
combination of macro- and micro-costing when performing an evaluation to produce the 
best available estimates of costs of the intervention and its comparator. In the UK, the NICE 
reference case does not specify whether a macro- or micro-approach is used [36]; however, 
it does recommend that researchers use cost data collected as part of routinely collected 
data, such as the NHS Drug Tariff and the British National Formulary for medications and 
prescriptions [86, 87], and NHS reference costs for healthcare resource groups (HRGs). [88]   
 
A further consideration for costs is that an evaluation must report the price year for which 
the costs were calculated. [43] This allows replication of the evaluation in the future. When 
using costs from the literature, they are often from an earlier price year, and need to be 
updated to account for medical price inflation. This is done using one of the price inflation 
indices, for example the Hospital Pay and Prices Index in the UK and the Consumer Price 
Inflator in the US. [89, 90] To inflate costs to a particular year, the following equation can 
be used [89]: 
 ܥ݋ݏݐே௘௪௬௘௔௥ ൌ  ܥ݋ݏݐை௟ௗ௬௘௔௥ ൈ ܫ݊݀݁ݔே௘௪௬௘௔௥ܫ݊݀݁ݔை௟ௗ௬௘௔௥  (1.9) 
 
For example, if an evaluation is conducted using 2011-2012 prices, and used an estimate 
for a particular disease reported in in 2004-2005 prices to cost £500, using the Hospital Pay 
and Prices Index this figure can be inflated to 2011-2012 prices thus: 
 ܥ݋ݏݐଶ଴ଵଵିଶ଴ଵଶ ൌ  ? ? ? ? ൈ ? ? ?Ǥ ? ? ? ?Ǥ ?ൌ  ? ? ? ?ൈ  ?Ǥ ? ? ? ?ൌ  ? ? ? ?Ǥ  ? (1.10) 
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Hence, £500 in 2004-2005 is now £608.50 in 2011-2012 prices, and this value is used in the 
model. Future price inflation is not considered when estimating future costs [83], however 
future costs are discounted, as considered in the next section. 
 
1.6.6 Discounting 
 
Interventions may have costs and consequences which occur at different times, and hence 
the differential timing must be taken into account. [33] Economists assume that individuals 
have a positive rate of time preference; that is we prefer to receive benefits now and incur 
costs in the future. [91] This is assumed because individuals have a short-term view of life, 
preferring to live for today rather than tomorrow; that the future is uncertain so people 
prefer to take the certain benefits now;  and finally individuals expect to be more wealthy 
in the future so money today is of higher value than money in the future. [33]  Hence, it can 
be assumed, under a positive rate of time preference, individuals must value future costs 
less than they dŽŶŽǁ ?ƐŽĂ ? ? ? ?ďŝůůŝŶƚĞŶǇĞĂƌƐ ?ƚŝŵĞŵƵƐƚŚĂǀĞůĞƐƐǀĂůƵĞƚŚĂŶ ? ? ? ?ďŝůů
now) and that any future benefits must be valued less they do now (so a £100 gift must 
ŚĂǀĞŵŽƌĞǀĂůƵĞŶŽǁƚŚĂŶĂ ? ? ? ?ŝŶƚĞŶǇĞĂƌƐ ?ƚŝŵĞ ? ?ŝƐĐŽƵŶƚŝŶŐĨƵƚƵƌĞĐŽƐƚƐĂŶĚďĞŶĞĨŝƚƐ
is achieved by applying a discount rate r, to calculate the present value of a future cost 
[33]: 
 ܸܲ ൌ  ܨ௡ሺ ? ൅ ݎሻ௡ ݓ݄݁ݎ݁ܸܲ ൌ ݌ݎ݁ݏ݁݊ݐݒ݈ܽݑ݁ǡ ܨ௡݅ݏ݂ݑݐݑݎ݁ܿ݋ݏݐܽݐݐ݅݉݁݊ǡ ݎ ൌ ݀݅ݏܿ݋ݑ݊ݐݎܽݐ݁ 
(1.11) 
 
Total discounted future costs can be calculated using this approach; however the equation 
is slightly different whether the costs are being attributed at the end of the year or the 
beginning of the year. [33] For costs attributed at the end of the year, the total present 
value of future costs can be calculated thus: 
 ෍ ܸܲ ൌ ෍ ܨ௡ሺ ? ൅ ݎሻି ௡௡௡ୀଵ ൌ ܨଵሺ ? ൅ ݎሻ൅ ܨଶሺ ? ൅ ݎሻଶ ൅ ڮ ൅ ܨ௡ሺ ? ൅ ݎሻ௡ ݓ݄݁ݎ݁ܸܲ ൌ ݌ݎ݁ݏ݁݊ݐݒ݈ܽݑ݁ǡ ܨ௡ ൌ ݂ݑݐݑݎ݁ܿ݋ݏݐܽݐݐ݅݉݁݊ǡݎ ൌ ݀݅ݏܿ݋ݑ݊ݐݎܽݐ݁ 
(1.12) 
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For costs attributed at the beginning of the year, the total present value of future costs can 
be calculated thus: 
 ෍ ܸܲ ൌ  ෍ ܨ௡ሺ ? ൅ ݎሻି ௡ ൌ ܨ଴ ൅ ܨଵሺ ? ൅ ݎሻ൅ ڮ ൅ ܨ௡ሺ ? ൅ ݎሻ௡௡௡ୀ଴  ݓ݄݁ݎ݁ܸܲ ൌ ݌ݎ݁ݏ݁݊ݐݒ݈ܽݑ݁ǡ ܨ௡ ൌ ݂ݑݐݑݎ݁ܿ݋ݏݐܽݐݐ݅݉݁݊ǡ ݎ ൌ ݀݅ݏܿ݋ݑ݊ݐݎܽݐ݁ 
(1.13) 
 
While discounting future costs is considered uncontroversial, there is considerable debate 
as to whether to discount future benefits. [91] The main argument against discounting 
future benefits is that health cannot be invested to produce future gains, unlike wealth, 
which can. Furthermore, the process of discounting could be seen as discriminating against 
preventative and public health programmes, where many of the benefits are gained a long 
time in the future. [92] However, one argument against not discounting future benefits is 
the Keeler-Cretin paradox, which suggested that if you discounted costs and not benefits, 
then  certain interventions would be indefinitely postponed because they would always be 
cheaper in the future and have the same effectiveness. [93] Furthermore, there is evidence 
to suggest that certain individuals discount health benefits more, for example smokers tend 
to value future health benefits less than non-smokers. [94] Because discounting future 
costs aŶĚ ďĞŶĞĨŝƚƐ ĐĂŶ ŚĂǀĞ ƐƵĐŚ ĂŶ ŝŵƉĂĐƚ ŽŶ ƚŚĞ ĞǀĂůƵĂƚŝŽŶ ?Ɛ ĚĞĐŝƐŝŽŶ ? ŝƚ ŝƐ ŶŽǁ
considered good practice to perform sensitivity analyses on the discount rate to determine 
what impact the discount rate has on the results. [43] The NICE reference case 
recommends that for the UK both costs and benefits should be discounted at 3.5%, with a 
sensitivity analysis performed on 1.5%. 
 
1.6.7 Decision analytic modelling in economic evaluation 
 
As has been previously mentioned, this thesis will be focusing on the use of decision 
analytical models in economic evaluation. There are many decision analytic methods which 
can be used in economic evaluation; however, this thesis will focus on the two most 
common methods, decision trees and Markov cohort simulation. This section will briefly 
outline each approach, when they are appropriate, and the limitations of the approach, as 
well as briefly summarising the alternative methods. 
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1.6.7.1 Decision Trees 
 
A decision tree is considered the simplest form of model. It represents an individual 
ƉĂƚŝĞŶƚ ?ƐƉŽƐƐŝďůĞƉƌŽŐŶŽƐĞƐĂĨƚĞƌĂŶ ŝŶƚĞƌǀĞŶƚŝŽŶĂƐĂ ƐĞƌŝĞƐŽĨƉĂƚŚǁĂǇƐ ? ƌĞĨĞƌƌĞĚ ƚŽĂƐ
branches. [33, 41] For example, an evaluation is being performed on a hypothetical 
smoking cessation intervention compared to no intervention. For simplicity, it assumed 
that an intervention can either make a successful or unsuccessful quit attempt, with the 
intervention only affecting the chance that a quit attempt is successful. This scenario can 
be represented in a decision tree, as demonstrated in Figure 1.1. 
 
Figure 1.1: An example decision tree for a hypothetical smoking cessation intervention 
 
 
The decision tree demonstrates the four possible pathways: use the intervention and 
ƐƵĐĐĞƐƐĨƵůůǇ ƋƵŝƚ ? ƵƐĞ ƚŚĞ ŝŶƚĞƌǀĞŶƚŝŽŶ ďƵƚ ďĞ ƵŶƐƵĐĐĞƐƐĨƵů ŝŶ ƋƵŝƚƚŝŶŐ ? ĚŽŶ ?ƚ ƵƐĞ ƚŚĞ
ŝŶƚĞƌǀĞŶƚŝŽŶ ďƵƚ ƐƵĐĐĞƐƐĨƵůůǇ ƋƵŝƚ ? ĂŶĚ ĚŽŶ ?ƚ ƵƐĞ ƚŚĞ ŝŶƚĞƌǀĞŶƚŝŽŶ ĂŶĚ ďĞ ƵŶƐƵĐĐĞƐƐĨƵů ŝŶ
quitting. Each pathway has associated pay-offs on the right hand side, representing the 
costs and benefits (in this example termed outcomes). From Figure 1.1 it can be seen that 
there are three types of nodes, which can be defined as (from right to left): 
x Terminal node (triangle): these represent the end of the pathways, and are linked 
with the associated payoffs, namely costs and benefits 
Costs Outcome
P=qI C(IntS) O(IntS)
P=1-qI C(IntU) O(IntU)
P=qN C(NoS) O(NoS)
P=1-QN C(NoU) O(NoU)
Smoking individual
Expected cost (Int)
Expected cost (No)
Expected outcome (No)
Expected outcome (Int)
Successful quit attempt
Unsuccesful quit attempt
Cessation intervention
Successful quit attempt
No intervention
Unsuccesful quit attempt
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x Chance node (circle): these represent a situation where an individual could 
potentially move to at least one of two or more branches. Here the 
individual/decision maker has no control over what happens to the individual, it is 
an uncertain event, so the pathway is chosen by a probability. A probability is a 
value which represents the chance (or confidence) that an event occurs. [95] The 
alternatives at each chance node must be mutually exclusive (cannot occur at the 
same time), hence the associated probabilities for each node must sum to one 
x Decision node (square): a node where the individual can choose which path to 
take, e.g. use the intervention or not 
To perform the evaluation and to determine whether the intervention is worth using, the 
decision tree is rolled back from right to left. This requires the calculation of the expected 
costs and outcomes for both the intervention and no intervention arms. The expected costs 
and outcomes for the intervention arm are calculated thus: 
 ܧݔ݌݁ܿݐ݁݀ܿ݋ݏݐሺ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊ሻ ൌ ൫ݍܫ ൈ ܥሺܫ݊ݐܵሻ൯ ൅ ൫ሺ ? െݍܮሻ ൈ ܥሺܫ݊ݐܷሻ൯ (1.14) 
 ܧݔ݌݁ܿݐ݁݀݋ݑݐܿ݋݉݁ሺ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊ሻൌ ൫ݍܫ ൈ ܱሺܫ݊ݐܵሻ൯ ൅ ൫ሺ ? െݍܫሻ ൈ ܱሺܫ݊ݐܷሻ൯ ݓ݄݁ݎ݁ݍܫ ൌ ݌ݎ݋ܾܾ݈ܽ݅݅ݐݕ݋݂ݏݑܿܿ݁ݏݏ݂ݑ݈݈ݕݍݑ݅ݐݐ݅݊݃ǡ ܥሺܫ݊ݐܵሻൌ ݐ݋ݐ݈ܽܿ݋ݏݐ݋݂݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊݌݈ݑݏܿ݋ݏݐ݋݂ܽݏݑܿܿ݁ݏݏ݂ݑ݈ݍݑ݅ݐܽݐݐ݁݉݌ݐǡ ܥሺܫ݊ݐܷሻൌ ݐ݋ݐ݈ܽܿ݋ݏݐ݋݂݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊݌݈ݑݏܿ݋ݏݐ݋݂ܽݑ݊ݏݑܿܿ݁ݏݏ݂ݑ݈ݍݑ݅ݐܽݐݐ݁݉݌ݐ ܱሺܫ݊ݐܵሻ ൌ ܾ݂݁݊݁݅ݐܽݏݏ݋ܿ݅ܽݐ݁݀ݓ݅ݐ݄ܽݏݑܿܿ݁ݏݏ݂ݑ݈ݍݑ݅ݐܽݐݐ݁݉݌ݐǡ ܽ݊݀ܱሺܫ݊ݐܷሻ ൌ ܾ݂݁݊݁݅ݐܽݏݏ݋ܿ݅ܽݐ݁݀ݓ݅ݐ݄ܽݑ݊ݏݑܿܿ݁ݏݏ݂ݑ݈ݍݑ݅ݐܽݐݐ݁݉݌ݐ 
(1.15) 
 
The expected costs and outcomes for the no intervention arm are calculated using the 
same equations above, just adjusting the parameters and payoffs to suit the no 
intervention arm. Once this is complete, it is now possible to determine which arm offers 
more value for money; how this is determined is introduced later in this chapter. 
 
The advantage of the decision tree is that it is very simple to build and evaluate, and can be 
very transparent/easy to interpret for non-economists. [41] It lends itself to situations 
where there is no time dependency, or the patient follows a logical flow, e.g. being 
diagnosed, treated, and cured or dead. [41] However, there are several limitations with the 
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decision tree approach. Firstly, decision trees implicitly assume that events occur over an 
instantaneous discrete period. [33] This means that time is not explicitly defined, and 
hence elements of the evaluation which rely on time such as discounting are very difficult 
to implement. Secondly, a decision tree can very quickly become complex, referred to as 
bushy, when dealing with long-term prognoses, such as chronic diseases. [33] Decision 
trees do not allow recursion to a previous branch (looping), which means that each relapse 
in a chronic disease has to be built in as separate branches. [41] If following a disease for 
many years, this could very quickly to lead to a decision tree which has thousands of 
branches, and consequently a model which would be very time consuming to populate and 
evaluate. Hence, decision trees are not used for modelling long-term follow-ups or chronic 
conditions.  
 
1.6.7.2 Markov cohort simulation models 
 
To address the limitations of decision trees, Markov models use a more straightforward 
and flexible approach, where patieŶƚƐĂƌĞĂůůŽǁĞĚƚŽŽĐĐƵƉǇĂƐĞƌŝĞƐŽĨ ‘ƐƚĂƚĞƐ ?ĂƚĂŶǇŐŝǀĞŶ
point in time. [33, 39, 41] The model runs in cycles, which represent a discrete time period 
(e.g. one year, six months, etc), and in each cycle patients can transition from one state to 
another. The chance that a patient transits to another state, or remains in the state they 
are in, is determined by the transition probability, which is defined in the evaluation. The 
number of cycles that the model runs for and the length of each cycle is determined by the 
research question; for example a model investigating the treatment of dyspepsia 
(indigestion) may use one month cycles to capture the frequent relapses associated with 
the disease, while a model for lung cancer survival may use six month cycles because of the 
slow rate of relapse.  A model can either be run for a set number of cycles, or can be run 
until all the individuals have entered the absorbing state. An absorbing state represents a 
state which individuals can enter but not exit. In healthcare related Markov models, this 
state often represents death. Markov models are often used in cohort simulation, whereby 
a number of individuals (e.g. 1,000) are fed into a particular health state at the start of the 
model, and then allowed to cycle through the various health states, allowing the model to 
calculate the number of individuals in each health states in any given cycle. Figure 1.2 
demonstrates a simple Markov model of a chronic disease, e.g. cancer. 
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Figure 1.2: A simple Markov model of cancer 
 
 
In Figure 1.2, a patient could start off by being cancerous, receive treatment and transit to 
being cured, remain without cancer for some time (i.e. remain in the cured state for several 
cycles), before the cancer recurs, and then eventually die. The probability that an individual 
will move states can be represented by the following transition matrix: 
 
Table 1.1: Transition matrix for the Markov in Figure 1.2 
 Transit to 
Transit from Cancerous Cured ± no 
cancer 
Cancer 
recurrence 
Dead 
Cancerous R P(Cure) 0 P(Mortality 
from 
cancer) 
Cured ± no 
cancer 
0 R P(Recurrence) P(Mortality 
no cancer) 
Cancer 
recurrence 
0 0 R P(Mortality 
recurrence) 
Dead 0 0 0 1 
R = remainder; all rows should add up to one, e.g. in Cancerous row, R = 1 ± 
P(Cure) ± P(Mortality from cancer) 
P = probability of transit 
 
The transition matrix demonstrates that death is the absorbing state, as individuals who 
enter are never allowed to exit. The transition matrix also demonstrates that once a patient 
Cancerous
Cured - no 
cancer
Cancer
recurrence
Dead
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has had a cancer recurrence, they cannot transit back from being cured, which suggests 
that this model is assuming that recurrence can only happen once. Furthermore, all rows in 
the transition matrix should sum to one, and to allow for this, it is good practice to denote 
a particular transition to be one minus the other probabilities in the row, which in this 
model is the probability of remaining within the cycle. In addition to the normal state 
(where individuals can remain in the state for more than one cycle) and the absorbing 
state, there is the additional tunnel state. A tunnel state represents a state in which an 
individual can only remain for one cycle. At the end of that cycle, they must transit to 
another state; they cannot remain in the tunnel state. 
 
As mentioned, in each cycle the number of individuals in all the states is calculated. Each 
state can be given a particular cost and benefit. Hence the total cost and benefit in each 
cycle can be calculated by multiplying the number of individuals in a particular state by its 
associated cost/benefit, and then summing the same calculations for all the states. The 
total cost/benefit per patient can then be calculated by summing the associated 
costs/benefits for each cycle, then dividing this value by the number of individuals in the 
cohort. To model the impact of an intervention, the transition probabilities can be changed 
to represent the effect the intervention has on the patients moving states. For example, a 
new intervention could change the associated probability values for P(cure) and 
P(recurrence), which would then affect the expected costs/benefits per person.  
 
The advantages of the Markov model approach is that it is now easy to build in parts of the 
evaluation which are reliant on time, e.g. discounting. [33] Discounting can easily be 
achieved by weighting each the costs and benefits in each cycle by the discount rate. 
Additionally, the Markov has simplified what would have been a very bushy decision tree 
for the cancer situation into a relatively small Markov model with only four states. [41] 
Because of this, Markov models are particularly useful if modelling long-term time horizons 
(e.g. lifetime), or chronic diseases which may have a lot of looping between states.  
 
However, there is an important limitation associated with the Markov model, which is 
referred to as the Markov assumption. The Markov assumption states that the transition 
probabilities for a health state depend only on that state and not on the historical 
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experience an individual may have had in previous cycles of the model; in other words the 
model is memoryless. [41] For example, in the Markov model demonstrated in Figure 1.2, 
the chance that a cured individual transits to having a recurrent cancer is the same, 
independent of whether the individual has been in the cured state for one cycle or a 100 
cycles. Although it is possible to work around the Markovian assumption using additional 
states to represent historical outcomes, it can quickly mean that the Markov model 
becomes as unwieldy as the decision tree that it was designed to replace. [33] Therefore, if 
transit probabilities are dependent on the previous state history of the patient, then a 
Markov model might not be appropriate for performing the evaluation.  
 
1.6.7.3 Alternative methods in decision analytic modelling 
 
Although Markov models and/or decision trees are the most common forms of modelling 
in economic evaluation, there are several alternatives. Some of these are: 
x Patient level simulation (microsimulation): models the progression of individuals 
through the healthcare process. [41, 96] Individuals in the simulation have 
potentially heterogeneous characteristics that can affect the progression through 
the model. However, they are allowed to progress through the model 
independently of each other and environmental constraints. These individual 
microsimulations allow individuals to progress while keeping a track of the history 
of which nodes that the patients progress through, which is useful if probabilities, 
costs, and benefits are reliant on the previous history of the individual. [96] This 
allows the model to include the impacts of several co-morbidities, while allowing 
them to interact with each other. Furthermore the model does not necessarily 
have to rely on an equal discrete time cycle, but could use time to next event. 
However, the limitations with the microsimulation approach are that they are 
heavily reliant on the parameters for future prognoses, which may be difficult to 
populate within the limitations of the available data. [33] Furthermore, controlling 
for uncertainty in the model is computationally intense and can be time 
consuming.[33] 
x Discrete event simulation: models the progress of a group of individuals through 
ƚŚĞ ŚĞĂůƚŚĐĂƌĞ ƉƌŽĐĞƐƐ ? ĂůůŽǁŝŶŐ ĨŽƌ ŝŵƉĂĐƚƐ ĨƌŽŵ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ
and outcomes, as well as allowing for individuals to interact with each other, e.g. 
28 
 
ĂŶŝŶĚŝǀŝĚƵĂů ?ƐĚĞĐŝƐŝŽŶŶŽƚƚŽĚŽŶĂƚĞĂŶŽƌŐĂŶĐĂŶŝŵƉĂĐƚŽŶǁŚĞƚŚĞƌĂŶŽƚŚĞƌĐĂŶ
receive a transplant. [41] Discrete event simulation has no fixed time cycle, rather 
patients change states when an event occurs, which then in turn may impact on 
the chances of a patient having a subsequent event. [96] This type of model is 
particularly useful when there is non-linearity in the healthcare system 
performance due to inherent variability within patients, such as infectious diseases. 
[96] However, discrete event simulation suffers from similar limitations as 
microsimulation, such as availability of data to populate the model, and 
computational slowness. [96] 
x Dynamic models: these models allow interaction between patients without 
separating individuals. [96] The models work on the basis that the states of the 
system can change, ĂŶĚƚŚĂƚƚŚĞƌĂƚĞŽĨĐŚĂŶŐĞĐĂŶďĞĂĨƵŶĐƚŝŽŶŽĨƚŚĞƐǇƐƚĞŵ ?Ɛ
state itself, hence the model allows feedback. This is particularly useful for 
infectious diseases, where higher levels of infection can increase the risk of 
infection but also reduce the number of individuals in the susceptible pool. [96] 
However, these models can be incredibly complex, especially if the decision 
problem is complicated and not all the relationships are established. [97] 
 
1.6.8 Statistics for the comparison of interventions and rules for decision making 
 
To be able to determine whether an intervention is cost-effective or not, an incremental 
analysis is required. [33] Although it is possible to calculate the average cost-effectiveness 
(ACER,ܣܥܧܴ ൌ  ாሺ௖௢௦௧ሻாሺ௢௨௧௖௢௠௘ሻ), an ACER does not generate the comparative information 
required to determine whether an intervention is cost-effective compared to its 
comparator. [33]One of the outputs of decision analytic models (DAMs) is the expected 
costs and expected outcomes (benefits) associated with each intervention being evaluated. 
Hence, we can calculate the incremental cost and benefit of the new intervention thus: 
 ܫ݊ܿݎ݁݉݁݊ݐ݈ܽܥ݋ݏݐൌ ܧݔ݌݁ܿݐ݁݀ܿ݋ݏݐே௘௪௜௡௧௘௥௩௘௡௧௜௢௡ െ ܧݔ݌݁ܿݐ݁݀ܿ݋ݏݐ஼௢௠௣௔௥௔௧௢௥ (1.16) 
 ܫ݊ܿݎ݉݁݊ݐ݈ܽܤ݂݁݊݁݅ݐൌ ܧݔ݌݁ܿݐ݁݀ܾ݂݁݊݁݅ݐݏே௘௪௜௡௧௘௥௩௘௡௧௜௢௡െ ܧݔ݌݁ܿݐ݁݀ܾ݂݁݊݁݅ݐݏ஼௢௠௣௔௥௔௧௢௥ 
(1.17) 
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One way to evaluate the results is to plot the incremental costs and benefits on the cost-
effectiveness plane, which is demonstrated in Figure 1.3. 
 
Figure 1.3: The cost-effectiveness plane 
 
 
The cost-effectiveness plane can be divided into four regions; A, B, C, and D. If the 
incremental costs and benefits for the new intervention are plotted in region A, the new 
intervention is said to be dominated by usual care. This is because the new intervention is 
more expensive and less effective than usual care, and hence it would be unnecessary to 
perform an evaluation since it would be illogical to introduce the new intervention. 
However, if the incremental costs and benefits for the new intervention are plotted in 
region C, the opposite situation exists. In region C, the intervention is more effective than 
usual care, and is cheaper in terms of healthcare costs, therefore the new intervention can 
be said to dominate usual care. Again, it would be unnecessary to perform an evaluation 
here as it is logical to choose the new intervention, since it is better than usual care. 
However, in regions B (where the new intervention is both more effective and more costly 
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than usual care) and D (where the new intervention is cheaper than usual care but less 
effective), it cannot be determined whether the new intervention is dominant over or 
dominated by usual care, and hence it is necessary to determine if the new intervention 
weakly dominates usual care. 
 
One method to determine weak dominance is to calculate the incremental cost-
effectiveness ratio (ICER). [33] This is the ratio of incremental costs over incremental 
effectiveness. The equation for the ICER is: 
 ܫܥܧܴ ൌ ܧሺܿ݋ݏݐሻ௡௘௪௜௡௧௘௥௩௘௡௧௜௢௡ െ ܧሺܿ݋ݏݐሻ௨௦௨௔௟௖௔௥௘ܧሺ݋ݑݐܿ݋݉݁ሻ௡௘௪௜௡௧௘௥௩௘௡௧௢௡ െ ܧሺ݋ݑݐܿ݋݉݁ሻ௨௦௨௔௟௖௔௥௘ (1.18) 
 
In regions B and D, the ICER will return a positive value; however in regions A and C it will 
return a negative value, which is very difficult to interpret, hence it is best practice not to 
report the ICER if the intervention appears to be dominant or dominated. To determine 
whether the intervention weakly dominates usual care, a decision rule is required. This can 
be represented as [98]: 
 ܹ݁ܽܿܿ݁݌ݐݐ݄݁݊݁ݓ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊݂݅ݐ݄݁ܫܥܧܴ ൑ ߣ ݓ݄݁ݎ݁ߣݎ݁݌ݎ݁ݏ݁݊ݐݏ݋ݑݎݓ݈݈݅݅݊݃݊݁ݏݏݐ݋݌ܽݕ݂݋ݎܽ݀݀݅ݐ݅݋݈݊ܽ݋݊݁ݑ݊݅ݐ݃ܽ݅݊݅݊ܾ݂݁݊݁݅ݐ 
 
This means that if the ratio of incremental costs and benefits is less than or equal to what a 
policy maker is willing to pay for an additional one unit gain in benefits, then the new 
intervention could be deemed as cost-effective, or value for money. This threshold value 
can be represented on the cost-effectiveness plane by a straight line passing through the 
origin and a point representing a one unit increase in benefit and the threshold value, as 
can be seen in Figure 1.4 below, with point A representing a intervention where the ICER is 
less than the threshold value. 
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Figure 1.4: The threshold value on the cost effectiveness plane 
 
 
If the ICER is aďŽǀĞ ʄ  ?Ğ ?Ő ? ƉŽŝŶƚ  ŝŶFigure 1.4), then the new intervention cannot be 
deemed cost-ĞĨĨĞĐƚŝǀĞĂŶĚƵƐƵĂůĐĂƌĞǁŽƵůĚďĞƚŚĞƚƌĞĂƚŵĞŶƚŽĨĐŚŽŝĐĞ ?dŚĞʄƌĞƉƌĞƐĞŶƚƐ
ƚŚĞƉŽůŝĐǇŵĂŬĞƌ ?ƐƚŚƌĞƐŚŽůĚǀĂůƵĞ ?ŝ ?Ğ ?ǁŚĂƚƚŚĞƉŽůŝĐǇŵĂŬĞƌŝƐƉƌĞƉĂƌĞĚƚŽƐĂĐƌŝĨŝĐĞĨŽƌĂ
one unit gain in benefit. What this value is and how it is calculated is discussed further later 
in this chapter. Although the point estimate for an ICER is relatively easy to compute, 
because it is a ratio statistic, the variance is not defined. This makes computing the 
confidence interval around the ICER problematic, although this can be addressed to some 
extent using non-parametric bootstrapping for within-trial analyses and probabilistic 
sensitivity analyses (PSAs) in models. [99] In decision modelling, the model can be 
programmed to use the ICER to determine which option to choose at each decision node.  
 
An alternative to the ICER is the incremental net monetary benefit statistic (INB). This is the 
incremental difference between the net monetary benefit for each intervention (NMB).  
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The NMB can be calculated by [99]: 
 ܰܯܤ ൌ ሺߣ ൈ ܧሺ݋ݑݐܿ݋݉݁ሻூ௡௧௘௥௩௘௡௧௜௢௡ሻ െ ܧሺܿ݋ݏݐሻூ௡௧௘௥௩௘௡௧௜௢௡ ݓ݄݁ݎ݁ߣ ൌ ݐ݄݁݌݋݈݅ܿݕ݉ܽ݇݁ݎᇱݏݐ݄ݎ݁ݏ݄݋݈݀ݒ݈ܽݑ݁ (1.19) 
 
Hence, the INB can be calculated by taking the difference in the NMB between the new 
intervention and usual care: 
 ܫܰܤ ൌ  ܰܯܤே௘௪௜௡௧௘௥௩௘௡௧௜௢௡ െ ܰܯܤ௎௦௨௔௟௖௔௥௘ (1.20) 
 
It is also worth noting that the INB is a rearrangement of the ICER, and hence can be 
defined as: 
 ܫܰܤ ൌ ൫ߣ ൈ ሺܧሺ݋ݑݐܿ݋݉݁ሻே௘௪௜௡௧௘௥௩௘௡௧௜௢௡ െ ܧሺ݋ݑݐܿ݋݉݁ሻ௎௦௨௔௟௖௔௥௘ሻ൯ െሺܧሺܿ݋ݏݐሻே௘௪௜௡௧௘௥௩௘௡௧௜௢௡ െ ܧሺܿ݋ݏݐሻ௎௦௨௔௟௖௔௥௘ሻ (1.21) 
 
The decision rules for the INB are quite simply [39]: ݓ݁ݎ݆݁݁ܿݐݐ݄݁݊݁ݓ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊݂݅ݐ݄݁ܫܰܤ ൏  ? ݓ݁ܽݎ݁݂݂݅݊݀݅݁ݎ݁݊ݐܾܽ݋ݑݐݐ݄݁݊݁ݓ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊݂݅ݐ݄݁ܫܰܤ ൌ  ? ݓ݁ܽܿܿ݁݌ݐݐ݄݁݊݁ݓ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊݂݅ݐ݄݁ܫܰܤ ൐  ? 
 
This makes the INB very easy to interpret, since a positive monetary figure suggests that 
there is a net benefit from the new intervention and hence it should be adopted, while a 
negative value suggests there is a net loss and therefore that the new intervention 
ƐŚŽƵůĚŶ ?ƚďĞĂĚŽƉƚĞĚ ?dŚĞĂĚǀĂŶƚĂŐĞŽĨƚŚĞ/EŝƐƚŚĂƚƐŝŶĐĞŝƚ ŝƐŶŽƚĂ ratio statistic, it is 
now possible to fit a confidence interval on the point estimate. [100] In decision analytic 
models, it is more common for the model to use the NMB statistic rather than the ICER 
since it is assumed we will always attempt to maximise benefits. [39] For example, if a 
decision node had three choices, and all of which had an ICER below the threshold value, 
the model faces a complex decision process. However, if the model calculates the NMB for 
each intervention, it can then easily choose whichever offers the highest NMB. 
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1.6.8.1 ĞƚĞƌŵŝŶŝŶŐƚŚĞƉŽůŝĐǇŵĂŬĞƌ ?ƐƚŚƌĞƐŚŽůĚǀĂůƵĞ 
 
For a decision maker to determine whether a new intervention offers value for money, 
they must compare the ICER with a threshold value, i.e. a value which represents their 
willingness to pay for health gain. [54] In countries with a state-funded healthcare system 
like the UK, this is particularly important since they often practise healthcare rationing 
within a finite budget. [101] Although there are many ways a decision could be made, e.g. 
allowing doctors to choose what they think is best; first come first served basis, these 
approaches could be argued to not only be unfair/discriminatory to certain individuals but 
could also lead to inefficiency, hence wasting the scarce resources that the decision maker 
is seeking to prolong. [76, 101] It can also be argued that the threshold value reflects 
ƐŽĐŝĞƚǇ ?ƐƉerceived opportunity cost, demonstrating what society is prepared to sacrifice to 
gain some additional benefit, and that the ICER represents the value judgement; the value 
for money of the intervention. [33, 34] 
 
In the UK, the governing body NICE is responsible for determining the availability of 
interventions/treatments on the NHS. Part of its remit is to determine whether the new 
intervention/procedure offers value for money, and hence has a threshold value reported 
in incremental cost per QALY. The current NICE guidance states that this threshold is [36]: 
x ICER<£20,000 per QALY: strong evidence of cost-effectiveness given the 
acceptability of the technology to the NHS. An intervention with a ICER below 
£20,000 per QALY will only be rejected if the committee does not believe the 
plausibility of the evaluations inputs or the uncertainty surrounding the ICER  
x  ? ? ? ? ? ? ? ƉĞƌ Y>zA? /Z AM ? ? ? ? ? ? ? ƉĞƌ Y>z P ŵŽĚĞƌĂƚĞ ĞǀŝĚĞŶĐĞ ŽĨ ĐŽƐƚ-
effectiveness. Decision will rely on the certainty around the ICER, whether changes 
in health-related quality of life have been adequately captured, the innovative 
nature of the technology and whether it adds demonstrable and distinctive 
benefits which may not have been captured by QALYs, or whether the treatment  
has special considerations for palliative care 
x  ? ? ? ? ? ? ?ƉĞƌY>zA?/Z PǁĞĂŬĞǀŝĚĞŶĐĞŽĨĐŽƐƚ-effectiveness. The committee will 
need very strong evidence for the new technology  
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The NICE threshold values can be represented on the cost-effectiveness plane, as 
demonstrated in Figure 1.5. 
 
Figure 1.5: NICE threshold values for determining cost-effectiveness of new technologies and interventions, 
as presented on the cost-effectiveness plane 
 
 
Initially, NICE denied that it was applying these threshold values, and argued that it was 
down to the individual decision committees to determine whether or not an intervention 
was considered cost-effective. However, Devlin et al used a discrete choice analysis to elicit 
that the threshold was estimated at £20,000 - £30,000 per QALY, although there was 
evidence that it may be higher. [102] The NICE threshold value has been criticised, with the 
initial behaviour of NICE not stating the threshold value being described as opaque, and 
that it was considered to be too high. [103] However, some have argued that it is not 
E/ ?ƐĐŽŶƐƚŝƚƵƚŝŽŶĂůƌŽůĞƚŽĚĞƚĞƌŵŝŶĞƚŚĞǀĂůƵĞŽĨĂŶĂĚŝƚŝŽŶĂůY>z ?ĂƐƚŚĂƚŝƐĂƌŽůĞĨŽƌ
ƉŽůŝƚŝĐŝĂŶƐ ?ĂŶĚƚŚĂƚE/ ?ƐƉƵƌƉŽƐĞŝƐƚŽƐĞĂƌĐŚĨŽƌƚŚĞƚŚƌĞƐŚŽůĚŝŵƉůŝĞĚďǇƚŚĞƉƌĞǀĂŝůŝŶŐ
NHS budget. [104] However, more recent literature has continued to investigate the value 
of the threshold. Claxton et al performed an econometric analysis on changes in healthcare 
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expenditure and its impacts on mortality and QALY gains, to give a best estimate of the 
NICE threshold. [34] The analysis returned a value of £12,936 per QALY based on 2008 
expenditure, and when controlling for uncertainty, the probability that the threshold was 
below £20,000 per QALY was 0.89 and below £30,000 per QALY was 0.97. However, the 
authors acknowledge that due to assumptions, it was difficult to infer whether the £12,936 
per QALY threshold was an underestimate or an overestimate of the true threshold value. 
Despite this, they concluded that it was more likely than not that the value was an 
overestimate, and the true value was likely to be somewhat lower. However, this work has 
been brought into question, with Barnsley et al suggesting that, in reality, Claxton et al are 
underestimating the threshold value. [105] Barnsley et al highlight that, firstly, the central 
threshold estimate of £12,936 per QALY is highly sensitive to the assumption that the 
unexplained 28% of primary care trusts budgets is distributed according to the estimated 
responsiveness to changes in budget, and that relaxing this assumption drives the estimate 
up to £18,317 per QALY. Furthermore, Barnsley et al argued that, regarding the 
uncertainty, the evidence suggested that although there was a smaller probability that the 
threshold had been substantially underestimated than slightly overestimated, there was 
almost no chance that it had been substantially overestimated, suggesting that Claxton et 
Ăů ?ƐĐŽŶĐůƵƐŝŽŶƐƚŚĂƚƚŚĞƚŚƌĞƐŚŽůĚǀĂůƵĞǁĂƐƚŽŽŚŝŐŚƚŽďĞŝŶĐŽƌƌĞĐƚ ?ĂŶĚƚŚĂƚŝŶƌĞĂůŝƚǇŝƚ
was more likely to be higher and in line with the current NICE reference case. [36] More 
recently, Schaffer et al attempted to estimate the cost-effectiveness threshold in Scotland 
by investigating services which had just received, or were about to receive, investment in 
2012/13, and by comparing these figures with literature based estimates for QALY gains, 
calculate the implied threshold. [106] They found that there was a great deal of uncertainty 
in the QALY threshold, with the median threshold across the several services estimated to 
be £1,516 to £1,017,844 per QALY gained. However, the authors identified that in none of 
the decisions was cost per QALY data used, which may explain why there was such 
variation in the threshold value.  
 
Despite the discussion on the value of the NICE threshold, it is important to realise that the 
value is there to prevent inefficient treatments being funded, as they can imply a cost to 
not only the NHS but to society as a whole. Every approval has a so-called opportunity cost, 
and it is important that NICE is able to determine which new technologies are going to have 
a minimal opportunity cost across the healthcare system. For example, Claxton et al 
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highlighted that in 2011 NICE considered whether ranibizumab should be approved for 
widespread use for the treatment of diabetic macular oedema, and initially rejected the 
technology on the grounds that it was unlikely to be cost-effective [34], with an ICER of 
£19,075 in the base case, and the probability of being cost-effective at £20,000 per QALY of 
49.3%. [107] The appraisal of ranibizumab estimated that it would cost the NHS £80millon 
per annum to treat the eligible population. [34, 107]Assuming that budget was finite, 
money earmarked for other treatments would need to be transferred from other disease 
areas, with Claxton et al estimating that the funding of ranibizumab would have displaced 
6,184 QALYs from elsewhere in the NHS, including 411 additional deaths and 1,864 life 
years foregone. [34] 
 
More recently, Schaffer et al investigated how NHS organisations which could be 
considered to have fixed budgets accommodated financial shocks arising from NICE 
technology appraisals, and how prioritisation decisions were made in the NHS by those 
budget holders. [108] The authors focused on the seven local health boards in NHS Wales, 
with semi-structured interviews. The authors found that the majority of NICE 
recommendations were anticipated by using horizon scanning, which created contingency 
funds which were adequate enough to cover the extra expenditure in that financial year. 
There was little evidence of service displacement, but there were signs that some of the 
additional funds came from improving efficiency, though there seemed to be an equal 
spread amongst local health boards as to whether efficiency savings came from the same 
ĚŝƐĞĂƐĞĂƌĞĂŽĨƚŚĞŶĞǁƚĞĐŚŶŽůŽŐǇŽƌĨƌŽŵƚŚĞŵĞĚŝĐŝŶĞƐ ?ďƵĚŐĞƚĂƐĂǁŚŽůĞ ?,ŽǁĞǀĞƌ ?ŽŶ
occasion the Welsh government stepped in as the funder of last resort, suggesting that the 
part of the opportunity cost may be outside the NHS. Compared to the work by Claxton et 
al [34], Schaffer et al have implied that the opportunity cost is already anticipated, and 
ŚĞŶĐĞĚŽĞƐŶ ?ƚůĞĂĚ to the QALYs lost as suggested by Claxton et al; however, part of it lies 
outside of the NHS. [108] 
 
1.6.9 The role of uncertainty and its impact on economic evaluation 
 
An important requirement for economic evaluation in terms of decision making is to 
indicate how uncertainty in the available evidence translates into decision uncertainty, i.e. 
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the probability that the recommended decision is the correct one. [39] It has been argued 
that controlling for uncertainty is as important as assessing the deterministic cost-
effectiveness estimates. [109, 110] Uncertainty matters because it is important to provide 
correct evaluation of expected cost and effect, to consider whether current evidence is 
sufficient, and to estimate the possible consequences of an uncertain decision for the NHS. 
[110] There are several key concepts in uncertainty, and several approaches that can be 
used to control for it: 
x Variability: Individual patients differ from one another (e.g. clinical events they 
experience, health related quality of life, risk of disease). [39] Cannot be reduced 
through the collection of additional data. [39] 
x Parameter uncertainty: The precision associated with input parameters (probability 
of event, mean costs, utility values). [39] This imprecision is a result of the input 
parameters estimated for a population from the best evidence available. In theory, 
can be reduced by the acquisition of further data. This can be controlled for by 
using probabilistic sensitivity analyses, which is discussed in detail later in this 
section. 
x Heterogeneity: The extent of inter-patient variability in a particular measurement 
on the basis of one or more patient characteristics, (e.g. the risk of a disease may 
be higher in men). [39] This can be controlled for with sub-group analysis allowing 
for decision uncertainty for particular patient characteristics; however parameter 
uncertainty will still exist. 
x Structural uncertainty:  Refers to the impact of the assumptions made to simplify 
the complex healthcare process and prognoses that patients can experience. 
[33]These judgements on the appropriate structure of the model can have 
important impacts on the results of the analysis. Two methods exist to control for 
structural uncertainty; model averaging, where alternative models are constructed 
with different specifications, and the results averaged; and model selection on the 
basis of prediction performance or appropriateness. [111, 112] 
x Methodological uncertainty:  The choice of model used to perform the evaluation 
may engrain a series of structural assumptions, making controlling for structural 
uncertainty difficult. [33] This may require the construction of two models using 
two different methods (e.g. Markov simulation versus microsimulation), however it 
is difficult to undertake, and this puts the decision maker in the position of also 
deciding which is the most appropriate model. [33] 
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x Decision uncertainty:  The distribution of possible cost-effectiveness estimates due 
to parameter uncertainty. [39] There is a strong argument for basing decisions on 
the expectation of this distribution, as it demonstrates the confidence the 
researchers have in the decision being the correct one. [39, 109] Providing 
evidence of decision uncertainty is now an important part of the NICE reference 
case.[36] 
 
1.6.10 Controlling for parameter uncertainty 
 
There are several approaches for controlling for parameter uncertainty. One approach is to 
use one-way sensitivity analyses. [33] This involves varying a parameter through a plausible 
range of values, though it is possible to vary two parameters at a time. [33] Although these 
deterministic approaches to demonstrate uncertainty are still considered useful for 
demonstrating the sensitivity of the ICER [112], the deterministic approach has been 
criticised in that it only allows a small number of parameters to vary, which could be 
considered unrealistic; there is no control for correlation between input parameters, and it 
does not produce a summary measure of the implications of uncertainty. [33, 109] 
 
An alternative approach to deterministic sensitivity analyses is to use a probabilistic 
sensitivity analysis (PSA). [39] In decision analytic modelling, this involves placing suitable 
distributions on the input parameters within the model, then repeatedly sampling the input 
parameters using Monte Carlo Simulations to produce a distribution of expected 
incremental costs, expected incremental benefits, and the associated ICER. [39] For within-
trial analyses, PSAs involve randomly sampling the incremental costs and benefits using 
non-parametric bootstrapping. [40] The number of iterations performed in either the 
bootstrapping or Monte Carlo simulation should be enough that the estimates reach 
stability, and hence it has been recommended that at least 1,000 replications should be 
performed to produce reasonable estimates for confidence interval calculation. [100] There 
is no given rule as to the number of iterations required, but it is considered good practice 
to determine whether the analysis has achieved stability. [113] This can be investigated by 
repeatedly running the analysis from a small number of bootstraps (e.g. 10) to a large 
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number (e.g. 5000) to determine whether stability has been achieved in the expected 
estimates for the mean and standard error of the ICER. [113] 
 
There are several distributions that can be used for fitting to parameters to perform a PSA. 
It is recommended that distributions are fitted to all parameters within the DAM [112], 
however when finding the appropriate information for a particular parameter, a mean is 
reported but not a standard error or other estimate of uncertainty. In these situations, it is 
good practice that some conservative estimate for the standard error is used [112], and 
therefore in this thesis a 10% error is used as per practice of several other models. [114-
116] Some of the most common distributions used in economic evaluation are: 
x Normal distributionሺܺ ?ܰ݋ݎ݉ሺߤǡ ߪሻሻ: A common continuous probability 
ĚŝƐƚƌŝďƵƚŝŽŶ ? ǁŝƚŚ ŵĞĂŶ ʅ ĂŶĚ ǀĂƌŝĂŶĐĞ ʍ2. [39] The normal distribution is useful 
due to the central limit theorem, which states that the sampling distribution of the 
mean is normally distributed irrespective of the underlying distribution of the data 
if there is sufficient sample size. [39] Hence, if the dataset being used for a 
particular parameter is of a large enough size, the normal distribution can be used 
to sample this value. However, if the dataset is not large enough, or the 
information for a particular parameter is a single estimate (e.g. proportion smoking 
from national statistics), the normal distribution cannot be used. [39] Furthermore, 
the normal may sample values outside the plausible range of the parameter, for 
example a normal distribution fitted to a probability could in theory sample a value 
greater than one, which is impossible for a probability. [39] Hence we have to use 
an alternative distribution. 
x Beta distribution (ܺ ?ܤ݁ݐܽሺߙǡ ߚሻሻ: A continuous probability distribution defined on 
the intervalሾ ? െ  ?ሿ, which can partition the interval into two parts. [39]The Beta 
distribution is used in Bayesian statistics for representing a probabilistic 
distribution of probabilities and proportions. It will return values for ݔ such that  ? ൏ ݔ ൏  ?. The distribution is parameterised using two positive shape parameters ߙ and ߚ, such that the distribution has mean ఈఈାఉ and variance ఈఉሺఈାఉሻమሺఈାఉାଵሻ. This 
means that the Beta distribution is flexible, and allows us to change the shape of 
the distribution easily. The Beta distribution is used to sample the values for 
probabilities where there are only two possible outcomes (e.g. success or failure), 
and for utility weights. [39] 
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x Dirichlet distribution ሺܺ ?ܦ݅ݎሺߙሻሻ: A continuous multivariate probability 
distribution, parameterised by the vector ߙ and the number of categories, ܭ, which 
is defined on the interval ሾ ? െ  ?ሿ, splitting the interval into two or more parts. 
[39]The number of categories must be such that ܭ ൒  ?, and that ߙଵǡ ڮ ߙ௄ are the 
concentration parameters, where ߙ௜ ൐  ?. The Dirichlet distribution will return 
values ݔ such that ݔଵ ൅ ڮ ൅ ݔ௜ ൌ  ?Ǥ This is the multivariate generalisation of the 
beta distribution.  The Dirichlet distribution is often used when sampling 
probability values where there are more than two possible outcomes. [39] 
x Gamma distribution ሺܺ ?߁ሺߙǡ ߚሻ: A continuous probability distribution defined on 
the interval ሾ ? െ  ?ሿ, parameterised by a shape parameter ߙ and a rate parameter ߚ. [39] Because the Gamma distribution is bounded by zero, and is right-skewed, it 
can be used to sample ݔ such that ݔ ൐  ?. The Gamma distribution has mean ߙߚ, 
and variance ߙߚଶ. In Bayesian statistics, the Gamma distribution has a special 
relationship with Poisson data because it is conjugate to the Poisson distribution, 
and therefore can be used to characterise Poisson data. The Gamma distribution is 
used when sampling costs since these are also right-skewed and costs data is often 
based upon Poisson data. [39] 
x Lognormal distribution: A continuous probability distribution of a random variable 
whose logarithm is normally distributed. [39] The distribution is parameterised by ߤ and ߪ ? ǁŚŝĐŚ ĂƌĞ ƚŚĞ ŵĞĂŶ ĂŶĚ ƐƚĂŶĚĂƌĚ ĚĞǀŝĂƚŝŽŶ ŽĨ ƚŚĞ ǀĂƌŝĂďůĞ ?Ɛ ŶĂƚƵƌĂů
logarithm. The Lognormal distribution is used for sampling occurring variables that 
are the product of a number of other occurring variables. Since odds ratios (OR) 
and relative risks (RR) are the products of the number of people who develop a 
disease contingent of exposure, it would seem appropriate to assume the ORs and 
RRs are Lognormally distributed, hence the Lognormal distribution is used to 
sample ORs and RRs. [39] 
 
Both the Beta and the Gamma distributions require the distribution to be fitted. For the 
Beta distribution, there are two approaches. One approach is to specify the shape 
ƉĂƌĂŵĞƚĞƌ ɲ ĂƐ ƚŚĞ ŶƵŵďĞƌ ŽĨ ƚŝŵĞƐ ƚŚĞ event has occurred, while the second shape 
ƉĂƌĂŵĞƚĞƌɴĐĂŶďĞƐƉĞĐŝĨŝĞĚĂƐƚŚĞŶƵŵďĞƌƚŝŵĞƐƚŚĞĞǀĞŶƚŚĂƐŶŽƚŚĂƉƉĞŶĞĚ ?ǁŚŝĐŚĐĂŶ
also be specified as the total number of patients minus the number of patients who have 
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the events. [39] However, if ƚŚĞĚĂƚĂƉƌĞƐĞŶƚƐĂŵĞĂŶĂŶĚƐƚĂŶĚĂƌĚĞƌƌŽƌ ?ƚŚĞɲĂŶĚɴĐĂŶ
be specified as per Briggs et al [39]: 
 ሺߙ ൅ ߚሻ ൌ  ߤሺ ? െ ߤሻߪଶ െ  ? (1.22) 
 ߙ ൌ ߤሺߙ ൅ ߚሻ (1.23) 
 
For the gamma distribution, the method of moments can be used to determine the shape 
ƉĂƌĂŵĞƚĞƌɲĂŶĚƌĂƚĞƉĂƌĂŵĞƚĞƌɴ ?ĂŶĚĐĂŶďĞƐƉĞĐŝĨŝĞĚĂƐƉĞƌƌŝŐŐƐĞƚĂů[39]: 
 ߙ ൌ ߤଶߪଶ (1.24) 
 ߚ ൌ ߪଶߤ  (1.25) 
 
For the Dirichlet distribution, the approach to fitting the distribution is similar to the Beta 
distribution. The counts (numbers) of each type of event matching the categories of the 
Dirichlet are used to specify the distribution. [39] However, many software packages do not 
include the Dirichlet distribution as a sampling distribution. One way of generating a 
Dirichlet distribution is to use the normalised sum of independent gamma variables. [39] 
Briggs et al specified that the normalised gamma is specified as ܺ ?ܩܽ݉݉ܽ൫ߙ௝ǡ ߚ൯ 
[39],where ݔଵǡ ݔଶǡ ڮ ǡ ݔ௞are the draw variables with shape parameters ߙଵǡ ߙଶǡ ڮ ǡ ߙ௞, with a 
ĐŽŵŵŽŶƌĂƚĞƉĂƌĂŵĞƚĞƌɴ ?,ĞŶĐĞƚŚĞƌĞƋƵŝƌĞĚŝƌŝĐŚůĞƚƉƌŽďĂďŝůities are then: 
 ߨ௝ ൌ ߙ௝ ? ߙ௝௞௝ୀଵ  (1.26) 
 
It is this approach that will be used to fit the Dirichlet distribution in this thesis. 
 
1.6.11 Presentation and interpretation of uncertainty 
 
A common approach for presenting the results is to use a scatterplot of the cost-
effectiveness plane. [39]  This involves plotting each pairwise incremental cost and 
incremental benefit from each individual iteration from the Monte Carlo simulation.  An 
example scatterplot for a hypothetical healthcare intervention is given in Figure 1.6. 
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Figure 1.6: Scatterplot of incremental costs and QALYs with 95% confidence ellipse for a hypothetical 
intervention 
 
 
The advantage of using the scatterplot is that it allows decision makers to see in which 
quadrants of the cost-effectiveness plane the iterations are estimated. Furthermore, as has 
been demonstrated in Figure 1.6 ? ƚŚĞ ĂǀĞƌĂŐĞ /Z ĐĂŶ ďĞ ƉůŽƚƚĞĚ ĂƐ ǁĞůů ĂƐ E/ ?Ɛ
threshold values, hence comparison can be made between the two.  
 
However, plotting the 95% confidence interval can be problematic when the iterations pass 
over the vertical axis and/or horizontal axis, mainly because of the different interpretations 
of the ICER in the south west quadrant compared to the north east quadrant. [39] Hence, a 
better way of demonstrating the amount of uncertainty in the iterations is the Cost-
Effectiveness Acceptability Curve (CEAC). [39, 117] This is a plot of the willingness to pay 
versus the probability of cost-effectiveness, which can be defined as the number of 
iterations which can be considered cost-effective at a particular willingness to pay. For 
example, a CEAC for the intervention displayed in Figure 1.6 is represented below. 
43 
 
Figure 1.7: CEAC for a hypothetical intervention 
 
 
From Figure 1.7, it can be determined that at a willingness to pay of £20,000 per QALY, the 
probability that the intervention is cost-effective is approximately 9%, suggesting that only 
9% of the iterations in the Monte Carlo simulation were considered cost-effective at a 
willingness to pay of £20,000. However, at a willingness to pay of £30,000 the probability 
that the intervention is cost-effective is 90%, suggesting that 90% of the iterations were 
considered cost-effective at that willingness to pay. Furthermore, the CEAC informs us that 
there are no iterations which are cost-saving, since it starts at zero. [118] If there were 
iterations which had cost-savings, then even if the decision maker was not willing to pay for 
any health benefit, there would still be a chance that the intervention was cost-effective. 
[118] Additionally the CEAC informs the decision maker that there is no chance that the 
intervention leads to no health benefit. [118] If there were any iterations in the simulation 
that had not lead to any health benefit for the patient, then the CEAC would not have 
reached one. This is because as the williŶŐŶĞƐƐ ƚŽ ƉĂǇ ĨŽƌ ŚĞĂůƚŚ ďĞŶĞĨŝƚ ĂƉƉƌŽĂĐŚĞƐ A? ?
there would have been iterations where there was no health benefit, and hence would not 
have been deemed cost-effective. [118] It is now considered good practice to represent the 
results of an analysis of uncertainty using CEAC curves. [119] 
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1.6.12 Good practice in decision analytic modelling 
 
There has recently been some international consensus on good practices in decision 
analytic modelling for economic evaluation developed in the literature, [119] This is 
important for this thesis as it outlines the standards to which any new improved economic 
model will have to conform. Some of the key areas, and details of their main standards, 
which are particularly relevant to this thesis are as follows: 
x Conceptualising the model: the decision problem is clearly stated, along with the 
target population and health outcome used; the model structure is not defined by 
the data; although model simplicity is preferred, complex decision problems may 
require complex models. [120] For this thesis, the decision problem being 
answered is: are smoking cessation interventions for pregnant women cost-
effective?  The target population is clear; pregnant women and their infants. To 
define the structure of the new improved model, a critical assessment of previous 
evaluations will be performed to help inform the structure of the new model, as 
well as a review of the literature to identify relevant conditions and where their 
impacts may lie. Furthermore, it is likely that the new model is going to be far more 
complex than anything previously constructed; however whether the level of 
complexity is sufficient to answer the decision problem can only be discussed once 
the model has been described. 
x Specific requirements regarding state transition modelling:  the number of states 
are manageable and include all characteristics relevant to the decision problem; 
specifications of states and transitions should reflect the biological/theoretical 
understanding of the disease/condition; states should capture the type of 
intervention and need to be homogenous with respect to the observed and 
unobserved; the time horizon needs to be large enough to capture all health 
effects and costs; and transition probabilities should be derived for the most 
representative data available. [121] It is likely that this thesis will require cohort 
simulation when investigating the lifetime impacts of smoking on the mother [66], 
as well as any long-term impacts of smoking during pregnancy on the infant. These 
standards are important when specifying the relevant Markov models later in this 
thesis. 
x Parameter estimation and uncertainty:  uncertainty must be systematically 
explored and reported, if a parameter has little information on the uncertainty 
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associated with it then a conservative approach should be adopted and not the 
exclusion of the parameter from the uncertainty analysis; distributional forms 
should be continuous; both deterministic and probabilistic sensitivity analyses can 
be conducted; and if probabilistic sensitivity analyses are performed then CEACs 
should be reported. [112] In this thesis, uncertainty will be explored, although the 
specification of this uncertainty will be reported later in the thesis. The distribution 
forms will be as defined in section 1.6.10 of this thesis, and the results will be 
presented as recommended by the standards.  
x Model transparency and validation: every model should have both technical and 
non-technical documentation outlining the model, demonstration of validation, 
and search from previously published analyses. [122] This thesis will provide the 
bulk of the technical documentation associated with the model, since it will 
describe how the authors critically assessed the previous literature to help aid the 
model structure, identified relevant conditions for the model and required 
parameters to populate the model, and will demonstrate the validity of the model 
by performing an analysis on the SNAP intervention which has been previously 
evaluated. [123] 
 
 A definition of strong economic evidence 1.7
 
Across countries, policy makers have different requirements for what constitutes strong 
economic evidence. These guidelines for individual health services across the world outline 
what is expected from economic evaluations in their respective countries. For any 
ĞǀĂůƵĂƚŝŽŶ ? ŝƚ ŝƐ ŝŵƉŽƌƚĂŶƚƚŽŬŶŽǁǁŚĂƚƚŚĞ “ŐŽůĚƐƚĂŶĚĂƌĚ ?ƌĞƋƵŝƌĞŵĞŶƚƐĂƌĞ ?Table 1.2 
gives a brief summary of the reference cases for five countries. 
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Table 1.2: Summary of reference cases for economic evaluation in several countries 
Country Austria [44] Australia [37] Canada [38] UK [36] US [45] 
Source of effectiveness 
data 
Meta-analysis 
preferred; other 
sources acceptable if 
not available 
RCT data Systematic review Systematic review or 
good quality RCT 
Systematic review, 
however any data is 
acceptable if justified 
Perspective of analysis ZĞƐĞĂƌĐŚĞƌ ?Ɛ
discretion 
Societal and healthcare 
sector 
Societal and healthcare 
sector, ideally a lifetime 
horizon 
Public sector 
perspective 
Primary: payer, 
secondary: societal, 
employer 
Costs Include direct and 
indirect, market prices 
for opportunity cost 
(shadow prices 
accepted). Losses of 
productivity quantified 
using human capital 
method 
Direct medical costs, 
social service costs and 
indirect costs. Do not 
include productivity 
costs. 
All relevant costs to the 
study perspective; 
unrelated costs during a 
normal life year should 
be excluded but can be 
included as a sensitivity 
analysis 
All relevant costs; any 
productivity/costs 
borne by patients 
and/or carers not 
reimbursed by the 
public sector are 
excluded 
All relevant non-trivial 
magnitude costs, 
valued using 
opportunity cost 
Outcome measurement ZĞƐĞĂƌĐŚĞƌ ?Ɛ
discretion; must be 
economically or 
Natural and patient 
related units 
Should be valued in 
QALYs 
Non-monetary 
outcome, preferably 
QALYs or DALYs 
Should include both 
benefits and harms of 
alternatives 
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clinically orientated. 
HRQoL outcomes only 
used where medical 
treatment has no 
prospect of cure. 
Type of analysis Any method is 
acceptable using 
incremental analysis 
Any method is 
acceptable; must report 
incremental analysis 
CUA unless 
inappropriate, then CEA 
using life years gained. 
Must be incremental. 
Any method 
acceptable, can be 
conducted alongside a 
good quality RCT or 
using modelling 
techniques; must 
report an incremental 
analysis 
CEA must be done 
where possible; other 
methods may be used 
as a secondary 
analysis; incremental 
analysis should always 
be reported 
Comparator Standard therapy Best clinical 
care/standard care 
Not stated Standard care Standard care or best 
available 
Discounting 5% per annum applied 
to costs and benefits 
Costs: 5% per annum 
Outcomes: 0 or 5% per 
annum 
Costs and benefits at 5% 
per annum. 
3.5% per annum 
applied to costs and 
health outcomes 
Costs at 3% per annum 
Sensitivity analysis Must include discount 
rate  variation 
One-way sensitivity 
analysis on all variables 
One-way and two-way 
sensitivity analyses on 
Deterministic 
sensitivity analysis for 
Performed on 3-5 
parameters and 2-3 
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between 3 and 10%, 
ŽƚŚĞƌǁŝƐĞ ƌĞƐĞĂƌĐŚĞƌ ?Ɛ
discretion 
using extreme values; 
two-way sensitivity 
analysis on all variables 
shown to be sensitive in 
the one-way analyses 
all model inputs; must 
conduct a sensitivity 
analysis with discount 
rate set at 0 and 3% 
key structural 
assumptions; PSA to 
explore uncertainty 
due to imprecision in 
model parameters 
assumptions which 
have the greatest 
impact on the results. 
Discount rates varied 
between 0 and 7%, 
must include 5% 
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There seems to be consensus around the source of effectiveness data, with all bar Australia 
preferring data from systematic reviews, with good quality RCT data acceptable if no meta-
analysed data is available. There also seems to be unanimity that the comparator should be 
standard or best available care and that the type of analysis is generally up to the 
ƌĞƐĞĂƌĐŚĞƌ ?Ɛ ĚŝƐĐƌĞƚŝŽŶ ? ,ŽǁĞǀĞƌ ? ƚŚĞ ƉĞƌƐƉĞĐƚŝǀĞ ŽĨĂŶĂůǇƐŝƐ ƐĞĞŵƐ ƚŽ ǀĂƌǇ from the 
narrow view of the payer in the US to the broader societal view as found in Australia and 
Canada. Both Canada and the UK use HRQoL measures as outcomes, yet the US, Austria 
and Australia prefer outcome measures in a natural scale. The UK, Australia and Canada 
exclude productivity costs, which are included in Austria and the US. Discounting is applied 
to both costs and outcomes for all countries except the US, where it is only applied to cost. 
Discount rates appear to be reasonably uniform across all countries. All countries require 
some form of sensitivity analysis to be conducted, but only the UK requires a PSA. 
 
A narrative review highlights a similar finding to that above. [124] Firstly, the use of CEA or 
CUA was preferred, expressly because the outcomes were measured in non-monetary 
units; a CBA was acceptable only if this information was unavailable or a suitable outcome 
could not be found. Secondly, the reporting of the results of the incremental analysis was 
considered important, and reporting average cost-effectiveness was not considered 
sufficient for providing evidence. Thirdly, any modelling used had to be appropriate, i.e. it 
had to have been designed specifically for the situation and fully justified. Finally, any time 
horizon used had to include all relevant consequences over the short-, and preferably the 
long-term. The review also highlighted that there was little agreement on areas such as the 
perspective of analysis, resources used and costs, and valuation of resources used. The 
authors suggested that the differences were caused by the varying ways that the health 
systems were set up across countries, specifically the dissimilarity between those that had 
nationalised sectors, where a more/closer to societal perspective was taken, and those 
where the health sector was private, which utilised a more agency perspective. 
 
While there is considerable variation in international policy makers ? requirements, recent 
work has been undertaken to produce a standardised reporting format for economic 
evaluations; the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
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statement. [43] The CHEERS checklist includes 24 questions covering all aspects of 
reporting economic evaluations, and is reproduced in Table 1.3. 
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Table 1.3: The CHEERS checklist, as taken from Husereau et al (2013)[38]  
Item 
number 
Section Item Recommendation 
1 Title and 
abstract 
Title Identify the study as an economic evaluation or use more ƐƉĞĐŝĨŝĐƚĞƌŵƐƐƵĐŚĂƐ ‘ ‘ĐŽƐƚ-
ĞĨĨĞĐƚŝǀĞŶĞƐƐĂŶĂůǇƐŝƐ ? ? ?ĂŶĚĚĞƐĐƌŝďĞƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶƐĐŽŵƉĂƌĞĚ ? 
2 Abstract Provide a structured summary of objectives, perspective, setting, methods (including study 
design and inputs), results (including base case and uncertainty analyses), and conclusions. 
3 Introduction Background and objectives Provide an explicit statement of the broader context for the study. Present the study question 
and its relevance for health policy or practice decisions. 
4 Methods Target population and 
subgroups 
Describe characteristics of the base case population and subgroups analysed, including why they 
were chosen. 
5 Setting and location State relevant aspects of the system(s) in which the decision(s) need(s) to be made. 
6 Study perspective Describe the perspective of the study and relate this to the costs being evaluated. 
7 Comparators Describe the interventions or strategies being compared and state why they were chosen. 
8 Time horizon State the time horizon(s) over which costs and consequences are being evaluated and say why 
appropriate. 
9 Discount rate Report the choice of discount rate(s) used for costs and outcomes and say why appropriate 
10 Choice of health outcomes Describe what outcomes were used as the measure(s) of benefit in the evaluation and their 
relevance for the type of analysis performed. 
11a Measurement of Single study-based estimates: Describe fully the design features of the single effectiveness study 
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effectiveness and why the single study was a sufficient source of clinical effectiveness data. 
11b Synthesis-based estimates: Describe fully the methods used for identification of included studies 
and synthesis of clinical effectiveness data. 
12 Measurement and 
valuation of preference 
based outcomes 
If applicable, describe the population and methods used to elicit preferences for outcomes. 
13a Estimating resources and 
costs 
Single study-based economic evaluation: Describe approaches used to estimate resource use 
associated with the alternative interventions. Describe primary or secondary research methods 
for valuing each resource item in terms of its unit cost. Describe any adjustments made to 
approximate to opportunity costs. 
13b Model-based economic evaluation: Describe approaches and data sources used to estimate 
resource use associated with model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit cost. Describe any adjustments made 
to approximate to opportunity costs. 
14 Currency, price date, and 
conversion 
Report the dates of the estimated resource quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for 
converting costs into a common currency base and the exchange rate. 
15 Choice of model Describe and give reasons for the specific type of decision-analytical model used. Providing a 
figure to show model structure is strongly recommended. 
16 Assumptions Describe all structural or other assumptions underpinning the decision-analytical model. 
53 
 
17 Analytical methods Describe all analytical methods supporting the evaluation. This could include methods for dealing 
with skewed, missing, or censored data; extrapolation methods; methods for pooling data; 
approaches to validate or make adjustments (such as half cycle corrections) to a model; and 
methods for handling population heterogeneity and uncertainty. 
18 Results Study parameters Report the values, ranges, references, and, if used, probability distributions for all parameters. 
Report reasons or sources for distributions used to represent uncertainty where appropriate. 
Providing a table to show the input values is strongly recommended 
19 Incremental costs and 
outcomes 
For each intervention, report mean values for the main categories of estimated costs and 
outcomes of interest, as well as mean differences between the comparator groups. If applicable, 
report incremental cost-effectiveness ratios. 
20a Characterising uncertainty Single study-based economic evaluation: Describe the effects of sampling uncertainty for the 
estimated incremental cost and incremental effectiveness parameters, together with the impact 
of methodological assumptions (such as discount rate, study perspective). 
20b  Model-based economic evaluation: Describe the effects on the results of uncertainty for all input 
parameters, and uncertainty related to the structure of the model and assumptions. 
21 Characterising 
heterogeneity 
If applicable, report differences in costs, outcomes, or costeffectiveness that can be explained by 
variations between subgroups of patients with different baseline characteristics or other 
observed variability in effects that are not reducible by more information. 
22 Discussion Study findings, limitations, 
generalisability, and 
Summarise key study findings and describe how they support the conclusions reached. Discuss 
limitations and the generalisability of the findings and how the findings fit with current 
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current knowledge knowledge. 
23 Other Source of funding Describe how the study was funded and the role of the funder in the identification, design, 
conduct, and reporting of the analysis. Describe other non-monetary sources of support. 
24 Conflicts of interest Describe any potential for conflict of interest of study contributors in accordance with journal 
policy. In the absence of a journal policy, we recommend authors comply with International 
Committee of Medical Journal Editors recommendations. 
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As expected, there are some similarities between the CHEERS statement and the 
ŝŶƚĞƌŶĂƚŝŽŶĂů ƉŽůŝĐǇ ŵĂŬĞƌ ?Ɛ ƐƚĂŶĚĂƌĚƐ ?although the CHEERS statement is a broader 
publication checklist and as such covers areas which may not be relevant to the policy 
maker, such as source of funding, conflict of interest, and title and abstract. However, the 
topics where the CHEERS and international guidelines agree, which is relevant for this 
thesis, include the study perspective, choice of comparator, discounting, measurement of 
effectiveness, estimating resources and costs, reporting of incremental costs and 
outcomes, and characterising uncertainty. Furthermore, it is worth noting that regarding 
costs, the CHEERS statement requests that currency, price date, and conversion is reported, 
which is not a stated requirement of the international guidelines. This is an important 
consideration as the model is not reproducible where the price year is not reported, since 
costs would likely require inflating and this would be impossible to undertake. With regards 
to characterising uncertainty, although CHEERS is not explicit, it is apparent that this should 
be investigated through the use of PSA. However, only the NICE reference case 
recommends the use of this [36], which suggests that other countries ? standards do not 
meet those of the international academic community. This thesis is aimed at both the 
academic community as well as the policy makers based at NICE, and hence it would 
therefore seem appropriate that working to the criteria as set out by the NICE reference 
case and the CHEERS checklist would be sensible, as well as the good modelling practices 
previously discussed in this chapter. [119] It is hoped that by following these guidelines, 
any new model of smoking cessation interventions within-pregnancy will be both useful for 
the academic community as well as the policy maker in the UK. 
 
 Cost-effectiveness of cessation interventions in non-pregnant 1.8
populations 
 
^ŵŽŬŝŶŐ ĐĞƐƐĂƚŝŽŶ ŝŶƚĞƌǀĞŶƚŝŽŶƐ ĂƌĞŽĨƚĞŶ ĚĞƐĐƌŝďĞĚ ĂƐ ƚŚĞ  ‘ŐŽůĚ ƐƚĂŶĚĂƌĚ ? ŽĨŚĞĂůƚŚĐĂƌĞ
cost-effectiveness, implying that they are cost-effective [125], and the literature is well 
developed and established. In 1998, Parrot et al used the previously-developed PREVENT 
model to estimate the health gains associated with smoking cessation in the UK. The 
authors combined the findings from PREVENT with the differences in the healthcare costs 
of current smokers and lifetime non-smokers. [126] The cost-effectiveness estimates are 
reproduced in Table 1.4. 
56 
 
Table 1.4: Cost-effectiveness of cessation interventions in non-pregnant smokers (from PREVENT model) 
Intervention Effectiveness Per annum 
cost to UK 
health 
authority (£) 
Per annum 
cost to UK 
society (£) 
Discounted 
life years 
gained 
Incremental cost-
effectiveness per discounted 
life year gained (UK health 
authority) (£) 
Incremental cost-
effectiveness per discounted 
life year gained (UK societal) 
(£) 
Brief advice 0.006 122,899 150,116 708 Reference ? 
Brief advice and self-help 
materials 
0.008 208,548 244,837 945 361.39 399.67 
Brief advice, self-help 
materials, and advice to 
use NRT 
0.009 286,437 740,285 1063 660.08 4,198.71 
Brief advice, self-help 
materials, advice to use 
NRT, and specialist 
smoking cessation 
service 
0.011 331,156 1,134,913 1300 188.69* 1,665.10* 
 ?A?tĞĂƐƐume brief advice is the base intervention rather than comparing to no intervention as this would give estimates of the average cost-effectiveness 
rather than a incremental analysis 
*=The decrease in ICER suggests that brief advice, self-help materials, advice to use NRT, and specialist cessation service weakly dominates brief advice, 
self-help materials and advice to use NRT, based on the rules suggested by Karlsson et al (1996). [127] Hence we exclude brief advice, self-help materials 
and advice to use NRT, and compare that brief advice, self-help materials, advice to use NRT, and specialist cessation with brief advice and self-help 
materials. The new ICERs for UK health authority and societal are £345.37 and £2,507.30 respectively. From a UK health authority perspective, brief advice, 
self-help materials, advice to use NRT, and specialist cessation service weakly dominates brief advice and self-help materials, hence repeating the process 
estimates a ICER of £351.79 when comparing brief advice, self-help materials, advice to use NRT, and specialist cessation service with brief advice alone.  
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The potential cost-effectiveness is clearly demonstrated; the highest ICER for the UK health 
authority was £345.37 per discounted life year as brief advice, self-help materials, advice to 
use NRT, and specialist cessation service weakly dominated all other interventions when 
compared to brief advice alone. However, when including costs associated with the UK 
societal perspective, the ICER per discounted life year was £2,507.30 for brief advice, self-
help materials, advice to use NRT, and specialist cessation service. Compared with other 
healthcare interventions, these ICERs seem relatively low; e.g. the use of aspirin for the 
prevention of colorectal cancer estimated an ICER of £10,169 per life year gained. [128]  
 
Flack et al developed a cohort simulation model for informing recent NICE guidance on 
cessation interventions, identifying that all, except brief advice plus self-help materials and 
NRT, were dominant compared to no intervention. [129] Brief advice with self-help 
material and NRT reported an ICER of £984 per QALY. Smoking cessation interventions are 
very cost-effective when compared to other aspects of healthcare, e.g. screening 
interventions for preventing harmful drinking in young adults have ICERs between £2,535 
and £11,823 per QALY [130]; drugs for the treatment of early thrombolysis in acute 
myocardial infarction (MI) have ICERs between £7,219 and £10,247 per QALY [131]  
 
Shearer et al performed a systematic review to determine the cost-effectiveness of 
cessation interventions in Australia. [125] Effectiveness data was obtained from 
international literature, while costs were estimated from the perspective of the Australian 
Government. The study looked at seven interventions versus an assumed background quit 
rate of 4%. The interventions were: 
x brief advice 
x telephone counselling 
x NRT plus counselling 
x NRT plus proactive telephone counselling 
x Bupropion plus counselling 
58 
 
x Bupropion plus proactive telephone counselling 
x Bupropion plus NRT with counselling 
 
Quit rates ranged from 6% for brief advice to 32% for bupropion plus proactive telephone 
counselling. Interventions were compared with the next best alternative, e.g. telephone 
counselling was compared with brief advice. Only telephone counselling appeared to be 
dominant. Bupropion plus NRT and counselling appeared to be dominated, while the 
others appeared to have positive ICERs, ranging from AUD 116 (£77.113) per incremental 
quit rate for bupropion plus proactive telephone counselling to AUD 14,340 (£9,531.804) 
for bupropion plus NRT and counselling. The authors concluded that telephone counselling 
was the most cost-effective, but other interventions, such as proactive forms of telephone 
counselling alongside pharmacotherapies, could also be considered cost-effective. 
Bupropion appeared to be more cost-effective than NRT, and interventions using combined 
bupropion and NRT were not cost-effective.   
 
Tengs et al demonstrated that in the US, cessation interventions were relatively cheap per 
life year saved, with most interventions being dominant in that they produced health gains, 
but saved healthcare costs overall. However, not all cessation interventions were 
dominant, though the most expensive was estimated to cost up to USD 13,000 (£7,727.205) 
per life year saved for nicotine gum and cessation advice for women aged 65-69. [132] This 
study investigated 587 lifesaving interventions, with a median cost per life year saved of 
USD 42,000 (£24,964.806) which includes interventions outside healthcare (e.g. 
environmental control). This was over three times higher than that of the most costly of the 
15 smoking cessation interventions, suggesting that cessation interventions were relatively 
cheap in terms of average cost-effectiveness, however the authors did not report an 
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incremental analysis, therefore it cannot be determined whether the cessation 
interventions were cost-effective. Cromwell et al examined the cost-effectiveness of the 
implementation of the Agency for Health Care Policy and Research (AHCPR) smoking 
cessation clinical practice guidelines. [133] The study estimated that the implementation of 
the guideline would cost USD 6.3 billion (1995 prices) (approximately £3.7 billion7) in the 
first year, generating 1.7 million new quitters, with an average cost per quitter of USD 
3,779 (£2,238.688), USD 2,587 (£1,655.169) per life year saved, and USD 1,915 (£1,225.2210) 
per QALY saved. Across the different interventions, cost per QALYs saved ranged from USD 
1,108 to USD 4,542 (£658.60 to £2,699.7611), with the more intensive interventions being 
more cost-effective. 
 
 The necessity of separate evaluations during pregnancy 1.9
 
There are differences between pregnant and non-pregnant smokers which mean that 
within-pregnancy cessation interventions require distinctive economic evaluations. These 
are: 
x The spontaneous quit rate amongst pregnant smokers is much higher than the 
general population. In the evaluation of cessation interventions for non-pregnant 
smokers, Flack et al used a spontaneous quit rate of 1.2% [129], while the latest 
statistics for smoking in England estimate that around 27% of women made a quit 
attempt in 2009. [134] However, estimates from the IFS 2010 suggest that in the 
UK, 54% of women quit smoking by the end of pregnancy. [135] This difference 
must be taken into consideration in evaluations of cessation interventions during 
pregnancy. 
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x The rate of relapse to smoking after pregnancy appears lower than in the general 
population. In England, around 86% of individuals who made a cessation attempt 
report smoking again within 12 months [134], while in California 88% had relapsed 
by 12 months. [136] Amongst pregnant quitters, relapse one year after pregnancy 
may be lower; Godfrey et al estimated that between 67% to 80% relapse by one 
year [4], and the 2010 IFS suggests that 31% report active smoking again by 10 
months postpartum. [135] 
x Cessation during pregnancy has additional health impacts not only on the mother, 
but her offspring as well, unlike cessation at other times where the impacts are 
predominantly focused on the abstaining individual. This includes both within-
pregnancy as well as passive smoking impacts.  
 
 
 Economic evaluations of smoking cessation interventions during 1.10
pregnancy 
 
Economic evaluations of cessation interventions in the general population often exclude 
pregnant women, possibly because of the added complications associated with pregnancy 
and the impact on the infant. The current evidence suggests an economic benefit from 
cessation interventions during pregnancy. What follows is a brief summary of the 
literature; a more in-depth appraisal will be conducted in Chapter 3. 
 
1.10.1 Systematic review of previous evaluations 
 
A systematic review conducted in 2008 identified eight evaluations of cessation 
interventions during pregnancy. [6] Included studies were conducted in the US, using a 
mixture of CBA or CEA. The review authors noted that there was no incremental CEA or 
CUA, but this statement was incorrect, as several included studies reported measures of 
effectiveness, such as incremental cost per LBW infant avoided, and incremental cost per 
sudden infant death averted. Furthermore, the studies described as CBAs were in relatively 
cost-offset studies, since the estimated benefits came from healthcare costs averted.  Four 
studies were conducted alongside a trial, three studies were separate modelling studies, 
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and one did not report what type of study it was. Two reported a societal perspective, two 
an agency, two were Health Maintenance Organisation (HMO), one a within-program, and 
one did not specify the perspective. Time horizons were end of pregnancy (three studies), 
first year of life for the infant (two studies), lifetime (two studies), and one study used 35 
years after pregnancy. Interventions were predominantly counselling plus written 
materials; one was a home correspondence intervention, and three hypothetical 
interventions. Where the comparator was stated, it was some form of usual care (UC). 
Costs were either collected within the study or from established literature sources, 
although one study did not state the costs ? source. Outcomes varied across all the studies, 
although no studies reported using QALYs. Outcomes included quit rates, LBW averted, 
pre-term births avoided, perinatal deaths avoided, neonatal intensive care (NICU) costs 
averted, life years gained or saved, SIDS averted, and long-term disability savings.  
 
The results of all included studies suggested that cessation interventions during pregnancy 
were cost-effective. Cost benefit ratios were estimated to be between 2.1 and 3.1 for the 
HMO / program, 3.3:1 for NICU costs averted, and 6.6:1 for long-term disability costs 
averted. One study estimated that the cost savings from the intervention were between 
USD 365,728 and USD 968,320 (£219,656.24 to £581,572.9912). The highest breakeven cost 
for an intervention was USD 237 (£140.8713) per participant. The cost of preventing a LBW 
was USD 4,000 (£2,402.814) while another study suggested that the cost per life year gained 
was USD 11,000 (£6,538.4015). The authors of the review concluded that although the 
literature suggested that interventions were cost-effective, there was still scope for further 
work, especially if some standardised methods could be adopted. The review concluded 
that any future evaluation should be planned alongside an RCT, with costs including NICU 
and maternal healthcare cost savings, and extended to a societal lifetime perspective by 
using QALYs discounted at three percent per annum for both the mother and the infant. 
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1.10.2 A within-trial analysis of cessation during pregnancy 
 
Ruger et al undertook a cost-effectiveness analysis using decision tree modelling of an MVI 
cessation intervention compared to UC. [137] The model was done alongside an RCT of 
low-income pregnant women in the Boston metropolitan, USA. UC was received by all 
participants, and consisted of a five minute presentation outlining the harmful effects of 
smoking during and after pregnancy, and self-help materials. MVI consisted of three home 
visits which educated clients about the impact of smoking on mothers, foetuses, and 
newborns; evaluated their smoking behaviour; helped increase self-efficacy for cessation 
and abstinence; and provided information on reducing exposure to environmental tobacco 
smoke (ETS). Each session lasted one hour. Costs of the interventions were collected as 
part of the clinical trial, using a micro-costing approach. The model was extended to the 
societal perspective, incorporating the NICU costs associated with the first year of life, and 
the cost savings for maternal healthcare (cardiovascular and lung disease). No difference in 
NICU costs was found, therefore in the base case it was assumed that the difference was 
USD 0, but in the sensitivity analyses the costs were varied between USD 1000 and USD 
5000. All costs were reported in 1997 USD, and were updated accordingly. 
The primary outcome measure for the both the trial and the evaluation was cessation and 
relapse prevention. Cessation was defined as a woman who had smoked at baseline (less 
than 28 weeks pregnant) and was abstinent at follow up (6 months postpartum). A relapse 
prevented was a woman who had quit smoking within three months of baseline and 
remained abstinent at follow up. Infant outcomes collected were birth weight and post-
delivery status. Life-years saved and QALYs were calculated using published estimates from 
ƚŚĞ ŵĞƌŝĐĂŶ ĂŶĐĞƌ ^ŽĐŝĞƚǇ ?Ɛ ĂŶĐĞƌ WƌĞǀĞŶƚŝŽŶ ^ƚƵĚǇ(CPS II). [138] These estimates 
allowed for a 35% probability of relapse over the remaining lifetime, and were discounted 
at 3%. It was estimated that female quitters and abstainers aged 25-29 years saved 1.43 life 
years and 1.94 QALYs. One- and two-way sensitivity analyses were performed on the MVIs 
effectiveness for cessation and relapse prevention, life years gained, QALY weights, 
intervention cost, inclusion of maternal medical cost savings, and inclusion of cost savings 
for infant healthcare during the first year of life. The study performed two incremental 
analyses, one for smoking cessation, and one for relapse prevention.  
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The model estimated that the cost per participant was USD 309.20 (£206.89)16 for MVI 
versus USD 4.85 (£3.25)17 for UC. At six months postpartum follow up, MVI had a similar 
smoking cessation rate to UC (7/110 versus 8/100 respectively), but a much higher rate for 
relapse prevention (9/21 versus 5/28 respectively). The authors concluded that in the base 
case, MVI was dominated by UC for smoking cessation, but for relapse prevention, MVI had 
an ICER of USD 851 (£569.40)18 per life-year saved and USD 628 (£420.19)19 per QALY. In 
the sensitivity analyses, increasing the quit rate by 2% eliminated the domination of UC 
over MVI, with an ICER of USD 117,100 (£78,375.03)20 per life-year saved and USD 86,300 
(£57,760.59)21 per QALY. Further increase in the smoking cessation rates brought the ICERs 
down considerably, with a 3% increase leading to an ICER of USD 19,500 (£13,053.30)22 per 
life-year saved and USD 14,400 (£9,640.80)23 per QALY. MVI remained dominated by UC 
under lower life-years saved, lowest QALY weights, and the inclusion of maternal and infant 
medical costs, with only MVI becoming cost-saving under the relapse prevention scenario. 
In the two-way sensitivity analyses, MVI only became cost-effective for smoking cessation 
with increased rates of cessation. The authors concluded that MVI was not a cost-effective 
intervention for cessation during pregnancy. 
 
1.10.3  A hypothetical modelling study 
 
Taylor adopted the Flack et al model to evaluate cessation interventions within a pregnant 
population for recent NICE guidance on cessation during pregnancy. [129, 139, 140] A 
virtual cohort of 1,000 pregnant smokers who were encouraged to quit smoking during 
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pregnancy was modelled in six-monthly cycles over their entire lifetime using a Markov 
chain. The Markov chain consisted of three states; current smoker, former smoker, and 
dead. Interventions were those identified in the Cochrane review by Lumley et al [141], 
using the pooled effectiveness estimates, and an incremental CUA was performed using no 
intervention as the comparator. In each cycle, the model calculated the number of 
participants suffering from five potential morbidities: 
x Lung cancer (LC) 
x Coronary heart disease (CHD) 
x Coronary obstructive pulmonary disease (COPD) 
x Myocardial infarction (MI) 
x Stroke 
 
Outcomes were measured in QALYs, and both HRQoL and cost estimates came from 
established literature sources. Infants were included in the model, although no infant or 
pregnancy specific co-morbidities were modelled. The additional costs for infants born to 
mothers who smoked during pregnancy associated with the first five years of life were 
derived from the work by Petrou et al in the Oxford Record Linkage Study. [142] The model 
assumed that the relapse to smoking rate after pregnancy was 70% by 12 months 
postpartum, based upon expert opinion.  
 
The model demonstrated that cessation interventions delivered during pregnancy could be 
considered fairly cost-effective. When compared to no intervention, the model generated 
ICERs of £4,005 per QALY for CBT; £3,033 per QALY for Stages of Change (SoC); £1,992 per 
QALY for feedback; and £2,253 per QALY for pharmĂĐŽƚŚĞƌĂƉŝĞƐ ?ŽƚŚƌĞǁĂƌĚƐĂŶĚ ‘ŽƚŚĞƌ ?
interventions were dominant when compared to no intervention. The incremental net 
benefit statistic suggested (assuming a willingness to pay of £20,000 per QALY) that the 
smallest monetary benefit was £27,645,619 for SoC interventions, suggesting that society 
can gain £27,645,619 worth of benefit for every abstaining mother who used the SoC 
intervention. All other interventions reported a net benefit greater than £125,000,000.  
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1.10.4 Critical appraisal of the previous literature 
 
The current literature suggests that the majority of pregnancy cessation interventions are 
likely to be cost-effective. However, there are relatively few economic evaluations which 
have attempted to demonstrate this and those models which currently exist could be 
improved. The systematic review by Ruger et al identified that the previous literature had 
no standardised approach, making it challenging to draw comparisons across cessation 
interventions, as well as across the healthcare sector as a whole. [6] Furthermore, Ruger at 
Ăů ?Ɛ ĂƐƐĞƐƐŵĞŶƚ ŽĨ ƚŚĞ ƋƵĂůŝƚǇ ŽĨ ƚŚĞ ůŝƚĞƌĂƚƵƌĞ ƵƐŝŶŐ ƚŚĞ ƐƚĂŶĚĂƌĚŝƐĞĚ D: ĐŚĞĐŬůŝƐƚ
suggested that the overall quality of previous economic evaluations was poor, which 
suggests there is scope for a higher quality economic evaluation. ůƚŚŽƵŐŚ ZƵŐĞƌ Ğƚ Ăů ?Ɛ
subsequent within-trial evaluation attempted to address some of the standardised issues 
from the review, the evaluation still has several limitations. Although NICU costs for the 
first year of life were included, costs associated with long-term chronic conditions for the 
infant beyond the first year were not. Furthermore, only short-term chronic morbidities 
were included for the lifetime ĞƐƚŝŵĂƚŝŽŶŽĨ ƚŚĞŵŽƚŚĞƌ ?Ɛ,ZYŽ>ĂŶĚĐŽƐƚƐ ?^ŵŽŬŝŶŐŚĂƐ
been linked with several long-term chronic conditions [143], and the Taylor model included 
three additional conditions. [139] This would suggest that this evaluation is missing some 
key costs and HRQoL impacts, which might affect the cost-effectiveness estimates of the 
MVI intervention. 
 
The model constructed by Taylor was the first to undertake an evaluation of cessation 
interventions within the UK. [139] While this appeared to be more comprehensive than the 
other literature, there are still some limitations of this model. It excludes maternal specific 
morbidities, including ectopic pregnancy, placenta previa, and pre-eclampsia, because no 
data was available regarding ƚŚĞŝŵƉĂĐƚŽĨƚŚĞƐĞŵŽƌďŝĚŝƚŝĞƐŽŶƚŚĞŵŽƚŚĞƌ ?ƐƵƚŝůŝƚǇĂŶĚ ?
or associated costs. Furthermore, no infant morbidities are included, with the impact on 
HRQoL coming from differences in mortality rates in the first five years of life for infants 
born to smoking versus non-smoking mothers. The omission of both the maternal and 
infant morbidities would suggest that this model is not capturing the true costs and 
outcomes associated with smoking during pregnancy, and that the Taylor model is 
underestimating the true cost-effectiveness of cessation interventions during pregnancy.  
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Additionally, a limitation of both the US literature and the model by Taylor is that none 
includes a PSA. Although one- and two-way sensitivity analyses have been included, no 
robust methods for capturing both structural and parameter uncertainty have been 
undertaken. Surprisingly, the evaluation conducted by Taylor in 2009 was conducted for 
the development of NICE guidance on cessation interventions within-pregnancy [140], and 
should thus have included a PSA, since this has been a requirement of the NICE reference 
case since 2004. [144] Therefore, the current literature does not inform the policy maker 
on the extent of decision uncertainty associated with within-pregnancy cessation 
interventions, and hence they have no information regarding the likelihood that the 
resulting decision from the evaluations is the correct one. This could be problematic 
because even though the deterministic result suggests the intervention offers value for 
money, in reality, when controlling for parameter uncertainty shows that this may only be 
the case 20% of the time, suggesting that 80% the cessation intervention is not cost-
effective. The decision maker may feel that this is unacceptable and not wish to fund the 
cessation intervention; however the current literature does not allow a statement to be 
made regarding the probability of cost-effectiveness. Consequently, improved, more 
comprehensive economic models are needed to accurately demonstrate the cost-
effectiveness of cessation interventions delivered during pregnancy. 
 
Although Ruger et al utilised the BMJ checklist [6], even if the CHEERS checklist was applied 
to the literature [43], it can be argued that the quality of economic evaluations is poor. As 
has been discussed, a requirement of the CHEERS checklist is that there is a robust 
exploration of uncertainty, which has clearly not been undertaken. The author also argues 
that the current literature does not have a suitable time horizon, with only two evaluations 
considering longer term/lifetime impacts of smoking [137, 139], and that the cost and 
effectiveness estimates may be underreported because the evaluations are missing key 
conditions, including placenta-abruption/previa, pre-eclampsia, LBW, and SIDS. Indeed, 
Taylor highlighted that he excluded the within-pregnancy conditions because of a lack of 
data required to parameterise the model, which not only goes against good modelling 
practice [119], but also seems incorrect, as other previous evaluations were able to include 
these conditions. [65] The author concludes that not only does this suggest that there is a 
need for a high quality evaluation of cessation interventions within-pregnancy, but there is 
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also scope for a systematic review of previous evaluations using a standardised checklist 
which could inform the author of the key improvements required in a new high quality 
evaluation. Furthermore, the lack of consensus on previous evaluations suggests that, 
when comparing with the international gold standard for policy makers, the current 
literature does not meet these standards. As Ruger et al identified [6], all eight studies 
ŝŶĐůƵĚĞĚ ŝŶ ƚŚĞ ƌĞǀŝĞǁ ǁĞƌĞ ĐŽŶĚƵĐƚĞĚ ŝŶ ƚŚĞ h^ ? ĂŶĚ ĂƐƐƵĐŚ ƵƐĞĚ Ă ŶĂƌƌŽǁ ƉĂǇĞƌ ?Ɛ
perspective for costs and outcomes, which may meet US guidelines [45], but does not meet 
the guidelines for Australia, Canada and the UK, where a broader perspective is required. 
[36-38]  Furthermore, although the US, Austria, Australia, and Canada seem satisfied with 
deterministic sensitivity analyses [37, 38, 44, 45], the UK requires PSAs [36]. Not one of the 
eight models included in the review by Ruger et al [6] meet this requirement, nor does the 
evaluation by Ruger et al on MVI [137], nor the model by Taylor [139]. Thus, the author 
argues that there is insufficient evidence for any policy maker to make a decision regarding 
the cost-effectiveness of cessation interventions within-pregnancy. 
 
 Should the health benefits associated with smoking in pregnancy for 1.11
both mother and child be incorporated? 
 
It is likely that any new improved economic model will include both the cost and benefits 
from smoking in pregnancy for both the mother and child. In previous evaluations of 
cessation interventions, the practice has been to sum both the QALYs associated with the 
mother and the infant. [139] The NICE reference case does not state whether the QALYs 
associated with the mother and her infant should be both included and/or combined. [36] 
However, the reference case does state that all direct health effects should be included, 
and that the time horizon should be long enough to capture all the major impacts of the 
intervention. [36] While it would be uncontroversial that the QALYs associated with the 
mother should be included in the model, since the intervention is directly impacting on her, 
it could be argued that the infant QALYs are irrelevant. However, as has been 
demonstrated, smoking in pregnancy has been shown to directly impact on foetal and 
infant mortality [3], as well as the chance that the infant develops asthma during their 
childhood. [70] This would suggest that there are direct impacts on the health of the infant 
and their associated QALYs, as there would be a QALY loss not only associated with 
premature mortality, but also from co-morbidities. Since the NICE guidance states that the 
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evaluation should include all relevant health benefits, it would seem logical that the infant 
benefits should be included in the evaluation, because they can be considered a direct 
health impact. However, in a model developed for the NICE guidance on in vitro 
fertilisation, QALYs associated with the infant were not included, since it was argued that 
additional lives were not improvements in health. [145] This would seem to suggest that 
from a NICE perspective, there may be some controversy when it comes to including infant 
QALYs. However, the author would argue that with smoking in pregnancy, there are 
improvements in health for the infant. Furthermore the model will be focused on infants 
that are already created, and hence they are relevant in this situation, since they are 
quality of life losses not only associated with morbidity but also mortality.  
 
However, recent work by Goldhaber-Fiebert et al has demonstrated that there is 
considerable variation in the inclusion of QALYs associated with the infant when 
investigating interventions affecting fertility and childbearing. [146] The authors performed 
a review of the literature, looking for economic evaluations which investigated issues 
around fertility and childbearing, which included smoking cessation in pregnancy as well as 
contraception for males and females, folate supplementation, fertility treatments , and the 
treatment of within-pregnancy complications. The authors demonstrated that in studies 
where the evaluation was being performed on an intervention which had a positive 
outcome (e.g. smoking cessation within pregnancy, in vitro fertilisation), then generally 
both QALYs associated with the mother and her infant were included. However, where 
studies were evaluating interventions where there was no positive outcome, such as 
contraception and elective termination, these studies only focused on the QALYs 
associated with the mother/father and did not include QALYs associated with the infant. 
Indeed, the authors cited that such studies positively argued that the introduction of infant 
QALYs would bias against such interventions. [147] Goldhaber-Fiebert et al concluded that 
there was no consensus on whether to include or exclude QALYs associated with the infant, 
that current international guidance does not address this issue, and that policy makers 
should be focusing on doing so. [146] Furthermore, they concluded that the inclusion of 
infant QALYs may be biasing the results of the evaluations in favour of the intervention, 
and that both policy makers and researchers should reflect on this potential bias when 
considering the results of these types of evaluations. This statement implies that the 
inclusion of infant QALYs could be causing interventions to be seen as value for money, 
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when in reality they may not be, leading to an incorrect decision being made and the 
NHS/society wasting valuable resources on an intervention which should not be funded. 
 
Although the inclusion of infant QALYs seems to be controversial [146], in this thesis infant 
QALYs will be included in the new improved economic model. This is because it appears to 
match current NICE guidance [36], as well as previous work within this topic area. [139] 
However, consideration will be given as to whether this may be the same result in the 
future, and hence the author will investigate the possibility that the model may be required 
to present both mother QALYs and infant QALYs separately.  
 
 Justification of thesis work 1.12
 
In summary, the justification for further work on cessation interventions during pregnancy 
can be summarised as follows: 
1. There are differences between pregnant and non-pregnant smokers which justify 
pregnancy-specific economic evaluations. 
2. There are few economic evaluations of cessation interventions during pregnancy, 
with only one study conducted outside the US 
3. Smoking during pregnancy has been associated with several conditions that can 
impact on the health of a mother and her offspring, both within-pregnancy and 
longer term; these conditions have generally been omitted from previous 
evaluations. These may have been omitted due to lack of evidence or time 
constraints, however they are an important part of new economic evaluation 
4. Generic health related quality of life measures appear underutilised in previous 
studies, although there is some debate as to whether QALYs associated with the 
infant should be included with those of the mother. However, due to previous 
studies including these and the lack of clear guidance from policy makers, these 
values will continue to be included 
5. Most previous studies employ a within-pregnancy time frame, but smoking during 
pregnancy may have longer lasting impacts. 
6. None of the previous evaluations have tackled the impact of uncertainty robustly 
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 Aims and objectives  1.13
 
Primary aim: To develop an economic model which captures the impacts of smoking during 
pregnancy on the costs and health related quality of life of both the mother and her infant. 
Secondary objectives: 
1. To identify for inclusion in an economic model, all morbidities which are 
likely to have a causal association with smoking during pregnancy. 
2. To systematically review and critically assess the quality of current 
economic literature of smoking cessation during pregnancy. 
3. To use systematic review to determine accurate estimates of point 
prevalence abstinence from smoking at different time points after 
childbirth  
4. To develop a model that estimates the impact of smoking during pregnancy 
on costs and HRQoL for the mother until the end of pregnancy 
5. To develop a model that estimates the impact of smoking during pregnancy 
on costs and HRQoL for the infant and to directly link this to the maternal 
 ‘ǁŝƚŚŝŶ-ƉƌĞŐŶĂŶĐǇ ?model (objective 4). 
6. To develop a model which estimates the impact of smoking behaviour after 
pregnancy on health and healthcare costs of the mother for the remainder 
of her life 
7. To construct a childhood model for the infant up to and including the age 
of 15 that is directly linked to the maternal smoking behaviour model after 
pregnancy (objective 6). 
8. To combine the above four models (which will now be referred to as 
 ‘ĐŽŵƉŽŶĞŶƚƐ ? ? ŝŶƚo an overall Economic impacts Of Smoking In Pregnancy 
(ESIP) model. 
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 Structure of Thesis 1.14
 
This section outlines each chapter and its context within the wider thesis. 
 
Chapter 2: Identification of maternal and infant outcomes related to smoking during 
pregnancy 
Description: Scoping reviews of the epidemiological literature to identify the conditions 
which have a causal association with smoking during pregnancy for the mother and infant, 
their incidence and their impact on the HRQoL. 
Context: Identifies the most important conditions relating to smoking in pregnancy for 
inclusion in ESIP. 
 
Chapter 3: Economic Evaluations of Smoking Cessation interventions during Pregnancy: A 
Systematic Review 
Description: A systematic review of the previous literature on the economic evaluation of 
smoking cessation interventions during pregnancy. 
Context: Critically assesses the previous literature to determine the most important aspects 
requiring further improvement in ESIP. 
 
Chapter 4: Smoking abstinence in the postpartum period after receiving a smoking 
cessation intervention: A systematic review 
Description: A systematic review of randomly controlled trials of the proportion of mothers 
abstinent from smoking for up to two years postpartum 
Context: This meta-analysis generates the most accurate data currently available on the 
proportion of abstinence at various time points in the postpartum period used to model 
smoking behaviour immediately after pregnancy in the mother lifetime model. 
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Chapter 5: The ESIP model: Description of the maternal-ĨŽĞƚĂů  ‘ǁŝƚŚŝŶ-ƉƌĞŐŶĂŶĐǇ ?
component 
Description: Outlines the structure and rationale for the within pregnancy components for 
the mother and the infant. These two models are directly linked in order to generate the 
impacts of smoking during pregnancy on the costs and health-related quality of life for the 
mother and estimate the costs and adverse pregnancy outcomes for the infant. 
Context:  These are the first two components of the ESIP model. 
 
Chapter 6: dŚĞ DŽƚŚĞƌ ?Ɛ >ŝĨĞƚŝŵĞ ŽŵƉŽŶĞŶƚ  ?D> ? ŽĨ ESIP: The impacts of smoking 
behaviour and related morbidities 
Description: Outlines the structure and rationale of the lifetime component for the mother. 
This models the smoking behaviour of the mother after pregnancy to estimate the impacts 
on costs and health-related quality of life for the rest of her lifetime. 
Context: This is the third component of ESIP  
 
Chapter 7: The ESIP model: Description of the childhood component 
Description: Outlines the structure and the rationale of the childhood component for the 
ŝŶĨĂŶƚ ?dŚŝƐŵŽĚĞůƐƚŚĞŝŵƉĂĐƚŽĨƚŚĞŵŽƚŚĞƌ ?ƐǁŝƚŚŝŶ-pregnancy and postpartum smoking 
behaviour on the health related quality of life and healthcare costs of the infant up to and 
including the age of 15 years. 
Context: This is the fourth component of ESIP  
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Chapter 8: The ESIP model: How ESIP brings four components together to model the 
impacts of smoking and smoking cessation during pregnancy 
Description: Describes the linking of the four components into the overall ESIP model; 
outlines how ESIP controls for uncertainty using a probabilistic sensitivity analysis, and how 
ESIP was constructed using Microsoft Excel. 
Context: This chapter draws together the three previous chapters into the ESIP model. It 
also discusses the limitations of the thesis and suggests avenues for further research. 
 
Chapter 9: Validity of the MWPC and IWPC 
Description: Describes a validation exercise, comparing the ESIP predictions of within-
pregnancy complications and infant birth outcomes with estimates from the population 
statistics. 
Context: Demonstrates the validity of the MWPC and IWPC. 
 
Chapter 10: Using ESIP to evaluate the SNAP intervention 
Description: Using data from the SNAP trial, ESIP is programmed to perform an analysis of 
the SNAP intervention: nicotine replacement therapy versus placebo. Both deterministic 
and probabilistic results are presented. 
Context: Demonstrates the validity of the ESIP model as a whole for estimating the cost-
effectiveness of within-pregnancy cessation interventions, and gives an example of how 
ESIP can be used to evaluation such interventions. 
 
Chapter 11: Conclusions of this thesis 
Description: A final summary of the achievements of this thesis, discussion of its 
limitations, their impacts, and its strengths, context in policy and scope for future 
improvements 
Context: This draws together the thesis as a whole 
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 Chapter 2: Identification of maternal and infant outcomes 
related to smoking during pregnancy 
 
 Introduction  2.1
 
For any economic evaluation, it is critical that morbidities included have the closest links 
with the intervention/disease being modelled. An evaluation could be described as 
misspecified if it omits important impacts on health, as it can lead to the production of 
misleading results, and theoretically to incorrect judgements by policy makers, with 
patients potentially missing out on valuable healthcare or, conversely, receiving an 
intervention which does not provide value for money by falling outside the established 
cost-effectiveness thresholds.  
 
Although smoking during pregnancy has been linked with many harmful conditions, 
previous evaluations have omitted some, if not all, of these. For example, Taylor identified 
that smoking during pregnancy was linked with ectopic pregnancies, placenta previa, 
premature separation of the placenta (PROM), and pre-eclampsia. [139] However, his 
model  failed to identify the extent to which  these co-morbidities impacted on the 
ŵŽƚŚĞƌ ?ƐƵƚŝůŝƚǇĂŶĚ ?ŽƌĂƐƐŽĐŝĂƚĞĚĐŽƐƚƐ ?ĂŶĚƚŚĞƌĞĨŽƌĞĞǆĐůƵĚĞĚthem from the analysis. A 
systematic review of previous evaluations also identified this issue, with published studies 
only using cessation at birth as their primary outcome, generally failing to include maternal 
ŚĞĂůƚŚ ĐŽŶƐĞƋƵĞŶĐĞƐ ĂŶĚ ƚŚĞ ůŽŶŐĞƌ ƚĞƌŵ ŝŵƉĂĐƚƐ ŽĨ ŝŶĨĂŶƚƐ ? ŵŽƌďŝĚŝƚŝĞƐ ?[6] All this 
demonstrates that the current literature appears to be omitting important conditions; this 
chapter describes how the author identified the most important conditions for inclusion in 
ESIP.  
 
 Objectives  2.2
 
2.2.1 Primary Objective:  
Identify the key maternal and infant morbidities that potentially warrant inclusion in an 
improved economic model for evaluating cessation interventions. 
 
75 
 
2.2.2 Secondary Objectives: 
x To identify those maternal and infant morbidities which have any association with 
smoking in pregnancy 
x To determine the strength of evidence for each association and hence whether 
there is a plausible causal link 
x To  identify the incidence within pregnant women of those morbidities which are 
considered to be causally associated with smoking in pregnancy  
x Where possible, to identify QALY weights to be associated with each morbidity 
considered to be causally associated with smoking in pregnancy 
 
 Methods 2.3
 
2.3.1 Conditions associated with smoking and pregnancy 
 
Objective: To identify any maternal and infant morbidity which has an association with 
smoking in pregnancy 
 
It was felt that a formal systematic review was not appropriate as the main focus was to 
identify any condition which might be associated with smoking and pregnancy, and not to 
quantify the impact of smoking during pregnancy.  
 
The review involved an electronic search of the database Medline (inception through to 
June 2011) for any epidemiological review articles that mentioned/discussed the 
relationship between smoking during pregnancy and a condition that affected the health of 
the mother or the infant. It was not seen as necessary to screen further databases as 
Medline is one of the largest medical databases, and this would have likely led to 
duplication without identifying further useful papers. The following search terms were 
used: 
 
x Smoke 
x Smoking 
x Tobacco 
x Pregnancy 
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x Pregnant Women 
x Epidemiology 
x Public Health 
x Review 
 
The review process involved one reviewer who screened titles and abstracts to identify 
relevant studies. The inclusion criteria were that studies had to be review articles (not 
necessarily systematic) that looked at one or more aspects of the epidemiology of smoking 
during pregnancy. Exclusion criteria were: 
 
x Studies with no exclusive focus on smoking in pregnancy. 
x Studies with no focus on pregnancy or infants born to smoking mothers. 
 
The reviewer collated studies together into a table, and summarised their findings with 
respect to different conditions.  The conditions were categorised by the individual upon 
whom they have a direct effect; the categories were: 
 
x Morbidities affecting mothers only 
x Morbidities affecting infants only 
x Morbidities affecting both mother and infant 
 
Since the purpose of this review was to identify any morbidity which had any association 
with smoking during pregnancy, the authors felt that the quality of the included articles 
was not informative, and therefore no quality assessment was done on included studies. 
There was also the consideration that no appropriate checklist could be identified as 
applicable to all studies (e.g.  a checklist for systematic review quality would not necessarily 
be relevant to non-systematic reviews). Furthermore, clinical input was deemed 
unnecessary for this review, since any spurious associations would be excluded by the 
second review detailed below.  
 
2.3.2 Summarising the strength of evidence 
 
Objective: To determine the strength of evidence for each association 
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To determine the strength of evidence a further scoping review was conducted. This 
involved searching Medline from inception through to July 2011. Search terms included the 
conditions identified in the initial scoping review and: 
 
x Smoke 
x Smoking 
x Tobacco 
x Pregnancy 
x Pregnant Women 
x Newborn Infant 
 
The following study designs were considered: case-control; cohort; RCTs; non-systematic 
reviews; and meta-analyses. Case-reports and qualitative studies were excluded. Studies 
needed to investigate whether or not there was an association between one of the 
conditions / morbidities identified in the first scoping review and smoking and to report 
either a negative or positive association (e.g. as an odds ratio or relative risk). Exclusion 
criteria included: 
 
x Studies without an exclusive focus on smoking in pregnancy. 
x Studies with no focus on pregnancy or infants born to smoking mothers 
 
Citations identified were screened by title and abstract by the lead reviewer and grouped 
under headings relating to the conditions on which they were providing information. A 
second opinion from another reviewer was not sought on each study since the only data-
extraction requirements were to determine the type of study and whether it 
supported/undermined the association identified in the previous review. The review 
consisted of a narrative synthesis describing the strength of evidence associated with the 
conditions, permitting a qualitative judgement to be made on inclusion of the conditions in 
the improved economic model. The qualitative weighting of studies used in decision 
making was based upon the hierarchy of evidence suggested by Evans et al. [148] This gives 
the strongest preference to systematic reviews, followed by RCTs, cohort studies, 
observational studies, non-randomised controlled trials, before and after studies, and case-
control studies.  
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Consideration was also given to the criteria of strong evidence as suggested by Hill. [149] 
Hill defined that for a causal link to be established the evidence had to meet nine criteria: 
 
1. Strength 
2. Consistency 
3. Specificity 
4. Temporality 
5. Biological gradient 
6. Plausibility 
7. Coherence 
8. Experiment 
9. Analogy 
 
Not all of the Hill criteria were used, but the review focused on strength, consistency, 
specificity, temporality, and plausibility. Based upon these criteria, it was determined that 
strong evidence of a condition being linked with smoking during pregnancy was where one 
or more systematic reviews identified a positive association between smoking in pregnancy 
and an outcome. If there were no systematic reviews, but a large number  ?A? ? ? of studies 
supported an association, then it was judged that there was also a potentially strong 
association between the condition and smoking during pregnancy. This focus on either a 
systematic review or a large body of evidence acted as measures of the included criteria. It 
would be unlikely that these criteria would not be met if there was not review or meta-
analysis evidence of an association, as these require existing bodies of evidence from which 
to determine the pooled effect. Similarly, if there were a large number of studies 
supporting an association, then this would seem to meet the criteria for consistency and 
plausibility. Furthermore, strength would also be measured due to the size of the effect 
linked with smoking during pregnancy, since the focus was on studies that would report 
significance in the size of the effect; if there was little impact of smoking in pregnancy, the 
size of the effect would either be small or non-existent, and most likely non-significant. 
Temporality would also be met, as it is likely that all included studies would be reporting 
results of women who had either been exposed or not exposed to smoking during 
pregnancy with regards to their outcomes at end of pregnancy or after pregnancy, hence 
looking at the incidence of the disease after the causal event. Specificity would also be met 
because we would be focusing in on a particular group of women; those who are pregnant. 
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If a condition was found to have strong evidence linking it with smoking during pregnancy, 
it was considered that there was a high chance that this was a causal condition, making it 
an important inclusion in any economic model. If there were few studies (<8), or the results 
of studies contradicted each other, then it was assumed there was little or no evidence for 
causality. Table 2.1 summarises the judgement criteria. A descriptive analysis was 
conducted, outlining the number and type of studies which supported a positive and 
negative association for the condition.  
 
Table 2.1: Criteria and judgments on strength of evidence in review two 
Criteria Judgement Causal link 
No studies identified No evidence for a link with 
smoking during pregnancy 
None 
A small number (<8) of studies 
identified, but no systematic review 
evidence 
Weak evidence of a link with 
smoking during pregnancy 
None 
A large number (A? ? ? of studies, but 
contradictory, including contradictory 
systematic reviews, and/or a large 
number of studies identifying one link 
but a systematic review identifying no 
link 
Contradictory evidence with 
smoking during pregnancy, 
therefore no association can 
be identified 
None 
A large number  ?A? ? ? of cohort and RCT 
studies identifying an association with 
smoking during pregnancy, with little 
or no contradictory evidence, but no 
systematic review 
Strong evidence of an 
association with smoking 
during pregnancy 
Potential causal 
link 
A large number  ?A? ? ? of cohort and RCT 
studies and one or more systematic 
reviews identifying an association 
with smoking during pregnancy, with 
little or no contradictory evidence 
Very strong evidence of an 
association with smoking 
during pregnancy 
Potential causal 
link 
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2.3.3 Incidence of morbidities 
 
Objective: To identify the incidence within pregnant women of those morbidities which are 
considered, from the reviews conducted above, to be causally associated with smoking in 
pregnancy  
 
UK incidence data was sought, primarily from national databases/statistics considered 
likely to generalize all UK pregnant women. The databases identified as being the most 
relevant were: 
 
x NHS Maternity Statistics for England, Hospital Episode Statistics (HES) 
x Office for National Statistics (ONS) 
x European Surveillance of Congenital Anomalies (EUROCAT) 
 
However, if data on conditions were unavailable from these resources, any source of UK-
specific incidence data was considered, including government documentation, and cohort 
studies.  
 
2.3.4 Identifying utility weights for causally associated morbidities 
 
Objective: To identify utility weights associated with each morbidity judged to have a 
causal association with smoking in pregnancy 
 
To identify utilities associated with morbidities identified in the second review, a further 
Medline search was conducted, from inception till October 2013. Relevant studies were 
economic evaluations and/or surveys of health related quality of life using either 
questionnaires or preference-based measures to calculate QALYs. The search was 
performed for conditions that had been determined as having a potential causal link with 
smoking during pregnancy. However, certain conditions, such as SIDS and early and late 
foetal loss, required no search for utility data as a dead infant is attributed a utility value of 
zero. The details of the electronic search are given in Appendix 12.1. Citations were 
screened by title and abstract and retrieved in full if they appeared to include utility data at 
follow up, with details of the timing and duration of the utility loss. 
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2.3.5 Deciding if a condition warrants inclusion in the improved economic model 
 
The main criterion for deciding whether a condition potentially warranted inclusion in the 
improved economic model was whether there was strong evidence of a causal link 
between smoking during pregnancy and the increased/decreased occurrence of the 
condition. Although the review also included incidence data regarding the conditions and 
utility weights, these did not influence whether the condition was potentially includable. 
Because the review was conducting what could be considered a comprehensive summary 
of the available literature, it was felt that seeking clinical opinion on whether the inclusion 
of the condition was correct was unnecessary because it would be highly unlikely that 
strong evidence of a causal association would be associated with an irrelevant condition, 
and hence clinical opinion would be superfluous to the decision process.  
 Results 2.4
 
2.4.1 Morbidities linked with smoking 
 
Searching identified 63 citations, of which the full text of 31 articles was reviewed. This 
identified 32 conditions which had any association with smoking during pregnancy. The 
results of this can be found in Appendix 12.2. 19 conditions impacted on the mother only; 
11 impacted on the infant only, and two impacted on both mother and infant.  
 
2.4.2 Strength of evidence 
 
The second search identified 4,323 citations. Some conditions retrieved many citations, e.g. 
LBW (689 citations), whilst others had very few e.g. placenta accreta (two citations). All 
studies were screened by title and abstract; 766 citations were judged relevant. It was 
beyond study resources to perform a full text review, so judgements were made on the 
basis of information included in study abstracts. Where an abstract was unclear, the full 
text was retrieved (41 studies). If a study appeared to be a systematic review, full text was 
again retrieved (39 citations). Further details of cited articles can be found in Appendix 
12.2; a brief summary of this large literature follows. 
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2.4.3 Outcomes / morbidities for which no evidence was identified: 
 
No studies were identified supporting any association between smoking during pregnancy 
and pregnancy bleeding of unknown origin, stroke, pulmonary embolism, MI, influenza, 
bronchitis, gastro intestinal ulcers, or uterine fibroids. There was judged to be no evidence 
linking these conditions with smoking during pregnancy, despite articles identified in the 
initial review claiming otherwise. 
 
2.4.4 Outcomes / morbidities for which limited evidence was identified: 
 
A small number of studies were identified supporting an association between smoking in 
pregnancy and pregnancy accreta (one case control), pregnancy rhinitis (one survey), deep 
vein thrombosis (two case control), asthma (two case control and one cohort), vomiting 
during pregnancy (one cohort and one survey), and lower quality of life for the infant (one 
cohort).  Therefore, for these conditions, the judgement was that there is insufficient 
evidence to support the notion of a causal association between these morbidities and 
smoking during pregnancy. 
 
There was contradictory evidence for gestational diabetes and childhood cancers. For 
gestational diabetes, only three studies identified reported an association with smoking in 
pregnancy (one cohort, one cross-sectional and one RCT), while two systematic reviews 
and two cohort studies found no association. The judgement was made that there was no 
association between smoking during pregnancy and gestational diabetes in the mother. For 
childhood cancers, six case-control studies reported an association with increased risk of 
cancer due to smoking during pregnancy. However, two non-systematic reviews and 13 
case-control studies reported no association. Consequently, the evidence linking smoking 
during pregnancy and childhood cancers did not meet our criteria for beŝŶŐ ‘strong ?. 
 
Limited and unclear evidence was also identified for otitis media (two observational studies 
reporting an association and one not); infants ? subsequent fertility (two cohorts and one 
RCT reported no association, one cohort reported an association) and obesity in infants 
(two reviews, six cohorts, and eight observational studies reported some association while 
one review reported no association). One case control and two cohort studies attributed an 
association with impaired cognitive development in infants and smoking during pregnancy, 
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while six cohort studies identified no such association. Since none of the identified studies 
include a systematic review, and the evidence seemed contradictory, the judgement was 
made that there was no evidence for an association between these conditions and smoking 
during pregnancy. 
 
An increased risk of behavioural problems in childhood was linked with smoking during 
pregnancy in 67 studies (seven review, 15 cross sectional, nine case control, 19 cohort, and 
16 longitudinal), while only 13 (four review, two cross sectional, two case control, two 
cohort, and three longitudinal) suggested there was no association. However, one 
systematic review was identified, which estimated that there was no association. Although 
the majority of studies seemed to identify a positive association with smoking during 
pregnancy, the evidence appears highly contradictory, especially since the systematic 
review found no association. Thus, even though there are many studies investigating the 
link between smoking during pregnancy and behavioural problems, the evidence is far from 
conclusive.  
 
2.4.5 Outcomes/ morbidities where strong evidence was identified: 
 
For maternal conditions, strong evidence supporting a potentially-causal association was 
identified for placenta previa (one systematic review, six case control, and five cohort 
studies), placental abruption (two systematic reviews, 11 cohort and six case control 
studies), PPROM (one systematic review and seven case control), and ectopic pregnancy 
(one systematic review, one review, eight case control, and one cross sectional). For pre-
eclampsia, 26 studies (including three systematic reviews) reported a negative (i.e. 
protective) association with smoking in pregnancy, while five cohort studies found no 
association or an increased risk. Since the evidence was stronger for the protective impact, 
the judgment was made that there was strong evidence supporting that association, and 
hence smoking had some protective effect. 
 
For materno-foetal conditions, the majority of evidence implied there was an association 
between smoking during pregnancy and both pre-term birth and early and late foetal loss. 
For foetal loss, one systematic review, 30 cohort, 11 case control and 12 reviews suggested 
there was an increased risk from smoking during pregnancy, while five cohorts and two 
case controls identified no association; therefore, it was judged that there was strong 
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evidence of a detrimental association and a potentially-causal link. For premature birth, no 
systematic reviews were identified; however, 28 cohort and 12 case control articles all 
supported a positive association, while five cohorts and two case controls supported no 
association. With such a large number of studies supporting a positive association with an 
increase in premature births amongst smokers, it was decided that there was strong 
evidence of an increased risk of preterm birth from smoking during pregnancy. 
 
For infant conditions, strong evidence was found for an association with SIDS. Strong but 
contradictory evidence was also found for LBW, behavioural problems, congenital 
anomalies, and respiratory illness. For LBW, there was strong evidence linking smoking 
during pregnancy with a reduction in birth weight, with one systematic review, six reviews, 
one cross sectional, 36 case control, and 117 cohort studies supporting this association. 
However 11 studies (six cohort, four case control, and one cross sectional study) suggested 
there was no association. For respiratory illness, one systematic review, 44 cohort, nine 
reviews, seven case control and two cross sectional  studies suggested there was a link 
between smoking during pregnancy and an increased risk of respiratory illness in the infant, 
while only three cohort studies suggested there was no association.  For congenital 
anomalies, an increased risk due to smoking during pregnancy was identified in two 
systematic reviews, six cohort, nine case control, and two review studies. Seven cohort and 
two case control studies identified no association. It was judged that since the vast majority 
of evidence, often with higher quality study designs, favoured positive associations, there 
was strong evidence of a potentially-causal association with smoking during pregnancy for 
these outcomes.  
 
2.4.6 Incidence of outcomes for which strong evidence was identified 
 
For all the conditions identified as having strong evidence associated with smoking during 
pregnancy, a further search of national statistics was undertaken to determine the annual 
frequency of occurrences in the UK population as a whole. The incidence for each condition 
is reported in Table 2.2, Table 2.3, and Table 2.4. 
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Table 2.2: Incidence of conditions that impact on the mother only 
Morbidity Incidence 
Placenta previa Occurs in 0.66% of deliveries [150] 
Placental abruption Occurs in 0.4% of deliveries [150] 
Pre-term premature rupture of the 
membranes 
Occurs in 9.64% of deliveries [150] 
Ectopic pregnancy Rate of 1.7 per 100 deliveries [150] 
Pre-eclampsia Occurs in 1.97% of deliveries [150] 
 
Table 2.3: Incidence of conditions that impact on both the mother and infant 
Morbidity Incidence 
Pre-term birth Occurs in 5.69% of deliveries [150] 
Early and late foetal loss Rate of 4.9 Stillbirths per 1,000 total births 
[151] 
Miscarriage occurs at a rate of 5.9 per 100 
deliveries [150] 
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Table 2.4: Incidence of conditions that impact on the infant 
Morbidity Incidence 
SIDS Rate of 0.2 per 1,000 live births [152] 
For a child born less than 2500 grams (LBW), 
rate is 0.5 per 1,000 live births, and 0.2 per 
1,000 live births over 2500 grams [153] 
LBW Rate of 70 births per 1,000 live births [153] 
Congenital anomalies Rate of 179.43 for all congenital anomalies 
(excluding chromosomal) per 10,000 births 
[154] 
Respiratory illness 21% of children have a diagnosis of asthma. 
19% of children report wheezing [155] 
 
2.4.7 Identification of utility weights associated with morbidities for which strong 
evidence was identified 
 
A search was performed to identify relevant utilities associated with includable conditions 
which could be used within an economic model. This returned 942 citations covering all 
conditions except placental abruption. From the 942 citations, 11 studies were identified as 
reporting relevant utility data; no relevant studies were identified for placenta previa, 
placental abruption, and PPROM. Table 2.5, Table 2.6, and Table 2.7 summarise the 
evidence found. 
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Table 2.5: HRQoL weights attributable to morbidities impacting on the mother only 
Morbidity Utility weights identified 
Ectopic pregnancy A 0.01 utility decrement for a mother who suffered from an ectopic 
pregnancy, which was applied for one cycle only.  [156] 
Pre-eclampsia One study identified that was a lack of data regarding utilities for pre-
eclampsia and therefore consulted the clinical guideline development 
group who had commissioned the model. This group of experts 
recommended that there was no impact on utility. [157] 
 
Table 2.6: HRQoL weights attributable to morbidities that impact on both the mother and the infant 
Morbidity Utility weights identified 
Pre-term birth See LBW 
LBW In children born with very LBW (below 1501 grams), up to age five, the 
utility weights were 0.915 for those born at 23 weeks gestation, 0.950 
for those born 24-25 weeks, 0.960 for those born 26-27 weeks and 28-
29 weeks, and 0.970 for those born at 30-31 and >31 weeks. [158] 
Extremely LBW infants (below 1000 grams) between the ages of zero 
and five were awarded utility weights between 0.7 to 0.9 for mild 
disability, 0.4 to, 0.8 for moderate disability, and 0.1 to 0.7 for severe 
disability. [159] 
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Table 2.7: HRQoL weights attributable to morbidities impacting on the infant only 
Morbidity Utility weights identified 
Congenital 
anomalies 
Children born with Spina Bifida: average utility 0.55. [160] Children 
born with undiagnosed craniosynostosis have a utility of 0.95 and a 
standard error of 0.24. [161, 162] 
Respiratory illness Estimated average utility for mild intermittent asthma was 0.91 
(standard deviation (s.d.) of 0.18), mild persistent asthma was 0.90 
(s.d. of 0.18), and severe persistent asthma was 0.83 (s.d. of 0.21) in 
children under the age of 18. [163] Utilities for elementary school aged 
children with asthma estimated (range) as 1.0 (0.98 to 1.0) for a 
symptom free day, 0.9 (0.84 to 0.96) for symptomatic, 0.70 (0.64 to 
0.76) for recovering from attack, 0.43 (0.37 to 0.49) for an attack that 
required a visit to an emergency department, and 0.06 (0.01 to 0.11) 
for an attack which required hospitalisation. [164] Utility loss for an 
episode of wheezing 0.0018 (0.0003 to 0.005) among children aged 
less than five years. [165] Asthmatic patients aged 12-19 years had a 
utility of 0.90 (s.d. of 0.12). [166]  
 
Whilst reviewing the papers, it became apparent that there was some evidence of an 
impact of losing the child on the health of the mother. Partridge et al incorporated this 
impact by awarding women who had lost their child during pregnancy with a utility of 0.9. 
[167]  
 
 Discussion 2.5
 
This chapter demonstrates how widespread the impact of smoking during pregnancy is; 
systematic searches have summarised the strength of the evidence associated with 
morbidities likely to be caused by smoking in pregnancy. There is evidence for a causal 
relationship between this and 11 major morbidities. Furthermore, utilities for maternal 
conditions appear to be relatively sparse.  
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2.5.1 Strengths of the reviews 
 
The Hill criteria were utilised in our judgement of whether there is a causal relationship 
between smoking and several conditions which have an impact on the health of the mother 
and/or her infant. [149] These criteria have been widely accepted as guidelines for drawing 
causal inferences for nearly fifty years. [168] However, the Hill criteria have been criticised 
in recent years. Philips et al argued that the basic mechanism of determining causality is in 
scientific common sense deduction rather than through the use of predetermined specific 
criteria. [169] Other researchers argue that the study design may rule out deducing 
causality, and that the Hill criteria are only of use for inferring the best explanation of the 
data. [170] However, it has been argued that the criteria still apply, but rather than using 
them to prove causality, the counterfactual approach should be adopted for each criterion 
to try and disprove causality. [171] Howick et al argued that the Hill criteria were still useful 
for determining causation, but that they should be organised into three categories; direct 
evidence from studies (probabilistic association between intervention and outcome is 
causal and not spurious),  mechanistic evidence (of the alleged causal process), and parallel 
evidence (other evidence of the hypothesis). [172] Howick et al suggested that the revised 
form of the Hill criteria put more emphasis on direct evidence of the association and its 
effect size, which appears to be particularly relevant to the approach the author has used 
in applying the criteria in this chapter. All this suggests that even though the Hill criteria are 
debated in the current literature, their application is still judged to be a relevant method 
for investigating causality. 
 
Our judgement may not have used all of the criteria suggested by Hill [149]; however, our 
definition of a causal relationship does meet several. Most importantly the judgement 
meets the criterion of consistency, since we defined strong evidence as one or more 
systematic reviews, and/or a large number of studies with reasonably strong research 
design consistently indicating associations. It also meets specificity, as we are dealing with 
a generally homogenous population, pregnant women; temporality, since the conditions 
are observed either during, or at the end of pregnancy; while the mother has either been 
smoking before pregnancy and quit upon conception / in early pregnancy or has smoked 
throughout gestation. Finally we also meet plausibility; since we already know that in the 
general adult, non-pregnant population smoking has many diverse impacts it would seem 
likely that smoking during pregnancy can plausibly have impacts on those conditions 
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identified. Although not reported, the strength of the effect is also touched on with this 
review. The actual strength of the impact of smoking is not that important, however, since 
we stated that the CI did not cross one (i.e. no association), we have already constrained 
our review to focus on those conditions where there is a statistically significant effect, 
meeting the first of the Hill criteria. We have not investigated whether the current 
literature meets the requirements of biological gradient, coherence, experiment, and 
analogy; by not meeting these criteria we may be incorrect in assuming that there is a 
causal relationship. However, while we have not investigated biological gradient 
specifically, included studies may report this information, although it is not summarised in 
this review. We decided not to focus on biological gradient because we were interested in 
the impact of smoking versus not smoking rather than smoking exposure, since we are 
investigating cessation interventions aimed at stopping smoking and not reducing smoking. 
If we were focusing on interventions to reduce smoking, then the biological gradient aspect 
would have been important as we would require evidence of the impact in the reduction of 
smoking from a heavy smoker to a light smoker. We did not include coherence and 
experiment because we were interested in epidemiological evidence in pregnant 
populations rather than the results of laboratory studies; Hill himself cannot nullify 
evidence of an effect from epidemiological studies. [149] Finally we did not include analogy 
because we were only interested in the impact of smoking during pregnancy on the risk of 
the diseases occurring, and not whether any other factors may have a similar impact as 
they could be considered exogenous from our model. However, it is hoped that by focusing 
primarily on systematic review and meta-analysis evidence, these will have controlled for 
any similar factors which may have had a confounding effect on the impact of smoking in 
pregnancy. This would mean that our criteria for strong evidence, and hence a causal 
relationship, meets five of the nine criteria, suggesting that we are likely to be correct when 
suggesting a potential causal relationship between smoking and the 11 conditions. 
 
This work is not a standard systematic review. To meet the objective of critically assessing 
the evidence for 32 conditions linked with smoking during pregnancy, 32 systematic 
reviews would have been required, which is beyond the scope of this thesis. However, this 
review does employ elements such as a systematic search, which means it is likely to be 
sufficiently robust for identifying potentially relevant morbidities for economic evaluations 
of cessation during pregnancy. The review appraised approximately 4,000 citations, giving a 
comprehensive overview of morbidities linked with smoking during pregnancy. It is also 
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likely that correct judgements are being made, as only those with a large number of studies 
suggesting a consistent association are deemed to have a causal link with smoking during 
pregnancy. 
 
2.5.2 Limitations of the reviews 
 
There are several limitations of this review. Although a systematic search strategy was 
used, we did not formally assess the quality of the included studies, making it impossible to 
determine whether the findings are based upon high quality studies. In an attempt to 
counteract the potential bias this may cause, the authors defined strong evidence as the 
existence of one or more systematic reviews supporting a particular association. Systematic 
reviews are seen as the gold standard in the hierarchy of evidence, and often incorporate 
quality assessment as part of their reviewing process. In all but one of the outcomes the 
authors judged there was strong evidence to support an association from at least one 
systematic review. In the case of premature birth, where no systematic review was 
identified, there were a very large number of studies supporting the association, so our 
assumption of strong evidence would appear justified.  
 
A second limitation was that the electronic searching was limited to one database. We 
could, therefore, have failed to identify important studies that might be contradictory to 
findings. However, Medline is an established database with a broad remit, so it would be 
unlikely that unsearched databases would add substantially to the evidence found. Further 
searching could have led to the inclusion of more poor quality studies which may have 
increased the difficulty of making judgements on the strength of evidence.  
 
Another limitation was that we were unable to determine the impact of publication bias. As 
part of a meta-analysis, funnel plots can investigate this, but as our synthesis of data was 
qualitative no funnel plot was available; thus there could be unpublished studies which we 
did not find and which contradict our conclusions. In the case where the decision was made 
without evidence from systematic reviews, there was such a difference in number of 
studies supporting the association compared to the number of studies not supporting it 
that it is unlikely that the wrong decision has been made. 
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2.5.3 Implications for the proposed model 
 
These reviews highlight a total of 11 conditions that have some causal relationship with 
smoking in pregnancy and potentially warrant inclusion in the improved economic model. 
The predominant impact of smoking during pregnancy appears to be negative on the 
health of the mother and the infant; however, there does appear to be some protective 
effect on pre-eclampsia in the mother. It is important that the economic model includes 
both negative and positive health impacts; this is because there may be important cost and 
HRQoL implications which could be important determinants of the cost-effectiveness of 
interventions being evaluated. The omission of these conditions could suggest that the 
previous literature has been misspecified and therefore the improved economic model 
should attempt to include most, if not all, of the causally associated diseases. 
 
The first review highlighted 18 pregnancy-specific maternal conditions, 14 of which had 
negative impacts on the health of the mother. However, only six conditions appeared to 
have a causal association. Although we have no way of assessing publication bias, the 
review could highlight some publication bias existing in the conditions where we found no 
evidence, or contradictory evidence, i.e. in that small studies criticizing the association have 
not been published. However, the second scoping review might garner the possibility that 
the authors of the epidemiological reviews from the first review were mistaken in their 
judgments of these conditions. 
 
The incidence of the six maternal conditions linked with smoking in pregnancy is relatively 
low. Furthermore, we have no evidence to support any HRQoL impact, both within-
pregnancy and longer term. The literature reviewed would suggest that any HRQoL impact 
is relatively short-lived, which might explain why there seems to be little evidence of a 
change. It could be reasonably argued that these conditions do not warrant inclusion in any 
economic model; however it is likely that there are substantial related healthcare costs, 
especially since all require some form of emergency care, which, along with the strong 
evidence of a causal association, imply that these maternal conditions should be included 
in any economic model, despite the infrequency and lack of HRQoL impact. 
 
The review has also highlighted that there is strong evidence of a causal association 
between smoking and foetal loss during pregnancy and within one year of birth. This 
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includes conditions like ectopic pregnancy, miscarriage, stillbirth and SIDS and implies that 
there are preventable deaths occurring. This is significant because there is potentially a 
tremendous gain from preventing these deaths. Furthermore, we found evidence to 
suggest that foetal loss has a detrimental impact on the mother. Miscarriage and foetal loss 
have been associated with postnatal depression which can last up to 12 months after the 
miscarriage and beyond. [173, 174] This is an important consideration since smoking during 
pregnancy increases the chances of foetal loss both during pregnancy and after birth. The 
impact was incorporated into an economic evaluation by awarding a utility of 0.9 (rather 
than 1) to women who lost their child during pregnancy. [167] The model used by Partridge 
et al used this weight for 50 years, the remaining life expectancy; however it could be 
argued that this depressive state is a more transient condition, since little evidence of long-
term impacts appear to exist. The persistence of any effect is important; for example, a 
short term impact lasting for no more than one year might not be influential in economic 
terms but longer term impacts are potentially worth considering. 
 
There was also strong causal evidence of an association with several birth outcomes for the 
infant, such as premature birth and LBW. However, these two conditions seem to be very 
closely linked and this was reflected in some of the estimates of HRQoL impacts. The 
PERFECT study demonstrated this clearly with the greatest losses in QALYs associated with 
infants by age five which had been born with very LBW and prematurely. [158] In a 
separate study of a Finnish cohort, the authors demonstrated, using a multiple regression 
analysis, that length of gestation had a bigger impact on the quality of life than birth 
weight, with a utility increase of 0.28 (95% CI 0.21 to 0.36) per one extra week gestation 
from 23 weeks and longer, while a 100 gram increase in weight increased utility by 0.007 
(95% CI -0.04 to 0.06). [175] The link between birth weight and prematurity is logical, since 
the shorter the gestational period, the higher the chance the foetus has not developed 
fully, and therefore the more likely the foetus will be born with LBW. 
 
The HRQoL impacts on infants for LBW and premature birth would appear to be small, and 
dependent on other factors. As mentioned, the PERFECT study attributed the lowest utility 
of 0.915 to infants born at 23 weeks and with very LBW. [158] This suggests a utility loss of 
0.085 per year period up to the age of five. However, only 0.1% of live births in England and 
Wales in 2011 occurred at less than 24 weeks gestation, with a mortality rate of 89%, and 
most deaths occurring within the first week of life. [176] The majority (81%) of pre-term 
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infants are born between 32 and 36 weeks gestation [176], where the PERFECT study 
estimated that children aged five or less had an estimated utility of 0.97, a loss of 0.03. 
[158] In the other studies identified, LBW and/or premature birth were not associated with 
any loss in quality of life per se, rather this was dependent on whether or not a LBW infant 
developed a disability. This was the case in Doyle et al, where the utility was determined by 
the degree of disability the child was assumed to have. [159] It has been estimated that 
around 62% of infants born at 27 weeks gestation or before have some form of disability, 
with around 51% being oxygen dependent at home or in hospital, and 17% having some 
form of brain injury. [177] With such serious disabilities, which can have severe long-term 
impacts, it is easy to understand why the utilities should be assigned dependent on 
whether the child has a disability or not. However, 2011 ONS data for England and Wales 
estimated that 0.4% of live births were LBW and 27 weeks gestation or less; of these 
infants, 83% were dead within one year of birth. [176] Although the literature suggests that 
an infant born prematurely and/or LBW can suffer a severe utility loss due to a disability, 
the occurrence seems so infrequent as to not warrant inclusion in the model. Furthermore, 
additional research would be required to determine the nature and strength of 
relationships for the disabilities and LBW/premature birth, which is beyond the scope of 
this thesis. 
 
Smoking during pregnancy had potentially-causal relationships with only two infant 
conditions. For the other seven conditions, evidence was contradictory; this may be due to 
the studies not being powerful enough to identify an association or that indeed no such 
association exists. The most important finding of these reviews was that there was no 
positive impact of smoking during pregnancy on the health of the child; all nine conditions 
had detrimental effects. These impacts seem to be important in both the short- and long-
term. The two causally- associated conditions, congenital anomalies and respiratory illness, 
can both have lasting and significant impacts on the health of the child. A congenital 
anomaly in pregnancy could either be a minor disability or alternatively could be very 
severe; however, they are among the most infrequent conditions linked with smoking in 
pregnancy. Respiratory illness, on the other hand, is one of the most prevalent chronic 
diseases that can occur in childhood. In a worst case scenario, respiratory illness can lead to 
a severe HRQoL loss for the child. However, more frequently there appears to be a 
relatively minor impact on health. These reviews highlight that a vital component of 
evaluations of smoking in pregnancy are the health impacts on the infant.  
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One important consideration for ESIP is that adopting this process of identifying morbidities 
with causal associations has resulted in a lower risk of misspecification. From the initial 
review, all 32 conditions could have been considered worthy of inclusion; however, it has 
been demonstrated that 21 of these conditions have no evidence of a causal association, 
and therefore appear to have no justification for inclusion. For example, Godfrey et al 
included otitis media in their costing analysis of smoking during pregnancy. [4] This review 
did not find any evidence of a causal association between smoking during pregnancy and 
otitis media, and therefore the inclusion could be considered a misspecification error. ESIP 
has avoided this potential error, and thus could be deemed more robust. 
 
 Summary 2.6
 
In conclusion, smoking during pregnancy has been linked with many conditions, both 
impacting on the health of the mother and the health of her offspring. However, only 11 
conditions have strong evidence suggesting that smoking during pregnancy causes them, 
and hence warrant consideration for inclusion in the improved economic model. Utility for 
the mother does not seem to be impacted by several of the pregnancy specific maternal 
morbidities. For LBW and premature birth, HRQoL seems to be most reduced in the 
presence of both conditions; however, the occurrence of LBW or premature birth does not 
seem to have any lasting impact on the utility of the infant unless the child develops a 
disability, which appears to be relatively infrequent. This has several important implications 
for the development of an improved economic model: 
 
1) Pregnancy specific maternal conditions which are likely to be caused by smoking 
(pre-eclampsia, placenta previa, placental abruption, and ectopic pregnancy) occur 
infrequently and have little sustained impact on maternal HRQoL. 
2) Infants born prematurely and/or with LBW experience no long-term impacts on 
health from these conditions. These conditions seem to be closely linked and 
therefore the discrete impacts on HRQoL from one or other condition are very hard 
to ascertain. 
3) The majority impact on HRQoL of LBW or premature infants is determined by 
whether or not they are born with a disability, or develop one in childhood.  
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4) Congenital anomalies have a large impact on ŝŶĨĂŶƚƐ ?HRQoL; however, they occur 
infrequently. 
5) Respiratory illnesses have a relatively high incidence and a large, long-term impact 
ŽŶƚŚĞŝŶĨĂŶƚ ?ƐHRQoL.    
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 Chapter 3: Economic Evaluations of Smoking Cessation 
interventions during Pregnancy: A Systematic Review 
 
 Introduction 3.1
 
As Chapter 1 demonstrates, there are relatively few evaluations of smoking cessation 
during pregnancy. For the proposed model to be robust, it is important to critically assess 
the previous literature to identify any weaknesses or omissions. Ruger et al attempted to 
do this in 2008 with a systematic review [6], however this could now be considered 
outdated; therefore it would seem pertinent to update it for the purpose of this thesis. This 
updated review would help focus the author on the areas with significant issues or 
oversights in order for the proposed economic model to be considered an improvement on 
the previous literature. 
 
 Review aims and objectives 3.2
 
3.2.1 Primary objective 
To identify and critically assess economic evaluations of smoking cessation interventions in 
pregnant women. 
 
3.2.2 Secondary objectives 
For included evaluations, to identify the: 
1) extent to which impacts of smoking on the mother are considered, including  both 
smoking specific morbidities and associated pregnancy specific outcomes  
2) extent to which impacts of smoking on infants are considered 
3) length of time horizon and follow up period of the economic evaluations 
4) extent to which relapse to smoking after childbirth is considered by the economic 
evaluations 
5) specific modelling techniques that have been employed and critically assess them 
6) areas where the methodologies of the evaluations require further development 
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7) identify if there are any suitable decision analytic model structures which may 
influence the design of the new improved economic model 
 
 Methodology 3.3
 
3.3.1 Database selection 
 
11 databases were searched: ASSIA, CINAHL, Econlit, Embase, Maternity and Infant Care, 
Medline, NHS EED, PsycArticles, PsycINFO, PubMed and Tufts Cost-Effectiveness Analysis 
Registry.  
 
To capture evaluations conducted for government policy purposes (or similar studies) in 
ƚŚĞ  ‘ŐƌĞǇ ůŝƚĞƌĂƚƵƌĞ ?  ?ƐƚƵĚŝĞƐ ƉƵďůŝƐŚĞĚ ŽƵƚƐŝĚĞ ƉĞĞƌ ƌĞǀŝĞǁĞĚ ũŽƵƌŶĂůƐ ? ? ƚǁŽ ďƌŽĂĚ
databases, Web of Knowledge and Web of Science were searched. These databases 
ŝŶĐŽƌƉŽƌĂƚĞ ĂŶ ĂƌƌĂǇ ŽĨ  ‘ŐƌĞǇ ůŝƚĞƌĂƚƵƌĞ ? ƐŽƵƌĐĞƐ ? ŝŶĐůƵĚŝŶŐ ĐŽŶĨĞƌĞŶĐĞ ƉƌŽĐĞĞĚŝŶŐƐ ?
governmental and business reports and theses. Additionally, the websites of NICE in the UK 
and the US Surgeon General were searched to identify any evaluations conducted as part of 
public health or health technology guidance. [178, 179] 
 
An initial search was conducted on all databases from inception through to July 2011; this 
was later updated up to August 2014 during thesis writing up.  
 
3.3.2 Search terms 
 
The search strategy was developed using terms from a previous review and the Cochrane 
Pregnancy and Childbirth Group. [6, 180] Search terms were: 
 
x smoking 
x smoking cessation 
x relapse 
x relapse prevention 
x tobacco  
x pregnant women 
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x pregnancy 
x antenatal 
x prenatal 
x Pregnan* 
x Fetus 
x Foetus 
x Fetal 
x Foetal 
x Newborn  
x cost 
x cost analysis 
x cost effectiveness 
x cost-effectiveness 
x cost benefit 
x cost utility 
x economic evaluation 
x economic 
x QALY 
x quality adjusted life year* 
x quality-adjusted 
x quality of life 
x cost per life year;  
 
For the search of the NICE and US Surgeon General websites, the terms smoking, smoking 
cessation, and pregnancy were used.  
 
3.3.3 Inclusion criteria  
 
Studies were included if they were in English, reported an original, formal economic 
ĞǀĂůƵĂƚŝŽŶ ?ǁŝƚŚĂĚŝƌĞĐƚĐŽŵƉĂƌŝƐŽŶďĞƚǁĞĞŶĐŽƐƚƐĂŶĚŽƵƚĐŽŵĞƐ ?Ğ ?Ő ?  ‘ĐŽƐƚƉĞƌƋƵŝƚƚĞƌ ? ?
Studies not published in English were not included because it was felt that the translation 
process would not be adequate and could lead to misinterpretation of the model.   
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Population: Women who had experienced a cessation intervention during pregnancy 
and/or their offspring, or hypothetical cohorts modelling cessation during pregnancy 
and/or after this. 
Interventions: Any interventions or combination of interventions, both real and 
hypothetical, aimed at encouraging pregnant smoking women to quit.  
 
ŽŵƉĂƌĂƚŽƌƐ PEŽŝŶƚĞƌǀĞŶƚŝŽŶŽƌ ‘ƵƐƵĂůĐĂƌĞ ?(UC) 
 
Outcomes: Clinical or economic outcomes considered relevant to the mother and/or child 
(e.g. smoking status at end of pregnancy, LBW averted, SIDS averted, and QALYs).   
 
Design: Any study design could be included. The following economic evaluations would be 
considered: 
x cost-benefit analysis (CBA); outcomes in monetary units compared to costs 
x cost-effectiveness analysis (CEA); outcomes in natural scale (e.g. length of stay in 
hospital) compared to costs  
x cost-utility analysis (CUA); where outcomes on a generic scale (e.g. QALYs) 
compared to costs 
 
3.3.4 Exclusion criteria 
 
Exclusion criteria were: 
x Studies with no economic analyses.  
x Studies which did not include an outcome relevant to both smoking and pregnancy. 
 
3.3.5 Identification of papers 
 
Citations were screened by title and abstract by the lead reviewer and potentially-relevant 
texts were retrieved. If a protocol for an ongoing RCT was identified, the principal 
investigator was asked to provide any available analysis. Two reviewers working 
independently assessed full texts for inclusion, extracted data, and applied a quality 
assessment checklist (see Section 3.3.7). If the two reviewers disagreed on the data 
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extraction or quality assessment, a third reviewer was consulted. A manual search was 
conducted of references to identify other potentially-relevant studies, which were then 
identically screened and reviewed.  
 
3.3.6 Data extraction 
 
Data extracted included: 
 
x setting (real data versus hypothetical modelling) 
x description of intervention 
x description of comparator 
x outcomes measured 
x characteristics of resource estimates 
x characteristics of cost estimates 
x study assumptions 
x modelling assumptions 
x discounting 
x sensitivity analysis performed 
x type of economic evaluation 
x results of economic evaluation 
x comparison with other economic evaluations 
 
The following characteristics were noted: 
 
x author(s) 
x years of study  
x publication year  
x study type and design 
x topic and study question 
x funding source 
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3.3.7 Quality assessment 
 
To assess methodology quality, a suitable assessment checklist needed identifying. A brief 
scoping review of Medline was conducted in March 2011 to identify relevant economic 
evaluation checklists. However, since this search was conducted, the CHEERS statement 
has been produced and is now the accepted gold standard for the quality of economic 
evaluation studies. [43] Since this review was conducted in the autumn of 2011 and 
updated in August 2014, the results of the review which informed the construction of the 
improved economic model were based on the QHES assessment, therefore it was decided 
to continue to utilise the QHES rather than adopting the CHEERS statement. The scoping 
review search identified these health economic quality checklists: 
 
x British Medical Journal Checklist (BMJ) [181] PŽŵƉƌŝƐĞƐ ? ? ‘ǇĞƐ ?ŶŽ ?ŶŽƚĐůĞĂƌ ?ŶŽƚ
ĂƉƉůŝĐĂďůĞ ? ƌĞƐƉŽŶƐĞ ƋƵĞƐƚŝŽŶƐ ĐŽǀĞƌŝŶŐ ƚŚƌĞĞ ƚŽƉŝĐ ĂƌĞĂƐ P ƐƚƵĚǇ ĚĞƐŝŐŶ ? ĚĂƚĂ
collection, and analysis and interpretation of results.  
x Consensus Health Economic Criteria (CHEC) [182] PŽŶƐŝƐƚƐŽĨ ? ? ‘ǇĞƐ ?ŶŽ ?ƌĞƐƉŽŶƐĞ
questions focusing on the methodological quality of economic evaluations. 
x Quality of Health Economic Studies (QHES) [183] P ŽŶƚĂŝŶƐ  ? ?  ‘ǇĞƐ ?ŶŽ ? ƌĞƐƉŽŶƐĞ
questions focusing on the both the methodology of economic evaluations and the 
broader study, with each question carrying a weighted point score out of a total of 
100. 
x Assessing Quality in Decision Analytic Cost-Effectiveness Models [184]: Focuses on 
ŶŝŶĞĚŝŵĞŶƐŝŽŶƐŽĨƋƵĂůŝƚǇ ?ĞĂĐŚǁŝƚŚĂƐƵďƐĞƚŽĨ ‘ǇĞƐ ?ŶŽ ?ƌĞƐƉŽŶƐĞƋƵĞƐƚŝŽŶƐ ? 
x Reporting Format for Economic Evaluations [185]: Covers 13 major dimensions 
ǁŝƚŚ ‘ǇĞƐ ?ŶŽ ?ƌĞƐƉŽŶƐĞƋƵĞƐƚŝŽŶƐ ? 
 
Checklists developed by Sculpher [184] and  Nuijten  et al. [185] were identified but 
rejected because they focused on advanced modelling techniques and virtually no previous 
studies had used such methods. [6] The BMJ, CHEC, and QHES checklists are similar in that 
they are all subjective measures which incorporate descriptive components. However, 
unlike the BMJ and CHEC checklists, the QHES had a quantitative aspect, with each 
question carrying a weighted point score, out of a maximum of 100, which could allow 
interpretation of the overall quality of study, and a direct comparison with other studies in 
the same topic area. Furthermore, the QHES has been demonstrated to have good internal 
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validity [186-188], produces similar results to other quality checklists [187], and covers the 
same topics as other checklists but is very easy in its application. [188] These were 
identified as the advantages for using the QHES checklist, and hence the QHES was adopted 
as the method of quality assessment for the review. The QHES instrument can be seen in 
Table 3.1. 
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Table 3.1: The QHES instrument 
  Questions Points Yes No 
1 Was the study objective presented in a clear, specific, and 
measurable manner? 
7     
2 Were the perspective of the analysis (societal, third-party 
payer, etc.) and reasons for its selection stated? 
4     
3 Were variable estimates used in the analysis from the best 
available source (i.e., randomized control trial - best, expert 
opinion - worst)? 
8     
4 If estimates came from a subgroup analysis, were the groups 
pre-specified at the beginning of the study? 
1     
5 Was uncertainty handled by (1) statistical analysis to address 
random events, (2) sensitivity analysis to cover a range of 
assumptions? 
9     
6 Was incremental analysis performed between alternatives for 
resources and costs? 
6     
7 Was the methodology for data abstraction (including the value 
of health states and other benefits) stated? 
5     
8 Did the analytic horizon allow time for all relevant and 
important outcomes? Were benefits and costs that went 
beyond 1 year discounted (3% to 5%) and justification given for 
the discount rate? 
7     
9 Was the measurement of costs appropriate and the 
methodology for the estimation of quantities and unit costs 
clearly described? 
8     
10 Were the primary outcome measure(s) for the economic 
evaluation clearly stated and did they include the major short-
term, long-term, and negative outcomes? 
6     
11 Were the health outcomes measures/scales valid and reliable? 
If previously tested valid and reliable measures were not 
available, was justification given for the measures/scales used? 
7     
12 Were the economic model (including structure), study 
methods and analysis, and the components of the numerator 
and denominator displayed in a clear, transparent manner? 
8     
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13 Were the choice of economic model, main assumptions, and 
limitations of the study stated and justified? 
7     
14 Did the author(s) explicitly discuss direction and magnitude of 
potential biases? 
6     
15 Were the conclusions/recommendations of the study justified 
and based on the study results? 
8     
16 Was there a statement disclosing the source of funding for the 
study? 
3     
  Total Points 100     
 
When interpreting QHES questions, points were only awarded if the reviewers believed 
that the most important criteria for the questions were met; if this was the case all points 
would be awarded. The reviewers did not award fewer points if the study only met some of 
ƚŚĞ ƋƵĞƐƚŝŽŶ ?Ɛ ĐƌŝƚĞƌŝĂ ? ƚŚĞ ƌĞƐƉŽŶƐĞ ƚŽ ĞĂĐŚ ƋƵĞƐƚŝŽŶ ĞŝƚŚĞƌ ďĞŝŶŐ Ă  ‘ǇĞƐ ?  ?ƚŚĞƌĞĨŽƌĞ ĨƵůů
ƉŽŝŶƚƐ ?ŽƌĂ  ‘ŶŽ ?  ?ŶŽƉŽŝŶƚƐ ? ?&Žƌ ŝŶĚŝǀŝĚƵĂůƋƵĞƐƚŝŽŶƐŽŶ ƚŚĞY,^ ? ƚŚĞƌĞǁĞƌĞƉĂƌƚŝĐƵůĂƌ
criteria to be met in addition to those included within the QHES question. These were: 
 
x Q5: How was uncertainty handled?  W The reviewers required that uncertainty was 
investigated using robust statistical techniques; for within-trial evaluations, this 
was done by using non-parametric bootstrapping, and for modelling evaluations, 
PSAs were required. The reviewers deemed that one- and two-way sensitivity 
analyses did not capture uncertainty robustly enough for Q5 to be met and points 
awarded. 
x Q8: Did the time horizon allow for all important outcomes?  W Chapter 2 showed 
that smoking in pregnancy impacts on the health of mothers and infants both 
within-pregnancy and across their lifetimes. For points to be awarded, studies had 
to have included a within-pregnancy and lifetime analysis horizon for both mother 
and infant. 
x Q10: Were the major short-term, long-term and negative outcomes included?  W
Chapter 2 identified that smoking in pregnancy is potentially-causally associated 
with nine conditions. If any of the following conditions was omitted from the 
evaluation, no points were awarded:   
o Placenta previa 
o Placental abruption 
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o Ectopic pregnancy 
o Pre-eclampsia 
o Pre-term birth  
o Early & late foetal loss  
o SIDS 
o LBW 
o Respiratory illness 
 
Although there is no established, standardised interpretation of the QHES score, we 
adopted the following grouping based upon the work by Spiegel et al [189]: 0-24, extremely 
poor  quality; 25-49, poor quality; 50-74; fair quality; 75-100 high quality.  
 
3.3.8 Data Synthesis 
 
It may have been possible to meta-analyse effectiveness and cost data to generate pooled 
estimations of incremental effectiveness and costs, allowing an ICER to be calculated across 
all studies. However, it was anticipated that this would be inappropriate due to the high 
degree of variation in interventions and population across all studies, and would not 
produce a meaningful result. Another possibility would have been not to conduct a meta-
analysis, but convert costs in the same currency and price year to allow comparison across 
all the studies as to which interventions appeared to be cost-effective. However the 
primary aim of this review was to critically assess previous evaluations to identify the 
potential short comings of the current literature, and therefore this analysis was deemed 
superfluous to addressing this question.  
 
We adopted a narrative synthesis with the primary objective of discussing the quality of the 
methods used in identified studies, as determined by the QHES. The results of the 
assessment from the QHES would be used to demonstrate the strengths and weaknesses of 
each individual study and of the literature as a whole. To facilitate this we allocated QHES 
scores to studies as an indicator of overall study quality and qualitatively inspected the 
ĐŽŵƉŽŶĞŶƚƐ ŽĨ ƐƚƵĚŝĞƐ ? ƐĐŽƌĞƐ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ǁŚŝĐŚ ĂƐƉĞĐƚƐ ŽĨ ĞǀĂůƵĂƚŝŽŶ ƋƵĂůŝƚǇ ǁĞƌĞ
commonly absent or poor across studies.  
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 Results 3.4
 
Searching until 2011 returned 3,986 citations; a further 31 potential studies were identified 
from the NICE website. The US Surgeon General website returned no potential studies. Of 
the 4,017 citations, the first stage of screening identified 18 studies to be included in the 
full review (see Figure 3.1). The updated search identified a further 1,391 citations. 
Screening identified one further study for inclusion, undertaken as part of NICE guidance. 
[190] The initial search identified one RCT which was ongoing [191], and the update 
identified three ongoing RCTs. [192-194] ŽŶƚĂĐƚ ǁŝƚŚ ƚŚĞ ƚƌŝĂůƐ ?principal investigators 
returned the unpublished data for three RCTs [123, 195, 196], while one was unavailable. 
[193] Two of the initial 18 studies were identified as conference abstracts. [197, 198] 
Further searching failed to uncover a full economic report associated with these abstracts, 
and attempts to contact the authors failed, hence they were excluded.  
 
Two further studies were excluded during data extraction. One study investigated the cost-
effectiveness of training general practitioners to deliver cessation interventions, and the 
main outcomes (acceptance of a training session, purchase of cessation materials, and use 
of the materials) were not related to cessation or pregnancy. [199] The other was found 
not to have a relevant cessation intervention. [200]  
 
18 studies were included in the full review.  13 studies were published in peer reviewed 
journals [65, 68, 69, 71, 137, 201-208], two with NICE guidance [139, 190], and three were 
unpublished RCTs. [123, 195, 196] 
 
After considering included studies, it was decided that meta-analysis was inappropriate 
because studies were of an extremely heterogeneous nature, and questions posed by the 
review could probably be satisfactorily answered by narrative review; therefore this was 
deemed more appropriate.    
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Figure 3.1: Review PRISMA diagram 
 
 
3.4.1 Characteristics of Studies 
 
Appendix 12.3, Table 12.3 and Table 12.4 report the key characteristics of included studies. 
Nine studies were CBAs [65, 68, 69, 201, 203-205, 207, 208], five were CEAs [71, 123, 195, 
202, 206],  three were CUAs [137, 139, 190], and one had both a CEA and CUA. [196] There 
was a wide variety of interventions. Three studies used a telephone-based intervention 
[201, 202, 206], one combined telephone and self-help materials [137], and one used 
financial incentives linked with UC. [196] Two used self-help materials [203, 208], while one 
study combined self-help materials and counselling. [69] Two studies used counselling 
interventions [201, 207], and four studies used hypothetical interventions. [65, 68, 71, 205] 
One study used multiple interventions identified from a systematic review [139], while 
another used interventions described in the literature. [190] One study investigated NRT 
versus placebo, both combined with behavioural support [123]; another compared physical 
activity with behavioural support versus behavioural support alone. [195] Comparators in 
all except one study were either no intervention or UC, which had varied definitions across 
studies. [123] 
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Nine economic analyses were part of clinical trials [69, 123, 137, 195, 196, 202-204, 208], 
four were part of observational studies [71, 201, 206, 207], and five were hypothetical 
studies based upon data in the literature. [65, 68, 139, 190, 205] 12 studies took a 
healthcare provider perspective for the analysis, while six studies undertook a societal one. 
[123, 137, 139, 190, 195, 196] 
 
Most evaluations used short time horizons for the analyses, with 10 studies considering 
only outcomes during pregnancy or immediately afterwards, while six reported considering 
ŽƵƚĐŽŵĞƐ ŽǀĞƌ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ůŝĨĞƚŝŵĞ[68, 69, 137, 139, 190, 196], and two studies 
considering the lifetime of the infant as well. [139, 190] One study incorporated healthcare 
costs associated with the first year of life of the infant [137], while another included NICU 
healthcare costs for LBW in the immediate postpartum period. [196] Six reported discount 
rates, with rates of 3% [137], 3.5% [139, 190, 196], 4% [68], and 5%. [71] Cost data was 
predominantly obtained from micro-costing analyses, and tended to be limited to costs 
associated directly with the intervention (salary, materials, etc.). These tended to be 
collected as part of the trials, or taken from reliable cost sources if not. Costs associated 
with LBW births and other infant outcomes were generally taken from the literature.  
 
Measures of smoking cessation were the most frequent primary outcomes (12 studies), 
while two studies used numbers of LBW infants prevented [68, 205], one used SIDS 
prevented [71], and three used QALYs. [137, 139, 190] Secondary outcomes were: LBW 
infants (six studies) [65, 69, 123, 137, 203, 204], premature birth (two studies) [65, 203], 
prenatal death (three studies) [68, 123, 139], life years (LY) (one study), [137], and QALYs 
(one study). [196] When smoking status was used as an outcome in trials, this was 
biochemically validated in eight studies. [69, 123, 137, 195, 196, 201, 206, 208] 
Deterministic sensitivity analyses, investigating assumptions made in economic analyses, 
were performed in ten studies [65, 68, 69, 137, 139, 196, 201, 205, 206, 208]; the most 
frequently- varied parameters were intervention effectiveness [65, 68, 69, 137, 201, 205], 
intervention cost [68, 69, 137, 139, 201, 206, 208], and background quit rate.  [65, 205] 
Four studies reported using robust statistical techniques in the sensitivity analysis. [123, 
190, 195, 196] 
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3.4.2 Findings of included studies 
 
Five studies were conducted in the UK. [123, 139, 190, 195, 196] All other studies were 
conducted in the US. All except one concluded that smoking cessation interventions were 
cost-effective or cost-beneficial. [137]  
 
Of three UK RCTs, the incremental cost per quitter was £4,926 for NRT [123], and £1,127 
for financial incentives [196], while the other found the physical activity intervention was 
more effective and cheaper than UC. [195] Although one RCT did collect EQ-5D data, there 
was no statistically significant difference between the two groups, and therefore no 
analysis was performed using these data. [123] One RCT extended the within-trial results to 
lifetime horizon for the mother using a previously developed model [209], and estimated 
an incremental cost per QALY of £482 for financial incentives. [196]The impact of 
uncertainty was explored in all RCTs, with Cooper et al finding the majority of the 
bootstrapping iterations laid within the north east quadrant, suggesting that NRT was likely 
to be more effective but more costly. [123] However, there was a lot of uncertainty in the 
cost estimates which meant that the iterations were spread around all four quadrants of 
the cost-effectiveness plane. Tappin et al explored uncertainty using a PSA [196], which 
suggested that at a willingness to pay of £20,000-£30,000 per QALY, the probability of the 
financial intervention being cost-effective against UC was 70%; however there was also 
some degree of uncertainty, with iterations spread across all four quadrants of the cost-
effectiveness plane. Furthermore, a value of information (VOI) analysis suggested that at a 
willingness to pay of £30,000, additional research was potentially worthwhile if it cost less 
than £3.3 million. Ussher et al found that at a willingness to pay of £20,000 per QALY, 
approximately 75% of iterations were cost-effective, but this never went above 80%. [195]  
 
One modelling study reported the largest ICER, of £4,005 per QALY, being associated with 
cognitive behavioural therapies (CBTs). Both rewards (interventions where the participant 
received a financial or non-ĨŝŶĂŶĐŝĂů ƌĞǁĂƌĚ ĨŽƌ ŵĞĞƚŝŶŐ ĐĞƌƚĂŝŶ ĐƌŝƚĞƌŝĂ ? ĂŶĚ  ‘ŽƚŚĞƌ
ŝŶƚĞƌǀĞŶƚŝŽŶƐ ?  ?ŶŽŶ d ? ĨŝŶĂŶĐŝĂů ? Žƌ ƉŚĂƌŵĂĐŽůŽŐŝĐĂů ŝŶƚĞƌǀĞŶƚŝŽŶƐ ? ǁĞƌĞ ĨŽƵŶĚ ƚŽ ďĞ
dominant over no intervention, while pharmacotherapies had an ICER of £2,253 per QALY, 
feedback had an ICER of £1,992 per QALY, and stages of change (SoC) interventions an ICER 
of £3,033 per QALY. [139] The other modelling study found that, even considering short-
term (defined as three year post intervention), cessation interventions appeared to be 
111 
 
cost-effective with ICERs of £5,445 and £1,331 per QALY for high versus low intensity 
behavioural support, £17,827 and £157,696 for high intensity versus UC, and £41,088 and 
£60,409 per QALY for conditional versus non-conditional incentives. [190] The ICERs 
decreased as the perspective was increased to include the lifetime for both the mother and 
her infant.  The PSA results suggested that all the interventions modelled achieved a 100% 
probability of cost-effectiveness by £31,000 per QALY in the lifetime analysis. The 
implication of these findings is that cessation interventions are cost-effective in the UK 
setting. 
 
One US study reported that their MVI intervention reported no additional benefit in QALYs, 
suggesting that the intervention was not cost-effective. [137] However, other studies in the 
US found cost-benefit ratios estimated from 2:1[204] to 2.8:1[203], though one study 
found the cost-benefit ratio to be between USD 1:17.93 to USD 1:45.83. [69] Another study 
found an effectiveness to cost ratio of USD 1:84 [206], while one suggested that long-term 
costs averted were USD 3.26 for every USD 1 spent on cessation interventions. [68] 
Neonatal cost savings of USD 881 (£523.6724) per maternal smoker were identified in a 
separate study, which found that an intervention costing USD 24 (£14.2725) per smoking 
mother would generate a net saving of USD 8 million (£4,755,20026) in healthcare costs 
nationally in the US [201]. Pollack et al estimated that a USD 45 (£26.7527) intervention 
would annually avert 108 SIDS at an estimated cost of USD 210,500 (£125,121.2028) per life 
saved. [71]  Another study suggested that the breakeven cost of the intervention was USD 
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32 (£19.0229) (varying between USD 10 and USD 237(£5.94 - £140.8730)) [65], while another 
suggested that cessation interventions were cost-effective if they cost USD 80 (£47.5531) or 
less and achieved an 18% quit rate. [205] It was suggested by Thorsen et al that if the 
maximum spent was USD 15,366 (£9,133.5532) on an intervention, savings of USD 137,592 
(£81,784.6833) in healthcare costs would be achieved. [207]  ICERs in the US were 
estimated in two studies, with one calculating an ICER per quitter of USD 298.76 
(£177.5834) [202], and the other estimating two ICERs per quitter of USD 50.93 (£30.2735) 
for one intervention and USD 118.83 (£70.6336) for the other. [208] Therefore, from the US 
perspective all studies except one suggest that cessation interventions delivered during 
pregnancy are potentially cost-effective. 
 
3.4.3 QHES assessment 
 
Table 3.2 summarises QHES assessment results. Six studies attained a score greater than 75 
indicating high quality [65, 123, 137, 190, 195, 196], six were deemed of fair quality [68, 
139, 202-205], and six poor quality. [69, 71, 201, 206-208] The median score was 58, with a 
range from 33 to 87, and an inter-quartile range of 38. Of the six high quality studies, four 
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were the most recently completed studies, while the older studies tended to be of poor or 
fair quality. 
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Table 3.2: Results of the QHES assessment 
Author Year Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Total 
Ayadi 2006 X X             X     X     X   35 
Cooper 2014 X X X X X X X   X   X X X X X X 87 
Dornelas 2006 X   X     X X   X   X X X   X X 67 
Ershoff 1983 X         X X   X   X X X   X X 59 
Ershoff 1990 X X X     X X   X   X X X   X X 71 
Hueston 1994 X         X X       X X X X X X 57 
Mallender 2013 X   X   X X X X X   X X X X X   86 
Marks 1990 X   X       X   X   X X   X X   57 
Parker 2007   X         X   X   X     X   X 33 
Pollack 2001 X           X       X     X X X 36 
Ruger 2008 X X X X   X X   X   X X X X X X 78 
Shipp 1992 X X X     X X   X   X X X X X X 77 
Tappin 2014 X X X X X X X   X   X X X X X X 87 
Taylor 2009 X         X X   X   X X X   X   56 
Thorsen 2004 X           X   X         X X X 37 
Ussher 2014 X X X X X X X   X   X X X X X X 87 
Windsor 1988 X           X   X   X       X   35 
Windsor 1993 X   X           X   X X     X X 49 
Frequency 17 8 10 4 4 11 16 1 16 0 16 14 11 11 17 13   
Percentage 94% 44% 56% 22% 22% 61% 89% 6% 89% 0% 89% 78% 61% 61% 94% 72%   
X = yes on QHES 
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3.4.4 Qualitative assessment of individual components of economic evaluations 
 
Qualitative assessment of individual QHES items (Table 3.2) indicates that almost all 
included studies had  clearly presented  objectives (Q1, 17 studies) and methodology for 
data abstraction (Q7, 16 studies); appropriate measurement of costs (Q9, 16 studies); used 
valid health outcomes (Q11, 16 studies); displayed an economic model clearly and 
transparently (Q12, 14 ƐƚƵĚŝĞƐ ? ?ŚĂĚũƵƐƚŝĨŝĂďůĞĐŽŶĐůƵƐŝŽŶƐďĂƐĞĚŽŶƐƚƵĚŝĞƐ ?ĨŝŶĚŝŶŐƐ ?Y ? ? ?
17 studies) and disclosed sources of funding (Q16, 13 studies). No studies reported an 
inappropriate costing method; however, many did not report the year from which cost 
estimates were calculated, preventing the re-use of cost data in subsequent studies.  
 
The following aspects of methodology were less comprehensively presented in evaluations: 
performance of incremental analyses (Q6, 11 studies), justification for choice of parameters 
used within economic models (Q13, 11 studies) and explicit discussion of potential biases 
from economic evaluations (Q14, 11 studies). Few studies used estimates for parameters 
ŽďƚĂŝŶĞĚ ĨƌŽŵ ƐŽƵƌĐĞƐ ũƵĚŐĞĚ ƚŽ ďĞ ƚŚĞ  ‘ďĞƐƚ ĂǀĂŝůĂďůĞ ?  ?Y ? ?10 studies), stated the 
perspective of economic analyses (Q2, eight studies), or specified sub-group analysis at the 
beginning of studies (Q4, four studies); however, most studies did not contain sub-group 
analyses, so this question has limited relevance. Outcome data were either collected within 
trials or estimated from the literature but, amongst studies using estimates, none used 
estimates derived from systematic reviews and, hence, literature sources used were not 
judged as being the best available evidence.   
 
Only four studies performed a robust analysis of uncertainty, the rest either used 
deterministic sensitivity analyses or reported no sensitivity analyses (Q5). No studies were 
judged to have included all major short- and long-term maternal and foetal outcomes 
(Q10), though one study came close, omitting just premature birth. [190] Only one study 
was judged to have a time horizon that incorporated both the effects within-pregnancy and 
lifetime as well for both the mother and infant (Q8).  
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 Discussion 3.5
 
This review found only 18 studies which included economic evaluations of cessation 
interventions delivered during pregnancy; only six of these (33%) were judged as high 
quality. Evaluations were generally well described, utilised appropriate health outcomes 
and drew realistic conclusions based upon their results, but significant aspects of analyses 
were deficient. Specifically, where estimated, smoking outcomes did not appear to be 
derived from the highest quality literature sources; no economic models comprehensively 
considered all major and relevant foetal and maternal health outcomes, only one employed 
an appropriate time horizon, four controlled for uncertainty of estimates using statistically 
robust methods, and only three studies reported a primary outcome measure using a 
generic health related quality of life outcome, such as QALYs.  
 
3.5.1 Limitations of review 
 
A limitation of this review is that the QHES is a subjective instrument, and some QHES 
questions might be considered open to different interpretations. This was highlighted by 
the need for discussion among reviewers to resolve occasional disagreements about how 
some QHES items related to studies. However, the other checklists identified in the scoping 
review were also subjective questionnaires and, therefore, this is likely to have been a 
problem with any quality checklist utilised. Furthermore, it has been suggested that the 
greatest influence on the quality assessment comes not from the utilised checklist but from 
the reviewer themselves. [210] We have attempted to avoid this issue by using at least two 
reviewers to assess the quality for each included study, however there is still potential for 
this to be an issue. Secondly, there were occasions where the reviewers felt QHES items 
were difficult to completely address and, rather than awarding all available points only for 
completely addressing a criterion and nothing for not doing so, rewarding partial 
achievement of QHES items could have been more appropriate. Certainly, other 
researchers have highlighted that certain questions on the QHES can result in ambiguous 
assessment. [211] For example, QHES question three deals with information sources, and it 
might be appropriate to score this item in a graded fashion with points awarded being 
dependant on the different types of study design which could generate information used in 
the evaluations (e.g. eight points for information from systematic review, seven for 
information from clinical trial and zero points for information from expert opinion). This 
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could have resulted in the points score calculated for each study better reflecting the 
overall quality of the methods used, potentially providing a more meaningful comparison. 
Finally, although the QHES is a good measure for the internal validity of the study, it does 
not measure external validity, and has not yet been demonstrated thus. [188] This means 
this review was unable to capture whether the results of the included studies could be 
generalised to the population, and hence a meaningful comparison across all the models 
may not be possible or appropriate.  Nevertheless, we believe that our use of QHES is 
appropriate to identify, across studies, those aspects of economic evaluations which might 
require development.   
 
Another potential limitation of the review is the inclusion of the additional specifications 
associated with questions five, eight, and 10 on the QHES instrument. This could have 
potentially added bias to favouring the improved economic model, suggesting that the 
conclusions from this review are prejudiced against the current literature. However, it is 
unlikely that these additional specifications are introducing bias, because they could be 
argued as critically important for any model/evaluation of cessation during pregnancy. For 
example, without performing a statistically robust analysis of uncertainty, it is impossible to 
say with confidence that the decision made on the basis of the evaluations results is the 
ĐŽƌƌĞĐƚŽŶĞ ?&ƵƌƚŚĞƌŵŽƌĞ ?ĂĚĞƚĞƌŵŝŶŝƐƚŝĐĂŶĂůǇƐŝƐŵĂǇũƵƐƚďĞĂ ‘ŚŝƐƚŽƌŝĐĂůĂƌƚĞĨĂĐƚ ?ĚƵĞƚŽ
the included parameters, and in reality the intervention is not value for money, and hence 
we have foregone benefits that would have been gained by making the correct 
decision.[109] With regards to the time horizon and inclusion of major outcomes, how can 
it be concluded that an evaluation is correctly specified if it only focuses on within-
pregnancy, excluding any long-term benefits of quitting and reductions in smoking 
attributable healthcare costs. This would suggest that the evaluation is incorrectly specified 
as it is not taking into account important benefits and healthcare costs, and hence any 
decision made on the results of this evaluation could be incorrect. Considering these 
pitfalls, the author believes that these additional specifications to the QHES are a necessity 
and do not introduce bias into this review. 
 
One final limitation is that there are possible issues with the QHES scoring system. The use 
of the scoring system is debatable in the literature, with some researchers suggesting that 
the advantage of a scoring mechanism is questionable. [211] Certainly, scoring systems in 
the quality assessment of RCTs have been brought into question, with criticisms 
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highlighting the lack of standard techniques and/or rigour in the development of the scales 
[212, 213], and that the scale used and whether the reviewers are blinded or open to 
authorship of the trial can greatly influence the quality assessment weighting in the meta-
analysis. [214, 215] Hence, it is likely that these issues also persist with the QHES scoring 
mechanism, although the QHES scoring mechanism was subsequently demonstrated to be 
valid after it was trialled on a group of 60 experts (30 health economists and 30 clinicians) 
across three disease states [183, 186], so it is unclear how much of an issue the use of the 
scoring mechanism is in this context. Additionally, it may be possible that high quality 
information has been eliminated from what has been considered an overall poor scoring 
study. This could be an issue, although it is difficult to determine how much impact this 
may have on the conclusions of this review. However, the focus of this review was to 
determine the limitations of the current literature, and not to inform on which 
interventions were considered the most value for money. As such, the QHES scorings do 
not influence the conclusions of the review, since the QHES was used to highlight the 
potential methodological fallings of previous evaluations, and thus the scoring is unlikely to 
bias the conclusions of this review.  
 
3.5.2 Strengths of review 
 
This review also has two important strengths. The broad search strategy has allowed the 
review to identify the majority of the literature published, and it is unlikely that an 
evaluation has escaped being identified. The review has also incorporated the more recent 
literature that had been published since the previous review. Therefore, this review is the 
most comprehensive in this subject to date.   
 
The use of the QHES has allowed a systematic identification of the shortcomings in the 
published evaluations. This is crucial for the improved model to be developed later in this 
thesis, since the review has identified the most important issues which need addressing for 
the new model to be an improvement on the previous literature. The important impact of 
identifying the shortcomings of the current literature is that the review demonstrates that 
the included studies are potentially inaccurately estimating the cost-effectiveness of 
cessation interventions. This would suggest that there is potentially misinformation being 
used in the decision-making process for healthcare interventions across the globe, with the 
increased chance that the wrong decision is being made. However, the current literature 
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does suggest that within-pregnancy cessation interventions are potentially cost-effective, 
so it is unlikely that an improved model will change this decision. But, the current literature 
cannot inform the decision maker as to how confident he/she may feel that delivering 
within-pregnancy cessation interventions is the correct decision. Furthermore, an improved 
economic model may take more outcomes into account which may be seen as relevant to 
the decision maker, and hence he/she may feel that the improved model is producing more 
robust estimates of the cost-effectiveness of cessation. This is an important justification for 
constructing an improved economic model.     
 
3.5.3 What is well established in the previous literature? 
 
The previous literature currently demonstrates that cessation interventions are generally 
cost-effective, particularly when considering incremental costs per quitter. Only one study 
found that cessation interventions during pregnancy were not cost-effective [137], all other 
studies estimating relatively low costs per quitter or benefit cost ratios of approximately 
3:1. Studies estimating incremental costs per quitter found that either the interventions 
were dominant over UC or reported relatively low values, mostly less than £5,000. This 
would suggest that, should the parameter of interest be the number of quitters generated 
by intervention, or the incremental cost per quitter, then this is already well established in 
the literature, requiring no further exploration. 
 
The costs involved with delivering an intervention have also been well explored in the 
previous literature. Out of the 12 studies which were conducted as part of an RCT or other 
observation study, 10 can be classified as having micro-costed the intervention included in 
the study. This is important because having accurate costs involved in delivering the 
intervention is required for demonstrating the cost-effectiveness. Inaccurate cost data is 
highly likely to generate inaccurate cost-effectiveness estimates. Determining accurate 
costs of interventions is also important for any hypothetical decision analytic model, since 
these can be used to model and estimate the longer term impacts of interventions, which 
would be difficult to capture within the short time frame of an RCT. However, while studies 
seemed to collect appropriate cost data, several did not report the prices used in the 
analysis, which can make reutilising these costs in subsequent estimations very difficult. 
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3.5.4 What requires improvement in the previous literature? 
 
Few studies reported using a generic HRQoL measure, with only four studies reporting 
incremental costs per QALY. [137, 139, 190, 196] One RCT collect EQ-5D at six months 
postpartum, but, due to insignificant differences between the intervention and control 
group, did not perform any analysis of this data. [123] Generic outcomes, like QALYs, can 
ŝŶĐŽƌƉŽƌĂƚĞ ďŽƚŚ ƉĂƚŝĞŶƚƐ ? ƋƵĂůŝƚǇ ŽĨ ůŝĨĞ ĂŶĚ ůŝĨĞ ĞǆƉĞĐƚĂŶĐǇ ŵĞĂƐƵƌĞƐ and are used by 
health providers to compare the benefits and costs of interventions which affect very 
different clinical conditions. Consequently, although the previous literature allows 
comparison between cessation interventions, the same comparisons cannot be made 
across the healthcare sector as a whole. This is very important for decision makers as they 
might be considering whether to fund cessation interventions in the context of a whole mix 
of interventions, and therefore the cost-effectiveness needs to be demonstrated using a 
standardised measure. The results of the included studies were mixed, with two suggesting 
that interventions were cost-effective, while one did not; therefore this requires further 
exploration. 
 
Most studies focused on a within-pregnancy time horizon, with only four studies 
considering the impacts of smoking during pregnancy on longer term outcomes [137, 139, 
190, 196], and one of these seems to be relatively constrained as to what longer term 
included. Smoking has serious health effects, both within pregnancy and general 
morbidities. Doll et al has demonstrated that smoking in general increases the risk of 
morbidities such as lung cancer and CHD, as well as increasing the general mortality rate 
compared to non-smokers. [66] Within-pregnancy, smoking increases the risks of several 
conditions, including ectopic pregnancy, miscarriage, and placental abruption. [2, 3] After 
pregnancy, smoking both within-pregnancy and after have also been demonstrated to 
impact on the health of the offspring, with increasing risks associated with respiratory 
diseases. [216] Therefore, to determine the cost-effectiveness of smoking cessation during 
pregnancy, the time horizon must not only capture within-pregnancy impacts, but also 
impacts over the lifetime, for both mother and infant. Most of the previous literature was 
trial-based, and estimated outcomes in keeping with the trial follow up period; however 
one trial extended their analysis using a Markov model to estimate the impact on the 
maternal lifetime QALYs and costs. [196] Of the decision analytic models, three focused on 
within-pregnancy impacts [65, 68, 205], while two looked at a broader time horizon. Taylor 
explored some of the impacts on both the mother ?s and infant ?s lifetime [139], but did not 
121 
 
take into account any within-pregnancy impacts. Ruger et al extended the results of the 
trial to a lifetime perspective using published estimates, but did not estimate any health 
related costs for the infant beyond the first year of life. [137] Only Mallender et al seem to 
develop a model which incorporated some of the impacts both within-pregnancy and 
across the lifetime. [190] 
 
Tied in with the time horizon problem, many studies were missing key conditions related to 
smoking in pregnancy. Most studies omitted maternal co-morbidities associated with 
smoking and pregnancy, e.g. placental abruption, placenta previa, pre-eclampsia. These can 
all lead to severe complications during pregnancy, and in a worst case scenario, death to 
the infant, the mother, or both. Of the within-pregnancy studies, only Shipp et al appeared 
to include maternal complications [65], although they are also likely to be captured within 
some of the RCTs. [123, 195, 196] Furthermore, birth and lifetime conditions for the infant 
were not included in many of the studies. From Chapter 2, smoking has been causally 
associated with premature birth, LBW, asthma, etc. Several studies attempted to capture 
the healthcare cost savings for adverse birth outcomes avoided from cessation [68, 69, 71, 
201, 203-205, 207], but only one study included the impact of LBW and asthma on the 
health of the child across their lifetime. [190] Unfortunately, this study excluded premature 
birth.  
 
Only four ƐƚƵĚŝĞƐĐŽŶƐŝĚĞƌĞĚǁŽŵĞŶ ?ƐƌĞůĂƉƐĞƚŽƐŵŽŬŝŶŐĂĨƚĞƌƉƌĞŐŶĂŶĐǇ ?[137, 139, 190, 
196] Very different rates of relapse were used; Ruger et al suggesting that 35% have 
relapsed over their remaining lifetime, while Taylor used 70% within one year postpartum. 
Tappin et al assumed a relapse rate of 60% and 30% in the intervention and control arms 
respectively [196], before applying longer term relapse probabilities for up to eight years 
after the intervention (5% per annum between years one and five, and 3% per annum 
between years six and eight) from studies of non-pregnant populations. Mallender et al did 
not use relapse per se, but estimated the number of women who would quit for good in 
any one year. Therefore, for one year after intervention, the one year quit rate as 
ĞƐƚŝŵĂƚĞĚŝŶƚŚĂƚƉĂƌƚŝĐƵůĂƌŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐƐƚƵĚǇǁĂƐƵƚŝůised, while a background quit rate 
of 2% was used at all other times. This lack of consistency suggests that relapse to smoking 
post-pregnancy is underexplored in the previous evaluations.  
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Ŷ ŝŵƉŽƌƚĂŶƚ ŝŵƉůŝĐĂƚŝŽŶ ŝƐ ƚŚĂƚ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ĚŝƌĞĐƚ ŚĞĂůƚŚ ƌŝƐŬƐ from smoking increases 
ǁŝƚŚ ŝŶĐƌĞĂƐŝŶŐ ƌĞůĂƉƐĞ ? ĂƐ ĚŽĞƐ ƚŚĞ ŝŶĨĂŶƚ ?Ɛ ĞǆƉŽƐƵƌĞ ƚŽƐĞĐŽŶĚ-hand smoke with the 
acknowledged health risks this entails. [24] Additionally, recent work suggests that if their 
mother smokes, an infant is over twice as likely to become an adult smoker [25], potentially 
exposing him or her to the associated lifetime adult health risks. Hence, by not including a 
rate of relapse to smoking after childbirth, most economic models are overestimating the 
number of mothers who remain abstinent after pregnancy, potentially overestimating the 
benefits of smoking cessation.   
 
A further issue is that the number of studies which robustly control for uncertainty is very 
low, with only the four most recently completed actually incorporating any statistically 
robust techniques. [123, 190, 195, 196] Controlling for uncertainty is important since it 
demonstrates that the correct decision has been made based on the results of the 
evaluation. Whilst in the past one- and two-way deterministic sensitivity analyses have 
been used for gauging the impact of uncertainty, these cannot control for the impacts 
associated with the uncertainty surrounding all parameters. [109] This is where a PSA is 
required. Two studies reported using a PSA, although Mallender et al only varied costs and 
quit rates for the interventions. [190] Tappin et al performed a broader PSA [196], covering 
the intervention costs, quit and short-term relapse rates, QALYs, and long-term disease 
costs, but not longer term relapse rates. Therefore, the capturing of uncertainty is 
potentially limited in the previous literature.  
 
3.5.5 The influence of the review on the design of the new improved economic model 
 
Although the current literature does not seem to have a definitive model structure for 
evaluating the within-pregnancy impacts of cessation, there are several previously 
published models which do have some influence on the ƐƚƌƵĐƚƵƌĞŽĨƚŚĞŵŽƚŚĞƌ ?ƐůŝĨĞƚŝŵĞ
component of the new improved economic model. Taylor, Mallender et al, and Tappin et al 
used Markov simulation for the long term impacts of cessation on the health of the 
mother. [139, 190, 196] Each of these models used Markov cohort simulation with states 
based around smoking behaviour (current smoker, former smoker, etc). It would seem 
ƉĞƌƚŝŶĞŶƚƚŚĂƚĂĚŽƉƚŝŶŐĂƐŝŵŝůĂƌƐƚƌƵĐƚƵƌĞĨŽƌƚŚĞŵŽƚŚĞƌ ?ƐůŝĨĞƚŝŵĞĐŽŵƉŽŶĞŶƚǁŽƵůĚďĞ
appropriate, although it may be necessary to alter the structures slightly to better suit the 
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improved economic model.  Such structure alterations will be the focus of Chapter 6,  
which introduces ƚŚĞDĂƌŬŽǀŵŽĚĞůĨŽƌƚŚĞŵŽƚŚĞƌ ?ƐůŝĨĞƚŝŵĞ ? 
 
3.5.6 Implications of the review 
 
Although there appears to be ever more literature on evaluations of cessation 
interventions during pregnancy, the required information for making decisions is still 
limited. There is strong evidence for cost per quitter outcomes, but comparable measures 
taking into account HRQoL have not been investigated. Furthermore, many of the models 
do not take into account the appropriate time horizons, focusing on within-pregnancy 
impacts, and excluding many of the important morbidities associated with smoking during 
pregnancy. This would suggest that the previous literature is not capturing the cost-
effectiveness of smoking cessation during pregnancy completely, and therefore could be 
misinforming decision makers, certainly around the probability that the decision is the 
correct one. This review has several important implications for the improved economic 
model: 
x Outcomes should be measured using some generic measure of HRQoL  
x The model should incorporate both the within-pregnancy and lifetime horizons for 
both the mother and infant, and therefore should include conditions both related 
to the mother and her offspring  
x Accurate modelling and incorporation of smoking behaviour after pregnancy for 
the mother 
x The model should include a PSA to control for uncertainty not only associated with 
the intervention, but with the included parameters as well 
  
 Summary 3.6
 
Given that smoking during pregnancy is an important public health issue, there are 
relatively few high quality economic evaluations demonstrating the cost-effectiveness of 
cessation interventions. There is a clear need for further evaluations to be conducted in 
this area. The next chapter investigates relapse after pregnancy, with the aim of addressing 
one of the key issues highlighted by this review. 
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 Chapter 4: Smoking abstinence in the postpartum period after 
receiving a smoking cessation intervention: A systematic review 
 
 Introduction 4.1
 
Although studies have investigated postpartum smoking behaviour, estimates of relapse to 
smoking after pregnancy vary. It has been estimated that 19% to 62% of women who 
stopped smoking in pregnancy have relapsed by three [217-223], 30% to 76% by six [217, 
221, 223-231], 32% to 59% by 12 [221, 227, 232, 233], 77% by 18 [234], and 59% by 24 
months postpartum. [235] Rattan et al investigated much later relapse in a longitudinal 
cohort study which had up to 21 years follow up. [230] Self-reported smoking using seven-
day point prevalence abstinence was reported at end of pregnancy, six months postpartum 
and five, 14, and 21 years after childbirth. Estimates for relapse were 43.5% at five, 35.5% 
at 14, and 35.8% at 21 years after childbirth. This variability amongst estimates for relapse 
to smoking in the postpartum period makes it difficult to choose a meaningful estimate for 
relapse rates to be used in economic models of cessation during pregnancy. A systematic 
review could help produce more accurate estimates of relapse in the postpartum period. 
This would be important, not only for predicting the smoking behaviour of mothers after 
pregnancy in general, but to investigate whether there are any differences in relapse 
behaviour between women who receive different cessation interventions in pregnancy, as 
ĂŶǇ ƐƵĐŚ ĚŝĨĨĞƌĞŶĐĞƐ ĐŽƵůĚ ŝŵƉĂĐƚ ŽŶ ŝŶƚĞƌǀĞŶƚŝŽŶƐ ? ĐŽƐƚ-ĞĨĨĞĐƚŝǀĞŶĞƐƐ ? dŽ ƚŚĞ ĂƵƚŚŽƌ ?Ɛ
knowledge, no systematic review of smoking rates after pregnancy has been published. 
Consequently, in this chapter a systematic review and meta-analysis is undertaken to 
determine patterns of abstinence from smoking in the postpartum period.  
 
 Aims and Objectives 4.2
 
4.2.1 Primary aim:  
To describe the rates of abstinence from smoking at different time points as far as possible 
after childbirth amongst women who attempted to quit smoking during pregnancy.  
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4.2.2 Objectives: 
1) To systematically search for and identify RCTs in which pregnant smokers receive a 
smoking cessation intervention 
2) To derive pooled estimates for the point prevalence of abstinence at different time 
points in the postpartum period 
3) To investigate whether or not pooled estimates for the point prevalence of 
abstinence vary with intervention/experimental and control/no intervention 
groups. 
 
 Methods 4.3
 
4.3.1 ZĂƚŝŽŶĂůĞĨŽƌƐƚƵĚŝĞƐ ?ŝŶĐůƵƐŝŽŶ 
 
It was anticipated that the most robust data on the rates of abstinence from smoking after 
pregnancy would be reported by clinical trials. Two Cochrane reviews have been conducted 
investigating psychosocial interventions and pharmacological studies. [27, 28] Both these 
reviews use a maximum sensitivity electronic and manual search of the available literature. 
It is highly likely that both these reviews will have identified all relevant trials, both 
published and ongoing, and therefore it was felt that any additional electronic searching 
would not have increased the sensitivity of the literature search, and hence was deemed 
unnecessary. All included and excluded studies that were cited in both Cochrane reviews 
were screened for inclusion in this systematic review. For any ongoing trials, the protocol 
was screened to determine whether the study included any postpartum follow-up, and 
ĐŽŶƚĂĐƚ ǁĂƐ ŵĂĚĞ ǁŝƚŚ ƚŚĞ ƚƌŝĂůƐ ? ƉƌŝŶĐŝƉĂů ŝŶǀĞƐƚŝŐĂƚŽƌ ǁŚĞƌĞŶĞĐĞƐƐĂƌǇ ƚŽ ĚĞƚĞƌŵŝŶĞ ŝĨ
there were any available results.  
 
4.3.2 Participants 
 
Pregnant smokers in any care setting were included. 
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4.3.3 Interventions 
 
Any intervention(s) aimed to encourage smoking cessation or prevent relapse to smoking 
during pregnancy. Control group participants could receive a placebo, another cessation 
intervention, or no intervention.  
4.3.4 Outcomes 
 
Quit rates; rates of point prevalence of abstinence from smoking. Rates reported at end of 
pregnancy and at least one other time point in the postpartum period. Biochemically 
validated and self-reported smoking cessation outcomes were considered.  
 
4.3.5 Study design 
 
Randomised and quasi-randomised controlled trials were included.  
 
4.3.6 Exclusion criteria 
 
Studies were excluded if: 
 
1) The intervention was delivered to women who were pregnant but not currently 
smoking 
2) Studies presented data in a format that could not be analysed and further 
information was not forthcoming from authors. 
3) Interventions were delivered only to smokers who had already quit (usually relapse 
prevention interventions) or studies enrolled both smokers and recent quitters 
with outcomes reported together. 
4) Studies reported smoking outcomes in the postpartum period, but not at end of 
pregnancy.  
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4.3.7 Data extraction 
 
Identified articles were screened by two reviewers and those deemed relevant were 
retrieved in full; two reviewers independently extracted data and performed quality 
assessments, discussing any discrepancies until agreement was secured. Data extracted 
from the studies included: 
 
x Trial design: country, trial year(s) , randomisation method  
x WĂƌƚŝĐŝƉĂŶƚƐ ?ĐŚĂƌĂcteristics 
x Description of control and experimental interventions, intervention provider, 
intervention intensity  
x Outcomes: abstinence rates in pregnancy four to eight weeks after randomisation, 
at the end of pregnancy and any time points afterwards;  method of biochemical 
validation and any cut-off point and which, if any, participants  were excluded from 
statistical analyses, with any justifications provided for this. 
 
4.3.8 Quality assessment 
 
Quality assessment was conducted by two reviewers using the Cochrane  ‘ZŝƐŬŽĨďŝĂƐ ?ƚŽŽů
developed by Higgins et al [236], with the following two modifications. Under the heading, 
 ?ƚƚƌŝƚŝŽŶ ďŝĂƐ ? ? Ă ƐĞĐƚŝŽŶ ǁĂƐ ĂĚĚĞĚ ƚŽ ŝŶĐŽƌƉŽƌĂƚĞ ǁŚĞƚŚĞƌ ƚŚĞ ƐƚĂƚŝƐƚical analysis had 
been conducted on an intention to treat basis (i.e. assuming that participants lost to follow 
up were smoking), or whether any randomised participants had been excluded from the 
ĂŶĂůǇƐŝƐ ?^ĞĐŽŶĚůǇ ?ƵŶĚĞƌ ‘KƚŚĞƌďŝĂƐ ? ?ĂƐĞĐƚŝŽŶǁĂƐĂĚĚĞĚto record whether biochemical 
validation had been undertaken, if the results were useable and if the validation had been 
done in an appropriate manner, i.e. had been conducted consistently (i.e. on all 
participants who either reported abstinence from smoking or all participants in the trial), 
and without bias towards certain types of participants. The risk of bias tool can be found in 
Appendix 12.4. 
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4.3.9 Data synthesis 
 
Initially it had been intended to calculate relapse to smoking in the postpartum period, as 
this would be the most relevant information required for any improved economic model. 
However, during the data extraction phase, it became clear that the required longitudinal 
data (i.e. women reporting abstinence at the end of pregnancy being also followed up in 
the postpartum period) was unavailable. Data was available about the postpartum smoking 
behaviour of all participants in trials. This is different to relapse data since it gives a pooled 
abstinence estimate for those who were smoking at the end of pregnancy and those who 
were not, and we are unable to tell if the women reporting smoking abstinence at later 
postpartum time points are the same who reported abstinence at the end of pregnancy. 
Therefore, the primary outcome from the meta-analysis was abstinence from smoking 
amongst all trial participants using seven day point prevalence estimates; this is why 
findings are described as abstinence patterns rather than relapse curves. 
 
Currently the two most common approaches for performing meta-analyses are fixed-
effects and random-effects. In a fixed-effect model we assume that there is one true effect 
size which is shared by all included studies, hence we can hypothesize that the combined 
effect is the estimate of this common effect size. [237] Therefore, we can assign weights to 
all studies based entirely on the amount of information captured by that study; the larger 
the study, the greater the weight it carries in the meta-analysis. It is assumed that the only 
error between the observed effect size and the true population effect size is caused by 
within-study estimation error. However, in a random effects meta-analysis, we assume that 
the true effect can vary from study to study (e.g. effect size maybe higher if the subjects 
are older), therefore the studies included in the meta-analysis are considered to be a 
random sample of the distribution of effects, with the pooled estimate assumed to be the 
mean effect of this distribution. [237, 238] Because a random-effects model is trying to 
estimate the mean of a distribution of true effects, weights assigned to included studies are 
ŵŽƌĞďĂůĂŶĐĞĚ ?ŚĞŶĐĞƐŵĂůůƐƚƵĚŝĞƐĂƌĞŶŽƚƚƌŝǀŝĂůŝƐĞĚĂŶĚůĂƌŐĞƐƚƵĚŝĞƐĚŽŶ ?ƚĚŽŵŝŶĂƚĞƚŚĞ
analysis. The random-effects model now controls for errors in both the within-study 
estimate of the true mean in a specific population and also the mean effect of all the true 
effects across different studies.  
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A random-effects (DerSimonian and Laird) meta-analysis was adopted. [238] This was 
because it was anticipated that there would be great deal of heterogeneity between 
included studies, since cessation interventions across trials were likely to vary not only in 
the pregnant population but also in intensity of the intervention. Furthermore, for the 
economic model, gaining information on the distribution of relapse estimates as generated 
by a random-effects analysis would be more useful when controlling for uncertainty than 
the point estimate generated by the fixed-effects analysis. A meta-analysis using intention 
to treat was conducted, synthesising weighted proportions of point prevalence abstinence 
rates, representing a summary measure of prevalence of abstinence at that time point. The 
results are presented as pooled proportions of smokers who were abstinent, with 95% CIs 
at the different time points; statistical heterogeneity between trials was quantified using 
the I2 statistic.  
 
To calculate the pattern of abstinence from smoking in early pregnancy until after 
pregnancy, it was necessary to identify appropriate time points for data aggregation. This 
was achieved by tabulating all time points at which smoking status was ascertained in 
included studies and then selecting those which were reported most. Where studies did 
not report smoking status at the selected time points, their data were allocated to the 
selected time point closest to the actual reported data collection time. To avoid potential 
heterogeneity generated by combining smoking data from time periods, the time points 
used to derive pooled estimates reflected those used by most individual trials. This resulted 
in review time points being relatively close together immediately after pregnancy, and then 
more spread out later in the postpartum period.  
 
The primary analysis involved pooling all participants from both the control and 
intervention groups to give a pattern of abstinence for all participants in the postpartum 
period. Furthermore, the primary analysis included both validated and self-reported 
abstinence. A secondary analysis was conducted by splitting control and intervention 
participants to explore whether there were differences in postpartum smoking behaviour 
between groups. Finally, a sensitivity analysis was conducted using biochemically-validated 
abstinence data only to explore any potential bias caused by self-reported abstinence. 
Meta-analyses and abstinence pattern graphs were generated using  Stata 11.2 [239], and 
the risk of bias summary drawn in Review Manager 5. [240]  
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 Results 4.4
 
The two systematic reviews [27, 28] on interventions for smoking cessation during 
pregnancy identified 177 trials which potentially provided data on abstinence during and 
after pregnancy. Of these, 13 were ongoing, and screening was performed using 
ŵĂŶƵƐĐƌŝƉƚƐ ĚĞƐĐƌŝďŝŶŐ ĞĂĐŚ ƚƌŝĂů ?Ɛ ƉƌŽƚŽĐŽů ? /ŶŝƚŝĂů ƐĐƌĞĞŶŝŶŐ ƌĞĚƵĐĞĚ ƚŚŝƐ ƚŽ  ? ? ƐƚƵĚŝĞƐ
which potentially reported outcomes in the postpartum period (see Figure 4.1). Four 
studies were identified as ongoing; contact with trials authors was unsuccessful for two 
trials [241, 242], one had completed but no results were available [193], and one had 
completed and the data was shared. [192, 195] During data extraction, 29 studies were 
excluded; details of which are given in Appendix 12.5, Table 12.5. 26 studies were included 
in this review, giving a cohort of 10,942 pregnant women. Characteristics of included 
studies are summarised in Appendix 12.5, Table 12.6.  
 
19 studies were RCTs [123, 195, 202, 243-258], five were cluster trials [259-263], and two 
were quasi-randomised. [264, 265] Control interventions were predominantly information 
booklets, with these being used in 15 studies. [202, 246-250, 253, 254, 257-260, 262, 264] 
Eight studies used counselling [123, 195, 251-254, 258, 261], three used placebo patches 
[123, 252, 258], one used non-contingent vouchers (rewards given to participants for 
attending the clinic) [250], and one did not report what the control intervention was. [255] 
Three studies reported the control intervention to be UC while not defining what UC 
involved. [243, 256, 263] One study reported that the control group received no 
intervention. [244] For the intervention groups, 17 studies reported using information 
booklets [202, 243, 245, 247-250, 254, 256-262, 264, 265], 20 reported using counselling 
[123, 195, 202, 243-248, 251-254, 256-261, 265], four used NRT [123, 252, 253, 258], three 
used social support interventions [248, 251, 259], and  two used MVI techniques. [255, 263] 
dŚĞ ĨŽůůŽǁŝŶŐ ŝŶƚĞƌǀĞŶƚŝŽŶĂů ĂƉƉƌŽĂĐŚĞƐ ǁĞƌĞ ĞŵƉůŽǇĞĚ ŝŶ ŽŶĞ ƐƚƵĚǇ ĞĂĐŚ P  ‘ƐƚĂŐĞƐ ŽĨ
ĐŚĂŶŐĞ ? ŝŶƚĞƌǀĞŶƚŝŽŶ[262], financial incentives [249], contingent vouchers (where the 
smoker was rewarded for meeting certain criteria) [250], letters of support [255], and 
physical activity. [195] However, in most trials the experimental intervention was a 
combination of different techniques, with only four studies reporting using an individual 
technique for the experimental intervention. [244, 246, 263, 264] In the control group, 14 
studies reported using a single technique for the control intervention. [243, 245, 247-249, 
251, 253, 256, 257, 261-265] 
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Figure 4.1: Review PRISMA diagram 
 
 
4.4.1 Risk of bias assessment 
 
The results of the risk of bias assessment are given in Figure 4.2. On the whole, the quality 
of the included studies was judged poor, with many not reporting the necessary 
information required to make an adequate judgement. Nine RCTs reported using 
computerised randomisation [123, 195, 248, 252-255, 257, 258], but 10 gave insufficient 
details about this. [202, 243-247, 249-251, 256] Two cluster RCTs reported using 
computerised randomisation [262, 263], one used the drawing of folded tags [259], and 
one did not state the method of cluster randomisation. [260] One quasi-randomised study 
was randomised by the days of the month a participant was born [264], while the other 
was by alternate day of the week. [265] Only six studies reported adequate concealment 
[123, 195, 253, 254, 258, 262], while three studies demonstrated inadequate concealment. 
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[248, 257, 259] 17 studies did not provide enough evidence on whether the concealment 
was adequate or not.[202, 243-247, 249-252, 255, 256, 260, 261, 263-265] Only four 
studies reported adequate blinding of participants [123, 252, 258, 261], with four studies 
reporting no blinding [248, 250, 253, 262], and 18 studies did not provide enough evidence 
for a judgement to be made. [195, 202, 243-247, 249, 251, 254-257, 259, 260, 263-265]  
 
An intention to treat analysis was not conducted in 23 studies. [202, 243-250, 254-257, 
259-261, 263-265] Common reasons for the exclusion of participants were miscarriage, 
premature birth, loss to follow up, lost samples, moved hospitals/areas, refused to 
participate, and delivered interventions to which they were not randomised. 17 studies 
reported using biochemical validation, either using salivary cotinine (five studies) [195, 245, 
248, 254, 260], urinary cotinine (five studies) [246, 250, 251, 257, 265], carbon monoxide 
(six studies) [123, 195, 202, 246, 252, 259], salivary thiocynate (one study) [249], and blood 
thiocynate (one study). [264] For salivary cotinine, cut-off ƉŽŝŶƚƐǀĂƌŝĞĚďĞƚǁĞĞŶA? ? ?ŶŐ ?ŵ>
ĂŶĚA? ? ?ŶŐ ?ŵ> ?ǁŚŝůĞ ĨŽƌƵƌŝŶĂƌǇĐŽƚŝŶŝŶĞ ŝƚǀĂƌŝĞĚďĞƚǁĞĞŶA? ? ?ŶŐ ?ŵ>ĂŶĚA? ? ? ?ŶŐ ?ŵ> ?
ǁŝƚŚŽŶĞƐƚƵĚǇƌĞƉŽƌƚŝŶŐA? ? ? ?ŶŵŽů ?> ?Ƶƚ-off points for carbon monoxide varied between 
A? ?ƉƉŵĂŶĚA? ? ?ƉƉŵ ?&ŽƌƐĂůŝǀĂƌǇƚŚŝŽĐǇĂŶĂƚĞ ?ƚŚĞĐƵƚ-off ƉŽŝŶƚǁĂƐA? ? ? ?ƵŐ ?ŵ> ?ĂŶĚĨŽƌ
blood thiocynate 100 ng/mL, which seemed to be an acceptable cut-off point compared to 
the other biochemical validation tests. There was evidence of selective reporting in eight 
studies. [202, 244, 245, 248, 253, 255, 258, 263]  
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Figure 4.2: Summary of the risk of bias assessment 
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4.4.2 Publication bias 
 
Funnel plots were plotted and examined for evidence of bias in studies; these were done 
for all time points at which data were pooled; however, this was difficult due to the 
relatively small number of studies at later time points and, for some points, funnel plots 
could not be calculated. As all studies reported data at the end of pregnancy, Figure 4.3 is 
the funnel plot for the end of pregnancy.  
 
Figure 4.3: Funnel plot of bias assessment 
 
 
Figure 4.3 demonstrates that there is potential evidence of publication bias. There appear 
to be relatively few small studies included in the review, suggesting these studies have not 
been published. Another implication from the funnel plot is that published smaller studies 
tend to have higher estimates of abstinence compared to larger studies. This could also be 
explained by publication bias, suggesting that studies which appear not to achieve a high 
proportion of abstinence may be excluded from publication.  However, the funnel plot also 
indicates a large degree of variation in the studies, suggesting a large amount of 
heterogeneity within the studies. This should be considered when interpreting the results 
of the meta-analysis.  
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4.4.3 Patterns of abstinence amongst all participants 
 
Pooled proportions of abstinence were generated at four to eight weeks post-
randomisation, end of pregnancy, and in the postpartum period  at four, six and eight 
weeks; and three, six, 12, 18, and  24 months after childbirth. The results from pooling all 
participants are given in Appendix 12.6, Figure 12.1. The pattern of abstinence given in 
Figure 4.4 demonstrates that abstinence rates are at their highest at four to eight weeks 
post randomisation, before dropping slightly at end of pregnancy. In the postpartum 
period, abstinence would appear to decrease sharply at four weeks postpartum, but then 
increase again at six weeks and eight weeks postpartum, beĨŽƌĞĚĞĐůŝŶŝŶŐĂƐƉĂƌƚŝĐŝƉĂŶƚƐ ?
progress through the postpartum period. The highest proportion of abstinence in the 
postpartum period occurred at eight weeks postpartum. There would appear to be a 
substantial decline in abstinence between three and six months, however the CIs of 
abstinence at these two time points considerably overlap.  
 
4.4.3.1 Four to eight weeks post randomisation 
Six studies reported data. [123, 195, 252, 253, 257, 258] The pooled proportion abstinent 
was estimated at 0.156 (95% CI 0.107 to 0.205). Heterogeneity was high with an I² of 
92.2%, p<0.001.  
 
4.4.3.2 End of pregnancy 
All 26 studies reported data at the end of pregnancy. [123, 195, 202, 243-265] The 
estimated proportion abstinent was 0.126 (95% CI 0.107 to 0.146). The I² was 91.7%, 
p<0.001, suggesting a high degree of heterogeneity. 
 
4.4.3.3 Four weeks postpartum 
Two studies reported abstinence rates at four weeks postpartum [244, 262], the pooled 
proportion abstinent reported as 0.036 (95% CI 0.010 to 0.062). The I² was 66.0%, p=0.086. 
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4.4.3.4 Six weeks postpartum 
Data was pooled from eight studies. [247, 248, 255, 257, 260, 261, 263, 265] The pooled 
proportion of abstinence was 0.118 (95% CI 0.085 to 0.152). The I² statistic was 88.5%, 
p<0.001. 
 
4.4.3.5 Eight weeks postpartum  
The pooled abstinence proportion was 0.136 (95% CI 0.113 to 0.159) among the two 
studies pooled. [249, 264] The I² was 0%, p=0.835.  
 
4.4.3.6 Three months postpartum 
Seven studies reported data at three months postpartum. [250, 251, 253-256, 258] The 
estimated pooled proportion abstinent was 0.111 (95% CI 0.070 to 0.152). There was a high 
degree of heterogeneity amongst studies, with the I² estimated at 87.8%, p<0.001 
 
4.4.3.7 Six months postpartum 
Data was pooled from 10 studies. [123, 195, 202, 245, 247, 250, 252, 255, 259, 263] The 
pooled abstinence proportion was 0.082 (95% CI 0.052 to 0.112). The I² was 94.9%, 
p<0.001.  
 
4.4.3.8 12 months postpartum 
The pooled proportion abstinent was 0.074 (95% CI 0.027 to 0.122) amongst the four 
studies reporting data. [123, 243, 246, 258] The I² was 95.5%, p<0.001. 
 
4.4.3.9 18 months postpartum 
Two studies were pooled [243, 262], with the proportion abstinent estimated at 0.036 
(0.020 to 0.052). The I² was 65.4%, p=0.089. 
 
4.4.3.10 24 months postpartum 
Two studies reported data at 24 months [123, 243], with an estimated abstinence 
proportion of 0.047 (-0.023 to 0.118). The I² was 98.2%, p<0.001. 
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Figure 4.4: Primary analysis: Pooled estimates of abstinence of all participants, from beginning of pregnancy
 
37
 
 
 
4.4.4 Pattern of abstinence amongst control and intervention participants 
 
To determine whether there was a difference in abstinence postpartum between 
intervention and control groups, a secondary analysis was conducted in which pooled 
abstinence estimates were split between the two. The results of this analysis are given in 
Appendix 12.6, Figure 12.2 and Figure 12.3. Figure 4.5 demonstrates the pattern of 
abstinence over time. The proportion of participants reporting abstinence is greater 
amongst intervention participants compared to control groups at all time points except one 
(18 months). Although intervention group abstinence appears higher, the difference 
between intervention and control groups ? abstinence would appear to decrease further 
into the postpartum period. There appears to be a kink in the pattern of abstinence 
amongst intervention participants, with a decline in abstinence at four weeks postpartum 
before increasing again at six weeks postpartum. This does appear to exist amongst control 
                                                          
 
37 PR = Post randomisation; 
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participants, but not with such a large change, and the CIs overlap. Amongst control 
participants, the highest proportion abstinent occurs at three months postpartum, whilst 
among intervention participants this is at eight weeks postpartum. This suggests that 
cessation interventions during pregnancy may help prevent relapse earlier in the 
postpartum period.  The proportion of participants reporting to be abstinent in both 
control and intervention groups decreases the more time elapses from the end of 
pregnancy. The same studies were used as in the primary analysis, and therefore only the 
pooled estimates of abstinence are reported here. 
 
4.4.4.1 Four to eight weeks post randomisation 
The proportion abstinent amongst controls was 0.113 (95% CI 0.047 to 0.179), while 
amongst interventions it was 0.187 (95% CI 0.131 to 0.244). The I² was high in both groups: 
95% (p<0.001) in controls and 86.3% (p<0.001) in interventions. 
 
4.4.4.2 End of pregnancy 
In control participants, the proportion abstinent was 0.093 (95% CI 0.070 to 0.117), while in 
interventions it was 0.146 (95% CI 0.122 to 0.170). The I² in the control group was 94.1% 
(p<0.001), and the intervention group 88.1% (p<0.001). 
 
4.4.4.3 Four weeks postpartum 
Amongst control participants, the proportion abstinent was 0.018 (95% CI -0.019 to 0.054), 
whilst in intervention participants it was 0.050 (95% CI 0.034 to 0.066). The I² in the control 
group was 90.9% (p=0.001), and the intervention group 0% (p=0.708). 
 
4.4.4.4 Six weeks postpartum 
The proportion abstinent was 0.091 (95% CI 0.044 to 0.139) amongst controls, and 0.141 
(95% CI 0.104 to 0.178) amongst interventions. The I² was higher amongst controls at 
91.9% (p<0.001) compared to 79.6% (p<0.001) in interventions. 
 
139 
 
4.4.4.5 Eight weeks postpartum 
Amongst intervention participants, the proportion abstinent was 0.177 (95% CI 0.142 to 
0.212), while in controls it was 0.075 (95% CI 0.047 to 0.102). The I² was 7.2% (p=0.299) and 
0% (p=0.498) respectively. 
 
4.4.4.6 Three months postpartum 
The proportion abstinent in intervention participants was 0.111 (95% CI 0.065 to 0.157), 
while in controls the abstinence was 0.099 (95% CI 0.047 to 0.152). The I² was 93.5% 
(p<0.001) in controls and 80.4% (p<0.001) in interventions. 
 
4.4.4.7 Six months postpartum 
Proportion abstinent was 0.069 (95% CI 0.039 to 0.098) for controls, and 0.091 (95% CI 
0.058 to 0.123) for interventions. I² was 91.4% (p<0.001) for controls and 89.7% (p<0.001) 
for interventions. 
 
4.4.4.8 12 months postpartum 
Amongst control participants the proportion abstinent was 0.060 (95% CI 0.025 to 0.095), 
while in interventions it was 0.085 (95% CI 0.024 to 0.146). I² was 85.6% (p<0.001) for 
controls and 93.9% (p<0.001) for interventions. 
 
4.4.4.9 18 months postpartum 
In intervention participants, the proportion abstinent was 0.027 (95% CI 0.014 to 0.041). In 
controls it was 0.045 (95% CI 0.031 to 0.058). I² was 0% (p=0.750) for controls and 0% 
(p=0.460) for interventions. 
 
4.4.4.10 24 months postpartum 
Proportion abstinent was 0.043 (95% CI -0.030 to 0.116) for controls and 0.051 (-0.017 to 
0.119) for interventions. I² was 97.1% (p<0.001) for controls and 95.8% (p<0.001) for 
interventions. 
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Figure 4.5: Secondary analysis: Pooled estimates of abstinence of all participants split by control and 
abstinence groups, from the beginning of pregnancy
38
 
 
 
4.4.5 Sensitivity analysis 
 
To determine the potential impact on the meta-analysis findings of data quality, a 
sensitivity analysis was conducted involving only abstinence data that had been 
biochemically validated. This was available for four to eight weeks post randomisation, end 
of pregnancy, four, six, and eight weeks postpartum, three and six months postpartum. 
Appendix 12.6, Figure 12.4 outlines the results of this analysis, while Figure 4.6 displays the 
pattern of abstinence. At two time points, four to eight weeks post randomisation, and 
eight weeks postpartum, all the data was biochemically validated. However, at the other 
five time points, the primary analysis included both biochemically validated and self-
reported abstinence. Comparing the biochemically validated abstinence with the 
abstinence estimated in the primary analysis, it can be seen that the abstinence rates for 
                                                          
 
38 PR = Post randomisation 
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the biochemically validated data are lower. Although validated data were not available for 
beyond six months, Figure 4.6 demonstrates that the abstinence rates seem to be 
decreasing with time from the end of pregnancy. However, there appears to be a different 
pattern of behaviour at four, six, and eight weeks postpartum. After the end of pregnancy, 
abstinence seems to deteriorate at four weeks postpartum, before increasing again at both 
six and eight weeks postpartum. Consideration should be given that the four weeks 
postpartum abstinence is based on only one study, which could potentially be an outlier. 
Abstinence then starts declining at three and six months. Overlooking time points where 
only biochemically validated data was reported, the results of the sensitivity analysis are 
below. 
 
4.4.5.1 End of pregnancy 
21 studies reported biochemically validated abstinence. [123, 195, 202, 243, 245-255, 257-
259, 262, 264, 265] The pooled abstinence was 0.120 (95% CI 0.100 to 0.139), and the I² 
was 92.2% (p<0.001).  
 
4.4.5.2 Four weeks postpartum 
One study reported biochemically validated abstinence. [262] The pooled abstinence was 
0.047 (95% CI 0.035 to 0.062). 
 
4.4.5.3 Six weeks postpartum 
Four studies reported biochemically validated abstinence. [248, 257, 260, 265] The pooled 
abstinence was 0.093 (95% CI 0.054 to 0.133), and the I² was 85.2% (p<0.001). 
 
4.4.5.4 Three months postpartum 
Three studies reported biochemically validated abstinence. [250, 251, 254] The pooled 
abstinence was 0.068 (95% CI 0.029 to 0.107), and the I² was 61.8% (p=0.073) 
 
4.4.5.5 Six months postpartum 
Five studies reported biochemically validated abstinence. [202, 245, 250, 252, 259] The 
pooled abstinence was 0.042 (0.022 to 0.062), and the I² was 73.0% (p=0.005) 
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Figure 4.6: Sensitivity analysis: Pooled estimates of abstinence of participants with biochemically validated 
abstinence, from the beginning of pregnancy
39
 
 
    
 Discussion 4.5
 
dŽƚŚĞĂƵƚŚŽƌ ?ƐŬŶŽǁůĞĚŐĞ ?ƚŚŝƐŝƐƚhe first time that a meta-analysis has been undertaken 
to derive pooled rates of abstinence from smoking in the postpartum period. The study 
demonstrates that by one year postpartum, only around 7% of trial participants remain 
abstinent, and that by two years postpartum this has declined to approximately 5% of 
participants. Most relapse seems to occur between three and six months postpartum, with 
abstinence only declining slightly beyond six months. However, the results at 18 and 24 
months postpartum are only based upon two studies, which should be taken into 
consideration when interpreting these results. When considering abstinence in relation to 
receipt of cessation interventions, at most time points in the postpartum period, the 
proportion abstinent is higher amongst intervention than control participants; however, 
this difference almost disappears after 12 months postpartum. Furthermore, the CIs for 
                                                          
 
39
 PR = Post randomisation; PP = Postpartum 
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control and intervention groups overlap for all time points except for end of pregnancy and 
eight weeks postpartum. Overall, although cessation interventions appear to be effective at 
reducing smoking during pregnancy, effects diminish after pregnancy and this is an 
important public health issue.  
 
4.5.1 Limitations of the review 
 
There are several limitations to this study. This review has described the patterns of 
abstinence, rather than relapse curves, in the postpartum period; this was because the 
longitudinal abstinence data required were not available. A relapse curve consists of either 
a line plotted between several points demonstrating relapse to smoking amongst a cohort 
of quitters, or a survival curve using data on the exact day a quitter goes back to smoking. 
[266] However, in this review, our cohort includes both smokers and quitters at the end of 
pregnancy, and only uses seven-day point prevalence data to generate abstinence data at 
the pre-specified time points. This creates two problems. Firstly, we cannot calculate 
relapse rates because the individuals reporting abstinence in the postpartum period are 
not necessarily the same as those who reported abstinence at the end of pregnancy. 
Secondly, relapse can happen at any time, and since we only report seven-day point 
prevalence around certain points, participants could have started smoking and then quit 
again, without it being captured. Consequently, because of these limitations, we cannot 
calculate relapse rates and/or relapse curves based upon our pooled results. However, the 
use of point prevalence abstinence data as an estimate for relapse is an advance on 
previous estimates, which have been based upon expert opinion or studies in non-pregnant 
populations. [137, 139] 
 
Not all included studies report data at every time point. Although there are 26 included 
studies in this review with 10,942 patients, for some time points there were relatively few 
studies which reported data. This suggests that at certain time points, the cohort of 
participants is restricted, which implies that the pooled estimate is not as precise as at 
others. Therefore, the results of the pooled estimates at the time points with few studies 
should be taken with caution. This could also potentially explain why the CIs on the 
proportions are generally quite wide, though heterogeneity amongst studies may also 
contribute.   
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There is a potential bias in the primary and secondary analyses because we include self-
reported abstinence as well as biochemically validated abstinence. This is because studies 
which report the longer term outcomes, such as 12, 18 or 24 months, only report self-
reported abstinence. There is evidence that self-reported abstinence is an inaccurate 
measure, with trial participants often reporting cessation, when in reality they are smoking, 
leading to a positive abstinence bias in the data. [267] To investigate this, we conducted a 
sensitivity analysis, where we restricted our meta-analysis to biochemically validated data 
only, which was only available up to the first six months postpartum. Although 
biochemically validated abstinence was consistently lower than the proportions estimated 
when including both types of data, there was no statistically significant difference in 
abstinence between the primary analysis and sensitivity analysis. This would suggest that 
although there may be slight bias caused by including self-reported data, it has little impact 
on the validity of our results and therefore we can conclude that self-reported data does 
not lead to any bias in the meta-analysis.  
 
Across all the pooled estimates, the heterogeneity was very high, suggesting that the 
studies included in the review are potentially too different to be combined together. A 
potential cause is the pooling of studies employing different cessation interventions; it is 
expected that different interventions will have different abstinence rates and women 
enrolled to trials investigating a variety of interventions are likely to vary themselves. 
Consequently, it is possible that heterogeneity is caused by the included trials utilising very 
different populations of pregnant women, with unknown differences in characteristics. 
Another potential source for the heterogeneity is the combining of slightly different follow 
up points into one time point estimate. For example, for six months postpartum, pooled 
estimates were spread from 24 weeks postpartum to 26 weeks postpartum. To try and 
avoid this heterogeneity, we tried to group time points relatively close together; however, 
this trade-off was still made. Consideration to this high heterogeneity should be given 
when interpreting the results of this meta-analysis. 
 
One final limitation is that there is potential evidence of publication bias occurring in our 
data, as suggested in the funnel plot Figure 4.3, which suggests that smaller studies with 
lower abstinence rates appear not to be published, and therefore this review could be 
missing data from these absent studies. It is unclear what impact including any missing 
studies would have on the results of this meta-analysis. 
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4.5.2 Strengths of the review 
 
This review has several important strengths. For the first time, data from trials of smoking 
cessation interventions have been combined to demonstrate patterns of abstinence in the 
postpartum period. Consideration should be given that all the studies were trials, and trial 
ƉĂƌƚŝĐŝƉĂŶƚƐĐŽƵůĚďĞĚĞĞŵĞĚĂ ‘ƐƉĞĐŝĂůŐƌŽƵƉ ?ŽĨƚŚĞƉŽƉƵůĂƚŝŽŶ ?ƐŽƚŚĞƌĞǀŝĞǁŵĂǇŶŽƚďĞ
as representative as one including other studies such as cohort and cross-sectional. 
However, this meta-analysis uses a cohort of 10,942 women, making it by far the largest 
study in this area. With such a large number of participants, the results are a potentially 
accurate measure of abstinence after pregnancy, and more representative of the general 
population of smoking pregnant women than smaller studies.  
 
Since the review only uses trial data, it could be considered that the review is using the best 
source of high quality data on smoking during and after pregnancy. Trial data is more likely 
to be collected consistently at a high standard, whereas cohort data has a greater tendency 
to have used routinely collected data of potentially lower standard. However, it is 
unsurprising that few trials report long term postpartum follow-up, either biochemically 
validated or self-reported, due to the high cost and workload of data collection, which can 
make it unpractical. Using routinely collected data would not only have increased the 
available studies for meta-analysing, it is also likely that the review would have been able 
to estimate relapse further than 24 months after pregnancy. However, routinely collected 
data is less likely to be have been biochemically verified, and more prone to bias than data 
collected by clinical trial. Therefore, it could be argued that the inclusion of cohort data 
would have introduced further bias into the meta-analysis, and hence potentially have 
degraded the quality of the review.  Furthermore, cohort studies are more likely to include 
women who spontaneously quit rather than utilising a cessation intervention, which would 
generate relapse rates which were not relevant to women who access cessation 
interventions during pregnancy. Crucially, the data at the end of pregnancy was generally 
robustly assessed, giving an accurate measure of smoking behaviour as a baseline to 
estimate relapse in the postpartum period. This may not be so well-recorded in 
observational studies. This would imply that this review is using the most accurate data 
available to estimate postpartum abstinence.  
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4.5.3 The review in context of the limited longitudinal data on relapse in the postpartum 
period 
 
Three studies included in the review report sustained abstinence at several time points in 
the postpartum period, but these data could not be meta-analysed because each study 
reported cessation at different time points. [123, 253, 262] Pollak et al estimated that by 
three months postpartum, 69% of women had relapsed. [253]. Lawrence et al estimated 
that at four weeks postpartum, relapse was 25%, and by 18 months postpartum, it was 
88%. [262] ĂŶĚŽŽƉĞƌĞƚĂů ?ƐĚĂƚĂƐŚŽǁƌĞůĂƉƐĞƚŽďĞƚŽďĞ ? ?A?ĂƚƐŝǆŵŽŶƚŚƐ ? ? ?A?Ăƚ ? ?
months, and 77% at 24 months. [123] 
 
Comparing these relapse rates with the abstinence estimates estimated in this review is 
very difficult. One potential method is to assume that all those individuals reporting 
abstinence in the postpartum period are the same as those participants reporting 
abstinence at the end of pregnancy. This allows a relapse percentage at the time point to 
be calculated by dividing the abstinence estimate at a postpartum time point by the end of 
pregnancy estimate. Using this approach, relapse is estimated at 71% four weeks, 12% by 
three months, 35% by six months, 41% by 12 months, 71% by 18 months, and 63% by 24 
months. Comparing these values with the longitudinal data estimates above suggests that 
our review estimates would appear to be conservatively estimating relapse in the 
postpartum period, except for four weeks postpartum where the review estimate is much 
higher. However, data at four weeks may be geŶĞƌĂƚĞĚďǇ ‘ŽƵƚůŝĞƌƐ ? ?ƐŝŶĐĞŽŶůǇƚǁŽƐƚƵĚŝĞƐ
(Lawrence et al and Dunkley [244, 262]) report data at this time point, and both had lower 
end of pregnancy estimates for abstinence than the pooled estimate (pooled: 0.126, 
Dunkley: 0.040, Lawrence et al: 0.063). However, these relapse rates should be interpreted 
with great caution, because the assumptions outlined above may be unrealistic. 
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4.5.4 The review in context of the current literature on relapse in the postpartum period 
 
The review findings seem to closely match what has been found in the literature. At six 
months postpartum, studies estimated that between 30% and 76% of women relapse to 
smoking. [217, 221, 223-231] For 12 months postpartum, the literature estimated that 32% 
to 59% of women relapsed [221, 227, 232, 233]. Studies investigating postpartum relapse 
after 12 months are relatively scarce, however Lemola et al estimated that 77% of women 
had relapsed by 18 months postpartum [234], and Martin et al estimated that 59% of 
women had relapsed by 24 months postpartum. [235] While the review supports the 
observational studies ? estimates of relapse for 12 and 24 months postpartum, with 
proportion abstinent at both these time points being very low, there do appear to be some 
slight differences in postpartum relapse behaviour. The observational studies suggest that 
there is a large drop in abstinence relatively quickly after pregnancy, within three months 
postpartum. The pooled estimates in this review do suggest that there is a decline in 
abstinence by three months postpartum; however, not to the same degree as in the cohort 
studies.  
 
The difficulty in comparing the observational studies with the review can be seen by 
contrasting the postpartum estimates from the review with the results by Rattan et al. The 
study estimated that amongst women who had stopped smoking during pregnancy, 44% 
had relapsed by five years postpartum, 36% at 14 years after childbirth, and 36% at 21 
years after childbirth. [230] However, Rattan was a observational study collecting self-
reported seven-day point prevalence estimates, which is potentially open to reporting bias 
if women chose not to report their actual smoking status. Furthermore, the study included 
women who were spontaneous quitters as there was no cessation intervention, implying a 
different population to the review. Many of the aforementioned cohort studies include 
women who had either stopped smoking before, or had quit very early in, pregnancy. [217, 
221, 223, 224, 227, 228, 231] The review includes women who are potentially more reliant 
on smoking, which could explain why the prevalence of smoking after pregnancy appears 
to be higher in this review compared to the literature. However, all the women included in 
this review will have received some form of cessation intervention, which could be very 
useful for predicting the impact of such interventions during pregnancy on the smoking 
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behaviour of women after pregnancy. This would be very useful for predicting the relapse 
rates of new cessation interventions. 
 
4.5.5 The review in context of the current literature of economic models of smoking 
cessation during pregnancy 
 
Four economic models have incorporated postpartum smoking behaviour. Mallender et al 
did not incorporate a relapse rate but assumed that 2% of smokers would quit permanently 
each year [190], so a comparison cannot be drawn. Tappin et al assumed relapse rates of 
60% and 30% at three months postpartum for the intervention and control groups 
respectively [196], before applying long-term estimates from studies on non-pregnant 
populations. In this review, the corresponding values at three months postpartum were 0% 
and 24%. Taylor estimated that 70% of women had relapsed at 12 months postpartum 
[139], while Ruger et al estimated 35% relapse over the remaining lifetime[137], whereas 
the corresponding figure from this review is 59%. The estimate used by Taylor was based 
upon expert opinion, which may  be considered inaccurate as it could be heavily prone to 
bias, although it seems to closely match the one year relapse rate as estimated by Cooper 
et al. [123] ZƵŐĞƌ ?Ɛ ĞƐƚŝŵĂƚĞ ĐĂŵĞ ĨƌŽŵ Ă ƌĞĐŽŵŵĞŶĚĂƚŝŽŶ ŝŶ ƚŚĞ  ? ? ? ? h^ ^ƵƌŐĞŽŶ
'ĞŶĞƌĂů ?ƐƌĞƉŽƌƚ ?ǁŚŝĐŚŝƐŶŽƚĨƌŽŵĂƉƌĞŐŶant population. [138] Assuming that this review 
gives more accurate estimates of relapse, both Tappin et al and Taylor seem to slightly 
overestimate  the number of women relapsing in the postpartum period, while Ruger et al 
is difficult to compare as it is from a non-pregnant population over an entire lifetime. This 
review suggests that 35% may be too low, but as it only looks at up to two years 
postpartum, what happens beyond that is unknown.  
  
4.5.6 Changes in smoking behaviour over the postpartum period 
 
This review not only highlights that postpartum rates of abstinence are lower than is 
currently perceived in the literature, but also highlights potential changes in the smoking 
behaviour of the mother in the postpartum period. Abstinence appears to be fairly 
consistent up to eight weeks postpartum, before declining; the two biggest drops in 
abstinence occur between three and six months postpartum and 12 and 18 months 
postpartum. Although we have no information on the reasons why the abstinence rates 
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dropped at these points, it may be possible that a new mother may choose to relapse to 
smoking as a method of coping with stress caused by the new child. Smoking is known to 
be a method of stress-relief and therefore it could potentially be used by the mother to 
help control for the stress associated with the new child. [218] An alternative possibility is 
ƚŚĂƚǁŽŵĞŶŚĂǀĞŶŽƚĂĐƚƵĂůůǇƌĞůĂƉƐĞĚ ?ŚŽǁĞǀĞƌƚŚĞǇĚŽŶŽƚƌĞƐƉŽŶĚƚŽƚŚĞƚƌŝĂů ?ƐƌĞƋƵĞƐƚ
at these time points. This means that in the intention to treat analysis they are counted as 
relapsed, which could be an incorrect assumption. Although there is some evidence of high 
attrition in some studies, we cannot quantify how much of an impact this has on our 
abstinence rates.  
 
Of interest is that the highest pooled rates of abstinence in the postpartum period were at 
eight weeks postpartum. These were even higher than at the end of pregnancy, which 
suggests that relapse to smoking after pregnancy may not be a continuous decline like it 
appears to be following quit attempts made by non-pregnant smokers. [268] One possible 
explanation for this is that mothers who did not report cessation at the end of pregnancy 
are now making a quit attempt because they are trying to do the best for the health of 
their new child. 
 A similar explanation could be used for understanding why there is a big drop in 
abstinence at four weeks postpartum and subsequent increase at six weeks postpartum. At 
four weeks postpartum, we could have mothers who have relapsed to smoking because 
they are no longer pregnant; conversely, by six weeks they may have resumed cessation 
because they realise that their smoking could impact on the infant. However, the 
abstinence estimates at four weeks are based on two studies [244, 262], which have lower 
rates of abstinence compared to other included trials, and therefore may be outliers, hence 
we cannot draw any conclusions as to whether there is a change in smoking behaviour 
between end of pregnancy and four weeks, and between four and six weeks postpartum.  
 
4.5.7 Comparing the smoking behaviour in the postpartum period with that of general 
smoking cessation interventions 
 
Compared to more general smoking populations, there are clear differences in relapse 
behaviour between pregnant and non-pregnant populations. Coleman et al conducted a 
systematic review of pharmacotherapic interventions linked with NHS Stop Smoking 
services. [268] 16 studies were included, with 8,679 participants, and interventions 
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consisted of behavioural support as well as NRT, bupropion and varenicline. The pooled 
estimates of abstinence were 49% (95% CI, 42-56%) at the end of one month, 44% (95% CI, 
40-48%) at three months, 31% (95% CI, 28-33%) at six months and 26% (95% CI, 23-29%) at 
12 months post-randomisation. These are much higher than our review, suggesting that a 
pregnant woman is more likely to relapse even though she has received an intervention. 
This implies that the use of general smoking population data for modelling postpartum 
relapse is incorrect and therefore it would seem more appropriate to use the results 
generated in this review in any improved economic model. 
 
Hughes et al investigated relapse amongst self-quitters in another systematic review. [266] 
A narrative synthesis was adopted due to the significant amounts of heterogeneity 
encountered. From the seven included studies, abstinence at  the end of one month post-
quit date was between 15 and 28%, 10 - 20% by three months, 3 - 5% between six and 12 
months. The authors concluded that most relapse occurred within eight days of quitting. In 
this review, abstinence rate at three months were relatively similar to the abstinence rates 
at the end of pregnancy, suggesting there was no such rapid drop. However, after three 
months the proportions abstinent in our review become very similar to the result found by 
Hughes et al. On the other hand, in this review all mothers were exposed to an 
intervention, whereas in the review by Hughes et al there was no cessation intervention. 
This might explain the apparent differences in relapse behaviour. 
 
 Summary 4.6
 
This review demonstrates that, excluding the four week post randomisation estimate, 
relapse appears to steadily increase over the postpartum period. The highest estimate for 
abstinence occurs at eight weeks postpartum, with around 14% of women reporting 
abstinence. Although there seemed to be some evidence of behaviour changes in the first 
few weeks postpartum, up till eight weeks postpartum abstinence seemed relatively 
steady. However, after three months postpartum, the relapse rates increased such that by 
12 months postpartum only 7% of women reported abstinence, declining to 5% at 24 
months. Although the review found evidence that the proportion of women in the 
intervention groups who relapsed were lower, the 95% CIs for control and intervention 
groups crossed, suggesting that there was no significant difference in relapse between the 
two groups. With so few people abstinent, smoking postpartum is an important health 
151 
 
issue that requires addressing, especially considering the health impacts of passive 
smoking. This review also highlights the poor quality of the trials that report data 
postpartum. To generate better estimates of postpartum abstinence, higher quality studies 
investigating postpartum smoking using biochemically validated abstinence, either using a 
clinical trial design or a high quality observational study on women who have received a 
cessation intervention, are required. However, a VOI analysis should be conducted to 
determine whether there is a requirement to investigate this further, as these studies are 
likely to be expensive, and may not yield a benefit in terms of information gained.  
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 Chapter 5: The ESIP model: Description of the maternal-foetal 
 ‘ǁŝƚŚŝŶ-ƉƌĞŐŶĂŶĐǇ ?ĐŽŵƉŽŶĞŶƚ 
 
 Introduction 5.1
 
Previous chapters of this thesis have discussed the preceding literature around the 
economic impacts of smoking cessation during pregnancy, as well as critiquing the 
previously-ĚĞƌŝǀĞĚ ŵŽĚĞůƐ ? ƐƚƌƵĐƚƵƌĞƐ ĂŶĚ ŐĂƉƐ ?Focus now shifts to describing the 
Economic impacts of Smoking In Pregnancy (ESIP) model. ESIP is formed of four standalone 
economic models which are referred ƚŽ ĂƐ  ‘ĐŽŵƉŽŶĞŶƚƐ ? ?The following chapters will 
describe each of the four component models which are brought together to form ESIP. 
Figure 5.1 gives a simplified structure of the complete ESIP model.  
 
Figure 5.1: Simplified overall ESIP model structure 
 
 
This chapter introduces and describes the first two component models, represented by the 
grey area in Figure 5.1 ?dŚĞĐŽŵƉŽŶĞŶƚƐĚĞƐĐƌŝďĞĚŝŶƚŚŝƐĐŚĂƉƚĞƌĂƌĞƚŚĞDĂƚĞƌŶĂů ‘tŝƚŚŝŶ-
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WƌĞŐŶĂŶĐǇ ? ŽŵƉŽŶĞŶƚ  ?DtW ? ĂŶĚ ƚŚĞ /ŶĨĂŶƚ  ‘tŝƚŚŝŶ-WƌĞŐŶĂŶĐǇ ? ŽŵƉŽŶĞŶƚ  ?/tW ? ?
These run simultaneously, focusing on the impacts of smoking and smoking cessation on 
materno-foetal delivery complications and birth outcomes within the time frame of 
ƉƌĞŐŶĂŶĐǇ ? >ĂƚĞƌ ĐŚĂƉƚĞƌƐ ŽƵƚůŝŶĞ ƚŚĞ DŽƚŚĞƌ ?Ɛ >ŝĨĞƚŝŵĞ ŽŵƉŽŶĞŶƚ  ?D> ? ĂŶĚ /ŶĨĂŶƚ
Childhood component (ICC), which capture the impacts of smoking during pregnancy on 
the health of the mother and infant after pregnancy. 
 
 Objectives 5.2
 
5.2.1 Primary objective: 
dŽĚĞƐĐƌŝďĞƚŚĞ  ‘ǁŝƚŚŝŶ-ƉƌĞŐŶĂŶĐǇ ?ĐŽŵƉŽŶĞŶƚƐĨŽƌŵŽƚŚĞƌĂŶĚŝŶĨĂŶƚĂƐƉĂƌƚŽĨƚŚĞ/^W
model.  
 
5.2.2 Secondary objectives: 
1) Outline and describe the rationale of the structure of the MWPC and the IWPC 
2) Identify  relevant parameters and describe how these fit together within the 
MWPC and IWPC  
3) Describe the link between the MWPC and IWPC and its function 
4) Identify relevant QALYs contingent on smoking status, apply appropriate 
decrements for complications, and fit these within the MWPC component 
5) Identify relevant costs for maternal pregnancy complications, and fit these to the 
MWPC  
6) Identify relevant costs for infant birth outcomes , and incorporate in the IWPC 
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 Overview of model structure  5.3
 
5.3.1 Justification for type of model 
 
A decision tree structure was chosen for the within-pregnancy components. For a 
discussion of modelling approaches, please see section 1.6.7. There were three reasons for 
this choice of approach: 
1) Pregnancy is a short time horizon, typically nine months or less. Therefore, since 
the time horizon was less than one year, discounting need not apply, and hence 
models which allow the introduction of time dependence did not seem to have any 
advantages in this setting 
2) We were assuming that the end of pregnancy was time zero in the lifetime models 
(discussed in Chapters 6 and 7), therefore that all events within-pregnancy were 
happening simultaneously 
3) All the decision trees were likely to be bushy, and consideration was given to 
alternative approaches. However, for a Markov model or other modelling approach 
to capture the same impacts and information, it was likely that they too would be 
very complicated with multiple states, and hence the decision tree was chosen as 
the simplest form to undertake this analysis 
 
5.3.2 Maternal model structure  
 
The model assumes that all women who enter the model are smokers at conception who 
can either remain as smokers throughout pregnancy or quit  before pregnancy ends; 
women who stop smoking temporarily in pregnancy are assumed to be part of the  ?ƐŵŽŬĞ
ƚŚƌŽƵŐŚŽƵƚƉƌĞŐŶĂŶĐǇ ?ĂƌŵŽĨƚŚĞĚĞĐŝƐŝŽŶƚƌĞĞ ?dŚĞŝŶŝƚŝĂůƉŚĂƐĞŽĨƚŚĞŵŽĚĞůŝƐŐŝǀĞŶŝŶ 
Figure 5.2. 
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Figure 5.2: Initial phase of decision tree structure for the mother 
 
 
Figure 5.3 illustrates the next part of the model structure, for smokers (Sub tree A); there is 
a similar sub tree for women who stop smoking in pregnancy. For both groups of women 
(quitters and smokers), the model then estimates numbers of women who suffer from an 
ectopic pregnancy or miscarriage. For pregnancies which ended in a delivery, the mother 
can deliver with or without a complication, and can be premature or full-term. Finally, the 
model then distinguishes those women who survive and those who die.  
 
  
Mother quits during pregnancy [See sub tree A]
Mother smoking at conception
Mother smokes throughout pregnancy [See sub tree A]
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Figure 5.3 PĞƚĞƌŵŝŶŝŶŐƉƌĞŵĂƚƵƌĞďŝƌƚŚĂŶĚŵŽƚŚĞƌ ?ƐƐƵƌǀŝǀĂůŽĨƉƌĞŐŶĂŶĐǇ ?^ƵďƚƌĞĞ ?
 
 
The final stages of the maternal model determine the frequency of stillbirths and LBW. The 
structure for this part of the decision tree is given in Figure 5.4.  
Mother dead
Ectopic pregnancy
Mother alive
Mother dead
Miscarriage
Mother alive
Mother dead
Premature birth < 37 weeks
Mother alive [Sub tree B]
[Sub tree A] Placental abruption Mother dead
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
Mother dead
Premature birth < 37 weeks
Mother alive [Sub tree B]
Placenta previa Mother dead
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
Pregnancy ends in delivery
Mother dead
Premature birth < 37 weeks
Mother alive [Sub tree B]
Pre-eclampsia Mother dead
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
Mother dead
Premature birth < 37 weeks
Mother alive [Sub tree B]
No complication
Mother dead
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
157 
 
Figure 5.4: Maternal: infant decision tree linkage to determining infant birth outcomes [Sub tree B] 
 
 
The reasons for adapting these structures for the MWPC are: 
1. As ectopic pregnancies and miscarriages occur early in pregnancy, it is necessary to 
determine the number of mothers who suffer these outcomes early in the model. 
2. The pregnancy complications included in the maternal decision tree are associated 
with higher risks of premature birth.  The length of gestation is important as it 
could impact on healthcare costs; for example a reduced cost of antenatal care due 
to fewer midwife visits. The model determines whether or not the woman survives 
pregnancy before determining infant birth outcomes. 
3. To capture maternal impacts of stillbirth and other adverse foetal outcomes, the 
model determines the number of infants born to living mothers who suffer these 
complications. An increase in the risk of stillbirth can be attributed to both small for 
gestational age and premature birth. [269-271] Although small for gestational age 
is not included in the MWPC, such infants are most likely born LBW, since the 
definition is infants born with weight below the 10th percentile for gestational age. 
To incorporate these associations, the MWPC determines whether the birth is 
premature and/or LBW before determining if stillbirth occurs, hence stillbirth and 
live birth are the last branches of the decision tree.  
 
  
Infant stillborn
Infant born with low birth weight
Infant liveborn
[Sub tree B]
Infant stillborn
Infant born with normal birth weight
Infant liveborn
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5.3.3 Infant model structure  
 
The IWPC estimates the impacts of the maternal complications on the birth outcomes for 
the infant. The model assumes that all singleton infants are conceived to a smoking 
mother, and are matched to the women included in the MWPC. To achieve the match 
between the infants with the women, the IWPC seen in Figure 5.5 has an almost identical 
structure to the MWPC. The differences between the MWPC and IWPC are: 
1. dŚĞƌĞŵŽǀĂůŽĨƚŚĞĂƌŵƐƌĞůĂƚŝŶŐƚŽƚŚĞŵŽƚŚĞƌ ?ƐƐƵƌǀŝǀĂůĨŽƌƚŚĞĞĐƚŽƉŝĐƉƌĞŐŶĂŶĐǇ
and miscarriage branches, as the IWPC assumes that all infants who suffer either of 
these conditions die. 
2. The addition of the birth weight and stillbirth branches (sub tree B, see Figure 5.4) 
ĂĨƚĞƌ ƚŚĞ  ‘ŵŽƚŚĞƌ ĚĞĂĚ ? Ăƌŵ ? ƐŝŶĐĞ ƚŚĞ ŝŶĨĂŶƚ ĐĂŶstill be born alive following 
maternal death. 
Infants are conceived to a smoking mother as per Figure 5.2, but rather than progress to 
 ‘^ƵďƚƌĞĞ ? ?ƚŚĞǇƉƌŽŐƌĞƐƐƚŽ ‘^ƵďƚƌĞĞ ?ƐŚŽǁŶŝŶFigure 5.5 below. Once they have 
ƉƌŽŐƌĞƐƐĞĚƚŚƌŽƵŐŚ ‘^ƵďƚƌĞĞ ? ?ƚŚĞǇĨůŽǁƚŚrŽƵŐŚ ‘^ƵďƚƌĞĞ ?ŝŶFigure 5.4 to determine 
their birth weight and birth status. As the structures are almost identical, the parameters 
used in the MWPC are replicated in the IWPC.  The structures for both the maternal model 
and infant models together are given in full in Appendix 12.9, Figure 12.5, Figure 12.6 and 
Figure 12.7. 
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Figure 5.5: Initial structure of infant decision tree: foetal loss and prematurity [equivalent to Sub tree A in 
Figure 5.3] 
 
  
Ectopic pregnancy
Miscarriage
Mother dead [Sub tree B]
Premature birth < 37 weeks
Mother alive [Sub tree B]
[Sub tree C] Placental abruption Mother dead [Sub tree B]
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
Mother dead [Sub tree B]
Premature birth < 37 weeks
Mother alive [Sub tree B]
Placenta previa Mother dead [Sub tree B]
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
Pregnancy ends in delivery
Mother dead [Sub tree B]
Premature birth < 37 weeks
Mother alive [Sub tree B]
Pre-eclampsia Mother dead [Sub tree B]
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
Mother dead [Sub tree B]
Premature birth < 37 weeks
Mother alive [Sub tree B]
No complication
Mother dead [Sub tree B]
Full gestation A? ? ?ǁĞĞŬƐ
Mother alive [Sub tree B]
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5.3.4 Note on included morbidities in the within-pregnancy components 
 
Chapter 2 identified nine conditions which have a strong association with smoking during 
pregnancy which arguably warrant inclusion in the within-pregnancy components. 
However, the MWPC and IWPC only include seven morbidities, with PROM / PPROM and 
congenital anomalies excluded. Congenital anomalies appear to be exceedingly rare, and 
the impact varied upon the type of abnormality developed. Therefore, because of the rarity 
of the condition, they were excluded.  
 
There was also strong evidence for a causal link between maternal smoking and PROM, but 
this was not included in the components because the NHS Maternity Statistics for England 
data did not report the number of occurrences by gestation length except for the year 
2012-2013, so it was not possible to differentiate between PROM and PPROM in most of 
the data. [150, 272] Furthermore, while PPROM appeared to have a strong association [2], 
no evidence could be identified for parameterising full gestation PROM.   
 
 Deriving probability parameters to populate model 5.4
 
5.4.1 Foetal loss before delivery 
 
It was necessary to estimate the number of pregnancies with foetal loss (FL) that did not 
require a delivery episode. FL was estimated using Hospital Episode Statistics for England 
(HES) NHS Maternity data, covering the years 2006 to 2013. [272] These data report the 
number of ectopic pregnancies and miscarriages requiring a hospital stay. Although some 
occurrences of these conditions do not require a hospital stay and hence are not included 
in these statistics, HES data provides the best available estimates for occurrence rates for 
smoking and non-smoking women. The numbers of occurrences are given in Table 5.1. 
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Table 5.1: Number of all pregnancies that did not end in delivery (foetal loss)
40
 
Year Delivery 
episodes 
Ectopic pregnancy 
episodes  
Miscarriage 
episodes 
2006-2007 629,207 9,941 43,155 
2007-2008 649,837 10,352 43,870 
2008-2009 652,638 10,348 43,390 
2009-2010 652,377 10,635 45,232 
2010-2011 668,195 11,157 43,005 
2011-2012 668,936 11,294 42,538 
2012-2013 671,255 11,199 39,800 
Total 4,592,445 74,926 300,990 
Probability of 
occurrence* 
 0.0151 0.0606 
Source: Table 1.i HES NHS Maternity Statistics 2012-2013 [150] 
* Miscarriage and ectopic pregnancies do not count as delivery episode, so the 
denominator is the sum of the number of deliveries, miscarriages, and ectopic pregnancies. 
 
5.4.2 Complications of delivery  
 
The mother could face three delivery complications: placental abruption; placenta previa; 
and pre-eclampsia. The frequencies with which these complications occurred were taken 
from HES NHS Maternity Statistics for England 2006-2007 to 2012-2013, details of which 
are given in Table 5.2.  
 
  
                                                          
 
40 Includes smoking and non-smoking women 
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Table 5.2: Number of all pregnancies that had a delivery complication
41
 
Year Placental 
abruption 
episodes 
Placenta 
previa 
episodes 
Pre-eclampsia 
episodes 
Deliveries with no 
complication* 
2006-2007 ? 2,183 3,540 11,119 612,365 
2007-2008 ? 2,375 3,758 11,718 631,986 
2008-2009 ? 2,422 3,985 12,120 634,111 
2009-2010 ? 2,506 4,093 12,778 633,000 
2010-2011 ? 2,458 4,368 13,017 648,352 
2011-2012 ? 2,491 4,446 12,598 649,401 
2012-2013 ? 2,666 4,420 13,211 650,958 
Total 17,101 28,610 86,151 4,460,173 
Probability of 
occurrence 
0.0037 0.0062 0.0188 0.9712 
* Number of delivery episodes (Table 5.1) minus deliveries with complications 
 ? Source: Table 22 NHS Maternity Statistics (relevant year) [273-278] 
 ? Source: Table 7.d NHS Maternity Statistics 2012-13 [150] 
 
5.4.3 Deriving smoking status-contingent probabilities for experiencing included 
conditions  
 
To derive the probability of a mother developing one of the five included conditions 
contingent on her smoking status by the end of pregnancy, the probability of occurrences 
in all pregnant women (i.e. smoking and non-smoking) was adjusted to allow for the impact 
of smoking. We assumed that delivery complications and FL events were mutually exclusive 
events and were therefore treated as independent of each other. Chapter 2 identified two 
meta-analyses which estimated the impact of smoking during pregnancy on the risks of 
developing each of these conditions. The relevant information is reproduced in Table 5.3. 
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Table 5.3: Impact of smoking in pregnancy on the risk of developing included conditions 
Condition Pooled odds ratio 95% confidence 
interval (CI) 
Source 
Ectopic pregnancy 1.77 1.31-2.22 Castles 1999 [2] 
Miscarriage 1.32 1.18-1.48 DiFranza 1995 [3] 
Placental abruption 1.62 1.46-1.77 Castles 1999 [2] 
Placenta previa 1.58 1.04-2.12 Castles 1999 [2] 
Pre-eclampsia 0.51 0.38-0.64 Castles 1999 [2] 
 
We assumed that women either smoked throughout pregnancy or stopped successfully 
during pregnancy. Those who smoked throughout included those who did not make a quit 
attempt and those with temporary periods of abstinence (relapsed by the end of 
pregnancy), and were assigned the risks associated with smokers. Abstinent women 
included all those who had successfully quit by the end of pregnancy, including those who 
had ceased very close to the end of their pregnancy, and were assigned the risks associated 
with never smokers. This was necessary because there were no available data on the 
relationship between timing of quitting and risk of conditions, and can be seen as a 
conservative assumption as the benefits from temporary abstinence are not claimed. 
 
To calculate the difference in probabilities, the method outlined by Flack et al for 
attributing the increase prevalence of diseases amongst smokers was adapted. [129] The 
following equation was used: 
 
 ࡭ ൌ ሺࡼࡿ ൈ ࡮ሻ ൅ ሺࡼࡺࡿ ൈ ࡯ሻ (5.1) 
 
Where ࡭ is the odds of the condition in all women (i.e. smokers and non-smokers), ࡼࡿ is 
the prevalence of smoking throughout pregnancy, ࡮ is the odds of the condition occurring 
in smokers, ࡼࡺࡿ is the prevalence of non-smoking during pregnancy (both quitters and 
never smokers), and ࡯ is the odds of the condition occurring in non-smokers. 
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The odds ܤ can also be expressed as: 
 
 ܤ ൌ ܥ ൈ ܱܴௌ (5.2) 
 
Where ܱܴௌ is the odds ratio for occurrence in smokers versus non-smokers.  
 
Replacing this in equation (5.1) gives: 
 
 ܣ ൌ ሺ ௌܲ ൈ ܥ ൈ ܱܴௌሻ ൅ ሺ ேܲௌ ൈ ܥሻ (5.3) 
 
Rearranging for C gives the equation: 
 ܥ ൌ ܣሺ ௌܲ ൈ ܱܴௌሻ ൅ ேܲௌ (5.4) 
 
This equation allows the odds C to be calculated. The odds B can then be calculated using 
equation (5.2). 
 
5.4.4 Worked example for ectopic pregnancy 
 
To demonstrate, the calculation of the probability of ectopic pregnancy contingent on 
smoking status is given as a worked example. The odds for all pregnant women, regardless 
of smoking status, for developing ectopic pregnancy are:  
 ܱ݀݀ݏሺ݁ܿݐ݋݌݅ܿ݌ݎ݁݃݊ܽ݊ܿݕȁ݈݈ܽ݌ݎ݁݃݊ܽ݊ݐݓ݋݉݁݊ሻ ൌ ݌௢ ? െ ݌௢ ൌ  ?Ǥ ? ? ? ? ? െ  ?Ǥ ? ? ? ?ൌ  ?Ǥ ? ? ? ? 
 
Where ݌௢ is the probability of ectopic pregnancy in all women (smokers and non-smokers) 
(see Table 5.1). 
 
From the latest IFS, it was estimated that 12% of women smoke throughout pregnancy, 
while 88% are either never smokers or stopped smoking before or during pregnancy (i.e. 
were abstinent by the end of pregnancy). [135]  
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From Castles et al, the odds ratio for smokers developing ectopic pregnancy was 1.77. [2] 
Substituting into equation (5.4) gives the odds for a non-smoker: 
 ܥ ൌ  ?Ǥ ? ? ? ?ሺ ?Ǥ ? ?ൈ  ?Ǥ ? ?ሻ ൅  ?Ǥ ? ?ൌ  ?Ǥ ? ? ? ? 
 
Using (5.2), the odds for a smoker developing ectopic pregnancy are: 
 ܤ ൌ  ?Ǥ ? ? ? ?ൈ  ?Ǥ ? ?ൌ  ?Ǥ ? ? ? ? 
 
The probabilities for ectopic pregnancy contingent on smoking status (݌௦ is the probability 
of ectopic pregnancy amongst smoking women, and ݌௡௦ is the probability of ectopic 
pregnancy amongst non-smoking women) can then be calculated by transforming the odds:  
 ݌௦ ൌ ݋݀݀ݏሺ݁ܿݐ݋݌݅ܿ݌ݎ݁݃݊ܽ݊ܿݕȁݏ݉݋݇݁ݎሻ ? ൅ ݋݀݀ݏሺ݁ܿݐ݋݌݅ܿ݌ݎ݁݃݊ܽ݊ܿݕȁݏ݉݋݇݁ݎሻ ൌ  ?Ǥ ? ? ? ? ? ൅  ?Ǥ ? ? ? ?ൌ  ?Ǥ ? ? ? ? 
 ݌௡௦ ൌ ݋݀݀ݏሺ݁ܿݐ݋݌݅ܿ݌ݎ݁݃݊ܽ݊ܿݕȁ݊݋݊Ǧݏ݉݋݇݁ݎሻ ? ൅ ݋݀݀ݏሺ݁ܿݐ݋݌݅ܿ݌ݎ݁݃݊ܽ݊ܿݕȁ݊݋݊Ǧݏ݉݋݇݁ݎሻ ൌ  ?Ǥ ? ? ? ? ? ൅  ?Ǥ ? ? ? ?ൌ  ?Ǥ ? ? ? ? 
 
This process was repeated for all conditions, the results of which are given in Table 5.4 and 
Table 5.5. 
 
Table 5.4 Probabilities of pregnancy not ending in delivery (foetal loss) ĐŽŶƚŝŶŐĞŶƚŽŶŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐ
status 
Condition Non-smoker Smoker 
Ectopic pregnancy 0.0138 0.0242 
Miscarriage 0.0585 0.0758 
Ends in delivery 0.9277 0.9000 
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Table 5.5: Probabilities of developing a pregnancy complication, contingent on smoking status 
Condition Non-smoker Smoker 
Placental abruption 0.0035 0.0056 
Placenta previa 0.0058 0.0092 
Pre-eclampsia 0.0200 0.0103 
No complication 0.9707 0.9749 
 
5.4.5 Premature birth 
 
The pregnancy complications included in the model (Table 5.5) are associated with 
increased premature birth, and to estimate prematurity associated with each, frequency 
data by length of gestation was sought. This is presented in Table 5.6.  
 
Table 5.6: Number and risk of premature birth by complication 
Condition Total complication 
episodes 
Premature episodes Risk 
Placental abruption 2,666 1,074 0.4029 
Placenta previa 4,420 1,163 0.2631 
Pre-eclampsia 13,211 3,618 0.2739 
No complication 650,658 40,787 0.0627 
Source: Table 7.d NHS Maternity Statistics for England 2012-13 [150] 
 
Shah et al estimated that smoking during pregnancy increased the risks of premature birth, 
with an odds ratio of 1.27 (95% CI 1.21 to 1.33). [67] It was assumed that smoking during 
pregnancy increased the risk of any premature birth across all complications. Using the 
same method as described earlier, the corresponding probability of premature birth 
contingent on smoking status was calculated for each complication as well as for 
pregnancies in which no complication was suffered; estimates are given in Table 5.7. 
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Table 5.7: Probability of premature birth within pregnancy morbidities and contingent on smoking status 
Condition Non-smoker Smoker 
Placental abruption 0.3952 0.4535 
Placenta previa 0.2570 0.3052 
Pre-eclampsia 0.2676 0.3169 
No complication 0.0608 0.0760 
 
5.4.6 Risk of maternal mortality  
 
To estimate the impact of maternal mortality for the model, ONS mortality statistics for 
England and Wales were used; from these, numbers of women with live births (including 
singleton and multiple pregnancies) and maternal deaths in pregnancy for 2003 to 2012 
were identified (Table 5.8). 
 
Table 5.8: Number of deaths during pregnancy from ONS mortality statistics 
Year Number 
of 
women 
giving 
birth 
Deaths 
during 
pregnancy 
Deaths 
from 
ectopic 
pregnancy 
Deaths 
from 
miscarriage 
Deaths 
from 
abruption 
Deaths 
from 
previa 
Deaths 
from pre-
eclampsia 
Other 
deaths 
during 
pregnancy 
2012* 721,574 46 0 0 1 0 4 41 
2011* 716,040 44 0 1 2 0 0 41 
2010* 715,467 35 1 0 0 0 2 32 
2009* 698,324 63 1 0 1 0 5 56 
2008* 701,297 44 3 2 0 0 3 36 
2007* 682,999 47 2 2 0 0 2 41 
2006* 662,915 41 2 0 1 1 4 33 
2005 ? 639,627 36 2 1 1 0 6 26 
2004 ? 633,728 46 3 1 0 0 3 39 
2003 ? 615,787 45 3 0 2 0 3 37 
Total 6,787,758 447 17 7 8 1 32 382 
* Source: Table 5.15,  Mortality Statistics: Deaths registered in England and Wales (Series DR) [279] 
 ?^ŽƵƌĐĞ PdĂďůĞ ? ? ? ? ?DŽƌƚĂůŝƚǇ^ƚĂƚŝƐƚŝĐƐ PĂƵƐĞ ?ŶŐůĂŶĚĂ ĚtĂůĞƐ ?^ĞƌŝĞƐ, ? ? [280] 
 
ONS estimates do not report the number of women giving birth that suffer complications; 
to ĞƐƚŝŵĂƚĞƚŚŝƐ ?ƚŚĞ ‘ĂůůƉƌĞŐŶĂŶĐǇ ?ƉƌŽďĂďŝůŝƚŝĞƐĨŽƌĐŽŶĚŝƚŝŽŶƐĂƐƌĞƉŽƌƚĞĚŝŶTable 5.1 and 
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Table 5.2 were multiplied by the total number of women giving birth. This derived an 
estimate of the total annual number of women suffering from one of the conditions to be 
included in the model. The mortality probability for each condition was then determined by 
dividing the actual number of deaths from that condition by the estimated number of 
maternities which suffered from it. As no literature was identified that suggested an 
increased mortality during pregnancy linked with smoking, it was assumed that smoking 
had no impact on maternal mortality in the presence of related conditions. Table 5.9 
reports mortality probabilities used. 
 
Table 5.9: Estimated number of conditions occurring and mortality risks during pregnancy 
Condition Death episodes  Derived occurrence 
episodes 
Risk of death 
Ectopic pregnancy 17 113,245* 0.00015* 
Miscarriage 7 402,459* 0.00002* 
Placental abruption 8 26,959 0.00030 
Placenta previa 1 44,695 0.00002 
Pre-eclampsia 32 133,590 0.00024 
No complication 
mortality 
382 6,582,514 0.00006 
* ONS data excludes women who suffer from a miscarriage or ectopic pregnancy. This was 
estimated by multiplying the number of maternities by the ratio of total number of 
miscarriages,  ectopic pregnancies, and delivery episodes over delivery episodes: 6,787,758 
x (4,968,361/4,592,445) 
 
5.4.7 Impacts of prematurity on infant birth weight and stillbirth 
 
Ŷ ŝŶĨĂŶƚ ?ƐďŝƌƚŚǁĞŝŐŚƚ ŝƐŚĞĂǀŝůǇ ƌĞůŝĂŶƚŽŶŐĞƐƚĂƚŝŽŶĂƚďŝƌƚŚ [281, 282], and stillbirth is 
associated with both prematurity and birth weight. [271] Data reporting: i) birth weight by 
gestation and ii) stillbirths by birth weight and gestation for the years 2006 to 2011 were 
taken from ONS Child Mortality Statistics and ONS Gestation-specific Infant Mortality in 
England and Wales. [283, 284] Table 5.10 reports the number of stillbirths and live births by 
birth weight and prematurity.  Prematurity was defined as birth occurring before 37 weeks 
gestation, and LBW was defined as an infant born weighing less than 2500 grams.  
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Table 5.10: Number of live births and stillbirths by birth weight and prematurity 
Year Premature LBW Premature normal 
birth weight (NBW) 
Full gestation LBW Full gestation NBW 
Live 
births* 
Stillbirths 
 ? 
Live 
births* 
Stillbirths 
 ? 
Live 
births* 
Stillbirths 
 ? 
Live 
births* 
Stillbirths 
 ? 
2011 30,837 2,158 19,857 141 19,850 356 649,080 1,156 
2010 30,097 2,092 19,903 131 20,148 386 648,437 1,105 
2009 30,668 2,120 19,720 140 20,090 351 6235,332 1,077 
2007-
2008 
61,172 4,063 38,260 260 39,598 676 1,258,343 2,216 
2006 31,516 2,097 18,812 156 18,608 326 600,529 1,023 
Total 184,290 12,530 116,552 828 118,294 2,095 3,791,721 6,577 
* Source: Tables 2/3 Gestation-specific infant mortality in England and Wales (relevant year) [176, 
285-288] 
 輀  Source: Table 9 Child Mortality Statistics (years 2008  W 2011) [289-292], Table 13 Mortality 
Statistics: Childhood, infant and perinatal, England and Wales (2006-2007) [293, 294] 
Note: 2007-2008 gestation specific data was aggregated 
Note: Although the gestation specific data defines prematurity as occurring before 37 weeks 
gestation, premature stillbirths are defined as occurring before 36 weeks gestation. This has been 
changed in the 2012 edition; however gestation-specific data is not yet available. 
 
DiFranza et al determined that the relative risk for LBW and stillbirth for smoking in 
pregnancy were 1.82 (95% CI 1.67 to 1.97) and 1.26 (95%CI 1.19 to 1.34) respectively. [3] 
The model assumes that smoking during pregnancy increases the risks of LBW and stillbirth 
for both prematurely born and full gestation infants. The impact of smoking on the 
probabilities of an infant being born with LBW and/or stillborn were incorporated using the 
methods outlined in the previous section around incorporating conditions relating to 
pregnancy complications; the probabilities are given in Table 5.11 and Table 5.12. 
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Table 5.11: Probability of LBW conditional on smoking status and gestation 
Gestation length Non-smoker Smoker 
Premature <37 weeks 0.5703 1.0000 
&ƵůůŐĞƐƚĂƚŝŽŶA? ? ?ǁĞĞŬƐ 0.0280 0.0509 
 
Table 5.12: Probability of a stillbirth conditional on birth weight, gestation, and smoking status 
Birth weight/Gestation 
length 
Non-smoker) Smoker) 
LBW/premature 0.0617 0.0778 
NBW/premature 0.0068 0.0086 
LBW/ full gestation 0.0169 0.0213 
NBW/ full gestation 0.0017 0.0021 
 
 Estimating maternal health related quality of life parameters for 5.5
inclusion in model 
 
To estimate the health-related impacts of smoking and smoking cessation during pregnancy 
required the calculation of QALYs.  To determine the impact of smoking and quitting on the 
health of the mother, along with any health loss associated with suffering from one of the 
included conditions, utility values were required to weight the life year during pregnancy. 
 
Utility values for currently smoking and former smoking women were calculated using the 
utility tariff described by Maheswaran et al [295]. This multivariate linear regression 
investigated the relationship between EQ-5D utility scores and several health risk 
behaviours while controlling for age and gender. This tariff allowed utilities to be calculated 
for an actively smoking and abstaining mother at the end of pregnancy without a within-
pregnancy complication. Since the utility lost for smokers was associated with the amount 
ƐŵŽŬĞĚ ?ĐĂƚĞŐŽƌŝƐĞĚĂƐ ‘ůŝŐŚƚƐŵŽŬĞƌ ? ?AM ? ?ĐŝŐĂƌĞƚƚĞƐĂĚĂǇ ? ? ‘ŵŽĚĞƌĂƚĞƐŵŽŬĞƌ ? ? ? ?- A 9 
ĐŝŐĂƌĞƚƚĞƐĂĚĂǇ ? ?ĂŶĚ ‘ŚĞĂǀǇƐŵŽŬĞƌ ? ?A?20 cigarettes a day), the average utility decrement 
for a smoker was calculated by taking a weighted average of the utility lost attributable to 
the different types of smokers within the study (Light 33%, Moderate 42%, Heavy 25%). 
The tariff is reported in Table 5.13. 
 
171 
 
Table 5.13: Utility tariff for smokers and non-smokers 
Risk factor Utility decrement  95% Confidence Interval 
 
Constant 0.987 0.974  W 1 
Never smoker 0   
Light smoker 0.044 0.031 - 0.058 
Moderate smoker 0.055 0.041 - 0.068 
Heavy smoker 0.087 0.067 - 0.107 
Former smoker 0.027 0.019 - 0.036 
Female 0.016 0.009 - 0.023 
16-24 0  
25-34 0.015 0.005 - 0.026 
35-44 0.033 0.022 - 0.044 
45-54 0.068 0.056 - 0.080 
55-64 0.094 0.081 - 0.107 
65-74 0.166 0.101 - 0.131 
75+ 0.138 0.122 - 0.155 
Source: Maheswaran et al [295] 
 
Chapter 2 determined that, of conditions with a potentially causal association with smoking 
in pregnancy, only ectopic pregnancy and miscarriage were associated with a utility loss 
(see Table 5.14). It was assumed there was no utility loss for the mother relating to 
placental abruption, placenta previa, pre-eclampsia, premature birth, and a LBW infant.  
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Table 5.14: Utility decrements associated with pregnancies which do not end in delivery 
Condition Mean utility 
decrement 
Standard 
error 
Ectopic pregnancy 0.01 0.01 
Loss of pregnancy/infant (applied to ectopic 
pregnancy,  miscarriage, and stillbirth) 
0.1 0.1 
Note: in the absence of information, it was assumed the standard error was the same as 
the mean utility decrement as a worst case scenario. 
 
Pregnancy does not last a full year, and therefore the life year (LY) has to be weighted by 
the proportion of a full year that a pregnancy lasts. There is a great deal of variation in 
pregnancy length. Most ectopic pregnancies are diagnosed between five and 14 weeks 
gestation, so 10 weeks was used as a midpoint. [296] Miscarriage can occur anytime in the 
first 23 weeks of gestation, although most miscarriages occur during the first trimester, 
before 14 weeks gestation [297], so a value of 14 weeks was chosen as midpoint. For the 
complications, NHS Maternity Statistics for England 2012-2013 reports numbers of births 
with complications by gestation. [150] The average gestation length was calculated from 
these data for each condition and is reported in Table 5.15.   
 
Table 5.15: Length of gestation used to weight LYs 
Condition Premature (weeks) Full gestation (weeks) 
Ectopic 10  
Miscarriage 14  
Placental abruption 33 39 
Placenta previa 33 38 
Pre-eclampsia 33 39 
No complication 33 40 
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LYs were weighted by the length of gestation, and then adjusted to take into account the 
utility values associated with being in a particular state, thus calculating a QALY for the 
MWPC. For example, the QALY for a 26 year old abstaining mother who suffers from 
ectopic pregnancy was calculated thus: 
 ܳܣܮܻ ൌ ሺܮܻ ൈ ݌ݎ݋݌݋ݎݐ݅݋݊ݏ݌݁݊ݐ݅݊݌ݎ݁݃݊ܽ݊ܿݕሻൈ ሺݑݐ݈݅݅ݐݕ݂݈݁݉ܽ݁݂݋ݎ݉݁ݎݏ݉݋݇݁ݎܽ݃݁݀ ? ?െ ݑݐ݈݅݅ݐݕ݀݁ܿݎ݁݉݁݊ݐ݁ܿݐ݋݌݅ܿ݌ݎ݁݃݊ܽ݊ܿݕሻൌ ቆ ? ൈ ൬ ? ? ? ?൰ቇ ൈ ൫ሺ ?Ǥ ? ? ?െ  ?Ǥ ? ? ?െ  ?Ǥ ? ? ?െ  ?Ǥ ? ? ?ሻ െ  ?Ǥ ? ?െ  ?Ǥ ?൯ൌ  ?Ǥ ? ? ? ? 
 Estimating infant health related quality of life parameters for 5.6
inclusion in the model 
 
Utility assignments to the infant when it is inside the womb are not made. Therefore, to 
model the potential impact of smoking and cessation on infants during pregnancy, the 
model estimates the number of adverse pregnancy outcomes related to the infant. The 
model records the number of infants lost (miscarried, ectopic, or stillborn), born 
prematurely, or born with LBW. The model also reports two overall measures. The first of 
these is an adverse live birth, defined as any birth which is LBW or premature, but ends 
with the infant alive. The other measure is any adverse pregnancy outcome, defined as any 
foetus lost to miscarriage or ectopic pregnancy, any infant stillborn, any born with LBW and 
any born prematurely. Unlike the MWPC, the IWPC uses these categories as the measures 
of effectiveness, generating an ICER per adverse live birth, and an ICER per adverse 
pregnancy outcome.  
 
 Costs of healthcare attributable to pregnancy and associated 5.7
complications 
 
Estimates for healthcare costs were taken from NHS Reference Costs 2011-12, which report 
Healthcare Resource Groups (HRG), with the cost analysis done from an NHS and Personal 
Social Services perspective, given in 2011-2012 prices. [298]. Costs for different areas of 
healthcare were derived by using a weighted median cost as recommended by the NHS 
Reference Cost team [299], whereby the costs for the different HRG codes are weighted to 
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reflect activity in different settings; elective inpatient, elective inpatient excess bed days, 
non-elective inpatient (short stay), non-elective inpatient (long stay), non-elective excess 
bed days, day cases, regular day/night admissions, outpatients, and community midwife 
services. These were in turn weighted by the activity in the different settings to give a 
weighted median cost per hospital care. The details of the HRG codes used in the costings 
are given in Table 5.16. For the cost of death, the cost of cardiac event was attributed as a 
proxy for the cost of emergency care since there is no HRG code for obstetric death. [4] 
Details of the costs are given in Table 5.17.  
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Table 5.16: HRG codes used to identify relevant NHS Reference Costs 
Condition/ 
Treatment 
HRG 
codes 
Description 
Ectopic 
pregnancy 
MB04A Ovary, Fallopian Tube or Pelvic Disorders, with complication 
MB04B Ovary, Fallopian Tube or Pelvic Disorders, without 
complication 
Miscarriage MB08Z Threatened or Spontaneous Miscarriage 
Ultrasound 
scan 
NZ21Z Ante-natal Standard Ultrasound Scan 
NZ22Z Ante-natal Specialised Ultrasound Scan 
Obstetric visits 501* Consultant led: First attendance non-admitted face to face 
501* Consultant led: First attendance non-admitted non face to 
face 
501* Consultant led: First attendance multi-professional non-
admitted face to face 
501* Consultant led: First attendance multi-professional non-
admitted non face to face 
501* Non-consultant led: First attendance non-admitted face to 
face 
501* Non-consultant led: First attendance non-admitted non face to 
face 
501* Non-consultant led: First attendance multi-professional non-
admitted face to face 
501* Consultant led: Follow up non-admitted face to face 
501* Consultant led: Follow up non-admitted non face to face 
501* Consultant led: Follow up multi-professional non-admitted 
face to face 
501* Consultant led: Follow up multi-professional non-admitted 
non face to face 
501* Non-consultant led: Follow up non-admitted face to face 
501* Non-consultant led: Follow up non-admitted non face to face 
501* Non-consultant led: Follow up multi-professional non-
admitted face to face 
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Birth NZ11A Normal Delivery with complication 
NZ11B Normal Delivery without complication 
NZ11C Normal Delivery with Epidural, with complication 
NZ11D Normal Delivery with Epidural, without complication 
NZ11E Normal Delivery with Induction, with complication 
NZ11F Normal Delivery with Induction, without complication 
NZ11G Normal Delivery with Post-partum Surgical Intervention 
NZ12A Assisted Delivery with complication 
NZ12B Assisted Delivery without complication 
NZ12C Assisted Delivery with Epidural, with complication 
NZ12D Assisted Delivery with Epidural, without complication 
NZ12E Assisted Delivery with Induction, with complication 
NZ12F Assisted Delivery with Induction, without complication 
NZ12G Assisted Delivery with Post-partum Surgical Intervention 
NZ13A Planned Lower Uterine Caesarean Section with complication 
NZ13B Planned Lower Uterine Caesarean Section without 
complication 
NZ14A Emergency or Upper Uterine Caesarean Section, with 
complication 
NZ14B Emergency or Upper Uterine Caesarean Section, without 
complication 
NZ15Z Caesarean Section with Eclampsia, Pre-eclampsia or Placenta 
Previa 
NZ25Z Labour without Specified Delivery 
Routine 
observation 
NZ16Z Ante-natal routine observation 
Death EB05Z Cardiac Arrest 
*service code for obstetrics visit 
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Table 5.17: Weighted means, lower quartile, and upper quartile costs for model outcomes 
  Description Weighted 
mean cost 
Lower 
quartile 
Upper 
quartile 
Foetal loss Treatment for ectopic pregnancy £1,749.23 £1,190.46 £2,075.46 
Treatment for miscarriage £554.70 £362.58 £671.52 
Antenatal 
care 
Community midwife visit £53.00 £37.00 £61.00 
Standard ultrasound scan £109.78 £60.04 £128.57 
Specialised ultrasound scan £121.02 £74.61 £159.83 
Obstetrician first visit £152.21 £112.95 £189.05 
Obstetrician subsequent visit £101.13 £69.23 £118.63 
Antenatal 
drugs 
Hypertension in pregnancy drug 
treatment cost 
£10.61 per pack of 56 tablets* 
Delivery Birth (with or without pre-
eclampsia) 
£2,079.81 £1,611.56 £2,451.21 
Emergency caesarean section 
birth (abruption) 
£3,466.59 £2,806.53 £3,970.53 
Caesarean birth (previa) £3,413.47 £2,762.22 £3,927.02 
Routine observation (per day) £571.15 £364.74 £760.93 
Death   £1,379.02 £773.73 £1,573.62 
*Data from BNF No 64, Sept 2012 [300] 
 
5.7.1 Estimating maternal healthcare costs 
 
ƐŝŶĚŝǀŝĚƵĂůƐ ?ĂŶƚĞŶĂƚĂůĐĂƌĞŝƐǀĞƌǇǀĂƌŝĂďůĞ ?ĞǆƉĞƌƚŽƉŝŶŝŽŶǁĂƐƐŽƵŐŚƚĨƌŽŵĂƉƌĂĐƚŝƐŝŶŐ
NHS midwife to deteƌŵŝŶĞŚŽǁƚŽĂƚƚƌŝďƵƚĞ ‘ƵƐƵĂůĐĂƌĞ ?(UC) costs. Costs were attributed 
using the following assumptions:  
x Pregnancies not ending in delivery (ectopic pregnancy and miscarriage): no 
antenatal care costs, hospital care costs from relevant HRG codes, and one 
ultrasound scan to diagnose the foetal loss 
x  “EŽƌŵĂů ? ƉƌĞŐŶĂŶĐǇ ending in delivery: receive up to eight community midwife 
visits plus two ultrasound scans for antenatal care, and the cost of a birth. The 
number of antenatal visits was weighted to take into account that some mothers 
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give birth before 37 weeks (premature birth) and therefore receive up to six 
midwife visits rather than eight. 
x Placental abruption: receive an emergency caesarean birth, at least one visit from 
an obstetrician, and remain in hospital for three days ? routine observation. Number 
of antenatal visits weighted by the number of abruptions that occurred before 37 
weeks:  premature pregnancies received six midwife visits and full-term 
pregnancies received eight midwife visits. 
x Placenta Previa: receive standard care plus an extra ultra-sound scan, up to the 
ƚŚƌĞĞ ŽďƐƚĞƚƌŝĐŝĂŶ ǀŝƐŝƚƐ ? ĂŶĚ ďŝƌƚŚ ďǇ ĐĂĞƐĂƌĞĂŶ ƐĞĐƚŝŽŶ ǁŝƚŚ ƚŚƌĞĞ ĚĂǇƐ ? ƌŽƵƚŝŶĞ
observation. Number of antenatal visits weighted by the number of women who 
give birth prematurely with previa. 
x Pre-eclampsia: receive standard antenatal care, plus three obstetrician visits, three 
further ultrasound scans, three days ? routine observation, and medication to lower 
ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ďůŽŽĚ ƉƌĞƐƐƵƌĞ ? ĐĐŽƌĚŝŶŐ ƚŽ E/ ?Ɛ ĐĂƌĞƉĂƚŚǁĂǇƐ ƚŚĞ first line 
treatment is to first offer the drug labetalol orally. [301] The normal dose is a 
200mg tablet taken twice a day, and the tablets are prescribed in packs of 56. 
Assuming a woman develops pre-eclampsia at week 20 of pregnancy, if she is 
premature then she will have received five packs, while if she is full gestation, she 
will have received six.  
x Cost of a delivery: The cost of a delivery episode is difficult since a woman can 
suffer a pregnancy complication but not have a complicated birth, and vice-a-versa. 
Both abruption and previa require a birth by caesarean section, and costs linked 
with the relevant HRG codes for caesarean births were applied. However, for a 
normal pregnancy and delivery with pre-eclampsia, any mode of delivery was 
applicable, so all costs related to HRG codes associated with birth were used.  
x Cost of death: If the mother died during pregnancy, either with or without a 
complication, costs of care up to that death would be incurred in addition to the 
cost of death itself. 
 
5.7.2 Costs in the infant model 
 
The majority of the costs associated with pregnancy in ESIP are maternal; however, there 
ĂƌĞ ĂůƐŽ ƐŽŵĞ ĂƚƚƌŝďƵƚĂďůĞ ŝŶĨĂŶƚ ŚĞĂůƚŚĐĂƌĞ ĐŽƐƚƐ ? 'ŽĚĨƌĞǇ Ğƚ Ăů ƌĞƉŽƌƚĞĚ ŝŶĨĂŶƚƐ ?
healthcare costs gestation and birth weight. [4] To calculate the appropriate costs, those 
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associated with premature and LBW infants were weighted using a similar process to 
calculating the weighted mean in the NHS reference costs. Godfrey et al also reported a 
cost for a stillbirth. The costs are reproduced in Table 5.18. 
 
Table 5.18: Costs relating to infant healthcare used in infant model 
Condition ƐƚŝŵĂƚĞĚĐŽƐƚ ? ? ? ? Standard deviation (£) 
Stillbirth 639  
Premature birth 2,648.55*  
Full gestation 824 940 
LBW 2,413.79*  
NBW 835 978 
Source: Godfrey et al. [4] Prices reported are for year 2006-2007 
*Weighted costs across several birth weight/gestation length categories 
 ?dŚĞƐƚƵĚǇ ƌĞƉŽƌƚĞĚƉƌŝĐĞƐ ĨŽƌ ƚŚĞ ĨŝŶĂŶĐŝĂů ǇĞĂƌ  ? ? ? ?-2007, and were inflated to 2011-
2012 prices using the Hospital and Community Health Services (HCHS) Pay & Price Index. 
[89] The inflation index was 1.1309. 
 
 Discussion 5.8
 
This chapter describes the rationale behind and development of the first stages of the ESIP 
model; the Maternal Within-Pregnancy Component (MWPC) and the Infant Within-
Pregnancy Component (IWPC). These components model the impact of smoking and 
cessation on the mother and her foetus by incorporating several key conditions. ESIP is the 
second economic model to incorporate many of the relevant conditions, but the first to 
explicitly link maternal and foetal/infant experience of morbidity, such that impacts of 
maternal pregnancy complications on infant outcomes are modelled within it.  
5.8.1 Strengths of the within-pregnancy components 
 
MWPC and IWPC have several improvements over the previous literature. Firstly, there is a 
direct link between the MWPC and IWPC, allowing for complications occurring in the 
MWPC to impact on the outcomes for the infant in the IWPC. As far as the author is aware, 
this is novel in the literature. This link is important, since it reflects what actually occurs in 
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pregnancy. For example, maternal experience of abruption or pre-eclampsia can directly 
influence her chance of having a premature birth. This in turn impacts on the infant, since a 
prematurely-born infant is more likely to be born with LBW. It can also impact on the 
healthcare costs required to treat an infant, since infants who are born prematurely and/or 
with LBW are often associated with higher costs due to increased stays in neonatal 
intensive care units. [302] Although Shipp et al included placental abruption, placenta 
previa, and pre-eclampsia, their model does not make the link between the mother and her 
infant, and therefore the birth outcomes modelled for the infant could be wrong. This 
would suggest that the previous literature may underestimate the impact of smoking 
during pregnancy, potentially underestimating the cost-effectiveness of cessation during 
pregnancy. 
 
ESIP, via MWPC and IWPC components, is only the second economic model to attempt to 
capture the impacts of smoking on ectopic pregnancy and miscarriage, which have been 
generally omitted from previous economic models. The omission of the conditions could 
imply that the previous literature is not only not capturing healthcare costs and HRQoL 
losses associated with these conditions, but could also be overestimating the number of 
conceptions which result in a live birth. This is important because the MWPC and IWPC 
potentially estimate the costs and HRQoL losses, as well as the number of live births, more 
accurately than the previous literature. Therefore, the cost-effectiveness estimates from 
ESIP could also be considered more precise.  
 
MWPC and IWPC may deal with the impacts of placental abruption, placenta previa, and 
pre-eclampsia more appropriately than previous models. While Shipp et al had included 
these, both previa and abruption were grouped together in one arm, therefore not 
accurately predicting either the numbers of women who suffer these conditions accurately, 
or the different impacts of these conditions on the gestation period if premature birth had 
been incorporated. Conversely, the MWPC incorporates both conditions separately, 
allowing for the differences in both the risks of developing either of the conditions, and the 
birth being premature (0.4029 for abruption versus 0.2631 for previa). This is preferable 
when trying to accurately estimate the number of pregnancies that will suffer from these 
conditions and the associated impacts on the health of the mother and birth outcomes for 
her infant, since there would appear to be different healthcare costs and birth outcome 
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risks between the two conditions. Overall, this suggests that MWPC and the IWPC give 
more accurate costs and benefits than the previous economic models. 
 
5.8.2 Limitations associated with the within-pregnancy components 
 
One potential limitation is that the model assumes that women who quit are allocated the 
same risks of those pregnancy complications and infant birth outcomes as those who were 
never smokers. This assumption was made to allow some measure of effectiveness of 
interventions in reducing the risks of pregnancy complications and adverse birth outcomes, 
since smoking in pregnancy has been demonstrated to increase the risk of these outcomes. 
However, it could be argued that because the woman is a smoker, and is likely to have 
smoked for at least some part of pregnancy, usually until they find out they are pregnant, 
then the risks of these complications/adverse birth outcomes are likely to be higher 
compared to a never smoker. However, there is evidence to suggest that infants born to a 
mother who quits early in pregnancy have the same birth weight as those born to never 
smokers, and that, furthermore, women who accessed smoking cessation interventions 
also had infants with higher birth weights compared to smokers. [303] Although there is no 
evidence for the other complications, we could assume that the assumption is justified. 
However, it would certainly be possible to adjust the probabilities if in the future work was 
done which resolved this issue. For example, if an accurate measure of the probability of a 
delivery complication or adverse infant birth outcome amongst smoking women who quit 
during pregnancy was estimated, this could be incorporated into the model and the risks 
for the quitters could be adjusted. 
 
Another limitation related to the smoker/non-smoker assumption is that the model 
assumes only two types of pregnant women with regard to smoking behaviour, those who 
had quit by the end of pregnancy, and those who were smoking at the end of pregnancy. 
This means that the described model fails to take into account any impacts of the timing 
and duration of any smoking cessation during pregnancy and its associated impact on 
pregnancy outcomes. This could be problematic as a woman who quits during the 30th 
week of her pregnancy may have different risks of developing smoking related 
complications compared to one who quits during her 10th week; however, the model 
currently groups both women together. This impact definitely exists for LBW, where 
women who quit before the third trimester (week 29) have substantially lower risks of LBW 
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compared to those who smoked throughout pregnancy. [304] This could lead to two 
impacts regarding the cost-effectiveness estimates generated by the within-pregnancy 
components. Firstly, the MWPC and IWPC could be slightly overestimating the number of 
women who benefit from smoking cessation during pregnancy, as several women could be 
counted as having quit who actually only quit just before the end of pregnancy. This would 
suggest that the model is overestimating the potential cost-effectiveness of cessation 
within-pregnancy. On the contrary, the model could be underestimating the number of 
women who benefit, since some women who have been counted as smokers may have 
actually been quit most of the way through pregnancy, but the model would not assign 
them any benefit. This would suggest the model is underestimating the potential cost-
effectiveness of cessation within-pregnancy. Unfortunately, the author cannot speculate as 
to how much this is a problem for the results of the MWPC and the IWPC. Further empirical 
research is needed to identify the impact of different cessation timings on the risks of 
developing the conditions. This limitation is likely to remain a problem for all subsequent 
economic models of cessation during pregnancy until further research is conducted. 
However, a potential method to correct this issue would be to introduce changes in 
smoking behaviour (such as quitting/relapsing) at different points in the model, perhaps by 
trimester. This could allow the introduction of work demonstrating the effects of timing of 
cessation. [304] This could be one avenue for further research.  
 
There are also some potential issues related to the costs used in the model. A brief 
literature search failed to identify a robust and reliable cost for a normal pregnancy. 
Although the model uses the weighted mean cost as recommended by the NHS Reference 
Cost team, and expert opinion was obtained from an experienced midwife, who gave 
details of the likely associated outcomes and costs, there is a high degree of variability in 
the antenatal and associated delivery costs, which may not have been captured.  For 
example, data around the length of hospital stay before delivery, number of hospital visits, 
and number of extra scans is unavailable. However, due to the limited data available, it 
would prove very difficult to counteract this limitation without capturing data around 
resource use during pregnancy in more detail. This could mean that the model is 
underestimating the costs associated with not only a normal pregnancy, but also the cost 
of the adverse events associated with pregnancy, giving conservative estimates of the true 
cost to the NHS. However, these costs are a relatively small part of the model, which can be 
changed easily should new information become apparent.  
183 
 
 
Another possible limitation with the components is that, again due to an absence of 
available data, there are no utility losses associated with placental abruption, placenta 
previa, and pre-eclampsia; it is possible that these may have an effect on maternal quality 
of life. This was clearly demonstrated in section 2.4.7, where we identified no utility 
decrements or weights with these conditions. Indeed, one included study recommended 
that there was no utility loss associated with pre-eclampsia after the authors consulted 
expert and clinical opinion. [157] Therefore, it would seem justifiable not to include a utility 
loss associated with these complications. However, a mother who suffers from previa or 
abruption is likely to notice a very severe impact on her HRQoL; although this might only be 
a short term impact, it would still be relevant in the time frame of this model. Therefore 
the MWPC could be overestimating the HRQoL associated with women who have a delivery 
with a complication. This could have implications for the cost-effectiveness estimates for 
cessation interventions, since the model is underestimating the health related impact of 
these conditions. However, to solve this issue would require further research in identifying 
a relevant utility loss to associate with these conditions. One possible solution could be to 
introduce an arbitrary utility loss, and, in a sensitivity analysis, investigate what impact this 
has on the model outputs.  
 
The within-pregnancy components also do not incorporate two conditions which have been 
identified as having a causal association with smoking during pregnancy; PROM / PPROM, 
and congenital anomalies. However, in most cases, PPROM and PROM result in a normal 
birth; therefore it could be considered that there is no significant difference in costs 
between those mothers who suffer from the complication compared with those who do 
not. [305] Furthermore, Chapter 2 did not identify that PROM / PPROM had any impact on 
HRQoL, and therefore its inclusion is very unlikely to change any valuation of the benefits 
of cessation.  
 
For congenital anomalies, there was far more information identified suggesting that there 
was a greater impact on HRQoL. However, these appear to have a great deal of variation, 
dependent on the type of abnormality the infant has developed. This would have been an 
added complication to the within-pregnancy components, as to generate reasonably 
accurate measures of HRQoL and healthcare costs associated with the anomalies, the 
within-pregnancy components would probably have to differentiate between diseases with 
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a lasting impact and those that do not. Since the conditions also have a relatively low 
incidence, it is very likely that the overall impact on the results from the IWPC and any 
subsequent childhood model would also have been negligible, despite the significant 
impacts on HRQoL and healthcare costs. Although the omission of congenital anomalies 
and PPROM / PROM is a limitation of the components, it is unlikely that the omission of 
these conditions is likely to have a major impact on the results of the within-pregnancy 
components. 
 
Another consideration is the utility values as reported by Maheswaran et al. [295] These 
values were estimated using a multivariate linear regression based on 14,117 participants 
aged 16 years old or greater, using EQ-5D data as collected from the 2008 Health Survey for 
England. The authors highlighted that there were limitations with this study, namely that: 
the data was self-reported and therefore susceptible to reporting bias; the survey was 
cross-sectional and hence it is not possible to establish temporality of the observed 
findings; and there could be adaptation to health states occurring, suggesting that the 
estimated utility decrements are not capturing the full decrement associated with the 
health state. These values differ slightly from those estimated by Kind et al, which  have 
been frequently used as the population norms for utility values [306], for example a non-
smoking 25 year old female has a utility weight of 0.8937 from Kind et al whereas 
Maheswaran et al estimate 0.956. This would suggest that the use of Maheswaran et al 
estimates may be overestimating the utility weights associated with the mother, and hence 
the model could be introducing a bias in favour of the intervention when considering its 
cost-effectiveness. However, the estimates generated by Kind et al were based on the 
results of 3,395 men and women across the UK. Maheswaran et al has approximately four 
times the number of participants, which suggests that it produces better estimates of the 
utility values. However, whereas Kind et al estimated values for the UK population, 
Maheswaran estimated values for England alone, and hence the utility weights can only be 
considered generalizable to population in England and not the UK. This will limit the 
generalisability of the MWPC to producing estimates of cost-effectiveness only for the 
population of England and not the UK, which may reduce the relevance of the cost-
effectiveness estimates to the decision makers. However, more recently, Sullivan et al have 
estimated a series of utility decrements for the UK population based on the EQ-5D score 
associated with 79,197 individuals. [307] Unfortunately, while this reports utility 
decrements for various conditions as well as age, gender, race, and inequality, it does not 
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report a utility decrement for both current and former smokers, and therefore was not 
used in this thesis because it did not provide the relevant information. 
 
Another consideration is that we have not reported a utility for a woman who is pregnant. 
It is likely that a woman who is pregnant will have a different utility value to a woman who 
is not pregnant; however there is some debate as to whether the generic quality of life 
measures (e.g. ED-5D, SF-6D) will be responsive to changes in quality of life amongst 
specialised populations, including pregnant women. [308] Some studies have highlighted 
that there appears to be no evidence on an impact on quality of life between pregnant and 
non-pregnant women[309], while other studies have suggested that there is a significant 
difference between pregnant and non-pregnant women. [310] However, the author is 
unaware of any utility values than have been calculated during pregnancy, which was 
further highlighted by Mogos et al. [308] 
 
5.8.3 The MWPC and IWPC in context of other literature 
 
There have been four previous report-comparable economic models. [65, 68, 190, 205] 
Shipp et al constructed two decision tree models to evaluate cessation in terms of 
pregnancy outcomes for the mother and birth outcomes for the infant. [65] For the 
maternal decision model, the included outcomes were placental abruption, placenta 
previa, pre-eclampsia, and antepartum haemorrhage, while the infant model included 
premature birth and full-term LBW. For the maternal model, it was assumed that there 
were two groups of women; ƚŚŽƐĞ ǁŚŽ ǁĞƌĞŶ ?ƚ ƐŵŽŬŝŶŐ Ăƚ ƚŚĞ ĨŝƌƐƚ ĂŶƚĞŶĂƚĂů ǀŝƐŝƚ ? ĂŶĚ 
those who were smoking and then exposed to a cessation intervention. It has already been 
discussed that one improvement that the ESIP model has over Shipp et al is that the MWPC 
and IWPC are linked such that the pregnancy outcomes for mother have direct impacts on 
the birth outcomes for the infant. A second improvement over Shipp et al is that in the 
development of ESIP, the author has systematically identified the conditions to be included 
in the model. Shipp et al included antepartum haemorrhage, yet the author found no 
evidence that a link between smoking during pregnancy and an increased risk of 
haemorrhage exists. The inclusion of this condition could be potentially overestimating the 
negative effects of smoking, inferring that the cost-effectiveness estimates by Shipp et al 
are inaccurate. One final issue with Shipp is that it is unclear whether the infant model 
assumes that all the prematurely born infants are treated as LBW or not. As demonstrated 
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in Section 5.4.7, not all premature births are LBW, and therefore Shipp et al could be 
overestimating the number of LBW infants, increasing the imprecision of the cost-
effectiveness estimates. 
 
Both Marks et al and Hueston et al constructed models that evaluated cessation in terms of 
birth outcomes for the infant. [68, 205] These models were relatively simple in structure, 
with Marks et al estimating the impact on the number of LBW and stillbirths, and Hueston 
et al estimating the number of LBW. Both these models only calculate the number of 
events avoided, and the potential cost savings from cessation. The structures determine 
ǁŚĞƚŚĞƌ ƚŚĞ ŝŶĨĂŶƚ ŚĂƐ ĂŶ ĂĚǀĞƌƐĞ ďŝƌƚŚ ŽƵƚĐŽŵĞ ĐŽŶƚŝŶŐĞŶƚ ŽŶ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ
behaviour. The IWPC is an improvement on these models because it takes into account 
both the impact of premature birth on birth weight and the joint impact of prematurity and 
birth weight on stillbirth. Furthermore, because of the link with the MWPC, the IWPC is 
likely to produce more precise estimates of birth outcomes because it takes into account 
whether the mother has suffered a pregnancy complication. Therefore, the IWPC would 
appear to have a more encompassing structure than these two studies.  
 
Although Mallender et al modelled cessation interventions in secondary care maternity 
services, the model managed to incorporate within-pregnancy outcomes. [190] A different 
approach was used where the prevalence of the conditions occurring within the cohort 
were calculated. This could be seen as potentially more flexible, in that it allows the 
incorporation of conditions such as PPROM, which ESIP excludes due to lack of data. 
However, one issue with approach used by Mallender et al is that the model approached 
ďŝƌƚŚ ŽƵƚĐŽŵĞƐ ĨŽƌ ƚŚĞ ŝŶĨĂŶƚ  ?Ğ ?Ő ? >t ? ĂƐŵƵƚƵĂůůǇ ĞǆĐůƵƐŝǀĞ ĞǀĞŶƚƐ ĨƌŽŵ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ
pregnancy outcomes. Secondly, Mallender et al has not used UK-specific prevalence data 
for the within-pregnancy maternal complications, even though such data exists and has 
been used in ESIP. Therefore, it could be argued that not only is ESIP more representative 
of what occurs during pregnancy, but also, from a UK perspective, it could be construed 
that the within-pregnancy components are generating more accurate estimates of within-
pregnancy complications.  
 
5.8.4 Implications for future research 
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One of the limitations of the model was attributing the correct costs, not only to the 
complications, but for the infant birth outcomes as well. Although there is some literature 
investigating the costs attributable to smoking during pregnancy for both the mother and 
the infant, retrieving reasonably accurate costs for the model proved to be relatively 
difficult. There does seem to be a great degree of variability in the costs associated with 
both a normal and a complicated birth, and it would certainly be beneficial if more specific 
costs and resource use could be identified.  
 
Another limitation of the ESIP model which could be improved upon with further research 
was the link between premature birth and the mother suffering a pregnancy complication. 
This was only based upon one year of HES data, and might explain some why the model 
seems to underestimate the number of premature births. As future editions of HES data 
become available, the data should be incorporated into the ESIP model to see if it becomes 
better at estimating the impact of smoking during pregnancy on premature birth. 
 
 Summary 5.9
 
This first stage for the ESIP model is very different from previous economic models, 
incorporating both foetal loss and smoking-related pregnancy complications with 
significant impacts on costs and HRQoL. The next two chapters outline the other 
ĐŽŵƉŽŶĞŶƚƐ ŽĨ ƚŚĞ ^/W ŵŽĚĞů ? ǁŚŝĐŚ ĞƐƚŝŵĂƚĞ ƚŚĞ ŝŵƉĂĐƚƐ ŵĂƚĞƌŶĂů ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ
behaviour and health over her lifetime, and on infant health to 15 years old. Furthermore 
there is a demonstration on the validity of the within-pregnancy components (MWPC and 
IWPC) in Chapter 9.  
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 ŚĂƉƚĞƌ ? PdŚĞDŽƚŚĞƌ ?Ɛ>ŝĨĞƚŝŵĞŽŵƉŽŶĞŶƚ ?D> ?ŽĨ ESIP: The 
impacts of smoking behaviour and related morbidities 
 
 Introduction 6.1
 
This chapter outlines the rationale for and methods used to create an ESIP component 
which models maternal smoking behaviour after pregnancy and its impact on health and 
healthcare costs. Within the overall ESIP model, this chapter describes the structure and 
parameterisation of the ESIP Maternal Lifetime Component (MLC), focusing on the grey 
highlighted area shown in Figure 6.1.  
 
Figure 6.1: Overall structure of the ESIP model; focus of this chapter highlighted in grey 
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 Background 6.2
 
Most previous economic literature on smoking cessation interventions during pregnancy 
ƵƐĞƐ Ă  ‘ǁŝƚŚŝŶ-ƉƌĞŐŶĂŶĐǇ ? ƚŝŵĞ ŚŽƌŝǌŽŶ ?[137, 139, 190] Only three models extended 
beyond pregnancy, despite smoking being associated with increased mortality and 
morbidity from many diseases, including lung cancer (LC) and coronary heart disease (CHD). 
[9, 66] Such diseases may affect women who smoke after pregnancy and can have 
significant treatment costs and impacts on the health of a patient. It has been estimated 
that around 18% of all deaths in 2011 were attributable to smoking, and therefore could 
have been potentially preventable. [134] Women ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌĂĨƚĞƌƉƌĞŐŶĂŶĐǇ ŝƐ
likely to be influenced by prior smoking behaviour, and this includes decisions made prior 
to as well as during pregnancy. If a woman remains abstinent after pregnancy, she no 
longer exposes herself to potential smoking-related morbidities, resulting in a benefit 
which accrues after childbirth and is additional to that derived from abstinence during 
pregnancy itself. However, if a woman relapses after pregnancy, any long-term benefit 
from cessation during pregnancy is likely to be reduced, or at worst entirely negated. 
Clearly, for an economic model to be comprehensive, it should capture the potentially 
major impacts of smoking behaviour after, as well as within, pregnancy.  
 
 Aims and objectives 6.3
 
6.3.1 Primary objective: 
 
To describe the ESIP component, which captures maternal smoking behaviour after 
pregnancy and estimates the impact on maternal lifetime health and healthcare costs.  
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6.3.2 Secondary objectives: 
 
1. To outline the structure of the Mother Lifetime Component (MLC) component and 
how the cohort flows through the Markov chains 
2. To model maternal smoking behaviour for the first two years postpartum using 
estimates for smoking behaviour after childbirth from Chapter 4 
3. To model the smoking behaviour of mothers beyond two years postpartum for the 
rest of their lifetime 
4. To estimate the numbers of maternal smoking related morbidities that occur 
amongst the cohort of women 
5. To determine costs and HRQoL measures for healthy women and those suffering 
from a morbidity 
 
 Maternal Lifetime Component: structure 6.4
 
dŚŝƐ ƐĞĐƚŝŽŶ ĚĞƐĐƌŝďĞƐ ƚŚĞ ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ D> ?Ɛ DĂƌŬŽǀĐŚĂŝŶ ŵŽĚĞů ǁŚŝĐŚ ŝƐ ƵƐĞĚ ƚŽ
determine maternal smoking behaviour after pregnancy and outlines how this is linked to 
the Mother Within-Pregnancy Component (MWPC). For the methods associated with 
Markov models, please see section 1.6.7.2. 
 
6.4.1 Basic Markov model structure 
 
A simple Markov model predicting smoking behaviour has already been constructed, and 
subsequently adapted with pregnancy-related postpartum parameters. [129, 139, 190] This 
general smoking behaviour Markov chain had three states: 
1. Current smoker  
2. Former smoker: a woman who smoked and has now stopped  
3. Dead 
This Markov structure was deemed inadequate for the MLC because women who might 
only have stopped smoking for a very short time were grouped as former smokers with 
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others who had been abstinent for much longer. As discussed in Chapter 4, most quitters 
relapse within one year whether pregnant or not. [134] Therefore, it would seem logical 
that they would not receive any benefit because the temporary abstinence is so short, and 
thus by grouping the short- and long-term abstainers together, the simple Markov would 
overestimate the HRQoL gains in the long-term. Consequently, it is appropriate that the 
MLC should adopt a different structure which is more reflective of long-term smoking 
patterns. The new structure for the smoking behaviour model constructed for the MLC is in 
Figure 6.2.   
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Figure 6.2: Basic Markov chain structure for the DŽƚŚĞƌ ?Ɛ>ŝĨĞƚŝŵĞŽŵƉŽŶĞŶƚ 
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dŚĞD>ĐŽŶƚĂŝŶƐĨŝǀĞƐƚĂƚĞƐǁŚŝĐŚƌĞƉƌĞƐĞŶƚƐƚĂŐĞƐŽĨǁŽŵĞŶ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌĂĨƚĞƌ
pregnancy. These are: 
1. Current smoker  
2. 0-1 year quitter: women maintaining abstinence for 12 months or less after quit 
attempt 
3. 1-2 years quitter: women maintaining abstinence for longer than 12 but less than 
24 months after quit attempt 
4. Long-term quitter: women who are abstinent from smoking for more than 24 
months after quit attempt 
5. Dead 
The MLC adopted annual cycles, to better fit available data. Both the 0-1 year quitter and 1-
2 years quitter are tunnel states; women cannot remain in these states for more than one 
cycle and must transit to one of the other linked states. However, they could remain in the 
other three states indefinitely.  
 
In any cycle, a woman who reported active smoking could transit to three possible states: 
remain an active smoker; make a quit attempt (become a 0-1 year quitter); or exit the 
cohort by dying. The model assumes that a woman can make an unlimited number of quit 
attempts throughout the rest of her life. Once a woman becomes a 0-1 year quitter, she 
again has three possible transitions: 1-2 years quitter; relapse to smoking; or die. For a 
woman who becomes a 1-2 year quitter, the three possible transitions are to become a 
long-term quitter, relapse to smoking, or die. Because 0-1 year quitter and 1-2 years quitter 
are tunnel states, a woman cannot remain in them for more than one cycle. For long-term 
quitters, the woman again has three possible transitions: remain abstinent (i.e. stay in the 
long-term quitter state), relapse to active smoking, or die. This generates the transition 
matrix given in Table 6.1, of which the parameterisation is described in Section 6.5. 
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Table 6.1: Transition matrix for the MLC 
Transition 
from: 
Transition to: 
Current smoker 0-1 year 
quitter 
1-2 year 
quitter 
Long-term 
quitter 
Dead 
Current 
smoker 
 ? െ ሺܲܳ஼ௌሻെ ܲሺܦ஼ௌሻ ܲሺܳ஼ௌሻ 0 0 ܲሺܦ஼ௌሻ 
0-1 year 
quitter 
 ? െ ሺܲܳଵ௒ሻെ ܲሺܦ஼ௌሻ 0 ܲሺܳଵ௒ሻ 0 ܲሺܦ஼ௌሻ 
1-2 year 
quitter 
 ? െ ሺܲܮܶܳሻെ ܲሺܦிௌሻ 0 0 ܲሺܮܶܳሻ ܲሺܦிௌሻ 
Long-term 
quitter 
ܲሺܴሻ 0 0  ? െ ሺܴܲሻെ ܲሺܦிௌሻ ܲሺܦிௌሻ 
Dead 0 0 0 0 1 
Where: ࡼሺࡽ࡯ࡿሻ is probability (quit|current smoker), ࡼሺࡽ૚ࢅሻ is probability (quit longer than 
one year|quit attempt made last year), ࡼሺࡸࢀࡽሻ is probability (quit longer than two 
years|quit longer than one year), ࡼሺࡾሻ is probability (relapse to smoking|quit longer than 
two years), ࡼሺࡰ࡯ࡿሻ is probability (dead|current smoker), ࡼሺࡰࡲࡿሻ is probability 
(dead|former smoker) 
 
For the first two cycles after pregnancy, the MLC uses pregnancy-specific parameters for 
quitting and relapse behaviour. This represents the slight differences in smoking behaviour 
in the immediate postpartum period compared to smoking behaviour at other times 
outside of pregnancy. After two years, the MLC uses general smoking behaviour 
parameters. Both the two year postpartum-specific and the general smoking behaviour 
parameters are outlined in the following sections.  
 
6.4.2 Starting states for the cohort of mothers 
 
Mothers who have quit smoking by the end of pregnancy start the MLC in the 0-1 year 
quitter state, demonstrating that they have made a quit attempt for less than 12 months. 
DŽƚŚĞƌƐ ǁŚŽ ƌĞŵĂŝŶ ƐŵŽŬŝŶŐ Ăƚ ƚŚĞ ĞŶĚ ŽĨ ƉƌĞŐŶĂŶĐǇ ƐƚĂƌƚ ƚŚĞ D> ŝŶ ƚŚĞ  ‘ĐƵƌƌĞŶƚ
ƐŵŽŬĞƌƐ ?ƐƚĂƚĞ ? ?ƐŝŐŶŝĨǇŝŶŐƚŚĂƚƚŚĞǇĂƌĞƐƚŝůůĂĐƚŝǀĞůǇƐŵŽŬŝŶŐ ?dŚis information can be found 
on Figure 6.2. 
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 Parameters for the MLC representing smoking behaviour  6.5
 
6.5.1 Mothers who quit during pregnancy 
 
The model utilises specific relapse data for the first two years postpartum, which are 
represented by the first two cycles of the MLC. Chapter 4 estimated the proportion of 
women who reported abstinence at one and two years after childbirth for all participants in 
RCTs. In the absence of more robust data, the pooled abstinence for all participants was 
used as a proxy for postpartum abstinence amongst the population of pregnant smokers 
who had received an intervention. The results from this meta-analysis are reproduced in 
Table 6.2. 
 
Table 6.2: Proportion (95% CI) of women abstinent at one and two years after pregnancy 
Years after pregnancy Proportion abstinent 95% confidence interval 
End of pregnancy 0.126 0.107 0.146 
1 0.074 0.027 0.122 
2 0.047 -0.023 0.118 
 
To calculate the appropriate relapse rates after pregnancy, the MLC assumes that the 
women who report abstinence at later time points are the same women who report 
abstinence at the end of pregnancy. The transition probabilities for remaining abstinent 
after 1 year (transiting from being a 0-1 year quitter to 1-2 year quitter) were estimated by 
dividing the proportion abstinent at one year after pregnancy by the proportion abstinent 
at the end of pregnancy. The probability of transitioning to the long-term quitter state once 
the mother was a 1-2 years quitter was calculated by dividing the proportion abstinent at 
two years postpartum by the proportion abstinent at one year postpartum. The calculated 
values are reported in Table 6.3. 
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Table 6.3: Transition probabilities for first two cycles after quitting during pregnancy 
Transition probability Calculated probability of remaining abstinent 
P(1-2 quit| 0-1 quit) 0.5873 
P(Long-term quit| 1-2 quit) 0.6351 
 
6.5.2 Mothers who smoke throughout pregnancy 
 
For mothers who smoke throughout pregnancy, there is only one parameter which is 
different from the general smoking behaviour parameters, and this is the probability of 
making a quit attempt in the first year postpartum. The latest IFS identifies that by 10 
months after birth, 13% of mothers who smoked throughout pregnancy had stopped 
smoking. [135] Although this is not 12 months after pregnancy, it was assumed to be a 
close approximation. Therefore, in the first cycle only after pregnancy, the model assumes 
the transition probability for women who smoked throughout pregnancy to become 0-1 
year quitters (make a quit attempt) is 0.13.  
 
6.5.3 General smoking behaviour parameters for the Markov chain 
 
The model takes a lifetime perspective, and this is imposed by allowing the cohort to reach 
the age of 100 years. Due to this, a general set of probabilities are required to determine 
ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ŝŶ ƚŚĞ ǇĞĂƌƐ ĂĨƚĞƌ ƉƌĞŐŶĂŶĐǇ ? dŚĞ ƉĂƌĂŵĞƚĞƌƐ ŽƵƚůŝŶĞĚ
below are applied in all cycles except the two immediately after pregnancy. The general 
values apply to both women who quit smoking during pregnancy and those who smoked 
throughout pregnancy. 
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6.5.4 General quitting behaviour amongst current smokers and short-term quitters 
 
  “^ŵŽŬŝŶŐ ŝŶ ŶŐůĂŶĚ ^ƚĂƚŝƐƚŝĐƐ ?  ?Table 6.4) reported, for England in 2008/09, the 
percentage of female smokers who make a quit attempt in any given year and the 
percentage of quitters who were still abstinent at one and two years later. [134] These 
were the most recent available data, despite being older than other statistics used in the 
model. However, Table 3.6 from the Statistics on Smoking: England report gave values 
going back ten years to 1999 [134], with the 2008/09 estimates appearing to be a good 
match to the previous ten years, and since there was no evidence of a change in quitting 
behaviour over these ten years, with the percentage of women making quit attempts 
fluctuating to no distinct pattern, it seemed appropriate to use these values. 
 
Table 6.4: Percentage of smokers who made any quit attempt last year and the length of time abstinent 
amongst those who those who those who have tried to give up. 
 Percentage (%) Source 
Current smoker making any 
quit attempt in a given year 
27 Table 3.6 Statistics on 
Smoking: England [134] 
Quitters who are abstinent 
for more than one year but 
less than two 
6 Table 3.7 Statistics on 
Smoking: England [134] 
Quitters who are abstinent 
for more than two years 
8 Table 3.7 Statistics on 
Smoking: England [134] 
 
The transition probability for a current smoker to become a quitter (0-1 year quitter) is 
0.27, as 27% of current smokers made any quit attempt in the last year, regardless of 
whether the attempt successful or not. The transition probability for 0-1 year quitter to 
remain abstinent (become a 1-2 years quitter) is 0.14, as this is the sum of the percentage 
of quitters who are still abstinent at 1 year (6% + 8% = 14%). This means that 86% of those 
who made a quit attempt in the previous cycle are not successful at abstaining for more 
than one year. The transition probability for a 1-2 years quitter to remain abstinent 
(become a long-term quitter) is 0.57, which is calculated by dividing 8% by 14% (the 
percentages of women abstinent for more than two years and more than one year but less 
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than two years respectively). This means that 43% of those that had successful remained 
abstinent for one year relapse to smoking before two years. 
 
6.5.5 Long-term relapse rates 
Yudkin et al reported relapse to smoking for up to eight years after a randomised trial of 
NRT. [311] This study reported abstinence at one year and eight years. The relevant data is 
displayed in Table 6.5. 
 
Table 6.5: Number of smokers abstinent at one year and eight years after a smoking cessation intervention 
Time period Numbers (all participants in trial) 
Abstinent at one year 153 
Abstinent at eight years 83 
Relapse between one and eight years 70 
Source: Yudkin et al [311] 
 
The MLC requires a transition probability to reflect the propensity of women entering the 
long-term quitter state, after having been abstinent for two years. By multiplying the 
number of women abstinent in zƵĚŬŝŶ ?Ɛ ƚƌŝĂů  ? ? ? ? ? ďǇ  ? ? ? ?  ?ƚŚĞ ƚƌĂŶƐŝƚŝŽŶ ƉƌŽďĂďŝůŝƚǇ
identified in the section above), the number of women abstinent at the end of two years in 
this trial was estimated as 87.  Using this figure along with data in Table 6.3, this suggests 
that approximately four participants relapsed between two and eight years in this trial; so 
dividing four by 87, the probability of relapse between years two and eight was estimated 
at 0.0507 and this was converted into an annual probability of 0.0086 using the method 
outlined by Fleurence et al. [312] This value was applied to all women in the long-term 
quitter state for all cycles of the model. Table 6.6 reports all the transition probabilities for 
ǁŽŵĞŶ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŝŶŐĞŶĞƌĂů ?ǁŚŝĐŚĂƌĞĂƉƉůŝĞĚĨƌŽŵƚǁŽǇĞĂƌƐĂĨƚĞƌƉƌĞŐŶĂŶĐǇ
onwards. 
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Table 6.6: Transition probabilities for general smoking behaviour outside of two years postpartum 
Smoking behaviour Transition probability 
Quit attempt given current smoker 0.27 
Remain abstinent for one year  0.14 
Remain abstinent for a second year after 
one year of not smoking 
0.57 
Relapse to smoking in any given year 
following at least two years of abstinence 
0.0086 
  
 Mortality in the Markov contingent of smoking status 6.6
 
To estimate the number of women who die in each Markov cycle, the transition probability 
for death was taken from ONS Cohort Life tables, Table B1. [313]; these estimated 
mortality rates by age, to age 100, for women born from 1981 to 2012, and projections for 
women born up to 2062.42 Doll et al demonstrated that mortality rates differ for smokers, 
former smokers, and never smokers, with the highest rates of mortality amongst smokers 
compared to never smokers.[9, 66] The estimates are reported in Table 6.7. 
 
Table 6.7: Rates of mortality per 1,000 people by age, contingent on smoking status 
Age Current smokers Former smokers Never smokers 
35-44 2.8 2 1.6 
45-54 8.1 4.9 4 
55-64 20.3 13.4 9.5 
65-74 47 31.6 23.7 
75-84 106 77.3 67.4 
85+ 218.7 179.7 168.6 
Source: Table 6, Doll et al, [66] 
                                                          
 
42
 Please note: due to constraints on thesis length, all values have not been reproduced in this 
ĚŽĐƵŵĞŶƚ ?,ŽǁĞǀĞƌ ?ƚŚĞKE^ĚĂƚĂĂƐƵƐĞĚďǇ^/WĐĂŶďĞĨŽƵŶĚƵŶĚĞƌƚŚĞ “KE^ŵŽƌƚĂůŝƚǇƐƚĂƚƐ ?ƚĂď
in the ESIP spreadsheet. 
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The above rates were converted to relative risks for current smokers versus never smokers 
and former smokers versus never smokers by dividing the current smoking/former smoking 
mortality rates by the never smoker ones (Table 6.8). Since Doll et al did not report any 
data for mortality before the age of 35, it was assumed that smoking status had no impact 
on mortality in women aged 34 years or less.  
 
Table 6.8: Relative risk of death by age, contingent on smoking status 
Age Current smoker Former smoker Never smoker 
0-34 1 1 1 
35-44 1.7500 1.2500 1 
45-54 2.0250 1.2250 1 
55-64 2.1368 1.4105 1 
65-74 1.9831 1.3333 1 
75-84 1.5727 1.1469 1 
85+ 1.2972 1.0658 1 
 
The ONS estimates give a general mortality probability for all women, which needed 
adjusting to account for the impact of smoking on mortality risk. This is required as the MLC 
is a smoking behaviour model, and therefore it is important to capture the impact of the 
higher death rates amongst current smokers and former smokers compared to never 
smokers. To adjust the general mortality probability, the same approach was used as 
described in Taylor and Flack et al [129, 139]. It can be assumed that this general 
population mortality probability is calculated using the following equation: 
 
 ܲሺ݀݁ܽݐ݄ீ௉ሻ ൌ ሺܲሺ݀݁ܽݐ݄஼ௌሻ ൈ ܧሻ ൅ ሺܲሺ݀݁ܽݐ݄ிௌሻ ൈ ܨሻ ൅ ሺܲሺ݀݁ܽݐ݄ேௌሻ ൈ ܩሻ (6.1) 
 
Where ܧ is the prevalence of current smokers, ܨ is the prevalence of former smokers, ܩ is 
the prevalence of never smokers, ܲሺ݀݁ܽݐ݄ீ௉ሻ is the probability of death in the overall 
population, ܲሺ݀݁ܽݐ݄஼ௌሻ is the probability of death amongst current smokers, ܲሺ݀݁ܽݐ݄ிௌሻ 
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is the probability of death amongst former smokers, and ܲሺ݀݁ܽݐ݄ேௌሻ is the probability of 
death amongst never smokers. 
 
Using relative risks for mortality amongst current smokers and former smokers compared 
to never smokers, it can be assumed that: 
 
 ܲሺ݀݁ܽݐ݄஼ௌሻ ൌ ܴܴ஼ௌ ൈ ܲሺ݀݁ܽݐ݄ேௌሻ (6.2) 
   
 ܲሺ݀݁ܽݐ݄ிௌሻ ൌ ܴܴிௌ ൈ ܲሺ݀݁ܽݐ݄ிௌሻ (6.3) 
 
Where ܴܴ஼ௌ is the relative risk of death for current smokers, and ܴܴிௌ is the relative risk of 
death for former smokers. 
 
Substituting equations (6.2) and (6.3) into (6.1) and rearranging allows the probability of 
mortality for never smokers: 
 
 ܲሺ݀݁ܽݐ݄ேௌሻ ൌ ܲሺ݀݁ܽݐ݄ீ௉ሻܩ ൅ ሺܴܴிௌ ൈ ܨሻ ൅ ሺܴܴ஼ௌ ൈ ܧሻ (6.4) 
 
The resulting probability for (6.4) can then be substituted in (6.2) and (6.1) to generate the 
probability of mortality amongst former and current smokers. 
 
The prevalence of smoking by age amongst women was taken from the latest smoking 
statistics for England.[134] This is reproduced in Table 6.9. For ages 0-15, it was assumed 
that the prevalence of current and former smokers was zero. 
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Table 6.9: Prevalence of smoking by age 
Age Current smoker (%) Former smoker (%) Never smoker (%) 
16-19 19 4 77 
20-24 28 7 65 
25-34 21 18 61 
35-49 23 22 55 
50-59 18 24 58 
60+ 12 30 58 
Source: Table 2.1, Statistics on smoking, England, 2013 [134] 
 
6.6.1 How smoking contingent mortalities were applied in the model 
 
The probability of death for women in the current smoker state was the probability of 
death associated with current smokers, while women in the 1-2 years quitter and long-
term quitter states received the probability of death associated with former smokers. 
Because most quit attempts tend to last less than 12 months, women in the 0-1 year 
quitter state received the probability of death associated with current smokers. This 
introduced a one year lag in gaining a reduced risk of mortality amongst women making a 
quit attempt. 
 
 Prevalence of smoking related diseases 6.7
 
Cigarette smoking has been attributed to increased risks of several conditions, including 
Coronary Heart Disease (CHD) [314], Chronic Obstructive Pulmonary Disorder (COPD) [66], 
lung cancer (LC) [66], and stroke. [302] Any smoking behaviour model should include these 
diseases as they pose a significant impact on HRQoL and healthcare costs. Although not 
included as states in the Markov cohort model, Taylor and Flack et al calculated the 
prevalence of five smoking related diseases amongst women each cycle. [129, 139] These 
conditions were CHD, COPD, LC, MI, and stroke.  
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The MLC adopts the same approach, including four smoking-related chronic conditions: 
CHD, COPD, LC, and stroke. In each cycle, the prevalence of each disease contingent on 
smoking status was calculated amongst the current and former smokers which were alive, 
and those who were identified as having a smoking related morbidity were attributed 
relevant healthcare costs and QALYs.  
 
MI is an acute condition, heavily associated with CHD. Since it is acute, it is possible for 
people to only suffer from an MI for a short period, and recover fully within the timespan 
of a cycle, unlike a stroke where the impacts on HRQoL can be permanent. Also, the 
association with CHD meant there was the possibility of double-counting some of the 
healthcare costs. As a result of these considerations, MI was excluded from the model. 
 
Data on the prevalence of each condition by age and sex (if possible) was sought. The 
prevalence of each smoking related morbidity amongst the UK female population is given 
in Appendix 12.7. 
 
6.7.1 Determining the prevalence of the smoking related morbidities contingent of 
smoking status 
 
For a UK model, evidence was sought for the relative risks of smoking associated with the 
four smoking related morbidities from UK sources; unfortunately no suitable UK 
information was identified. However, both Flack et al and subsequently Taylor used the 
relative risks from the US Surgeon General ?Ɛ report [129, 139, 143], and this was deemed 
acceptable. Therefore, the authors concluded that in the absence of better parameter 
estimates, and given that it corresponded with the previous literature, these estimates 
would be used for the MLC. TŚĞh^'ĞŶĞƌĂů^ƵƌŐĞŽŶ ?ƐƌĞƉŽƌƚĞƐƚŝŵĂƚĞƐ a series of relative 
risks for current and former smokers for use in their Smoking-Attributable Morbidity, 
Mortality, and Economic Costs (SAMMEC) model [143], and these  are reported in Table 
6.10. The MLC used these relative risks, combining them with the prevalence data reported 
in Appendix 12.7 and the incidence of smoking by age from Table 6.9 to determine the 
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prevalence of morbidities amongst current and former smokers, using the method as 
described in Section 6.6. 
 
Table 6.10: Relative risks of smoking related morbidities for females by age and smoking status 
Age Current smokers Former smokers 
CHD COPD LC Stroke* CHD COPD LC Stroke* 
35-54 4.98 6.43 13.30 2.44 2.23 1.85 2.64 1.00 
55-64 3.25 9.00 18.95 1.98 1.21 4.84 5.00 1.10 
65-74 3.29 38.89 23.65 2.27 1.56 15.72 6.80 1.24 
75+ 2.25 20.96 23.08 1.70 1.42 7.06 6.38 1.10 
*= RR are for cerebrovascular disease 
Source = Table 12.3 US Surgeon General report [143] 
 
6.7.2 Worked example: calculating the smoking status contingent prevalence of CHD 
 
Below is a worked example illustrating how the prevalence of CHD was incorporated into 
the MLC. From Table 12.7 in Appendix 12.7 the prevalence estimate of CHD amongst 50 
year old women is 1.3%.  
To estimate the prevalence of CHD amongst current smokers aged 50, the following 
calculation was performed: 
 
 ܥܪܦேௌହ଴ ൌ ܥܪܦହ଴ሺܧହ଴ ൈ ܴܴܥܪܦ஼ௌହ଴ሻ ൅ ሺܨହ଴ ൈ ܴܴܥܪܦிௌହ଴ሻ ൅ ܩହ଴ (6.5) 
 
Where ܥܪܦହ଴ is the prevalence of CHD amongst all 50 year olds, ܥܪܦேௌହ଴ is the 
prevalence of CHD amongst all 50 year old never smokers, ܧହ଴ is the prevalence of current 
smoking amongst 50 year olds, ܴܴܥܪܦ஼ௌହ଴ is the relative risk of CHD amongst 50 year old 
current smokers, ܨହ଴ is the prevalence of former smoking amongst 50 year olds, ܴܴܥܪܦிௌହ଴ is the relative risk of CHD amongst 50 year old former smokers, and ܩହ଴ is the 
prevalence of never smoking amongst 50 year olds. 
205 
 
 
ܥܪܦேௌହ଴ ൌ  ?Ǥ ? ? ?ሺ ?Ǥ ? ?ൈ  ?Ǥ ? ?ሻ ൅ ሺ ?Ǥ ? ?ൈ  ?Ǥ ? ?ሻ ൅  ?Ǥ ? ?ൌ  ?Ǥ ? ? ? ? 
 ܥܪܦ஼ௌହ଴ ൌ  ?Ǥ ? ? ? ? ൈ  ?Ǥ ? ?ൌ  ?Ǥ ? ? ? ? 
 
This implies that the prevalence of CHD amongst current smokers at age 50 is 3.22%. By 
applying the relevant relative risk for former smoker, the prevalence of CHD amongst 
former smokers is 1.44%.  
 
6.7.3 How the smoking-contingent prevalences were applied in the MLC 
 
In the MLC, there are four possible smoking behaviours for women. Those in the current 
smoking state received the prevalence of the diseases associated with current smoking, 
which represents the percentage of women who suffer from the disease given that they 
are current smokers. To calculate the number of women who have each of the four 
diseases in each cycle, the number of women in the current smoking state was multiplied 
by the prevalence of the disease for current smokers, thus generating an estimate of the 
number of current smokers who have one of the smoking related morbidities in each of the 
cycles. Women in the 1-2 years quitter and long-term quitter states received the 
prevalence of diseases associated with former smokers, and the process of multiplying the 
prevalence of the disease given a former smoker by the number of women in each of the 
abstinent states for each cycle was repeated. Because most quit attempts last less than 12 
months, women in the 0-1 year quitter state received the same prevalence of diseases as 
current smokers. This was then applied using the same method as described above. This 
introduced a one year time lag in gaining a benefit in reduced risks of diseases by quitting 
smoking.  
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 Health related quality of life measures 6.8
 
To allow the MLC to link with the MWPC, QALYs were used as the measure of HRQoL. 
Utilities reported by Mashewaran et al were used as outlined in Chapter 5 to calculate 
utility associated with current and former smokers in the cohort who did not experience 
any of the four smoking related morbidities outlined above. [295] For cohort members who 
developed co-morbidity, utility weights from Table 6.11 were used. Utilities associated with 
active smoking were awarded to women in the current smoker and 0-1 year quitter states, 
while women in the 1-2 years quitter and long-term quitter states received utilities 
associated with former smokers. The life year was then weighted by the utility to calculate 
QALYs, which were discounted by 3.5%, as recommended by the NICE reference case. [36]  
 
Table 6.11: QALY weights associated with smoking related morbidities 
Condition Mean utility score Standard deviation Source 
CHD 0.73 0.30* MEDMAN study 
[315] 
COPD 0.73 0.23 Starkie et al [316] 
LC 0.67 0.22 Pickard et al [317] 
Stroke 0.72 0.32 Haacke et al [318] 
*= Inter quartile range used as proxy 
 
 Costs associated with smoking related diseases 6.9
 
The model assumes that a cohort member who experiences none of the four included 
morbidities generates no cost to the NHS. Therefore, the only required costs were 
associated with those who developed these diseases. In keeping with the NHS and Personal 
Social Services Research Unit (PSSRU) perspective, the direct healthcare costs of diseases 
were identified from relevant literature on the economic burden of the disease, which 
identified a per patient annual cost to the NHS, and are reported in Table 6.12. Chapter 5 
identified the cost of a cardiac event, used as a proxy for the cost of a death; this was also 
applied in the lifetime model and was estimated at £1,379.02 (interquartile range of 
£799.89). Costs were discounted at a rate of 3.5% per annum, as recommended by the 
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NICE reference case. [36] The number of cohort members with a particular disease for each 
age was multiplied by the cost per patient for each respective morbidity, to give an 
estimated cost to the NHS of treating smoking related diseases. The number of cohort 
members dying in each cycle was multiplied by the cost of death. 
 
Table 6.12: Per patient annual cost associated with smoking related diseases 
Condition Cost (£) Standard error 
(£) 
Source Notes 
CHD 1,772.13 Not available Liu et al [319] 1999 prices, inflation 
index 1.497879 
COPD 813.14 Not available European 
Respiratory 
Society [320] 
2011 prices in euros 
reported, converted 
08/09/2014, 1 EUR = 
0.8026 GBP 
LC 9,209.42 Not available European 
Respiratory 
Society [320] 
2011 prices in euros 
reported, converted 
08/09/2014, 1 EUR = 
0.8026 GBP 
Stroke 20,939.20 147.96 Youman et al 
[321] 
2001/2002 prices, 
inflation index 1.368039 
 
 Discussion 6.10
 
dŚŝƐ ĐŚĂƉƚĞƌ ŚĂƐ ŽƵƚůŝŶĞĚ ƚŚĞ ũƵƐƚŝĨŝĐĂƚŝŽŶ ĂŶĚ ŵĞƚŚŽĚƐ ĨŽƌ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ůŝĨĞƚŝŵĞ
component of the ESIP model. The MLC attempts to capture the impact of smoking 
behaviour during pregnancy on subsequent maternal smoking behaviour throughout her 
lifetime, future healthcare costs and quality of life lost attributable to this. 
 
6.10.1 Comparison of MLC to previous economic evaluations 
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There are currently four previous models which attempt to capture the impact of smoking 
cessation during pregnancy on the lifetime of the mother. [137, 139, 190, 196] Ruger 
extended their model to a maternal lifetime perspective by estimating an average QALY 
across healthy individuals and individuals who suffered from either LC or CHD. The 
different QALYs for smokers and non-smokers were generated by assuming that a higher 
percentage of smokers suffered chronic conditions. The non-smoking QALY estimate also 
took into account that 35% of individuals who quit during pregnancy would relapse over 
their remaining lifetime This is neither a decision tree nor a Markov model approach, which 
makes comparison with the MLC challenging, despite the fact that the MLC too generates 
QALY gains for both quitters and smokers during pregnancy across their remaining lifetime. 
It could be argued that Ruger et al is not controlling for post-pregnancy smoking behaviour, 
which potentially means that the QALY estimates are inaccurate. Furthermore, the MLC 
uses pregnancy specific postpartum relapse data, which has a much higher relapse rate 
compared to Ruger et al, whose relapse value is from a male and female population. 
Therefore, it could be construed that the MLC is more precise in estimating HRQoL across 
the remaining lifetime. 
 
As has been mentioned in Section 6.4.1, Taylor adapted a general smoking behaviour 
model to a cohort of pregnant smokers. [139] The structure has already been briefly 
described in that section, but the Markov chain is demonstrated in Figure 6.3. The MLC has 
Ă ŵŽƌĞ ĐŽŵƉůĞǆ ƌĞƉƌĞƐĞŶƚĂƚŝŽŶ ŽĨ ǁŽŵĞŶ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ĂĐƌŽƐƐ ƚŚĞŝƌ ůŝĨĞƚŝŵĞ ĂŶĚ
makes particular use of new data on relapse to smoking in the two years immediately after 
childbirth and, as such, may model the impacts of smoking on maternal health more 
accurately. 
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Figure 6.3: Structure of Markov chain model by Taylor 
 
 
The model by Taylor assumed that once a woman made a quit attempt, they automatically 
had a better quality of life and lower risks of mortality and morbidity. This could be 
unrealistic, as there may be a time lag between the start of the quit attempt and when the 
woman actually achieves a gain in HRQoL and lower risks of mortality/morbidity. Doll et al 
demonstrated that the earlier in life an individual stopped smoking, the faster the risks 
associated with mortality/morbidity became closer to the risks in never smokers. [9, 66] 
The MLC introduces a one year time lag between when the woman starts a quit attempt 
and when she starts to receive gains in terms of reduced smoking related disease risks and 
HRQoL. This would suggest that the MLC is more accurate at predicting the number of 
women with a smoking related morbidity and/or mortality, which implies that the 
estimates of smoking-related healthcare costs and HRQoL are more accurate, providing 
more precise estimates of the cost-effectiveness of cessation interventions during 
pregnancy in the long-term smoking behaviour of the mother. Whether or not a one year 
time lag is enough is unclear, and could be a potential consideration for further research. 
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The slightly different structure of the MLC, with tunnel states for quitters under two years, 
could also be argued as being more representative of the changes in smoking behaviour. 
Taylor assumed that 70% of women would relapse after one year, and that there was no 
relapse after this. However, as the estimates from Smoking Statistics for England suggest, 
most women have relapsed to smoking before two years after the quit attempt, with 
around only 8% reporting abstinence. [134] This implies that by excluding relapse after one 
year, the Taylor model is underestimating the number of women who relapse to smoking 
by a considerable margin, thus overestimating the benefits from cessation interventions. 
Furthermore, the MLC allows for smoking women to make quit attempts after pregnancy. 
Smoking Statistics for England identified that in 2009, 27% of women made a quit attempt. 
[134] The Taylor structure does not allow for any subsequent quit attempts, and therefore 
does not capture the benefits that may occur in the longer term. The MLC allows for these 
quit attempts, and therefore is potentially more accurate at calculating long-term costs and 
QALYs for the cohort of pregnant smokers.  
 
Furthermore, the MLC has the added advantage of using pregnancy-specific relapse and 
quitting data for the first two cycles of the Markov chain. Taylor used expert opinion for 
informing the one year postpartum relapse rate. In the hierarchy of evidence proposed by 
Evans et al [148], expert opinion is considered the lowest form of evidence for evaluating 
interventions. Conversely, the MLC uses data from a systematic review, which is considered 
the best available evidence for the evaluation of interventions. Therefore the MLC is more 
likely to be accurately modelling the smoking behaviour of mothers in the postpartum 
period, especially for relapse rates.  
 
The model constructed by Mallender et al [190] adopted the same structure as Taylor, with 
two key differences: first of all, the quit rate after the first cycle was determined by the 
estimates associated with the interventions that were modelled, added to which was an 
arbitrary quit rate of 2% in each subsequent cycle. Secondly, Mallender et al assumed that 
the relapse rate was zero, arguing that the 2% added bonus represented the rate of all 
women who quit permanently. The MLC makes no such assumptions, since data given by 
Yudkin et al demonstrates that these assumptions are unrealistic. [311] Although most 
people who have been abstinent for longer than two years remain permanently so, a small 
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proportion will relapse to smoking over time; therefore a 0% relapse rate is too optimistic 
an assumption. Furthermore, the simplified structure adopted by both Taylor and 
Mallender et al fails to represent the major changes seen in smoking behaviour both 
around and beyond pregnancy, as has been detailed above.  
 
Tappin et al extended their within-trial analysis to incorporate the maternal lifetime by 
adapting a previously developed Markov model to calculate QALYs, healthcare costs, and 
smoking-attributable deaths. [196, 209] The Markov structure was virtually identical to 
Taylor, except that there were two death states: smoking-attributable deaths and non-
smoking-attributable deaths. Tappin et al improved on Taylor by allowing relapse to extend 
beyond one year postpartum, but the rates were informed by studies in non-pregnant 
populations. [311, 322] While this model improves on previous literature by capturing 
relapse up to eight years after pregnancy, the MLC incorporates some measure of longer 
term relapse, therefore capturing the impacts on costs and benefits accrued from this. 
Furthermore, Tappin et al do not allow for any subsequent quit attempts, which is included 
in the MLC, hence the MLC could be better capturing long-term maternal smoking 
behaviour. One final consideration is that Tappin et al did not include the impacts on 
HRQoL from long-term smoking related diseases, which are integrated in the MLC. Tappin 
et al did, however, attempt to estimate the total healthcare costs associated with a 
smoking related death, and therefore these may be viewed as providing further evidence 
on the long-term costs associated with smoking.  
 
6.10.2 Limitations of the MLC 
 
There are several limitations of the MLC model. Firstly, the MLC model does not 
incorporate any subsequent pregnancies. Some women are likely to have more than one 
child, and therefore may attempt to quit smoking again during pregnancy, and face the 
same risks and outcomes as they initially faced in the first stage of ESIP. This was not 
included in MLC, due to the complexity faced in incorporating such potential events, which 
is beyond the scope of the current project. MLC may not, therefore, be completely 
ƌĞƉƌĞƐĞŶƚĂƚŝǀĞŽĨǁŽŵĞŶ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌĂĨƚĞƌƉƌĞŐŶĂŶĐǇ ?ďƵƚƚŚĞŝŵƉůŝĐĂƚŝŽŶƐŽĨƚŚŝƐ
omission are not known.   
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MLC also allows women to make numerous quit attempts after pregnancy, due to the 
Markov assumption which asserts that the Markov model is memoryless. This lack of 
memory means that a relapsing woman can make many quit attempts, which could be 
unrealistic. There is evidence to suggest that the more quit attempts an individual makes, 
the more likely that they are to successfully quit smoking [323-326], with Caponnetto 
estimating that women who had made previous long-term quit attempts lasting longer 
than one year were 36% more likely to quit. [323] Furthermore, it has been estimated that 
it takes on average a woman 6.3 quit attempts across her lifetime to become a former 
smoker. [327] Because of the Markov assumption, women who relapse can make another 
quit attempt, but there is no limit to the number they make. The evidence suggests that in 
reality that women need only make six or seven attempts before they quit for good, and 
that the transition probabilities will change with each quit attempt to reflect their greater 
chance of success. Unfortunately, the model does not capture this behaviour, and 
therefore could be underestimating the number of women who have successfully quit in 
future cycles. This would mean that the MLC is not capturing the full benefits generated by 
cessation interventions, and hence the ICERs generated by the MLC could be too high, 
underestimating the cost-effectiveness of cessation interventions. One approach to correct 
this may be to introduce another series of states to represent previous history of quit 
attempts. Figure 6.4 gives an example of what the structure of this Markov might be. 
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Figure 6.4: Example Markov structure for modelling quitting behaviour based on previous quitting behaviour, assuming a woman takes up to five quit attempts before becoming a 
successful former smoker 
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As can be seen from Figure 6.4 ? ƚŽĐĂƉƚƵƌĞƚŚĞƉƌĞǀŝŽƵƐŚŝƐƚŽƌǇŽĨ ƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐ
and quitting behaviour would require a large number of additional states in the Markov, 
adding to the complexity of the MLC. Adopting this structure for modelling smoker 
behaviour would probably enable the MLC to better estimate smoking behaviour across 
ƚŚĞŵŽƚŚĞƌ ?Ɛ ůŝĨĞƚŝŵĞ ?ĂŶĚŚĞŶĐĞƉƌŽĚƵĐĞŵŽƌĞĂĐĐƵƌĂƚĞŚĞĂůƚŚĐĂƌĞĐŽƐƚĞƐƚŝŵĂƚŝŽŶƐĂŶĚ
Y>zĞƐƚŝŵĂƚĞƐĂĐƌŽƐƐƚŚĞĐŽŚŽƌƚŽĨǁŽŵĞŶ ?ƐůŝĨĞƚŝŵĞ ?ĞŶĂďůŝŶŐŵŽƌĞƉƌĞĐŝƐĞ estimates of 
the ICER and value for money of the interventions. However, a Markov model with this 
complexity would be very difficult to parameterise, and hence estimates for the transition 
probabilities in later states may be reliant on poor sources of data which could introduce 
bias and increase decision uncertainty in the evaluation. Furthermore, we are uncertain 
how many additional quitting/relapse states would be required. Although we have the 
estimate of 6.3 average quit attempts [327], this was based on US data, and UK women 
may require more (or fewer). Additionally, there would have to be extra analyses while the 
structural uncertainty associated with the number of additional quitting/relapse states 
were added, which would increase complexity in undertaking the evaluation. Therefore, 
the authors speculate that the introduction of this added complexity would not be of 
benefit to the evaluations of smoking cessation interventions with the current level of 
information; however consideration could be given to adopting this structure should 
sufficient evidence become available in the future. 
 
The MLC includes fewer smoking-related chronic morbidities than other models. The Taylor 
model added MI [139], and the SAMMEC model, which estimated only costs, incorporated 
a further seven diseases in addition to those given in the MLC. [143] As discussed in Section 
6.7, although there are substantial healthcare costs associated with MI, it is an acute 
condition, as it is possible for a heart attack sufferer to regain her previous health within 
one cycle of the model, and it is also heavily associated with CHD, leading to potential 
double-counting of healthcare costs. It was consequently excluded, as the MLC was 
primarily interested in chronic conditions as these tend to have the highest healthcare 
costs and impacts on HRQoL, and are therefore seen as the more important morbidities for 
inclusion. The exclusion of MI could potentially lead the MLC to underestimate the gains 
from quitting, however the chronic conditions included in the MLC all have extensive costs 
and health outcomes; thus the MLC is likely to capture most of the costs and health related 
outcomes associated with poor health due to smoking related behaviour. Furthermore, in 
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comparison with the SAMMEC model, the conditions which have the highest relative risks 
associated with smoking status are the four conditions included in the model, suggesting 
that it is capturing the most important conditions associated with smoking behaviour.  
 
One possible limitation is the use of group abstinence data rather than longitudinal relapse 
data from the Chapter 4 review. As pointed out in Chapter 4, it is not known whether the 
women who reported abstinence in the postpartum periods were the same women who 
reported abstinence at the end of pregnancy. True relapse rates can only be accurately 
measured amongst smokers who are abstinent initially and who remain abstinent when 
followed up, but our data is derived in a different way. This could result in MLC biased 
estimates of the proportion of smokers who relapse in the postpartum period. However, as 
was identified in Chapter 4, there are relatively few studies in which sustained abstinence 
across the postpartum period is reported, and the data in the systematic review is the best 
available at the current moment in time, implying that the MLC is constructed with the 
most up-to-date data.  
 
Another consideration is the small probability of relapse estimated from Yudkin et al which 
was applied to the long-term quitter state for all subsequent cycles of the model. [311] 
Yudkin et al have suggested that there is very little relapse beyond eight years [311], and 
that the MLC assumption of applying this small probability of relapse across all subsequent 
cycles would appear to be incorrect. However, the reasoning behind including this 
probability was that long-term quitters can still relapse to smoking, even after many years 
of being abstinent. Hawkins et al demonstrated that even 13 years after making a quit 
attempt, individuals were still relapsing. [328] This would suggest that the assumption of 
allowing long-term quitters to relapse irrespective as to how long they have been abstinent 
would appear to be correct. However, if this assumption is incorrect, then the MLC is likely 
to be overestimating the number of women who have relapsed to smoking, and hence the 
ICER estimates generated by the MLC are likely to be higher than the true value. One 
possible way of preventing this would be to introduce a series of tunnel states up to eight 
years post quit attempt, but this is likely to add to the complexity of the model, and would 
not capture those women who relapse much further after the quit attempt.  
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6.10.3 Future improvements for the MLC 
 
One important consideration is the relapse to smoking rates associated with quitting during 
pregnancy, and there are two possible avenues for further improvement. First of all, more 
accurate sustained postpartum abstinence data would be useful to accurately estimate 
relapse, though this would require several new studies, all measuring prolonged cessation 
at similar postpartum time points. A second improvement could be the incorporation of 
intervention specific rather than general intervention data. It would seem likely that 
different interventions would have different relapse rates after pregnancy, and currently 
the MLC has not been calibrated to capture this. However, data on postpartum relapse by 
intervention is extremely limited, so again this would require a significant amount of 
further research to generate appropriate data.  
 
Another improvement would be to better capture quit attempts in the remaining lifetime 
outside of the two year postpartum period. Relapse after quitting may change due to age 
or the number of previous quit attempts. Currently the MLC assumes that the relapse and 
quit rates is fixed across all ages after two years postpartum, which could be inaccurate. 
Incorporating data around the number of quit attempts before success (or ultimate failure) 
would allow the MLC to more accurately predict subsequent smoking behaviour. Further 
research should be conducted to determine whether relapse rates do change by age or by 
previous quit attempts. While changes in age would be relatively easy to incorporate into 
the MLC, it may be trickier to include subsequent quit attempts. This may be possible by 
incorporating a further series of tunnel states; however, this would add a further layer of 
complexity to the model. 
 
Another potential problem is the difference between short- and long-term quitters when 
attributing risks of morbidities and mortality. At the moment, the MLC has a built in lag of 
one year before quitters gain any benefit from quitting. This could be expanded to better 
estimate the impacts of quitting earlier in life compared with those who quit later. Again, 
through the use of tunnel states, it may be possible to incorporate a lag of five or 10 years 
into the MLC. The risks when applied to women in these states would thus be dependent 
on whether a woman has been quit for five or ten years. This would allow the model to 
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better capture the number of women who develop a smoking related morbidity, or die as a 
result of smoking. However, to incorporate this into the model, further research would also 
have to be done into the relapse rates associated with these states, otherwise the ESIP 
model may end up overestimating the number of women who have been quit in the longer 
time periods.  
 
 Summary 6.11
 
This chapter hĂƐ ŽƵƚůŝŶĞĚ ƚŚĞ D> ŽĨ ^/W ĂŶĚ ƐŚŽǁƐ ƚŚĂƚ ǁŽŵĞŶ ?Ɛ ůŝĨĞƚŝŵĞ ƐŵŽŬŝŶŐ
behaviour and associated morbidities are important considerations for inclusion in 
economic evaluations of cessation during pregnancy. Compared to the previous models, 
the MLC may be better for predicting maternal smoking behaviour, however there are still 
some areas of the MLC which require improvement. Chapter 7 describes the structure of 
the Infant Childhood Component (ICC), which predicts the ŝŵƉĂĐƚŽĨƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐ
during childhood on the health of her offspring.  
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 Chapter 7: The ESIP model: Description of the childhood 
component 
 
 Introduction 7.1
 
WƌĞǀŝŽƵƐ ĐŚĂƉƚĞƌƐŽƵƚůŝŶĞĚ ƚŚĞŵĂƚĞƌŶĂů  ‘ǁŝƚŚŝŶ ƉƌĞŐŶĂŶĐǇ ? ĂŶĚ  ‘ůŝĨĞƚŝŵĞ ? ĐŽŵƉŽŶĞŶƚƐ ŽĨ
the ESIP model. This chapter describes the rationale and methods used in the construction 
ŽĨƚŚĞ ‘ĐŚŝůĚŚŽŽĚ ?ĐŽŵƉŽŶĞŶƚŽĨƚŚĞ^/WŵŽĚĞů ?ĐŽǀĞƌŝŶŐƚŚĞŝŵƉĂĐƚƐŽĨŵĂƚĞƌŶĂůƐŵŽŬŝŶŐ
on infants up to the age of 15 years.  This is represented in Figure 7.1 as the shaded part of 
the ESIP model. This component shall be henceforth referred to as the Infant Childhood 
Component (ICC).  
 
Figure 7.1: The Infant Childhood Component (grey area) within context of the ESIP model 
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 Background 7.2
 
Only two previous economic models have attempted to consider the impacts of smoking 
across infant lives. [139, 190] Chapter 2 identified that maternal smoking in pregnancy 
appears to have a causal relationship with childhood respiratory illness. Smoking during 
pregnancy can have potentially life changing/threatening impacts on the health of the 
child, leading to an increased cost burden to the NHS, especially if there are thousands of 
cases of potentially preventable chronic illnesses. By not incorporating this impact on 
ĐŚŝůĚƌĞŶ ?Ɛ ŚĞĂůƚŚ ? ƚŚĞ ĐƵƌƌĞŶƚ ůŝƚĞƌĂƚƵƌĞ ĐŽƵůĚ ďĞ ƵŶĚerestimating the true cost and 
consequences of smoking during pregnancy, and consequently the cost-effectiveness of 
cessation interventions during pregnancy. 
 
TŚĞŝŵƉĂĐƚŽĨƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌĂĨƚĞƌƉƌĞŐŶĂŶĐǇƐŚŽƵůĚĂůƐŽďĞĐŽŶƐŝĚĞƌĞĚ ?
as this can have detrimental health effects on her offspring. A recent report conducted by 
ƚŚĞ ZŽǇĂů ŽůůĞŐĞ ŽĨ WŚǇƐŝĐŝĂŶƐ ĐŽŶĐůƵĚĞĚ ƚŚĂƚ ĐŚŝůĚƌĞŶ ?ƐĞǆƉŽƐƵƌĞ ƚŽ ƐŵŽŬŝŶŐ ŝŶĐƌĞĂƐĞĚ
their risk of developing lower respiratory infections, wheezing, asthma, middle ear disease, 
and bacterial meningitis. [329] The risks associated with breathing problems are also 
strongly correlated with exposure to maternal smoking, increasing by about 60% for lower 
respiratory tract illness and 65% for wheezing.  As most mothers who quit during 
pregnancy relapse within one year of giving birth (Chapter 4) and only around 13% of 
women who smoked throughout pregnancy actually make a quit attempt during the first 
year after pregnancy [134], maternal smoking behaviour after pregnancy potentially affects 
many children. Economic models of smoking during pregnancy do need to incorporate the 
impact of passive smoking on the health of the child. This chapter outlines how the ESIP 
childhood component attempts to achieve this.  
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 Objectives 7.3
 
7.3.1 Primary objective:  
 
To estimate the impact of maternal smoking behaviour during and after pregnancy on 
the health of her infant/child up to the age of 15. 
 
7.3.2 Secondary objectives: 
 
a) To construct a model which includes the relevant morbidities associated with 
smoking during childhood 
b) To estimate the impact of smoking during pregnancy and birth weight on the 
prevalence of the included morbidities in childhood 
c) To estimate the impact of passive smoking on the prevalence of morbidities in 
childhood 
d) To attribute QALYs and healthcare costs to healthy children and sick children 
during childhood 
e) To determine the cost-effectiveness of smoking cessation interventions during 
pregnancy within a childhood timeframe 
 
 The structure of the Childhood component 7.4
 
7.4.1 Basic Markov model structure 
 
dŚĞ ‘ĐŚŝůĚŚŽŽĚ ?ĐŽŵƉŽŶĞŶƚŽĨ^/WŚĂĚƚŽĐĂƉƚƵƌĞƚŚĞŝŵƉĂĐƚƐŽĨŝŶĨĂŶƚƐ ?ƉĂƐƐŝǀĞƐŵŽŬŝŶŐ
from exposure to continued maternal smoking, whilst also taking into account smoking 
during pregnancy. Since the model was primarily concerned with the impacts of cessation 
interventions for the mother during pregnancy, paternal smoking behaviour was not 
incorporated into this component. TŚĞĐŚŝůĚ ?ƐĞǆƉŽƐƵƌĞƚŽƉĂƐƐŝǀĞƐŵŽŬŝŶŐ ŝƐĚĞƚĞƌŵŝŶĞĚ
ďǇƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌĂĨƚĞƌƉƌĞŐŶĂŶĐǇ ?so ƚŚĞ/ŚĂƐƚŽƌĞĨůĞĐƚƚŚĞŵŽƚŚĞƌ ?Ɛ
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lifetime component (MLC). Therefore, the Markov structure for the ICC incorporates all the 
relevant states from the MLC (see Figure 7.2) but with two differences:  
1. Mothers who report active smoking, may choose to expose their child or not (e.g. 
smoke outside the house while the child is inside). Therefore there are two active 
smoking states instead of one.  
2. The addition of a death state for the infant.  
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Figure 7.2 PDĂƌŬŽǀŵŽĚĞůƐƚƌƵĐƚƵƌĞĨŽƌƚŚĞ ‘ĐŚŝůĚŚŽŽĚ ?ĐŽŵƉŽnent (ICC) of the ESIP model 
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dŚĞ / ĐŽŶƚĂŝŶƐ ƐĞǀĞŶ ƐƚĂƚĞƐ ůŝŶŬŝŶŐ ŝŶĨĂŶƚƐ ? ƉŽƚĞŶƚŝĂů ƉĂƐŝǀĞ ƐŵŽŬŝŶŐ ĞǆƉŽƐƵƌĞ ƚŽ
maternal smoking behaviour: 
1. Mother smokes, infant exposed to passive smoking  
2. Mother smokes; infant not exposed to passive smoking  
3. Mother 0-1 year quitter, infant not exposed to passive smoking  
4. Mother 1-2 year quitter, infant not exposed to passive smoking 
5. Mother long-term quitter, infant not exposed to passive smoking  
6. Mother dead, infant not exposed to passive smoking 
7. Infant dead 
 
As with the MLC, the states in which the mother makes a quit attempt (0-1 year quitter and 
1-2 year quitter) are tunnel states, so infants cannot remain in them for more than one 
year. The ICC assumes that a mother does not change her active smoking behaviour around 
her child, i.e. a child cannot transit from exposed to passive smoking to non-exposed if 
their mother remains an active smoker. For all the states except for infants with dead 
mothers, there are either four or five possible transitions that an infant can make in each 
cycle, which are represented in Figure 7.3 to Figure 7.8. The associated transition 
probability matrix is given in Table 7.1. 
 
  
224 
 
Figure 7.3: Possible transitions for children exposed to passive smoking who have a currently smoking mother  
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Figure 7.4: Possible transitions for children not exposed to passive smoking who have a currently smoking 
mother  
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Figure 7.5: Possible transitions for children whose mothers are in the 0-1 year quitter state 
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Figure 7.6: Possible transitions for children whose mothers are in the 1-2 year quitter state 
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Figure 7.7: Possible transitions for children whose mothers are in the long-term quitter state 
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Figure 7.8: Possible transitions for children if their mother is dead. 
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Table 7.1: Transition probability matrix for the ICC 
Transition from: Transiting to: 
Mother smokes infant 
passive smoking 
Mother smokes 
infant not passive 
smoking 
Mother 0-1 year 
quitter infant 
not passive 
smoking 
Mother 1-2 
years quitter 
infant not 
passive smoking 
Mother long-term 
quitter infant not 
passive smoking 
Mother 
dead infant 
not passive 
smoking 
Infant 
dead 
Mother smokes 
infant passive 
smoking 
 ? െ ሺܲܯܳ஼ௌሻെ ܲሺܯܦ஼ௌሻ െ ܲሺܫܦሻ 0 ܲሺܯܳ஼ௌሻ 0 0 ܲሺܯܦ஼ௌሻ ܲሺܫܦሻ 
Mother smokes 
infant not passive 
smoking 
0  ? െ ሺܲܯܳ஼ௌሻ െܲሺܯܦ஼ௌሻ െ ܲሺܫܦሻ) ܲሺܯܳ஼ௌሻ 0 0 ܲሺܯܦ஼ௌሻ ܲሺܫܦሻ 
Mother 0-1 year 
quitter infant not 
passive smoking 
ܲሺܧܵሻ ൈ ሺ ?െ ܲሺܯܳଵ௒ሻെ ܲሺܯܦ஼ௌሻ െ ܲሺܫܦሻሻ 
 ሺ ? െ ሺܲܧܵሻሻ ൈ ሺ ? െܲሺܯܳଵ௒ሻ െܲሺܯܦ஼ௌሻ െ ܲሺܫܦሻሻ 
0 ܲሺܯܳଵ௒ሻ 0 ܲሺܯܦ஼ௌሻ ܲሺܫܦሻ 
Mother 1-2 years 
quitter infant not 
passive smoking 
ܲሺܧܵሻ ൈ ሺ ?െ ܲሺܯܮܶܳሻെ ܲሺܯܦிௌሻ െ ܲሺܫܦሻ 
ሺ ? െ ሺܲܧܵሻሻ ൈ ሺ ?െ ܲሺܯܮܶܳሻെ ܲሺܯܦிௌሻ െ ܲሺܫܦሻ 
0 0 ܲሺܯܮܶܳሻ ܲሺܯܦிௌሻ ܲሺܫܦሻ 
Mother long-term 
quitter infant not 
ܲሺܧܵሻ ൈ ܲሺܯܴሻ ሺ ? െ ሺܲܧܵሻሻൈ ܲሺܯܴሻ 0 0  ? െ ሺܲܯܴሻെ ܲሺܯܦிௌሻ െ ܲሺܫܦሻ ܲሺܯܦிௌሻ ܲሺܫܦሻ 
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passive smoking 
Mother dead 
infant not passive 
smoking 
0 0 0 0 0  ?Ȃ ܲሺܫܦሻ ܲሺܫܦሻ 
Infant dead 0 0 0 0 0 0 1 
Where: ࡼሺࡹࡽ࡯ࡿሻ is probability (mother quit|current smoker), ࡼሺࡹࡽ૚ࢅሻ is probability (mother quit longer than one year|quit attempt made last year), ࡼሺࡹࡸࢀࡽሻ is probability (mother quit longer than two years|quit longer than one year), ࡼሺࡹࡾሻ is probability (mother relapses to smoking|quit longer than 
two years), ࡼሺࡱࡿሻ is probability (infant exposed to passive smoking), ࡼሺࡹࡰ࡯ࡿሻ is probability (mother dies|current smoker), ࡼሺࡹࡰࡲࡿሻ is probability 
(mother dies|former smoker), ࡼሺࡵࡰሻ is probability (Infant dies) 
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7.4.2 Starting states for the ICC 
 
As can be seen in Figure 7.1, children whose mothers had smoked throughout pregnancy 
enter the ICC model in one of the two states representing the mother as a current smoker, 
allowing for exposure / non-exposure to passive smoking. Children whose mothers had quit 
smoking during pregnancy enter the ICC model in the state where the mother is a 0-1 year 
quitter.  
 
7.4.3 Incorporating gender in the ICC 
 
Since there are differences in rates of mortality and childhood related morbidities for both 
males and females, it was required to split the ICC infant cohort by gender. From the latest 
birth data for England and Wales, it was estimated that 51% of live born children were 
male in 2012, and this is consistent with other years going as far back as 1839. [330] 
Therefore, the modelling was initiated with 51% of children born alive in the within-
pregnancy component assumed male. It was however assumed that LBW did not vary with 
gender; therefore 51% of LBW infants were male. 
 
7.4.4 The proportion of infants exposed to passive smoking 
 
In England, an estimated 23% of female smokers report smoking at home with children 
present. [134] Therefore, it is assumed that 23% of infants born with an actively smoking 
mother enter the exposed to passive smoking state, while the remaining 77% entered the 
not exposed to passive smoking state. This distribution was applied throughout all cycles of 
ICC to any infant in which the mother relapsed to smoking. 
 
7.4.5 Cycle length  
 
To match the maternal lifetime component, the ICC adopted cycles of one year in length. 
The model ran for 15 cycles, from age 0 to age 15 years, so the first cycle represented the 
estimates at age 1. 15 cycles were chosen as the final age of the model, as up to age 15 the 
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child can be heavily dependent on their mother. At age 16, it is assumed the child is no 
longer dependent on their mother, and hence is divorced from the influences of maternal 
smoking behaviour. Furthermore, UK national data reports smoking prevalence from age 
16 onwards [134], suggesting that a separate smoking behaviour model for the infant may 
be more appropriate from age 16 years and above. The smoking behaviour of the child 
beyond age 16 years and the associated impacts on HRQoL are beyond the scope of the ICC 
and this thesis. 
 
 Parameterisation of transition probabilities associated with 7.5
maternal  smoking behaviour 
 
The ICC attempts ƚŽĐĂƉƚƵƌĞƚŚĞŝŵƉĂĐƚƐŽĨƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŽŶƚŚĞŚĞĂůƚŚ
of the child, thus the ICC uses the same parameters for the transition probabilities as the 
MLC. Therefore, the two models are linked such that the values associated with the 
ŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌ ?ƉƌŽďĂďŝůŝƚǇŽĨƋƵŝƚĂƚƚĞŵƉƚ ?ƉƌŽďĂďŝůŝƚǇŽĨƌĞůĂƉƐĞ ?ƉƌŽďĂďŝůŝƚǇ
of death of the mother due to active smoking) are directly reproduced in the ICC, including 
the pregnancy-related two year postpartum values. This can be seen in Figure 7.2, where 
the transition pathways influenced by maternal smoking behaviour in the MLC are 
represented by the black dashed arrows, and the transition pathways influenced by 
maternal mortality in the MLC are represented by the grey dashed arrows. The thin black 
arrows represent transition pathways which are not influenced by the MLC. It should be 
noted that although the probability of relapse comes directly from the MLC, it is adjusted 
to take into account the proportion of mothers who expose their child to passive smoking. 
Since the determinants of these parameters were given in detail in Chapter 6 , these will 
not be reproduced here; instead focus is placed on the additional values specific to the 
infant. 
  
 Incorporating infant mortality 7.6
 
The transition probability for death was taken from ONS Cohort Life Tables, Table B1 [313] 
which, for children born between 1981 to 2012, reports mortality probabilities for males 
and females in the UK from birth to 100 years old, and projections for children born up to 
 ? ? ? ? ?/ƚǁĂƐĂƐƐƵŵĞĚƚŚĂƚƉĂƐƐŝǀĞƐŵŽŬŝŶŐŚĂĚŶŽŝŵƉĂĐƚŽŶĐŚŝůĚƌĞŶ ?ƐŵŽƌƚĂůŝƚǇ ?although 
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LBW increased the risk of mortality in childhood. The mortality probabilities were adjusted 
using the odds ratios in Table 7.2. 
 
Table 7.2: Odds ratios for increased risk of mortality during childhood associated with LBW 
Age (years) Odds ratio 95% confidence interval 
1-4 2.2 1.9 2.5 
5-9 1.7 1.3 2.1 
10-14 1.5 1.1 1.9 
15-19 0.9 0.7 1.1 
Source: Table 4, Li et al, 2003. [331] 
 
Due to the mortality data being used in the ICC, it was not possible to break down mortality 
in the first year to capture the impact of SIDS. Therefore, the ICC does not capture the 
impact of smoking during pregnancy on the increased rate of SIDS; however, the all-cause 
mortality rates used by the ICC will have incorporated a death rate for SIDS for both 
smoking and non-smoking mothers in the calculations of predicted mortality. 
 
 Incorporating smoking related smoking morbidities 7.7
 
As identified in Chapter 2 of this thesis, only respiratory illness was identified as having a 
causal link with smoking in pregnancy. Respiratory illness covers many diseases, including 
asthma; lower respiratory tract infections; and upper respiratory tract infections. We chose 
to focus the impacts of asthma on the infant during childhood since it is one of the most 
common childhood diseases; it has a large burden in terms of healthcare cost; and there 
was a strong link between asthma and exposure to smoking both within and after 
pregnancy. [329, 332]. Table 7.3 reports its prevalence in the UK by age and gender. 
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Table 7.3: Prevalence of asthma up to age 19 
Age (years) Males (%) Females (%) 
0-4 2.29 1.36 
5-9 11.41 7.88 
10-14 19.18 14.11 
15-19 22.34 18.27 
Source: Public Health England analysis [333] 
 
Asthma in childhood has also been linked with LBW. [334] Since the ICC calculated the 
number of infants who were born with LBW, it was decided to incorporate this impact into 
the prevalence of asthma independently to the impacts of smoking. Table 7.4 reports the 
odds ratios for the various impacts on the increased risk of asthma. 
 
Table 7.4: Odds ratios for increased risk of childhood asthma 
Condition Pooled odds 
ratio 
95% confidence interval Source 
LBW 1.28 1.09 1.50 Mu et al 
[334] 
Child aged 
0 - 2 years 
Mother smokes 
during pregnancy 
1.85 1.35 2.53 Burke et al 
[70] 
Passive smoking 
from mother 
2.47 0.65 9.39 Burke et al 
[70] 
Child aged 
3 - 4 years 
Mother smokes 
during pregnancy 
1.30 0.88 1.92 Burke et al 
[70] 
Passive smoking 
from mother 
1.05 0.88 1.25 Burke et al 
[70] 
Child aged 
5 - 18 years 
Mother smokes 
during pregnancy 
1.23 1.12 1.36 Burke et al 
[70] 
Passive smoking 
from mother 
1.20 0.98 1.44 Burke et al 
[70] 
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Using the methods already outlined in Chapter 5, the prevalence of asthma was calculated 
for LBW and normal birth weight children with the following exposures to smoking: 
x both during pregnancy and during childhood;  
x during pregnancy but not during childhood 
x childhood but not pregnancy  
 
No data were available on how quickly the risk of asthma changed after the mother had 
quit smoking, therefore the increased risk of asthma from passive smoking was only 
applied to those children who were subject to passive smoking while their mother is a 
current smoker. If the mother was not exposing her child to passive smoking, the risk of 
asthma to that child was assumed to be equal to those whose mothers were former 
smokers. The prevalence of asthma was applied in the same manner as that of smoking-
related morbidities for women in the MLC; with the estimated number of asthmatic 
children being dependent on the smoking behaviour of mothers43.  
 
 Health related quality of life 7.8
 
Chapter 2 identified several studies which reported utility values for children suffering from 
asthma. The largest study (Carroll et al) reported utility values for 4,016 children under the 
ĂŐĞŽĨ ? ?ǇĞĂƌƐďĂƐĞĚŽŶƉĂƌĞŶƚƐ ?ǀŝĞǁƐ ?dŚŝƐƐƚƵĚǇƵƐĞĚ the standard gamble technique to 
elicit utility values for asthma and perfect health. [163] Three possible utility values were 
estimated for children with mild intermittent, mild persistent and severe persistent 
asthma. It was assumed that since the utility values for mild intermittent and mild 
persistent asthma were almost the same, and since the model assumes that every child 
who developed asthma received treatment for it, the mild persistent asthma utility value 
was appropriate. These utility values were used to weight the life year, generating QALYs, 
and discounted by 3.5% per annum, as recommended by NICE guidance. [36] The values 
used in the ICC are reported in Table 7.5. 
                                                          
 
43
 Please note: due to constraints in this thesis, these values have not been reproduced in this 
documenƚ ?,ŽǁĞǀĞƌ ?ƚŚĞƉƌĞǀĂůĞŶĐĞǀĂůƵĞƐƵƐĞĚŝŶ^/WĐĂŶďĞĨŽƵŶĚƵŶĚĞƌƚŚĞ “Childhood asthma ?
tab in the ESIP spreadsheet. 
237 
 
 
Table 7.5: Utility values used in the childhood component of the ESIP model 
Condition Mean value Standard deviation 
Perfect health 1 - 
Asthma 0.9 0.18 
Source: Table III Carroll et al. [163] 
 
 Healthcare costs of morbidities 7.9
 
It was assumed there would be a treatment cost associated with childhood asthma. In 
keeping with the work performed in Chapter 6, the direct cost of healthcare for asthma 
was identified from the economic burden of disease literature. This was estimated at 
£1,565.27 per patient44. [320] The cost was estimated from a study which included both 
children and adult treatment, therefore appeared to be an appropriate estimate. This cost 
was applied per annum to all children who were estimated by the model as having asthma 
during childhood in each cycle. 
 
It was also assumed that there would be an NHS related cost attributable to death during 
childhood, which is consistent with previous work. [4] From Chapter 5, the cost of a cardiac 
event was used as a proxy, estimated to have a weighted mean cost of £1,379.02 and a 
quartile range of £799.89. [298] This cost relates to both children and adults, since it is not 
possible to split the NHS reference cost data for paediatric events. This cost was applied to 
all children who died in a cycle; all costs accrued were discounted at 3.5% per annum. [36] 
 
 Discussion 7.10
 
This chapter has described the childhood component (ICC) of ESIP. The ICC estimates the 
number of children who suffer from asthma associated with passive smoking, while taking 
into account the mothers ? smoking during pregnancy and ĐŚŝůĚ ?Ɛ birth weight, and 
                                                          
 
44
 Direct cost of healthcare: EUR 1950, converted 8/9/2014, 1 EUR = £0.8026, 
http://www.currency.me.uk/convert/eur/gbp 
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attributes relevant utilities and health costs to these children. This will allow the economic 
impact of maternal smoking during pregnancy and afterwards on infants and children to be 
estimated. 
 
7.10.1 Strengths of the childhood component 
 
There are several key areas where ESIP has the advantage over other models. The ICC is 
directly linked with the MLC ? ƐŽ ŝƚ ŝƐ ƉŽƐƐŝďůĞ ƚŽ ĞƐƚŝŵĂƚĞ ƚŚĞ ŝŵƉĂĐƚ ŽĨ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ
smoking behaviour after pregnancy on the health of her child. While there have been other 
economic ŵŽĚĞůƐǁŚŝĐŚŚĂǀĞĐŽŶƐŝĚĞƌĞĚƚŚĞ ‘ǁŝƚŚŝŶ-ƉƌĞŐŶĂŶĐǇ ?ĂƐƉĞĐƚŽĨƚŚĞůŝŶŬďĞƚǁĞĞŶ
ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ĂŶĚ ŚĞĂůƚŚ ĐŽŶƐĞƋƵĞŶĐĞƐ ŽŶ ƚŚĞ ŝŶĨĂŶƚ ?until now no 
model in this topic area has attempted to link post-pregnancy smoking behaviour and its 
consequences on the health and healthcare costs for the infant. By omitting the costs and 
consequences for the infant during childhood, the previous economic literature has missed 
the negative health consequences that can occur due to active smoking during childhood. 
This would suggest that the previous literature is producing inaccurate estimates of the 
cost-effectiveness of smoking cessation during pregnancy. 
 
Only two economic models have attempted to estimate the longer term impacts of 
sŵŽŬŝŶŐĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇŽŶĐŚŝůĚƌĞŶ ?ƐŚĞĂůƚŚ ?KŶĞŵŽĚĞůĚŝĚŶŽƚƚĂŬĞ ŝŶƚŽĂĐĐŽƵŶƚĂŶǇ
smoking related morbidities associated with childhood. [139] The other model 
incorporated the impact of smoking during pregnancy on the prevalence of asthma and 
otitis media, as well as the impact of LBW on the HRQoL of the infant. [190] As discussed in 
Section 2.5.3, the author found no evidence of a causal link with otitis media and therefore 
the inclusion could be viewed as a misspecification.  
 
It could be argued that the ICC is double-counting the impact of asthma, since it includes 
the links with asthma from exposure to smoking during pregnancy and exposure to passive 
smoking. Conversely, the author would argue that an infant exposed to smoking both 
within the womb and during childhood would have a greater risk of developing asthma 
compared to a child who is only exposed to either smoking within-pregnancy or during 
childhood. Thus, to control for this, the author first adjusted the prevalence of asthma to 
take into account the exposure to smoking within-pregnancy, then further adjusted the 
prevalence rates to take into account whether the child is exposed to passive smoking. 
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Using this approach, the ICC should have prevented any double-counting. However, if there 
is double-counting, then this would suggest that the ICC is overestimating the number of 
infants who develop childhood asthma, and thus overestimating the benefits from 
cessation, suggesting that the ICERs the ICC estimates are too low and should be higher. 
One approach to determine if this is the case is to use the ICC to replicate a cohort of 
infants and compare the prevalence of asthma within the ICC estimates with that of the 
cohort, although this is beyond the scope of this thesis. 
 
The birth weight of the child could be an important aspect, especially as it is associated 
with several morbidities and increased mortality during childhood. [331, 334] The ICC is 
also the first model in this topic area which incorporates the impact of LBW on increased 
morbidity and mortality. Since smoking during pregnancy can also influence birth weight, 
ďǇďƵŝůĚŝŶŐDĂƌŬŽǀĐŚĂŝŶƐĐŽŶƚŝŶŐĞŶƚŽŶƚŚĞĐŚŝůĚ ?ƐďŝƌƚŚǁĞŝŐŚƚ ?ƚŚĞ/ĐĂƉƚƵƌĞs both the 
direct impacts of smoking on children and the potential longer term impact of LBW on 
subsequent health. This suggests that the ICC is a more accurate representation of the 
health impacts of smoking during pregnancy on childhood health of the infant, giving 
accurate estimates of healthcare costs and health consequences.  
 
7.10.2 Limitations of the childhood component of the ESIP model 
 
Nonetheless, there are limitations associated with the ICC. The ICC only includes the 
impacts of passive smoking related to the mother. For example, it is likely that exposure to 
passive smoking from any adult that shares a home with a child will heighten morbidity 
risks, especially if it is ƚŚĞŵŽƚŚĞƌ ?ƐƉĂƌƚŶĞƌ ?ĐŚŝůĚ ?ƐĨĂƚŚĞƌ. However, the ICC is constructed 
to estimate the impacts of cessation interventions during pregnancy, which are delivered 
exclusively to the mother.  Therefore, it could be argued that we are not interested in the 
impact of other adults ? smoking behaviour, as this is external to the primary objective of 
the cessation intervention for the mother. Additionally, the exposure to smoking is likely to 
be higher from the mother than it is from any other adult, including the father/partner. In 
the Royal College of General Physicians report, Passive smoking and children [329], it was 
estimated that children whose father only smoked had cotinine levels that were 2.9 times 
higher than children with non-smoking parents; meanwhile children where only the mother 
smoked had 6.4 times higher levels of cotinine concentration. This would suggest that the 
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greatest exposure from passive smoking comes from the mother, and therefore the ICC is 
likely to be capturing the biggest impact of smoking behaviour after pregnancy. 
 
The ICC assumes singleton pregnancies and does not take multiple births into account. In 
2011, out of the 723,913 live births that occurred in England and Wales, 22,934 (or 
approximately 3%) were multiple births. [335] If a mother gives birth to more than one 
child, then the healthcare costs of passive smoking would be expected to increase as the 
ŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌnow impacts on two or more children, rather than one. This is 
not captured in the ICC, as one of the assumptions of the model is that the pregnancies are 
singleton. If this assumption is deemed unrealistic, it may be possible to model a cohort of 
maternities with multiple births by doubling the number of infants in the cohort, e.g. 100 
mothers give birth to 200 infants. However, multiple births are a relatively infrequent 
occurrence, and therefore perhaps not a major concern of decision makers. Furthermore, if 
a cessation intervention proved to be cost-effective for a single child, it is also highly likely 
that having more than one child will not change the cost-effectiveness, making an analysis 
of multiple births redundant. 
 
dŚĞ / ĂůƐŽ ĚŽĞƐŶ ?ƚ ĐŽŶƐŝĚĞƌ ĂŶǇ ƐƵďƐĞƋƵĞŶƚ ďŝƌƚŚƐ ? dŚŝƐ ŵĞĂŶƐ ƚŚĂƚ ƚŚĞ ŵŽĚĞů only 
estimates the impacts associated with the one infant, and does not take into account the 
ŝŵƉĂĐƚŽĨƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŽŶĂŶǇother children. This would suggest that 
the ICC is potentially underestimating the costs associated with smoking behaviour and the 
impact on the child. &ƵƌƚŚĞƌŵŽƌĞ ? ƚŚĞƌĞ ŵĂǇ ďĞ ĐŚĂŶŐĞƐ ŝŶ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ
behaviour due to the additional child, which would have an impact on the health 
consequences for the infant modelled in the ICC. However, the ICC adopts a one mother-
one child approach. Seeking to extend the model to address the implications of maternal 
smoking if younger siblings enter the family later in time would not be relevant to the 
current investigation, and is therefore excludable from the ICC. 
 
Another limitation is that the ICC does not directly capture the impact of smoking during 
pregnancy on the risk of the infant suffering from SIDS. Primarily, this was because of the 
limitations of the available data. Although the all-cause mortality rate incorporates some 
measure of SIDS, the ICC is unable to differentiate between SIDS and other causes of death 
in the first year. An implication of this is that the ICC is not capturing the benefits of 
cessation during pregnancy on the impact on the risk of SIDS, therefore underestimating 
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the cost-effectiveness of cessation interventions. Nevertheless, the incidence of SIDS is 
generally very low, and since the ICC is already attributing a healthcare cost of death, the 
incorporation of SIDS is unlikely to have a significant impact on its overall results. However, 
consideration should be given to a possible expansion of the ICC to differentiate SIDS from 
other mortality in the first year. 
 
An additional limitation is that the ICC only includes the impacts of smoking both within- 
and post-pregnancy on the rates of asthma amongst the cohort of infants. As Chapter 2 of 
this thesis demonstrated, we only found of a causal link between smoking and two 
conditions affecting the health of the infant: respiratory illness and congenital anomalies, 
and congenital anomalies were excluded on the basis that they occurred very infrequently. 
dŚĞ ƚĞƌŵ  ‘ƌĞƐƉŝƌĂƚŽƌǇ ŝůůŶĞƐƐ ? ĐŽǀĞƌƐ ƐĞǀĞƌĂů ĐŽŶĚŝƚŝŽŶƐ ? ǁŚŝĐŚ ŝŶĐůƵĚĞ ůŽǁĞƌ ƌĞƐƉŝƌĂƚŽƌǇ
tract infections as well as asthma, which have been demonstrated to have a link with both 
smoking during pregnancy and passive smoking. [336] Asthma was focused upon as it was 
one of the most common respiratory diseases, and has a large health burden, as stated in 
Section 7.7. However, it could be that focusing on asthma is excluding the other respiratory 
diseases, such as lower respiratory tract infection. These diseases could have a substantial 
economic burden in terms of healthcare costs and quality of life lost. [337] Their omission 
from the ICC suggests that it could be underestimating the healthcare costs attributed to 
smoking, as well as the benefits to be gained from cessation during pregnancy in terms of 
quality of life for the infant. This in turn suggests that the ICERs estimated by the ICC are 
too high, and that the true cost-effectiveness of cessation interventions could be lower. 
However, the author would argue that the inclusion of asthma is likely to capture most of 
the burden of childhood respiratory diseases, although the inclusion of other respiratory 
diseases as well as other childhood diseases could be included in any future work in 
developing the ESIP model. 
 
Another consideration is that the ICC does not take into account other impacts of LBW 
other than the increased prevalence of asthma amongst these children as well as the 
increased mortality (see Sections 7.6 and 7.7). There is some evidence that the quality of 
life of infants born with LBW is lower throughout their childhood compared to infants born 
with normal weight [338-340], although a systematic review suggests that the greatest 
impact on the quality of life occurs in the first few years of life and diminishes over time. 
[341] All this would suggest that the ICC should have put a lower utility value on infants 
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that are assigned to enter the LBW Markovs of the ICC compared to infants born with 
normal birth weight. The omission of the lower utility values for LBW infants suggest that 
the ICC is underestimating the benefits of cessation since cessation leads to a reduction in 
the number of LBW infants. This implies that the ICER estimates are higher than the reality, 
and hence ESIP may be underestimating the cost-effectiveness and value for money of 
cessation. However, it would be relatively easy to introduce a lower utility weight amongst 
LBW infants to correct this issue, should future researchers wish to do so. 
 
One final limitation is that the ICC only takes into account passive smoking impacts and 
there may be others that are not taken into account. For example, smoking is heavily linked 
with being in a lower socioeconomic status [342], and mortality and morbidity have been 
demonstrated to be higher in individuals who are lower socioeconomic status. [343] 
Furthermore, childhood asthma has been demonstrated as being linked with 
socioeconomic status [344], and since asthma is included in the ICC it would seem that 
socioeconomic status warrants inclusion. The omission of this impact could suggest that 
the ICC is not producing accurate estimates as to the number of infants exposed to 
morbidities and premature mortality within the model, since it is likely that a greater 
percentage of the cohort will of be low, rather than high, socioeconomic status, and 
therefore will have higher rates of morbidity and mortality than the higher status infants. 
This in turn would suggest that the ICER estimates are too high and ESIP is underestimating 
the cost-effectiveness of cessation interventions. However, it should be noted that if a 
cessation intervention was delivered as part of the NHS, women would have access to 
these interventions regardless of their socioeconomic status, and since the ICC uses 
national prevalence rates, the policy maker could be argued as interested in knowing the 
cost-effectiveness of cessation interventions to the average pregnant women, which ESIP 
currently calculates. One possible avenue of future work could be to perform a sub-group 
analysis of pregnant women by socioeconomic status to determine whether cessation 
interventions are more cost-effective for those who are of lower socioeconomic status. 
 
7.10.3 The childhood component in the context of current literature 
 
The model constructed by Taylor did not include impacts from smoking-related childhood 
ŵŽƌďŝĚŝƚŝĞƐ Žƌ ĂƚƚĞŵƉƚ ĂŶǇ ůŝŶŬĂŐĞƐ ďĞƚǁĞĞŶ ƚŚĞ ŵŽƚŚĞƌƐ ? ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌƐ ĂŶĚ
childhood impacts. [139] Instead, it simply estimated discounted QALYs for children born to 
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smoking and abstinent mothers, and assumed that those born to smokers had a slightly 
higher mortality rate under five years of age and higher costs due to increased healthcare. 
Estimates used were that, by age 79, a child born to a smoking mother would lose 0.02 
QALYs and cost £371 more than the child of an abstinent one. Because the ICC is so 
different to this model, it is difficult to make direct comparisons. However, the most 
important improvement the ICC has over this study is that it incorporates the impact of the 
ŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌĂĨƚĞƌƉƌĞŐŶĂŶĐǇ ?dŚŝƐǁŽƵůĚƐƵŐŐĞƐƚƚŚĂƚƚŚĞ/ŝƐƉƌŽĚƵĐŝŶŐ
better estimates of the impact of smoking after pregnancy on the health and healthcare 
costs associated with the child, and more precise estimates of the cost-effectiveness of 
cessation interventions during pregnancy.   
 
More recently, a model by Mallender et al took into account the impact of smoking during 
pregnancy on the prevalence of otitis media/ asthma on the HRQoL of the infant; this 
model also took into account some of the impacts of LBW. [190] This was done using a 
similar approach to the ICC, by calculating the prevalence of asthma amongst infants born 
to smoking and non-smoking mothers, as well as the number of infants born with LBW and 
NBW. The HRQoL estimates were not generated by Markov chains, but by extrapolating 
discounted QALYs over an assumed lifetime of 100 years. Furthermore, it treated asthma as 
a mutually exclusive morbidity to birth weight, which we know not to be the case. [334] In 
addition, the model excluded the impact of passive smoking, arguing that it was necessary 
ƚŽ ƚĂŬĞ ŝŶƚŽ ĂĐĐŽƵŶƚ ƉĂƐƐŝǀĞ ƐŵŽŬŝŶŐ ƌĞůĂƚŝŶŐ ƚŽ ƚŚĞ ŵŽƚŚĞƌ ?ƐƉĂƌƚŶĞƌ ? dŚĞ / ŝƐ ĂŶ
improvement because it takes into account 1) the dependency of asthma on birth weight 
and 2) that passive smoking has ĂŶŝŵƉĂĐƚĚŝƌĞĐƚůǇŽŶƚŚĞĐŚŝůĚ ?ƐŚĞĂůƚŚ ?dŚĞ/ĚŽĞƐŶŽƚ
ŝŶĐůƵĚĞƚŚĞƉĂƌƚŶĞƌ ?ƐƐŵŽŬŝŶŐ ?ŚŽǁĞǀĞƌ ?ƚŚĞŐƌĞĂƚĞƐƚŝŵƉĂĐƚŽŶŚĞĂůƚŚĂŶĚŝŶĐƌĞĂƐĞĚƌŝƐŬŽĨ
asthma comes from exposure to maternal passive smoking. [70, 329] Therefore the ICC is 
capturing what could be considered the most important aspect of passive smoking impacts. 
Conversely to the inclusion of otitis media in the model by Mallender et al, we identified no 
strong evidence of a causal association with smoking during pregnancy; however, if such a 
relationship did exist, a future improvement of the ICC could introduce this impact. 
 
7.10.4 Exposure to passive smoking in the home 
 
The 23% estimate as to the number of children who are exposed to smoke comes from 
Table 3.17 in the latest Statistics on Smoking: England report. [134] However, this value is 
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likely to change considerably. For example, in the US, the proportion of non-smokers who 
had levels of cotinine in their bodies (which suggested they had been exposed to second-
hand smoke) has decreased from 87.9% in 1988 to 25.3% in 2012. [345, 346] This decrease 
has been attributed to the increase in public health awareness and interventions 
attempting to curb the exposure to second-hand smoke. [346] However, it is still estimated 
that two in five children are exposed to regular passive smoking in the US [346], suggesting 
that the proportion is around 40%. In the UK, there have been further public health 
interventions, such as the 2003 restrictions of smoking in day care settings and the smoke-
free workplaces and enclosed public places smoking ban that was introduced in July 2007. 
/ƚŚĂƐďĞĞŶƐƵŐŐĞƐƚĞĚƚŚĂƚƐƵĐŚƉƵďůŝĐŚĞĂůƚŚŝŶƚĞƌǀĞŶƚŝŽŶƐƌĞĚƵĐĞĚĐŚŝůĚƌĞŶ ?ƐĞǆƉŽƐƵƌĞƚŽ
smoking, with a study in Scotland suggesting that the percentage of children exposed to 
second-hand smoke fell by 39% since the introduction of smoke-free legislation. [347] 
However, recent work has suggested that the proportion of children exposed to second 
hand smoke is much higher than the 23% used in the ICC.  In 2012, it was estimated that 
around 67% of pupils were exposed to any second-hand smoke, with 55% exposed at other 
ƉĞŽƉůĞ ?Ɛ ŚŽŵĞƐ ĂŶĚ  ? ?A? ĞǆƉŽƐĞĚ ŝŶ ƚŚĞŝƌ ŽǁŶ ŚŽŵĞ ? ǁŚŝůĞ  ? ?A? ǁĞƌĞ ĞǆƉŽƐĞĚ ŝŶ ƚŚĞŝƌ
family car. [348] However, it has been suggested that these values will decrease, especially 
with the forthcoming legislation regarding the banning of smoking in cars. [349] These 
public health interventions are likely to draw down the proportion of children exposed to 
passive smoking, and there is evidence that the introduction of previous smoke-free 
legislation has impacts on the prevalence of passive smoking at home, since the percentage 
of smoke-free homes increased from 61% in 2006 to 67% after the 2007 smoke free 
legislation. [350] Therefore, the October 2015 legislation banning smoking from cars is 
likely to have a similar impact. [349] 
 
The higher rates suggest that there is a great deal of uncertainty to be associated with the 
proportion of infants exposed to passive smoking. If the higher rates are correct, then the 
ICC is underestimating the number of children exposed to passive smoking; and hence 
underestimating the healthcare costs associated with passive smoking and the benefits to 
be gained from smoking cessation during pregnancy (and thereby preventing exposure to 
passive smoking). This would also suggest that the ICER estimates are too high for cessation 
interventions, and that ESIP is undervaluing the value for money of cessation interventions. 
However, because of the large degree of uncertainty associated with the proportion of 
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smoking at home, this parameter would certainly be an important consideration for both a 
one-way deterministic sensitivity analysis as well as for inclusion in a probabilistic 
sensitivity analysis.  
  
7.10.5 Potential future extensions of the ICC 
 
One potential area for future improvement would be to develop the evidence base around 
the childhood morbidities associated with smoking during pregnancy and/or passive 
smoking. Chapter 2 actually identified eight conditions that had some evidence linked with 
smoking during pregnancy; however, only respiratory illness was assessed to have a likely 
causal link. Certainly the relationship between smoking and pregnancy seemed unclear for 
some conditions. A report by the Royal College of Physicians suggested that passive 
smoking led to increased risks of several other conditions, including respiratory infections 
other than asthma, and bacterial meningitis. [329] This thesis primarily focused on the 
impacts of smoking during pregnancy, and as such the evidence associated with passive 
smoking and infant health has not been evaluated to the same degree. It could be argued 
that any childhood model containing passive smoking should consider all associated 
diseases. It would seem appropriate that a future extension to the ICC would be to evaluate 
the evidence for passive smoking and childhood diseases to ensure that it contains all 
relevant morbidities. Should further research identify one of the morbidities associated 
with smoking during pregnancy as having a causal link, it would be deemed appropriate for 
the ICC to include it. Furthermore, it would also be prudent to evaluate the current 
literature on morbidities associated with passive smoking to identify those with a causal 
link and thus ensure inclusion of all relevant smoking related morbidities.  
 
Another consideration is the expansion of the ICC to differentiate SIDS from other 
mortalities in the first year. As discussed in Section 7.10.2, although some measure of SIDS 
is incorporated in the all-cause mortality rate, limitations to the current data have 
prevented its inclusion as a specific cause of death. Although its incidence is generally low, 
it may be an improvement to the ICC to capture its prevalence separately to other causes 
of death, to ensure the benefits of cessation during pregnancy on reducing the risk of SIDS 
is reflected. Therefore its inclusion in an expansion of the ICC, given an improvement in the 
available data, could be seen as increasing the accuracy of the model. 
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Another avenue for possible research is better utility data. Currently, the ICC assumes that 
a healthy infant has a utility of 1, and asthmatic infant has a utility of 0.9. The utility of 1 for 
the healthy infant might been seen as unrealistic; however, there is very little research 
reporting utilities for children. One study estimated that the utility for school children aged 
11 years and older as 0.9 for healthy infants, which is very similar to the value used for 
asthmatic children in the ICC. [351] There may be almost no difference in utilities between 
a child with asthma and perfect health, although this would seem unlikely. There is also no 
utility data exploring differences in utilities by gender. Further research either undertaking 
improved utility estimates in children or identifying more reliable utility sources could be 
beneficial to the ICC. 
 
One possible limitation that could also be addressed is the inclusion of passive smoking 
ĨƌŽŵ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƉĂƌƚŶĞƌ ? ,ŽǁĞǀĞƌ ? ĂƐ ŚĂƐ ďĞĞŶ ĚŝƐĐƵƐƐĞĚ ŝŶ ƚŚĞ ĂďŽǀĞ ƐĞĐƚŝŽŶ ? ƚŚĞ
majority of the impact comes from maternal smoking and therefore it is unlikely that it 
would make a significant difference to the output of the model. Consideration should also 
be given to the added level of complexity which this would introduce, making the ICC very 
difficult to evaluate and analyse. 
 
 Summary 7.11
 
The ESIP childhood component attempts ƚŽ ĐĂƉƚƵƌĞ ƚŚĞ ŝŵƉĂĐƚ ŽĨ ƚŚĞŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ
behaviour, both during pregnancy and afterwards, on health and healthcare costs for the 
child up to and including the age of 15 years. The structure of the ICC allows direct links to 
the MLC, and estimates the number of infants exposed to passive smoking dependent on 
ƚŚĞŝƌŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌ ?ůƚŚŽƵŐŚƚŚĞƌĞĂƌĞƐĞǀ ƌĂůůŝŵŝƚĂƚŝŽŶƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚ
the ICC, this is the first economic model to link the mother and her child together in this 
manner. It is novel in that it includes smoking-related childhood morbidities.
247 
 
 Chapter 8: The ESIP model: How ESIP brings four components 
together to model the impacts of smoking and smoking cessation 
during pregnancy 
 
 Introduction 8.1
 
Chapters 5, 6, and 7 outlined the four components of the ESIP model in depth. Although 
ƚŚĞƐĞ ĂƌĞ ƌĞĨĞƌƌĞĚ ƚŽ ĂƐ  ‘ĐŽŵƉŽŶĞŶƚƐ ? ? ƚŚĞǇ ĂƌĞ ĨŽƵƌ standalone economic models; two 
within-pregnancy and two longer term, representing after pregnancy. ESIP combines these 
into a series of linked models, which give as comprehensive a picture as possible of the 
economic impacts of smoking during pregnancy, enabling the impacts of maternal smoking 
both during and after pregnancy to be modelled directly on the health and healthcare costs 
of the infant. The author will present how ESIP was constructed within a software package, 
and give guidance on how a user can evaluate a cessation intervention using ESIP, 
producing the results for both a deterministic and probabilistic analyses.  
 
 Aims and objectives 8.2
8.2.1 Primary aim:  
To describe the construction and use of ESIP 
8.2.2 Secondary objectives: 
1. Describe how the four ESIP components (MWPC, MLC, IWPC, and ICC) are 
linked  
2. Define how ESIP captures the differences in smoking behaviour between 
control and intervention groups 
3. Describe how ESIP determines whether an intervention is cost-effective or 
not 
4. Explain how ESIP was expanded to be probabilistic 
5. Illustrate how ESIP was constructed in a computer package 
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 Combining the four components 8.3
 
8.3.1 Assumptions in ESIP 
 
The following assumptions about the cohort of mothers and infants are required for ESIP to 
function: 
1. All women who enter the ESIP model are actively smoking at conception 
2. All pregnancies included in the ESIP are singleton 
3. All infants considered in the model are born to women who have been included in 
earlier components of ESIP 
4. There is no impact from included complications of pregnancy on mothers after 
pregnancy 
5. The chance of an adverse birth outcome does not vary with infant gender  
 
8.3.2 Brief summary of the four components 
 
The four components are summarised as follows: 
x Mother within-pregnancy (MWPC, see Chapter 5): Models the impacts of smoking 
during pregnancy on the following smoking-related pregnancy complications: 
ectopic pregnancy, miscarriage, abruption, previa and pre-eclampsia. Also captures 
the impact of foetal loss on the HRQoL of the mother. 
x Infant within-pregnancy (IWPC, see Chapter 5): Models the impact of maternal 
smoking behaviour on infant adverse pregnancy outcomes, including foetal loss 
(ectopic, miscarriage, stillbirth), LBW and premature birth.  
x Mother Lifetime (MLC, see Chapter 6): Models smoking behaviour after pregnancy 
on maternal risks of four chronic diseases (CHD, COPD, LC and stroke). 
x Infant Childhood (ICC, see Chapter 7): Models the impact of maternal smoking 
behaviour on the health of the child in relation to asthma.  
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8.3.3 ƌŝĞĨƐƵŵŵĂƌǇŽĨĐŽŵƉŽŶĞŶƚƐ ?ůŝŶŬƐ 
 
At the beginning of ESIP there is a cohort of women smoking at conception and an 
associated cohort of infants carried by and subsequently born to them. ESIP is a two stage 
ƉƌŽĐĞƐƐ ǁŚĞƌĞďǇ ƚŚĞ ĐŽŚŽƌƚƐ ŝŶŝƚŝĂůůǇ ĨůŽǁ ƚŚƌŽƵŐŚ ƚŚĞ ƌĞƐƉĞĐƚŝǀĞ  ‘ǁŝƚŚŝŶ-ƉƌĞŐŶĂŶĐǇ ?
components (MWPC and IWPC). Outputs from these are fed into a series of Markov chains 
representing maternal lifetime (MLC) and infant childhood (ICC). Within ESIP there are two 
types of links between the four components: 
x The influence link: This occurs where the IWPC shares parameters with the MWPC 
and also where the ICC shares parameters with the MLC; these links represent the 
ŝŵƉĂĐƚŽĨƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŽŶŚĞƌŽĨĨƐƉƌŝŶŐ ? 
x The flow link: This describes the sequential nature of ESIP components, which 
allows the lifetime components to take into account the within-pregnancy 
behaviour / outcomes. For example, the cohort of women must first pass through 
DtW ?ŝ ?Ğ ?ƉƌĞŐŶĂŶĐǇ ?ďĞĨŽƌĞD> ?ŝ ?Ğ ?ƚŚĞƌĞƐƚŽĨƚŚĞŝƌůŝ ĞƚŝŵĞƐ ? ?ƐŝŵŝůĂƌ ‘ĨůŽǁ
ůŝŶŬ ?ŽĐĐƵƌƐbetween IWPC and ICC. 
Figure 8.1 gives a simplified overall structure, highlighting the two types of links, and the 
following sections will describe how ESIP was constructed in greater detail. Figure 8.1 
depicts how the influence of maternal smoking behaviours in MWPC impact on the infant 
through the IWPC having the same estimate parameters (highlighted in bold capitals in 
Figure 8.1), as discussed in Chapter 5. The impact of maternal smoking post-pregnancy on 
ƚŚĞ ŝŶĨĂŶƚ ?Ɛ ĞǆƉŽƐƵƌĞ ƚŽ ƉĂƐƐŝǀĞ ƐŵŽŬŝŶŐ ŝƐ ĐĂƉƚƵƌĞd by the ICC sharing the same 
parameters as the MLC, as described in Chapter 7 and also shown in Figure 8.1. 
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Figure 8.1: Simplified overall structure of ESIP with all four components (MWPC, IWPC, MLC, and ICC), demonstrating how members of both cohorts flow through ESIP, and the influence 
links between the mother and her offspring 
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8.3.4 Linking the maternal within-pregnancy and maternal lifetime components 
 
The first stage for the maternal cohort is to flow into the MWPC, which estimates the costs 
and HRQoL that the women receive during pregnancy. Some of the output from the MWPC 
at the end of pregnancy includes the number of: 
x Women who quit and are alive 
x Women who quit and die during pregnancy 
x Women who smoke and are alive 
x Women who smoke and die during pregnancy 
These outputs then form the cohort sizes that enter the Markov chains in the MLC. In 
Figure 8.1, women who quit and are alive (regardless of within-pregnancy complications) 
enter an MLC Markov chain in the 0-1 year quitter state, representing the fact that they are 
making a quit attempt but have done so for less than a year. Women who smoke and are 
alive enter another series of MLC Markov chains in the current smoker state. For both 
quitters and smokers, the estimated healthcare costs and HRQoL form sunk costs 
attributed in cycle 0 of the MLC. A sunk cost is one that has already been incurred and 
cannot be recovered. To enter the MLC, any pregnant woman has to have flowed through 
the MWPC. The costs and HRQoL generated by the MWPC can be seen as unrecoverable in 
the MLC (i.e. they have occurred before the MLC model), and thus can be treated as a sunk 
cost. The MLC then runs the necessary number of cycles to a lifetime horizon when the 
cohort numbers are reduced to zero. 
 
8.3.5 Linking the infant within-pregnancy and lifetime components 
 
For the cohort of infants, the first stage of ESIP is to process through the IWPC At the end 
of pregnancy, some of the IWPC output includes the number of: 
 
x Infants born to an abstinent mother with LBW 
x Infants born to an abstinent mother with normal birth weight (NBW) 
x Infants born to a smoking mother with LBW 
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x Infants born to a smoking mother with NBW 
x Foetuses lost to an abstinent mother 
x Foetuses lost to a smoking mother 
 
Since the IWPC does not estimate the number of males and females, but the ICC requires 
this, the four virtual cohorts have to be split by gender (assumed to be 51% male). This 
generates eight virtual cohorts which then utilise eight corresponding Markov chains of the 
ICC, which are demonstrated in Figure 8.2.  
 
Children who are born to an abstinent mother enter the ICC in the state which represents 
ƚŚĂƚƚŚĞŵŽƚŚĞƌŚĂƐƋƵŝƚ ?ŝ ?Ğ ? ‘ŵŽƚŚĞƌ ?- ?ǇĞĂƌƋƵŝƚƚĞƌŝŶĨĂŶƚŶŽƚƉĂƐƐŝǀĞƐŵŽŬŝŶŐ ? ?ƌĞĨĞƌƌĞĚ
ƚŽ ĂƐ  ‘ŵŽƚŚĞƌ ŚĂƐ ƋƵŝƚ ? ŝŶFigure 8.1. The infants born to a smoking mother are split 
between the exposed and not-exposed passive smoking states as seen in Figure 8.1 In the 
actual / ƚŚĞ ƐƚĂƚĞƐ ĂƌĞ P  ‘DŽƚŚĞƌ ƐŵŽŬĞƐ ŝŶĨĂŶƚ ƉĂƐƐŝǀĞ ƐŵŽŬŝŶŐ ?ĂŶĚ  ‘ŵŽƚŚĞƌ ƐŵŽŬĞƐ
ŝŶĨĂŶƚŶŽƚƉĂƐƐŝǀĞƐŵŽŬŝŶŐ ? ?dŚĞƉƌŽƉŽƌƚŝŽŶĞǆƉŽƐĞĚƚŽƉĂƐƐŝǀĞƐŵŽŬŝŶŐŝƐƉƌŽŐƌĂŵŵĂďůĞ
by the user in ESIP, but is assumed to be 23% in the baseline analysis (see Section 7.4.4). A 
detailed representation of the ICC can be found in Chapter 7, Figure 7.2. The within-
pregnancy healthcare costs associated with the infants are then attributed to the relevant 
ICC chains as sunk costs. 
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Figure 8.2: Infant cohort flow through the infant within-pregnancy component (IWPC) into the infant 
childhood component (ICC), demonstrating how the IWPC generates eight virtual cohorts 
 
 
 Construction of ESIP in Microsoft Excel 8.4
 
This section describes how ESIP was constructed in a software package for performing 
economic evaluations of cessation interventions. Initially, this focuses on the construction 
of the deterministic model; the probabilistic model will be discussed later. ESIP was 
constructed in Microsoft Excel 2010 [352]; Excel was chosen because it: 
x contains many of the functions required to construct an economic model 
x is an easy to use  graphical interface, allowing straightforward interpretation and 
programming  
x is widely available, allowing easy circulation of the finished version  
 
dŚĞ ǆĐĞů ƐƉƌĞĂĚƐŚĞĞƚ ĐŽŶƐŝƐƚƐ ŽĨ ƐĞǀĞƌĂů  ‘ǁŽƌŬƐŚĞĞƚƐ ? which contain the various 
information and parameters required for ESIP to work. ESIP requires programming using 
254 
 
ƚŚĞ ‘ƉƌŽŐƌĂŵƐŚĞĞƚ ?worksheet to operate, which allows the user to select various options, 
including: 
1. Cohort size 
2. Base year 
3. Average age of mother 
4. Control and intervention group quit rates 
5. Control and intervention group costs 
6. Discount rates for costs and QALYs (initially set to 3.5% for costs and QALYs as per 
NICE guidance)[36] 
7. Proportion of infants who are male (initially set to 51%) 
8. Proportion of mothers who expose their child to passive smoking (initially set to 
23%) 
9. A reference age at which the user wishes the MLC model to estimate the outputs 
for (e.g. this could be set to average life expectancy for the mother, or simply to 
age 100) 
 
8.4.1 Adapting ESIP for within-trial analyses 
 
In Section 6.5.1, the general population relapse probabilities for up to two years 
postpartum were described for women who had quit during pregnancy. However, it was 
highlighted in Section 4.4.4 that there appeared to be a difference in postpartum relapse 
between control and intervention participants within trials, not only between the 
intervention and control groups, but also compared to the general population relapse. 
Therefore, as an added element of flexibility in ESIP, the user can select whether they wish 
to use specific relapse estimates for control and intervention participants.  The probability 
of remaining abstinent was calculated using the same method as described in Section 6.5.1. 
The relevant abstinence proportions are presented in Table 8.1, while Table 8.2 gives the 
calculated probabilities.  
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Table 8.1: Proportion abstinent (95% confidence interval) amongst trial participants by control and 
intervention groups for up to two years postpartum 
Years after pregnancy Control group Intervention group 
End of pregnancy 0.093 (0.070  W 0.117) 0.146 (0.122  W 0.170) 
1 0.060 (0.025  W 0.095)  0.085 (0.024  W 0.146) 
2 0.043 (-0.030 - 0.116)  0.051 (-0.017  W 0.119)  
 
Table 8.2: Transition probabilities for up to two years postpartum by control and intervention groups 
Transition probability Control group Intervention group 
P(1-2 quit|0-1 quit) 0.6452 0.5822 
P(Long-term quit|1-2 quit) 0.7167 0.6000 
 
8.4.2 Modelling the impact of interventions 
 
To enable the model to estimate the impact of different cessation interventions, the 
 ‘WƌŽŐƌĂŵƐŚĞĞƚ ?ǁŽƌŬƐŚĞĞƚŽĨƚŚĞExcel file has two cells allowing the user to input the quit 
ƌĂƚĞƐĨŽƌƚǁŽŐƌŽƵƉƐ PƚŚĞ ?ŶŽŝŶƚĞƌǀĞŶƚŝŽŶ ? ?ŽƌĐŽŶƚƌŽůŐƌ ƵƉ ?ĂŶĚƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶŐƌŽƵƉ ?
The comparator group rate represents the proportion who quit either without any 
intervention in a population study, or the quit rate of those found in the control group if 
the study is a clinical trial. The quit rate for the intervention group represents the 
proportion who quit if the smoking cessation intervention is utilised. There are a further 
four cells allowing the user to input the mean cost of the interventions and the 
ŝŶƚĞƌǀĞŶƚŝŽŶƐ ?ĐŽƐƚƐƚĂŶĚĂƌĚĞƌƌŽƌ ?dŚŝƐŝƐƐŚŽǁŶŝŶƚŚĞƐĐƌĞĞŶƐŚŽƚŝŶ Figure 8.3. 
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Figure 8.3 P^ĐƌĞĞŶƐŚŽƚŽĨƚŚĞ ‘WƌŽŐƌĂŵƐŚĞĞƚ ?ŽĨ^/W ?ĚĞŵŽŶƐƚƌĂƚŝŶŐƚŚĞƌĞůĞǀĂŶƚĐĞůůƐĨŽƌŝŶƉƵƚƚŝŶŐĂƉƉƌŽƉƌŝĂƚĞƋƵŝƚƌĂƚĞƐĂŶĚĐŽƐƚƐ 
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The ESIP model itself consists of four worksheets which contain the combined maternal and 
infant components required. These are: 
1.  “DŽƚŚĞƌ ďĂĐŬŐƌŽƵŶĚ ? P DĂƚĞƌŶĂů ĐŽŵƉŽŶĞŶƚƐ  ?DtW ĂŶĚ D> ? ĨŽƌ ƚŚĞ
background/control/spontaneous quitting group of women who are smoking at 
conception 
2.  “DŽƚŚĞƌ ŝŶƚĞƌǀĞŶƚŝŽŶ ? P DĂƚĞƌŶĂů ĐŽŵƉonents (MWPC and MLC) for the 
intervention group of women who are smoking at conception 
3.  “/ŶĨĂŶƚ ďĂĐŬŐƌŽƵŶĚ ? P /ŶĨĂŶƚ ĐŽŵƉŽŶĞŶƚƐ  ?/tW ĂŶĚ / ? ĨŽƌƚŚĞ
background/control/spontaneous quitting group of conceived infants 
4.  “/ŶĨĂŶƚŝŶƚĞƌǀĞŶƚŝŽŶ ? P/ŶĨĂŶƚĐŽŵƉŽŶĞŶƚs (IWPC and ICC) for the intervention group 
of conceived infants 
 
The quit rates and costs estimated for the background/control/spontaneous quitting group 
are fed into the worksheets ǁŝƚŚ  ‘ďĂĐŬŐƌŽƵŶĚ ? ŝŶ ƚŚĞŝƌ ƚŝƚůĞ ? ǁŚŝůĞ ƌĂƚĞƐ ĂŶĚ ĐŽƐƚƐ
associated with tŚĞ ŝŶƚĞƌǀĞŶƚŝŽŶ ŐƌŽƵƉ ĂƌĞ ƵƐĞĚ ŝŶ ƚŚĞ ǁŽƌŬƐŚĞĞƚƐ ǁŝƚŚ  ‘ŝŶƚĞƌǀĞŶƚŝŽŶ ? ŝŶ
their title.  
 
8.4.3 Output from the individual components 
 
The ESIP model returns outputs from each component, which is summarised on the 
 ?program sheet ? worksheet. This allows the user to look at the model estimates of various 
parameters for both the within-pregnancy, and the lifetime/childhood components for 
both mother and infant. For the maternal components, the following information is 
summarised from the output for both the control/background and intervention groups. The 
information reported for both maternal and infant components is summarised in Table 8.3. 
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Table 8.3: Estimated results computed bǇƚŚĞ^/WŵŽĚĞůĂƐƐƵŵŵĂƌŝƐĞĚŽŶƚŚĞ ‘ƉƌŽŐƌĂŵƐŚĞĞƚ ?ŝŶƚŚĞǆĐĞů
workbook 
 Maternal components Infant components 
Within-pregnancy 
components 
Number of quitters Number of infants alive at 
birth 
Quit rate Number of infants lost 
(ectopic, miscarried, 
stillborn) 
Expected cost per mother Number of stillbirths 
Expected QALYs per mother Number of premature births 
Number of maternal 
adverse pregnancy events 
Number of infants with LBW 
 Number of all infant adverse 
live births (LBW or 
premature or both) 
 Number of all adverse infant 
outcomes (all adverse live 
births plus all infants lost) 
 Expected cost per infant 
Lifetime/childhood 
components 
Percentage of cohort alive 
at reference age 
Percentage of cohort alive 
at age 15 years 
Percentage of those alive at 
reference age with a co-
morbidity 
Percentage of cohort dead 
at age 15 
Expected cost per mother Percentage of asthma 
amongst infants alive at age 
15 
Expected life years per 
mother 
Expected cost per child 
Expected QALYs per mother Expected life years per child 
 Expected QALYs per child 
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8.4.4 Outputs from the overall ESIP model 
 
The results above can be used to calculate statistics to demonstrate the cost-effectiveness 
of any cessation intervention during pregnancy. As discussed in section 1.6.8, the most 
commonly used is the incremental cost-effectiveness ratio (ICER). ESIP calculates the 
following ICERs: 
1. Incremental cost per quitter at the end of pregnancy for the mother 
2. Incremental cost per QALY at the end of pregnancy for the mother 
3. Incremental cost per quitter at reference age for the mother 
4. Incremental cost per life year gained at reference age for the mother 
5. Incremental cost per QALY at reference age for the mother 
6. Incremental cost per premature or LBW or both avoided  
7. Incremental cost per adverse pregnancy outcome for the infant (foetal loss, 
premature birth, LBW) at the end of pregnancy 
8. Incremental cost per life year gained by the age of 15 for the child 
9. Incremental cost per QALY for the child at age 15 
ESIP also estimates the incremental net benefit statistic (INB). ESIP calculates the following 
INB statistics: 
1. Incremental net benefit per QALY for the mother at the end of pregnancy 
2. Incremental net benefit per life year gained for the mother at the reference age 
3. Incremental net benefit per QALY for the mother at the reference age 
4. Incremental net benefit per adverse live birth avoided (IWPC) 
5. Incremental net benefit per adverse pregnancy outcome for the infant 
6. Incremental net benefit per life year gained for the child at age 15 
7. Incremental net benefit per QALY for the child at age 15 
The calculation of the ICER and INB statistics allow ESIP to inform the user of the cost-
effectiveness of the inputted interventions compared to its control group. Calculating the 
ICERs and INBs at the end of each component allows the user to determine the cost-
effectiveness of the interventions either at the end of pregnancy or at a particular 
reference age after pregnancy. Furthermore, the way the Excel spreadsheet is set up allows 
the interventions to be compared at a trial-based as well as a population- based level, by 
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simply changing the parameters in the program sheet (e.g. cohort size) to either match the 
population in the trial or the population as a whole. 
 
 Making ESIP probabilistic 8.5
 
8.5.1 Adding uncertainty to the ESIP model 
 
ESIP was adapted to conduct a probabilistic analysis by assigning statistical distributions to 
all parameters. The distributions described in Section 1.6.10 of this thesis were used for 
this, along with the various methods to fit the distributions to the parameters. Where no 
standard error for a particular parameter was identified, it was not excluded from the 
model, but a conservative estimate of 10% of the mean was assumed, as recommend by 
the CHEERS statement and other work. [43, 114-116] The utility decrements from 
Maheswaran et al were sampled once [295], and then used throughout the model, hence 
are only reported in the within-pregnancy part. For utility values regarding active smokers, 
the weighted average of the individual sampled decrement was calculated as described in 
Section 5.5. For cost associated with infants born with LBW and/or prematurely, the 
individual components were sampled and a weighted average value was calculated for 
inclusion in the model. The MLC parameters for abstinence one year after pregnancy and 
two years after pregnancy were calculated by sampling the proportions abstinent at the 
end of pregnancy, one year postpartum, and two years postpartum, then recalculating the 
associated probability before entering the MLC parameter alongside the Dirichlet 
estimated probabilities for Mother and Infant Mortality in the ICC. The PSA did not adjust 
the values for the fact they were self-reported outcomes. Table 8.4 gives the distributions 
assigned to the parameters in all components. The user should be aware that the 
parameterisation of the Dirichlet distribution related to mother and infant general 
population mortality (not adjusted for smoking behaviour) is not given. This is because the 
distribution is different for each year of age, and is also user selected when the user 
programmes in the base year of the evaluation and the age of the mothers in the cohort. 
This would mean that the author would need to report the parameterisation of 
approximately 10,000 Dirichlet distributions from the MLC and a further 1,500 distributions 
from the ICC. However, they were parameterised using the method described in section 
1.6.10 ǁŚĞƌĞ ƚŚĞ ƉƌŽďĂďŝůŝƚǇ ŽĨ ĚĞĂƚŚ  ?ƌĞƉƌĞƐĞŶƚĞĚ ŚĞƌĞ ĂƐ A? ? Ăƚ ƚŚĞ ĐŚŽƐĞŶ ĂŐĞ ǁĂƐ
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multiplied by 1,000, and fitted to the Dirichlet using the Gamma distribution as an 
approximation, so the parameterisation for each of the Dirichlet mortality values in the 
MLC and ICC would be ܺ ?ܩܽ݉݉ܽሺ ? ? ? ?ൈ  ?ǡ  ?ሻǤAlthough the standard error was not 
reported by the ONS estimates, the method of applying the Gamma distribution introduces 
a standard error, which can be calculated by ߪ ൌ ඥߤߚ. If the user wishes to view the 
estimated Dirichlet probabilities, these can be found in the ESIP spreadsheet under the 
ǁŽƌŬƐŚĞĞƚƐĞŶƚŝƚůĞĚ “ŝƌŝĐŚůĞƚƉƌŽďĂďŝůŝƚŝĞƐ ?ĨŽƌĞƐƚŝŵĂƚĞƐĂƐƐŽĐŝĂted with the mother and 
 “ŝƌŝĐŚůĞƚƉƌŽďƐĐŚŝůĚŚŽŽĚ ?ĨŽƌĞƐƚŝŵĂƚĞƐƌĞůĂƚŝŶŐƚŽƚŚĞŝŶĨĂŶƚ ?ƐĐŚŝůĚŚŽŽĚ ?
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Table 8.4: List of parameters with associated distribution used in the PSA 
Component Parameter Distribution Mean 
Standard 
Error 
Į ǃ 
Within-
pregnancy 
component 
(MWPC and 
IWPC) 
P(Ectopic pregnancy) Dirichlet 0.0151 0.0001** Á Á 
P(Miscarriage) Dirichlet 0.0606 0.0001** Á Á 
P(Not abortive) Dirichlet 0.9243 0.0001** Á Á 
P(Placental abruption) Dirichlet 0.0037 0.00003** 17,101Á Á 
P(Placenta previa) Dirichlet 0.0062 0.00004** 28,610Á Á 
P(Pre-eclampsia) Dirichlet 0.0188 0.0001** 86,151Á Á 
P(No complication) Dirichlet 0.9713 0.00007** 4,460,583Á Á 
P(Premature|abruption) Beta 0.4029 0.0095** 1,074 1,592 
P(Premature|previa) Beta 0.2631 0.0066** 1,163 3,257 
P(Premature|pre-eclampsia) Beta 0.2739 0.0039** 3,618 9,593 
P(Premature|no complication) Beta 0.0627 0.0003** 40,787 610,171 
P(LBW|premature) Beta 0.6126 0.0014** 184,290 116,552 
P(LBW|full gestation) Beta 0.0303 0.0001** 118,294 3,791,721 
P(Mother dies|ectopic) Beta 0.00015 0.00004** 17 110,726 
P(Mother dies|miscarriage) Beta 0.00002 0.000006** 7 444,864 
P(Mother dies|abruption) Beta 0.00032 0.0001** 8 25,268 
P(Mother dies|previa) Beta 0.00002 0.00002** 1 42,285 
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P(Mother dies|pre-eclampsia) Beta 0.00025 0.00004** 32 127,302 
P(Mother dies|no complication) Beta 0.00006 0.000003** 382 6,592,480 
P(Infant stillborn|LBW|premature) Beta 0.0680 0.0006** 12,530 17,160 
P(Infant stillborn|NBW|premature) Beta 0.0071 0.0002** 828 115,724 
P(Infant stillborn|LBW|full 
gestation) 
Beta 0.0177 0.0004** 2,095 116,199 
P(Infant stillborn|NBW|full 
gestation) 
Beta 0.0017 0.00002** 6,577 3,785,144 
OR(Ectopic) Log normal 1.77 0.2321  0.13 
OR(Miscarriage) Log normal 1.32 0.0765   
OR(Placental abruption) Log normal 1.62 0.0791   
OR(Placenta previa) Log normal 1.58 0.2755   
OR(Pre-eclampsia) Log normal 0.51 0.0663 -  
OR(Premature birth) Log normal 1.27 0.0306   
RR(LBW) Log normal 1.82 0.0765   
RR(Stillbirth) Log normal 1.26 0.0383   
Cost(Ectopic pregnancy) Gamma £1,749.23 £674.39 6.72779 260.001 
Cost(Miscarriage) Gamma £554.70 £236.94 5.48092 101.206 
Cost(Midwife visit) Gamma £53.00 £18.18 8.49685 6.23761 
Cost(Standard ultrasound scan) Gamma £109.78 £53.08 4.27769 25.6634 
264 
 
Cost(Specialised ultrasound scan) Gamma £121.02 £66.94 3.2683 37.0284 
Cost(Obstetrician first visit) Gamma £152.21 £57.95 7.2463 13.9561 
Cost(Obstetrician subsequent visit) Gamma £101.13 £37.75 7.2463 13.9561 
Cost(Normal birth) Gamma £2,079.81 £633.14 10.7905 192.744 
Cost(Emergency caesarean) Gamma £3,466.59 £872.97 15.7692 219.833 
Cost(Caesarean birth) Gamma £3,413.47 £873.91 15.2566 223.737 
Cost(Routine observation) Gamma £571.15 £310.59 3.38171 168.894 
Cost(Death) Gamma £1,379.02 £615.42 5.021 274.65 
Cost(Hypertension drugs 
(premature)) 
Gamma £53.05 £5.31* 100 0.5305 
Cost(Hypertension drugs (full 
gestation)) 
Gamma £63.66 £6.37* 100 0.6366 
Cost(Infant stillborn) Gamma £722.65 £72.27* 100 7.2265 
Cost(Premature 20-23 weeks 
gestaion) 
Gamma £1,261.00 £2,790.00 0.20 6,172.96 
Cost(Premature 24-27 weeks 
gestation) 
Gamma £7,362.00 £9,692.00 0.58 12,759.42 
Cost(Premature 28-31 weeks 
gestation) 
Gamma £6,920.00 £4,909.00 1.99 3,482.41 
Cost(Premature 32-36 weeks 
gestation) 
Gamma £1,917.00 £1,586.00 1.46 1,312.15 
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Cost(Full gestation) Gamma £824.00 £940.00 0.77 1,072.33 
Cost(Birth weight <1000g) Gamma £6,430.00 £9,642.00 0.44 2,715.08 
Cost(Birth weight 1000-1499g) Gamma £5,779.00 £5,310.00 1.18 23,227.45 
Cost(Birth weight 1500-1999g) Gamma £3,234.00 £3,119.00 1.08 3,191.13 
Cost(Birth weight 2000-2499g) Gamma £1,606.00 £1,256.00 1.63 3,359.02 
Cost(NBW) Gamma £835.00 £978.00 0.73 519.16 
Utility(Constant) Beta 0.987 0.0066 286.89 3.7787 
Utility(Active light smoker 
decrement) 
Beta 0.044 0.0069 38.9689 846.6872 
Utility(Active moderate smoker 
decrement) 
Beta 0.055 0.0069 60.2012 1,034.36662 
Utility(Active heavy smoker 
decrement) 
Beta 0.087 0.0102 66.2814 695.5739 
Utility(Former smoker decrement) Beta 0.027 0.0043 37.6880 1,358.1656 
Utility(Female decrement) Beta 0.016 0.0036 19.7333 1,213.5963 
Utility(Age 25-34 decrement) Beta 0.015 0.0054 7.7074 506.1193 
Utility(Age 35-44 decrement) Beta 0.033 0.0056 33.4004 978.7342 
Utility(Age 45-54 decrement) Beta 0.068 0.0061 114.9017 1,574.8291 
Utility(Age 55-64 decrement) Beta 0.094 0.0066 181.8800 1,753.0136 
Utility(Age 65-74 decrement) Beta 0.116 0.0077 202.9784 1,546.8351 
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Utility(Age 75+ decrement) Beta 0.138 0.0084 231.4999 1,446.0359 
Utility(Ectopic pregnancy 
decrement) 
Beta 0.01 0.01 0.98 97.02 
Utility(Loss of infant decrement) Beta 0.1 0.1 0.8 7.2 
Mother Lifetime 
Component 
(MLC) 
Proportion (abstinent at end of 
pregnancy) 
Beta 0.126 0.0099 140.0570 971.5067 
Proportion (abstinent at one 
year postpartum) 
Beta 0.074 0.0242 8.5597 107.1125 
Proportion (abstinent at two 
year postpartum) 
Beta 0.047 0.0360 1.5801 32.0397 
P(Quit attempt during first year 
postpartum given smoked 
throughout pregnancy) 
Dirichlet 0.13 0.0106** 130Á Á 
P(Abstinent at one year postpartum 
having quit during pregnancy) 
Dirichlet 
Dependent on sampled values from Proportion(abstinent at one year 
postpartum) divided by Proportion (abstinent at end of pregnancy) 
P(Abstinent at two years 
postpartum having quit during 
pregnancy) 
Dirichlet 
Dependent on sampled values from Proportion(abstinent at two 
years postpartum) divided by Proportion (abstinent at one year 
postpartum) 
P(Quit attempt during any year 
given current smoker) 
Dirichlet 0.27 0.0140** 270Á Á 
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P(Abstinent at one year after quit 
attempt) 
Dirichlet 0.14 0.0110** 140Á Á 
P(Abstinent at two years after quit 
attempt) 
Dirichlet 0.57 0.0156** 570Á Á 
P(Relapse given long-term quitter) Dirichlet 0.0086 0.0029** 8.6262Á 1 
RR(CHD|Smoker aged 35-54) Log normal 4.98 0.498*   
RR(CHD|Smoker aged 55-64) Log normal 3.25 0.325*   
RR(CHD|Smoker aged 65-74) Log normal 3.29 0.329*   
RR(CHD|Smoker aged 75+) Log normal 2.25 0.225*   
RR(CHD|Former smoker aged 
35-54) 
Log normal 2.23 0.223*   
RR(CHD|Former smoker aged 
55-64) 
Log normal 1.21 0.121*   
RR(CHD|Former smoker aged 
65-74) 
Log normal 1.56 0.156*   
RR(CHD|Former smoker aged 
75+) 
Log normal 1.42 0.142*   
RR(COPD|Smoker aged 35-54) Log normal 6.43 0.643*   
RR(COPD|Smoker aged 55-64) Log normal 9.00 0.9* 2.197  
RR(COPD|Smoker aged 65-74) Log normal 38.89 3.889*   
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RR(COPD|Smoker aged 75+) Log normal 20.96 2.096*   
RR(COPD|Former smoker aged 
35-54) 
Log normal 1.85 0.185*   
RR(COPD|Former smoker aged 
55-64) 
Log normal 4.84 0.484*   
RR(COPD|Former smoker aged 
65-74) 
Log normal 15.72 1.572*   
RR(COPD|Former smoker aged 
75+) 
Log normal 7.06 0.706*   
RR(LC|Smoker aged 35-54) Log normal 13.30 1.33*   
RR(LC|Smoker aged 55-64) Log normal 18.95 1.895*   
RR(LC|Smoker aged 65-74) Log normal 23.65 2.365*   
RR(LC|Smoker aged 75+) Log normal 23.08 2.308*   
RR(LC|Former smoker aged 35-
54) 
Log normal 2.64 0.264*   
RR(LC|Former smoker aged 55-
64) 
Log normal 5.00 0.5*   
RR(LC|Former smoker aged 65-
74) 
Log normal 6.80 0.680*   
RR(LC|Former smoker aged 
75+) 
Log normal 6.38 0.638*   
269 
 
RR(Stroke|Smoker aged 35-54) Log normal 2.44 0.244*   
RR(Stroke|Smoker aged 55-64) Log normal 1.98 0.198*   
RR(Stroke|Smoker aged 65-74) Log normal 2.27 0.227*   
RR(Stroke|Smoker aged 75+) Log normal 1.70 0.170*   
RR(Stroke|Former smoker aged 
35-54) 
Log normal 1.00 0.1*   
RR(Stroke|Former smoker aged 
55-64) 
Log normal 1.10 0.11*   
RR(Stroke|Former smoker aged 
65-74) 
Log normal 1.24 0.124*   
RR(Stroke|Former smoker aged 
75+) 
Log normal 1.10 0.11*   
RR(Death|Current smoker aged 
35-44) 
Log normal 1.75 0.175*   
RR(Death|Current smoker aged 
45-54) 
Log normal 2.025 0.2025*   
RR(Death|Current smoker aged 
55-64) 
Log normal 2.1368 0.21368*   
RR(Death|Current smoker aged 
65-74) 
Log normal 1.9831 0.19831*   
RR(Death|Current smoker aged Log normal 1.5727 0.1527*   
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75-84) 
RR(Death|Current smoker aged 
85+) 
Log normal 1.2972 0.12972*   
RR(Death|Former smoker aged 
35-44) 
Log normal 1.25 0.125*   
RR(Death|Former smoker aged 
45-54) 
Log normal 1.2250 0.12250*   
RR(Death|Former smoker aged 
55-64) 
Log normal 1.4105 0.14105*   
RR(Death|Former smoker aged 
65-74) 
Log normal 1.3333 0.13333*   
RR(Death|Former smoker aged 
75-84) 
Log normal 1.1469 0.11469*   
RR(Death|Former smoker aged 
85+) 
Log normal 1.0658 0.10658*   
Cost(CHD) Gamma £3,954.46 £395.46* 100 39.55 
Cost(COPD) Gamma £1,121.00 £112.10* 100 11.21 
Cost(Lung Cancer) Gamma £9,075.81 £907.58* 100 90.76 
Cost(Stroke) Gamma £1,627.76 £162.78* 100 16.28 
Cost(Death) Gamma £1,379.02 £615.42 5.021 274.65 
Utility(CHD) Beta 0.73 0.3 2.7079 1.0016 
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Utility(COPD) Beta 0.73 0.23 1.9899 0.7360 
Utility(Lung cancer) Beta 0.67 0.22 2.3907 1.1775 
Utility(Stroke) Beta 0.72 0.32 0.6975 0.2713 
Infant Childhood 
component (ICC) 
P(Mother exposes her child to 
smoking) 
Beta 0.23 0.0419** 
23 
 
77 
P(Mother makes quit attempt during 
first year postpartum given smoked 
throughout pregnancy) 
Dirichlet 0.13 0.0106** Á Á 
P(Mother abstinent at one year 
postpartum having quit during 
pregnancy) 
Dirichlet 
Dependent on sampled values from Proportion(abstinent at one year 
postpartum) divided by Proportion (abstinent at end of pregnancy) 
P(Mother abstinent at two years 
postpartum having quit during 
pregnancy) 
Dirichlet 
Dependent on sampled values from Proportion(abstinent at two 
years postpartum) divided by Proportion (abstinent at one year 
postpartum) 
P(Mother makes quit attempt during 
any year given current smoker) 
Dirichlet 0.27 0.0140** Á Á 
P(Mother abstinent at one year after 
quit attempt) 
Dirichlet 0.14 0.0110** Á Á 
P(Mother abstinent at two years 
after quit attempt) 
Dirichlet 0.57 0.0156** Á Á 
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P(Mother relapses given long-term 
quitter) 
Dirichlet 0.0086 0.0029** Á 1 
OR(Death|LBW, aged 1-4) Log normal 2.2 0.1531   
OR(Death|LBW, aged 5-9) Log normal 1.7 0.2041 0.  
OR(Death|LBW, aged 10-14) Log normal 1.5 0.2041   
OR(Death|LBW, aged 15-19) Log normal 0.9 0.1020 -  
OR(Asthma due to being born with 
LBW) 
Log normal 1.28 
0.1046 
 
  
OR(Asthma due to exposure during 
pregnancy, aged 0-2 years) 
Log normal 1.85 0.3010   
OR(Asthma due to exposure during 
pregnancy, aged 3-4 years) 
Log normal 1.30 0.2653   
OR(Asthma due to exposure during 
pregnancy, aged 5-18 years) 
Log normal 1.23 0.0612   
OR(Asthma due to exposure to 
passive smoking during childhood, 
aged 0-2 years) 
Log normal 2.47 2.2296   
OR(Asthma due to exposure to 
passive smoking during childhood, 
aged 3-4 years) 
Log normal 1.05 0.0944  0.351 
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OR(Asthma due to exposure to 
passive smoking during childhood, 
aged 5-18 years) 
Log normal 1.20 0.1173   
      
Cost(asthma) Gamma £428.51 £510.39 0.7049 607.9157 
Cost(Death) Gamma £1,379.02 £615.42 5.021 274.65 
Utility(Child with asthma) Beta 0.9 0.18 1.6 0.1778 
Relapse 
values 
associated 
with within-
trial 
analyses 
(see section 
8.4.1) 
Proportion(abstinent at end of 
pregnancy controls) 
Beta 0.093 0.0120 54.4765 531.2919 
Proportion (abstinent at one 
year postpartum controls) 
Beta 0.06 0.0179 10.5522 165.3182 
Proportion (abstinent at two 
years postpartum controls) 
Beta 0.043 0.0372 1.236 27.4326 
Proportion(abstinent at end of 
pregnancy interventions) 
Beta 0.146 0.0122 121.2637 709.3094 
Proportion (abstinent at one 
year postpartum interventions) 
Beta 0.085 0.0311 6.7401 72.5556 
Proportion (abstinent at two 
years postpartum interventions) 
Beta 0.051 0.0347 1.9997 37.2100 
Overall ESIP 
model 
P(Quit rate at end of pregnancy for 
comparator) 
Beta User specified User specified N/A N/A 
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P(Quit rate at end of pregnancy in 
intervention) 
Beta User specified User specified N/A N/A 
Cost(Comparator) Gamma User specified User specified N/A N/A 
Cost(Intervention) Gamma User specified User specified N/A N/A 
*= These are assumed standard errors, based on 10% of mean value 
**= The standard errors are not reported in the literature estimates, however they are approximated by backtracking the fitting of the 
distribution to give an estimate of the standard error that the parametrisation of the distribution assigns 
 These represent the natural log of the mean and its associated standard error for parameterising the log normal distribution, with 
YDOXHVLQWKHĮUHSUHVHQWLQJWKHPHDQRIWKHORJQRUPDOGLVWULEXWLRQDQGYDOXHVLQWKHǃUHSUHVHQWLQJWKHVWDQGDUGHUURURIthe log 
normal distribution 
Á These represent the values programmed into the Gamma distribution in Excel as a proxy to the Dirichlet distribution 
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8.5.2 Conducting the PSA in ESIP 
 
The PSA, as programmed in ESIP, randomly samples each parameter as specified above, 
and evaluates the model. Because of the large number of parameters with distributions 
fitted, there is likely to be a high degree of uncertainty in ESIP. As discussed in section 
1.6.10, it was decided that the PSA would require 10,000 iterations to achieve stability and 
to produce reasonable estimates as the CIs associated with the output.  The PSA can be 
activated from the  ‘Wrogram sheet ?worksheet in the Excel file, as ESIP can be run in both 
deterministic and probabilistic modes. 
 
8.5.3 Output from the PSA in ESIP 
 
The  ‘Simulation ?ǁŽƌŬƐŚĞĞƚŝŶƚŚĞǆĐĞůĨŝůĞƌĞĐŽƌĚƐƚŚĞƉĂƌĂŵĞƚĞƌƐ ?ĐŚŽƐĞŶǀĂůƵĞƐŝŶĞĂĐŚ
PSA iteration as well as the output generated by the model. This allows basic summary 
statistics such as mean and 95% CI for both the parameters and model outputs to be 
generated.  
 
Further output from the PSA includes a scatterplot of incremental costs against incremental 
outcome. The scatterplots allow the user to visually inspect the orientation of the PSA 
estimates on the cost-effectiveness plane. Scatterplots are available for both the combined 
output for mother and infant as well as the three individual ESIP components which have 
incorporated QALYs as their incremental outcome; MWPC, MLC and ICC. In addition, a 
scatterplot using incremental adverse pregnancy events for the infant avoided is generated 
for the IWPC.  
 
The ESIP model also calculates the cost-effectiveness acceptability curves (CEACs) which 
are used to represent uncertainty (see section 1.6.11). A CEAC plots the probability that an 
intervention (compared to the comparator) is cost-effective at a willingness to pay level 
chosen by a decision maker. [118, 353] The ESIP model generates CEACs for each ESIP 
component and the merged output for mother and infant, estimating the probability the 
intervention is cost-effective in terms of QALYs, life years gained (LYG), number of quitters, 
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and adverse pregnancy events/birth outcomes for the mother/infant. The willingness to 
pay can be chosen from between £0 to £100,000 per outcome, and CEACs are 
automatically generated by the PSA.  
 
 Discussion 8.6
 
This chapter has described the combination of the four standalone components to create 
ESIP. ESIP estimates the potential impacts of smoking and cessation in pregnancy not only 
on the health of the mother, but on the infant as well, and assesses any lasting impact on 
the health of both beyond pregnancy. Furthermore, ESIP allows comparisons between 
interventions, enabling it to estimate the cost-effectiveness of cessation interventions 
during pregnancy. This section aims to critically appraise ESIP, and suggest further 
refinements and future research. 
 
8.6.1 The ESIP model in context of the literature 
 
Although there are several studies that have addressed the topic of smoking and smoking 
cessation during pregnancy, there are relatively few economic models that have 
investigated the fiscal impacts of smoking/smoking cessation during pregnancy, most being 
within-trial evaluations. As Chapter 3 identified, most models focused on the within-
pregnancy impacts of smoking on the health and healthcare costs for the mother or infant 
[65, 68, 205], with only two studies looking at both the mother and the infant [65], one 
only included two separate, unlinked models, while the other incorporated the prevalence 
of maternal complications and adverse birth outcomes. Two studies were identified as 
modelling the long-term impact of smoking during pregnancy on the health/costs of the 
mother and her infant for the rest of their lives. 
 
One advantage of ESIP over the previous literature is that it combines four components to 
give a comprehensive visualisation of the natural flow of a cohort member from 
conception, through birth, and into the post-pregnancy period. Only four studies have been 
identified as exploring longer term impacts of smoking, with only two investigating long-
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term impacts on both the mother and her child,[139, 190], and the others only including 
long-term maternal outcomes. [137, 196] ESIP is novel in that it simultaneously examines 
the within-pregnancy time horizon and post-pregnancy impacts. This allows ESIP to 
estimate both the within-pregnancy (short term) cost-effectiveness of cessation 
interventions and the longer term cost-effectiveness for both mother and infant. For 
decision makers, this could be particularly useful, since ESIP generates the necessary 
information which may suit their different perspectives, e.g. a decision maker may be more 
interested in the short-term cost-effectiveness for the mother than in the longer term 
impacts for the infant.  
 
ESIP also has the advantage of being the first model in this topic area to incorporate the 
ŝŶĨůƵĞŶĐĞ ŽĨ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ŽŶ ƚŚĞ ŚĞĂůƚŚ ĂŶĚ ŚĞĂůƚŚĐĂƌĞ ĐŽƐƚƐ ŽĨ ŚĞƌ
infant, both within-pregnancy and throughout the childhood period. While Shipp et al 
constructed two separate models to estimate the impact of smoking on pregnancy 
outcomes for both the mother and infant [65], there was no direct link between the two, 
ƐŽƚŚĞŵŽƚŚĞƌ ?ƐǁŝƚŚŝŶ-pregnancy smoking behaviour did not impact on the ŝŶĨĂŶƚ ?Ɛhealth 
status at birth. ESIP incorporates this link, allowing the smoking behaviour within 
pregnancy to directly influence the pregnancy outcomes for the infant. The potential 
benefit of this link is that it is more representative of the impact of smoking within-
pregnancy, implying that ESIP may produce better estimates of the cost-effectiveness of 
cessation interventions undertaken during pregnancy. Furthermore, ESIP includes a link 
ďĞƚǁĞĞŶ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ƉŽƐƚ-ƉƌĞŐŶĂŶĐǇ ĂŶĚ ƚŚĞ ŝŶĨĂŶƚ ?Ɛ ĞǆƉŽƐƵƌĞ ƚŽ
passive smoking. Not only has this link not been incorporated before, but the information 
used to derive the parameters is potentially the most up-to-date estimates of smoking 
behaviour post-pregnancy.  
 
Another advantage of ESIP is that it includes a PSA. Only two previous studies attempted a 
PSA, whereas the rest of the literature performed the analysis deterministically. The PSA 
undertaken by Mallender et al only captures uncertainty associated with the quit rates and 
costs of the interventions, and not that associated with other incorporated model 
parameters. [190] Tappin et al included a PSA with distributions fitted to all parameters 
where there was information regarding the uncertainty associated with the parameter, 
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including the long-term costs of smoking-related diseases, intervention quit and immediate 
postpartum relapse rates, and HRQoL weights. [196] This broad PSA approach has also 
been adopted by ESIP, which illustrates the impact of uncertainty associated with the 
parameters and demonstrates how important it is to incorporate all of these, rather than 
the selective approach adopted by Mallender at al. Other previous literature primarily used 
one- or two-way sensitivity analyses, which may not comprehensively capture the effects 
of uncertainty in all parameters [109], potentially resulting in misleading information and 
an incorrect decision. A PSA helps to mitigate the likelihood of this error occurring, since it 
includes an assessment of the likelihood that any decision made as a consequence of ESIP 
output is correct. This information is potentially more useful to decision makers compared 
ƚŽƚŚĂƚŐĞŶĞƌĂƚĞĚĨƌŽŵƉƌĞǀŝŽƵƐŵŽĚĞůƐ ?ƐĞŶƐŝƚŝǀŝƚǇĂŶĂůǇƐĞƐ ? 
 
8.6.2 Limitations of the ESIP model 
 
One consideration is that in ƚŚĞW^ ?^/WƉŽƚĞŶƚŝĂůůǇďƌĞĂŬƐ ƚŚĞ  ‘ŝŶĨůƵĞŶĐĞ ůŝŶŬ ?ďĞƚǁ ĞŶ
the mother and the child after pregnancy (the MLC and ICC). In the deterministic analysis, 
^/WƐŚĂƌĞƐƚŚĞD>ƉĂƌĂŵĞƚĞƌƐǁŝƚŚƚŚĞ/ ?ĂůůŽǁŝŶŐƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌƚŽ
directly influence the health of her offspring. In the PSA, the parameters are no longer 
ƐŚĂƌĞĚďĞĐĂƵƐĞƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝour parameters in the ICC require a different 
distribution to the corresponding parameters in the MLC. This occurs because the MLC has 
a Dirichlet distribution with three categories, whereas the ICC has four categories, due to 
the addition of the risk of iŶĨĂŶƚ ?Ɛ ŵŽƌƚĂůŝƚǇ ? hŶůŝŬĞ ƚŚĞ ĚĞƚĞƌŵŝŶŝƐƚŝĐ / ? ŝƚ ŝƐ ůŝŬĞ Ǉ ƚŚĂƚ
during the PSA, the sampled parameter in the ICC is different to the corresponding 
parameter sampled in the MLC. The implication of this is that during the PSA, the link 
between the ICC and MLC is broken to some extent. The effect this has on the relationship 
between the two components is unclear and therefore the associated impact on the cost-
effectiveness estimates and output of ESIP is also undetermined. 
 
To try and mitigate the impact of this problem, the way the Dirichlet distribution is 
calculated in the ICC is such that in principle, the probabilities relating to the maternal 
smoking behaviour from the MLC are conservatively estimated. This would imply that the 
ICC will always slightly underestimate the changes in smoking behaviour compared to the 
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MLC. This effect is likely to be minimal and therefore the author does not anticipate any 
significant impact on the estimates of health and healthcare costs associated in the ICC. 
However, the user should be aware of this and consider whether this has a substantial 
impact on the output from ESIP. 
 
Another limitation is that any self-reported values were not adjusted in the PSA. This is 
particular relevant to the one year and two year postpartum estimates from Chapter 4 of 
this thesis. Because these values were self-reported, it is possible that the values used in 
the PSA are too high, since it is possible that individuals reported abstinence when they 
were in fact smoking. However, as discussed in Chapter 4, there was no evidence of 
significant self-reporting bias between the biochemically validated abstinence and the self-
reported abstinence, which suggests that using the self-reported data is not an issue. 
Furthermore, had solely biochemically validated data been used,  there would not have 
been any data at one year and two year postpartum, since this data is self-reported only. 
Additionally, rather than put the distribution on the probability, the author put the 
distribution on the estimates of the proportion abstinent as generated by the meta-
analysis, and allowed the model to recalculate the values based upon these estimates. This 
allows the probability to vary essentially between zero and one, reflecting the large 
uncertainty there is in the meta-analysis estimates, as well as controlling for any impact of 
self-reported data. This may introduce a greater amount of parameter, and hence decision, 
uncertainty into ESIP when compared to placing the distribution individually on the 
probability itself, but the author can only speculate as to how much this may be an issue, 
and warrant further investigation. 
 
8.6.3 The impact of the assumptions on the output of the model 
 
As discussed at the start of this chapter, ESIP makes five assumptions regarding the cohort 
of women and infants being modelled. Two of these assumptions are necessary for ESIP to 
function, such as that all infants are or were associated with a smoking mother, and that all 
women were current smokers at conception. It may be possible to relax the last 
assumption around the women smoking; however it would not seem logical that a 
cessation intervention would be given to those women who have already stopped smoking 
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at conception. These women are likely to be exposed to a relapse intervention, which is a 
different research question which would require a separate evaluation.  
 
The other assumption relating to the mother is that there is no lasting impact of included 
pregnancy complications on maternal health, based upon the information generated in 
Chapter 2. With its current structure, ESIP could not incorporate the lasting impact of a 
complication, however, should future research identify that lasting impacts exist, then one 
modification to ESIP could be to increase the number of maternal cohort chains such that 
any later impact could be incorporated. 
 
The assumption that all infant conceptions are singleton has been discussed in more detail 
in Chapter 7. This could be changed to either assuming that all conceptions are multiple 
(i.e. doubling or tripling the infant cohort size in relation to the mother cohort), or by 
increasing the infant cohort size by an appropriate figure representing the number of births 
in relation to the number of mothers (e.g. In 2012, it was estimated that the number of 
births (both liveborn and stillborn) in England and Wales was 733,232, while the number of 
maternities (number of women giving birth) was 721,574 [354], which suggests that the 
infant cohort should be 1.02 times greater than the cohort of mothers). It is unlikely that 
incorporating multiple pregnancies would make much difference to the outcomes from 
ESIP. Furthermore, it could be argued that, should interventions prove cost-effective for 
singleton births, then it is very likely that they are more so for multiple births. Therefore, 
the most conservative estimates for cost-effectiveness come from looking at singleton 
births and investigation into the cost-effectiveness of multiple births is not required. 
 
The final assumption is that gender does not have any impact on the chance of an adverse 
birth outcome for the infant. This means that gender is not important in the IWPC, and that 
both males and females have the same chance of being born prematurely, with LBW, and 
stillborn. However, there is some evidence which suggests that these birth outcomes are 
contingent on gender, with males more likely to deliver prematurely or stillborn [355, 356], 
while females appear to be at a greater risk of LBW. [357] This suggests that gender is an 
important consideration in the IWPC, and therefore the IWPC should split the cohort of 
infants into males and females.  However, it is unlikely that the inclusion of gender will 
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affect the overall estimates of adverse birth outcomes for the cohort, and unless there is a 
difference in healthcare costs for males and females, gender is unlikely to change the 
overall estimates of the cost-effectiveness at the end of pregnancy. However, the impact of 
gender might be important to incorporate into the ICC, since LBW is an important 
morbidity included in the model. Not including the impact of gender on birth outcomes for 
the infant would suggest that the ICC might be using inaccurate estimates of males and 
females, which could impact on the cost-effectiveness estimates generated by ESIP, 
although it is unclear what impact this may be. 
 
 Summary 8.7
 
This chapter has described how ESIP combines the four components to produce a 
comprehensive and novel economic model of the impacts of smoking during pregnancy. 
One advantage of ESIP compared to the previous literature is that it now includes a direct 
ůŝŶŬ ďĞƚǁĞĞŶ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ďŽƚŚ ǁŝƚŚŝŶ-pregnancy and afterwards on 
the health of the infant. ESIP also incorporates a PSA, implying greater relevance to the 
modern decision making process. However, when undertaking the PSA, ESIP breaks that 
link as it needs to resample the parameters in the ICC and MLC. How much this is an issue 
to the analysis is unclear.  Despite this consideration, ESIP gives the user and policy makers 
a far more comprehensive picture of the impacts on health and healthcare costs associated 
with smoking during pregnancy compared to the previous literature. In conclusion, the 
author suggests that ESIP is an improvement and is likely to produce more accurate cost-
effectiveness estimates than any previous economic model. The following two chapters 
demonstrate the validity of the within-pregnancy components and the overall ESIP model, 
as well as demonstrating how ESIP can be used to perform an evaluation of within-
pregnancy cessation interventions. 
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 Chapter 9: Validity of the MWPC and IWPC 
 
 Introduction 9.1
 
The within-pregnancy components (MWPC and IWPC) of ESIP are based upon readily 
available population data. Therefore, it is possible to investigate whether ESIP can 
reproduce the population estimates of the within-pregnancy complications and birth 
outcomes. If ESIP can reproduce reasonably accurate measures of the number of 
complications/ birth outcomes, it would seem appropriate to assume that ESIP is producing 
accurate estimates of the costs and benefits of smoking and cessation during pregnancy. 
This section describes a validation exercise to determine whether this is the case. We 
compared the output of a PSA of the MWPC and IWPC with bootstrapped population 
estimates to see how close the output from the MWPC and IWPC were to population 
estimates. The user should note that the parameterisation of the PSA in ESIP is given in 
section 8.5 of this thesis. 
 
 Objective 9.2
 
To determine whether the MWPC and IWPC produce reasonable estimates of the number 
of occurrences of within-pregnancy complications for the mother and birth outcomes for 
the infant under a PSA. 
 
 Methods 9.3
9.3.1 Method of estimating the population mean distribution of maternal complications 
 
To determine the distribution associated with the population mean estimates of the 
included conditions, non-parametric bootstrapping with replacement was utilised. [40] As 
discussed in section 1.6.10 of this thesis, to control for uncertainty and allow reasonably 
accurate 95% CI estimation, we performed 10,000 non-parametric bootstrap iterations of 
the HES data reported in Table 5.1 and Table 5.2. This was conducted using Stata v11.2. 
[239] Bootstrapped estimates were generated for the number of: 
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x Conceptions 
x Ectopic pregnancies 
x Miscarriages 
x Placental abruption occurrences 
x Placenta previa occurrences 
x Pre-eclampsia occurrences 
The bootstrapped mean number of conceptions for the population was used as the cohort 
size for ESIP. The quit rate was set to 88% as estimated from the latest IFS. [135] ESIP then 
performed a PSA (see Chapter 8), and the results of the two analyses were compared. 
Kernel density plots were created for each complication for both population bootstrapped 
estimates and model predictions. 
 
9.3.2 Method of estimating the population mean distribution of maternal deaths 
 
The above approach was adopted for estimating the number of maternal deaths. ONS data 
as reported in Table 5.8 was bootstrapped 10,000 times, as recommended as per section 
1.6.10, giving an estimated mean number of maternities and maternal deaths. ESIP was 
then programmed with the cohort size set at the mean bootstrapped number of 
maternities, and a quit rate of 88%. 
 
9.3.3 Method of estimating the population mean distribution of infant birth outcomes 
 
Data for LBW and stillbirth was taken from ONS records. [283] For premature birth, the 
data used in Table 5.10 was utilised. In the ONS dataset for Gestation Specific Infant 
Mortality, the years 2007 and 2008 were merged. [286] Because no other data was 
available, the values for premature births were split equally between the two years. The 
data used for the non-parametric bootstrapping is given in Table 9.1. 
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Table 9.1: Estimates of infant birth outcomes as used to inform the non-parametric bootstrapping 
Year Live births Stillbirths LBW (Live births 
+ stillbirths) 
Premature 
births (live 
births + 
stillbirths) 
2003 621,469* 3,585* 49,987* No data 
2004 639,721* 3,689* 50,697* No data 
2005 645,835* 3,483* 50,657* No data 
2006 669,601* 3,602* 52,544*  ? ? ? ? ? ? ? 
2007 690,013* 3,598* 51,648*  ? ? ? ? ? ? ? ? ? 
2008  ? ? ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ? ?  ? ? ? ? ? ? ? ? ? 
2009  ? ? ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ? ?  ? ? ? ? ? ? ? 
2010  ? ? ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ? ? 52,223 ? 
2011  ? ? ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ? ?  ? ? ? ? ? ? ? 
2012  ? ? ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ? ? No data 
*= Source: Table 8, Child Mortality Statistics for England and Wales 2003-2007 [293, 294, 
358-360] 
 ?A?^ŽƵƌĐĞ PdĂďůĞ ? ?ŚŝůĚDŽƌƚĂůŝƚǇ^ƚĂƚŝƐƚŝĐƐĨŽƌŶŐůĂŶĚĂnd Wales 2008-2012 [289-292, 
361] 
 ?A?^ŽƵƌĐĞ PTable 5.10, Chapter 5. 
 
Mean and CIs for the number of live births and birth outcomes were generated using non-
parametric bootstrapping with 10,000 iterations, as recommended in section 1.6.10. The 
cohort size was determined by the number of live births plus stillbirths. For this exercise, 
ESIP was programmed such that there were no pregnancies that did not end in delivery (i.e. 
no ectopic pregnancy and miscarriage). The quit rate in ESIP was set to 88%, and ESIP 
performed a PSA with 10,000 iterations, to allow accurate 95% CI estimation, as 
recommended in section 1.6.10. The results of the two analyses were then compared.  
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 Results 9.4
 
9.4.1 Maternal complications 
 
Table 9.2 reports the results of the two analyses. The final column shows the differences 
between the two means (bootstrapped population mean  W predicted ESIP mean). The 
ĐŽŚŽƌƚ ƐŝǌĞ ĨŽƌ ƚŚĞ W^ ǁĂƐ  ? ? ? ? ? ? ? ĐŽŶĐĞƉƚŝŽŶƐ ? &Žƌ Ăůů ĐŽŵƉůŝĐĂƚŝŽŶƐ ? ^/W ?Ɛ ŵĞĂŶ
estimated number of occurrences was below the bootstrapped population means, and the 
CIs did not cross. Figure 9.1 demonstrates the Kernel density plots for the bootstrapped 
population means and model estimates. Visual inspection suggested that ESIP produced a 
similar shaped distribution for all maternal complications, with both distributions for the 
population mean and ESIP output crossing for all complications. Differences in the means 
appeared to be relatively small. There appeared to be a greater degree of uncertainty in 
the ESIP estimates for ectopic pregnancy as this was the only complication where the 
predicted ESIP CI was wider than the population estimate. 
 
Table 9.2: Results of the non-parametric bootstrapping for HES NHS Maternity statistics for England 
compared to the ESIP model predicted output 
 Bootstrapped population 
estimates 
Model PSA estimates Difference 
in means 
Complication Mean 95% Confidence 
interval 
Mean 95% Confidence 
interval 
Conceptions 709,736 709,634 709,838 N/A  
Ectopic 
pregnancies 
10,706 10,703 10,710 10,694 10,689 10,699 12 
Miscarriage 43,004 42,993 43,015 42,971 42,963 42,980 33 
Placental 
abruption 
2,443 2,442 2,444 2,438 2,437 2,439 5 
Placenta 
previa 
4,087 4,085 4,090 4,079 4,078 4,080 8 
Pre-eclampsia 12,365 12,360 12,370 12,321 12,316 12,325 44 
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Figure 9.1: Kernel density plots for bootstrapped population mean estimates of occurrences and ESIP model output for maternal complications during pregnancy 
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9.4.2 Maternal deaths 
 
Table 9.3 reports the results of the bootstrapped population means and ESIP PSA 
predictions for the number of maternities and the number of deaths amongst mothers 
during pregnancy. The cohort for ESIP was set to 678,981. ESIP appeared to be 
conservatively estimating the number deaths during pregnancy, with a difference of four 
individuals between the population and ESIP means. The 95% CIs did not cross. From visual 
inspection of the Kernel distributions in Figure 9.2, both distributions appear to cross, 
although the peak of the model estimates appears to the left of the population estimates. 
The 95% CI was smaller in the ESIP estimates. 
 
Table 9.3: Results of the non-parametric bootstrapping for ONS statistics of the number of maternities and 
deaths during pregnancy for England and Wales compared to the ESIP model predicted output 
 Bootstrapped population 
estimates 
ESIP model PSA Output  
Occurrence Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Differences 
in means 
Number of 
maternities 
678,981 678,754 679,207 N/A 
Maternal 
deaths 
45 45 45 41 41 41 4 
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Figure 9.2: Kernel density plots for bootstrapped population mean estimates of occurrences and ESIP model 
output for maternal deaths during pregnancy 
 
 
9.4.3 Infant birth outcomes 
 
Table 9.4 reports the bootstrapped population mean estimate for infant birth outcomes 
and the results of the PSA analysis from ESIP. The cohort size in ESIP was set at 689,280. 
ESIP seemed to be conservatively estimating the number of adverse birth outcomes, with 
the means being lower than the bootstrapped population mean. The differences in the 
means were larger than compared to the previous analyses of maternal deaths and 
maternal complications. Visual inspection of the Kernel density distributions in Figure 9.3 
suggested that the distributions overlapped for LBW and stillbirth, but for premature birth 
it was very clear that the model distribution was considerably to the left of the population 
mean distribution. The visual inspection also demonstrated that the distributions for all 
three birth outcomes were more spread out compared to the population estimates, with 
the 95% CIs being 4.24 times, 2.46 times, and 4.11 times larger than the population CIs for 
LBW, premature birth, and stillbirths respectively.  
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Table 9.4: Results of the non-parametric bootstrapping for ONS statistics of birth outcomes for infants in 
England and Wales compared to the ESIP model predicted output 
 Bootstrapped population 
estimates 
ESIP model PSA output  
Birth 
outcome 
Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Differences 
in mean 
Number of 
conceptions 
689,280 689,049 689,511 N/A 
LBW 52,046 52,039 52,052 49,483 49,453 49,513 2,563 
Premature 
births 
52,365 52,362 52,369 47,606 47,597 47,614 4,759 
Stillbirths 3,634 3,634 3,635 3,493 3,491 3,495 141 
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Figure 9.3: Kernel density plots for bootstrapped population mean estimates of occurrences and ESIP model output for infant birth 
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 Discussion 9.5
 
This chapter reports a validation exercise for the within-pregnancy components of ESIP. Using non-
parametric bootstrapping to determine a CI and distribution for the population mean number of 
ĐŽŵƉůŝĐĂƚŝŽŶƐ ?ďŝƌƚŚ ŽƵƚĐŽŵĞƐ ? ƚŚŝƐ ǁĂƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚĞ ŽƵƚƉƵƚ ĨƌŽŵ ^/W ?Ɛ W^ ƚŽ ĚĞƚĞƌŵŝŶĞ
whether the output from ESIWĂƉƉĞĂƌƐƚŽďĞĂĐůŽƐĞĂƉƉƌŽǆŝŵĂƚŝŽŶ ?dŽƚŚĞĂƵƚŚŽƌ ?ƐŬŶŽǁůĞĚŐĞ ?ƚŚŝƐ
has never been done before for an economic model. However, the bootstrapped population 
estimates are based upon relatively constrained data, especially premature birth, which may not 
represent the true population mean for these conditions.  
 
9.5.1 Maternal complications within-pregnancy 
 
The MWPC of ESIP seemed to produce very close estimates to the population for all the foetal loss 
and pregnancy-associated complications. Visual inspection of the comparative plots between the 
MWPC estimates and the population distribution suggested that the MWPC was producing 
reasonable estimates of occurrences which closely matched and overlapped with the population 
distribution. There were small differences in the means between ESIP and the population, the 
biggest difference being for pre-eclampsia (absolute difference of 44). However, the MWPC 
generated slightly conservative estimates for all within-pregnancy complications. For all conditions 
except ectopic pregnancy, the MWPC had a slightly smaller 95% CI compared to the bootstrapped 
population estimate, suggesting the MWPC had captured most, but not all, of the uncertainty within 
the population mean. For ectopic pregnancy, the 95% CI was wider in the MWPC output than the 
population estimate, suggesting that the parameters include a greater degree of uncertainty than in 
the population. One explanation is the uncertainty associated with the odds ratio for ectopic 
pregnancy. The impact of this greater uncertainty on the overall output for the ESIP model is 
unclear. Furthermore, the author cannot offer any explanation for the conservative estimates for the 
number of complications.  
 
9.5.2 Death during pregnancy 
 
The MWPC also seemed to produce conservative estimates for the number of maternal deaths 
during pregnancy. There was slightly less uncertainty in the MWPC estimates compared to the 
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population estimates, suggesting that the MWPC was capturing most but not all of the uncertainty 
around the number of deaths during pregnancy. From the visual inspection of the Kernel density 
plots, the distributions did overlap, though the MWPC distribution was to the left of the population 
distribution. One possible explanation for this is that the MWPC slightly underestimates the number 
of women who suffer a complication during pregnancy, and since suffering from most within-
pregnancy complications is likely to increase the risk of death during pregnancy; this could be 
causing the MWPC to slightly underestimate the number of deaths during pregnancy.  
 
9.5.3 Birth outcomes for the infant at the end of pregnancy 
 
There appeared to be a greater difference between the IWPC predicted occurrences and the 
bootstrapped population estimates. For premature birth, LBW, and stillbirth, the IWPC appeared to 
generate consistently lower estimates of the number of occurrences. Differences in the means were 
a lot larger than the within-pregnancy maternal complications, with the ESIP output for LBW being 
2,563 less than the population estimate, 4,759 for premature birth output, and 141 for the stillbirth 
output.  However, for LBW and stillbirth the distributions did cross, while for premature birth, they 
did not. One explanation for the differences could be that the data used for determining whether a 
birth was premature or not comes from only one year of HES data [150], which could mean that 
either the year used was not representative of premature births (i.e. the number of premature 
births 2012-2013 was low in comparison to other years), or the prevalence of premature birth may 
be different in HES data compared to ONS estimates. Unfortunately, HES data reporting gestation 
length and complications is not available for any other year, and ONS data on prematurity is quite 
limited, therefore it is not possible to compare the 2012-2013 year with other years. Better 
estimates may be published in the future. 
 
The visual inspection of the Kernel density plots did demonstrate that the distributions for the IWPC 
appear to be a lot flatter and more spread out. This suggests that there would appear to be a great 
deal of uncertainty in the prediction of birth outcomes. While the author can offer no explanations 
as to the cause of the uncertainty around premature birth, it is possible that the conservative 
estimates for stillbirth and LBW are caused by inaccuracy in the estimates of premature births, since 
the IWPC assumes that birth weight and stillbirth are related to premature birth. Therefore, if the 
IWPC is underestimating the number of premature births, it would seem sensible that the IWPC 
would be producing low estimates of LBW and stillbirths. If improved data for premature birth could 
be identified, then the estimates of LBW and stillbirth might improve. The conservative estimates of 
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infant birth outcomes suggest that ESIP is underestimating the healthcare costs associated with 
these outcomes. Furthermore, since the ICERs reported by the IWPC are directly linked with these 
values, it would seem to suggest that ESIP is reporting ICER values that are potentially too high. This 
could mean that ESIP is not capturing accurately the value for money of cessation interventions, and 
this could be leading to incorrect policy decisions, however the author cannot determine to what 
extent this may be an issue. 
 
9.5.4 Implications of the validation exercise 
 
The conservative estimates of the number of complications and maternal deaths estimated by the 
MWPC would suggest that the associated costs would also be conservatively estimated, while the 
associated QALYs would be slightly overestimated (fewer women receive a the utility loss associated 
ǁŝƚŚĂĐŽŵƉůŝĐĂƚŝŽŶ ?ĚĞĂƚŚ ? ?ƐŝŐŶŝĨǇŝŶŐƚŚĂƚƚŚĞƌĞŵŝŐŚƚďĞĂƐůŝŐŚƚĚŝƐĐƌĞƉĂŶĐǇŝŶ^/W ?ƐŽƵƚƉƵƚ ?&Žƌ
maternal death, if ESIP is calculating that too many mothers survive to the end of pregnancy, this 
could be inflating the health related benefit at the end of pregnancy. This could impact on the 
lifetime modelling conducted based upon the MWPC results (e.g. the MWPC over estimates the 
number of women who are alive at the end of pregnancy which is used as the cohort size in the 
lifetime model), potentially producing exaggerated health benefits. This in turn could lead to ESIP 
producing ICERs which are very low, and that in reality the ICER for cessation interventions should be 
higher. Hence, this could in turn lead to incorrect policy decisions being made based upon the results 
of this model. However, the differences for both complications and maternal deaths are relatively 
small; therefore this may not be an important issue for ESIP or the policy maker.  
 
The IWPC also appears to be potentially underestimating the healthcare costs associated with birth 
outcomes. Because of this, it is likely that the estimates of value for money generated by ESIP are 
also conservatively estimated, suggesting that the ICERs calculated by the IWPC are too high. 
However, there is also an additional implication. For LBW and stillbirth, it is clear that there is a large 
amount of uncertainty, with the IWPC producing a distribution which has a much larger spread 
compared to the population distribution. It is unclear what impact this has on the overall healthcare 
costs associated with these conditions, as it could be both under- and overestimating these costs. 
However, it does suggest that ESIP is introducing a greater amount of parameter uncertainty into the 
evaluation than can be expected in the population, which would suggest that ESIP is adding to the 
degree of decision uncertainty regarding whether cessation interventions are cost-effective. This 
could be an issue to policy makers, however the author is unable to determine as to which direction 
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in terms of cost-effectiveness this greater parameter uncertainty impacts. If ESIP is overestimating 
the number of iterations that are cost-effective, then the policy maker will be fed an inflated 
estimate as to the probability of the intervention being cost-effective. However, if ESIP 
underestimates the number of iterations that are cost-effective, then the policy maker will be given 
an undervalued probability that the intervention is cost-effective.  
 
These results would imply that the output from the IWPC should be treated with some caution, since 
these discrepancies between the IWPC and the population data appear to exist; however, without 
better data available with which to better parameterise the IWPC, this problem is unlikely to be 
solved. 
 
 Summary 9.6
 
This chapter demonstrates a validation exercise of comparing the output of the within-pregnancy 
components as generated by running a PSA when the ESIP is attempting to replicate the population 
distribution as generated by non-parametric bootstrapping. The results suggest that the MWPC is 
slightly conservative in its estimates of within-pregnancy complications and maternal deaths, 
however the differences in the means are very small, and the PSA output seems to match the 
population distributions closely, suggesting that we could consider the MWPC as valid and  
accurately capturing the cost-effectiveness of within-pregnancy cessation. Conversely, our results 
suggest that the IWPC seems to be poor at predicting birth outcomes when the PSA is compared to 
the population distribution, with large differences in the means, and the ESIP distributions being 
much wider than the bootstrapped population distribution. This would suggest that the IWPC 
estimates could be incorrect, and hence the estimates of the cost-effectiveness should be treated 
with caution. The next chapter demonstrates the validity of the overall ESIP model, and how it can 
be used to produce an evaluation of a within-pregnancy cessation intervention. 
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 Chapter 10: Using ESIP to evaluate the SNAP intervention 
 Introduction  10.1
 
The previous chapters of this thesis have described the construction and parameterisation of the 
ESIP model; however, before ESIP can be utilised by the research community, it must be determined 
that it produces valid estimates of the cost-effectiveness of cessation interventions during 
pregnancy. To demonstrate this validity, ESIP has to be programmed and then allowed to perform an 
analysis on an intervention, for which there is already some evidence of cost-effectiveness. A 
recently published evaluation of a cessation intervention is the SNAP trial [123], which investigated 
the effectiveness and cost-effectiveness of NRT compared to placebo patch when given to pregnant 
women. This chapter reports the results use of SNAP data as a validation exercise for the ESIP model. 
 
 The SNAP Trial 10.2
 
10.2.1.1 Brief background to the SNAP trial 
 
A detailed report of the SNAP trial was published by Cooper et al. [123] In brief; the SNAP trial was a 
Health Technology Assessment Programme-funded study investigating the efficacy and safety of NRT 
within pregnancy. It was conducted in seven antenatal hospitals in the Midlands and North-West of 
England, recruiting between May 2007 and February 2010. The objectives of the trial were: 
x To compare the effectiveness and cost-effectiveness of NRT and placebo patches for 
achieving biochemically validated smoking cessation at delivery 
x To compare the effects of maternal NRT and placebo patch use during pregnancy on the 
behaviour, development, and disability among infants at two years of age.  
The trial design was a randomised, placebo-controlled, double-blinded, parallel group Phase IV trial 
with follow up at four weeks after randomisation; delivery and at six months; one year; and two 
years post-delivery. Randomisation was stratified by centre using a computer-generated sequence. 
The inclusion criteria for the trial were women between 12 and 24 weeks gestation who reported 
smoking at least five cigarettes daily, with an exhaled carbon monoxide reading greater than or 
equal to eight parts per million. The primary outcome measures were biochemically validated point 
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prevalence and prolonged abstinence at four weeks post-randomisation and delivery, and self-
reported point prevalence and prolonged abstinence at six months, one year and two years 
postpartum.  Secondary outcome measures included the absence of impairment amongst infants 
aged two years, the cost per quitter, and EQ-5D at six months. Statistical analyses were performed 
using an intention to treat analysis, with all recruited women who were lost to follow-up or excluded 
due to miscarriage/abortion treated as smokers.  
 
10.2.1.2 Interventions included in the SNAP trial 
 
The only difference between the control and experimental groups was that the experimental group 
received a four week supply of 15mg/16 hour NRT transdermal patches, whereas the control group 
received visually identical placebo patches which did not contain NRT. Both the control and 
experimental group received the following: 
x At enrolment; counselling covering cognitive and behavioural changes was delivered by 
research midwife for up to one hour, with the self-ŚĞůƉŵĂŶƵĂů  “dŚĞ^EWƚƌŝĂů ?ƐŐƵŝĚĞƚŽ
ƐƚŽƉƉŝŶŐƐŵŽŬŝŶŐĚƵƌŝŶŐƉƌĞŐŶĂŶĐǇ ? ?ll participants were asked to set a quit date within 
two weeks, and to start using the supplied patches on their quit date. 
x dĞůĞƉŚŽŶĞďĞŚĂǀŝŽƵƌĂůƐƵƉƉŽƌƚǁĂƐĚĞůŝǀĞƌĞĚďǇƌĞƐĞĂƌĐŚŵŝĚǁŝǀĞƐŽŶƚŚĞƉĂƌƚŝĐŝƉĂŶƚƐ ?ƋƵŝƚ
date, and at three days and one month afterwards.  
x Four weeks after the quit date, those biochemically validated as abstinent were offered a 
ĨƵƌƚŚĞƌĨŽƵƌǁĞĞŬƐ ?ƐƵƉƉůǇŽĨƉĂƚĐŚĞƐ ?ZĞƐĞĂƌĐŚŵŝĚǁŝǀĞƐĂůƐŽŽĨĨĞƌĞĚĂĨƵƌƚŚĞƌĨĂĐĞ-to-face 
counselling session at this follow up point, which focused on reinforcement of earlier 
sessions and ways to avoid relapse.  
x In addition, women could request further cessation support from both research midwives 
and local NHS Stop Smoking Services; however, this support was guided by the manual 
mentioned above.  
 
10.2.1.3 Brief summary of the SNAP trial results 
 
The trial recruited 1050 women, with 521 in the experimental group and 529 in the control group. 
The 1050 pregnancies resulted in 1034 live births (24 of which were twins), five miscarriages, seven 
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stillbirths, one elective termination, one missed abortion, and 14 where birth outcomes were 
unknown. There was no significant difference in rates of adverse events between the two groups. 
The validated cessation rate at delivery was 9.4% for the experimental group and 7.6% in the 
placebo group; therefore NRT was calculated to have an odds ratio for increased cessation of 1.26 
(95% CI 0.82 to 1.96), suggesting it was not statistically significant at aiding cessation at delivery. 
However, there was a significant increase in abstinence at four weeks post quit date, with 
abstinence rates of 21.3% versus 11.7% in the experimental and control groups respectively (odds 
ratio 2.05, 95% CI 1.46 to 2.88).  There was no significant difference in abstinence at the three 
follow-ups up to two years postpartum. Furthermore, there was no significant difference in the 
ŝŶĨĂŶƚ ?ƐƌĞƉŽƌƚĞĚƌĞƐƉŝƌĂƚŽƌǇƉƌŽďůĞŵƐĂƚƚǁŽǇĞĂƌƐŽĨĂŐĞ ?ŽĚĚƐƌĂƚŝŽĨŽƌƐǇŵƉƚŽŵƐŝŶEZdǀĞƌƐƵƐ
placebo 1.30, 95% CI 0.97 to 1.74), but there was a significant difference in infanƚƐ ǁŝƚŚ  ‘ŶŽ
ŝŵƉĂŝƌŵĞŶƚ ? ?ŽĚĚƐƌĂƚŝŽĨŽƌƐǇŵƉƚŽŵƐŝŶEZdǀĞƌƐƵƐƉůĂĐĞďŽ ? ? ? ? ? ? ?A?/ ? ? ? ?ƚŽ ? ? ? ? ? ? 
 
The total mean costs of delivering the intervention and healthcare resource use costs were 
approximately £91 higher in the experimental group. When including all women, the ICER was 
£4,929 per additional quitter, with a bootstrapped 95% CI of -£114,128 to £126,747. When 
restricting to singleton births only, the ICER was £4,156 per additional quitter, with a bootstrapped 
95% CI of -£65,994 to £82,059. The authors concluded that the CIs demonstrated that there was a 
substantial degree of uncertainty associated with the SNAP intervention. Although EQ-5D data was 
collected for both groups, no cost-utility analysis using this data was performed due to the non-
significant difference of EQ-5D scores and adverse birth outcomes between the control and 
intervention groups.  
 
 Programming ESIP 10.3
10.3.1.1 Programming the cohort to be included in ESIP 
 
In order to perform an analysis of the SNAP intervention, ESIP requires some programming. Firstly, 
some basic details of the cohort of the women included within the trial are required. These can be 
found in Table 10.1.  
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Table 10.1: Basic details for the cohort of women as programmed into ESIP 
Parameter Value 
Cohort size 1050 
Year of giving birth 2008 
Age of mother when giving birth 26 
 
The cohort size was determined by the number of women included within the trial (n=1050). Year of 
giving birth was programmed at approximate mid-point of recruitment. The trial recruited for 34 
months (May 2007 to February 2010), which suggests the mid-point of recruitment was September-
October 2008. Therefore 2008 was used as the base year for the analysis. Furthermore, the mean 
age of the cohort of women within the trial was 26 years, and there was no significant difference in 
mean age between the experimental and control groups (26.4 versus 26.2 respectively). 
 
10.3.1.2 Programming the SNAP intervention 
 
The delivery quit rates reported by the control and experimental groups were entered into the ESIP 
programming sheet. The Beta distribution was fitted using the method of moments (see section 
1.6.10. Details can be found in Table 10.2. 
 
Table 10.2 PŽŶƚƌŽůĂŶĚĞǆƉĞƌŝŵĞŶƚĂůŐƌŽƵƉƐ ?ĂďƐƚŝŶĞŶĐĞƌĂƚĞƐĂƚƚŚĞĞŶĚŽĨƉƌĞŐŶĂŶĐǇǁŝƚŚĂƐƐŽĐŝĂƚĞĚƉĂƌĂŵĞƚĞƌƐĨŽƌ
the fitting of the Beta distribution 
Trial group Proportion 
abstinent at end 
of pregnancy 
Beta distribution parameters 
Į ǃ 
Control .076 7.6 92.4 
Experimental .094 9.4 90.6 
 
The SNAP trial report also estimates the costs associated with delivering both the control and 
experimental intervention. These were estimated with mean (standard error) as £47.75 (19.03) and 
£98.31 (35.21) in 2009-2010 prices. However, ESIP uses cost data at 2011-2012 prices; therefore the 
mean cost of both interventions was inflated using the Hospital and Community Health Services 
(HCHS) Pay & Price Index [89], using the inflation index 1.0518. The standard error was not inflated 
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as this is a measure of the spread of the costs and therefore inflating the standard error would skew 
the associated uncertainty. The Gamma distribution was fitted to the control and experimental 
costs, and the details can be found in Table 10.3. 
 
Table 10.3: Cost of control and experimental interventions in 2011-2012 prices, with associated parameters for the 
fitting of the Gamma distribution 
Trial group Mean cost (£) Standard 
error (£) 
Gamma distribution 
parameters 
Į ǃ 
Control 50.22 19.03 6.9643 7.2111 
Experimental 103.40 35.21 8.6240 11.9898 
 
10.3.1.3 Perspective of analysis 
 
As has been outlined in earlier chapters describing ESIP and required by NICE guidance, an NHS and 
PSSRU perspective was adopted. [36] All costs were reported at 2011-2012 prices. All costs and 
QALYs were discounted at a base rate of 3.5%, as recommended by NICE guidance. [36] All other 
parameters within ESIP remained as described in earlier chapters of this thesis. ESIP was not 
programmed to use specific trial postpartum relapse rates, so used the general postpartum relapse 
estimates as reported in Chapter 4. To allow the combination of the results for the maternal and 
infant components, the cost of the control/experimental interventions were not included in the 
infant within-pregnancy and childhood components. Hence, the infant models were used to 
generate expected costs and gains which could then be combined with the results from the 
components representing the mother.  
 
Initially, a deterministic analysis was performed. One-way sensitivity analyses were performed under 
the following scenarios: 
x Varying the quit rate of the control group between 3.8% and 15.2% 
x Varying the quit rate of the experimental group between 4.7% and 18.8% 
x Varying the cost of the control group intervention between £25.11 and £100.44 
x Varying the cost of the experimental group intervention between £51.70 and £206.80 
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To determine the complete impact of uncertainty, all parameters with which uncertainty was 
associated were varied by performing a probabilistic sensitivity analysis (PSA) with 10,000 iterations.  
 
Both results from the deterministic and probabilistic analyses are presented from a within-
pregnancy time horizon for the mother, and the combination of both mother and infant. 
Additionally, a time horizon of age 100 years is presented for the mother and age 15 years for the 
infant, as well as the combination of both sets of post-delivery modelling estimates for mother and 
infant.  
 
 Results 10.4
10.4.1 Deterministic  
 
Table 10.4, Table 10.5, and Table 10.6 report the results for the deterministic analysis both within 
pregnancy and post-delivery for the mother, infant, and combined mother and infant.  
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Table 10.4: Results of the deterministic analysis for the mother 
MATERNAL: END OF PREGNANCY 
  Control Experimental Incremental 
Number of quitters 80 99 19 
Quit rate (%) 7.60 9.40 1.80 
Expected Cost per mother (£) 2,670.53 2,724.68 54.14 
Expected QALYS per mother 0.6336 0.6343 0.0007 
Incremental cost per QALY (£) 77,209.47 
Incremental cost per quitter (£) 3,008.00 
MATERNAL: LIFETIME 
  Control Experimental Incremental 
Percentage of cohort still alive 19.33 19.35 0.02 
Percentage of cohort with morbidity 49.84 49.82 -0.03 
Expected cost per mother (£) £9,743.70 £9,789.26 45.56 
Expected life Years 59.7254 59.7372 0.0117 
Expected QALYS 21.4208 21.4269 0.0061 
Incremental cost per life year gained (£) 3,882.06 
Incremental cost per QALY (£) 7,462.57 
Incremental cost per quitter (£) 2,531.14 
 
Table 10.5: Results of the deterministic analysis for the infant 
INFANT: END OF PREGNANCY 
  Control Experimental Incremental 
Number of infants alive 939 939 1 
Number of infants lost (ectopic, miscarried, 
stillborn) 
111 111 -1 
Number of premature births 77 77 0 
Number of infants with low birth weight 118 117 -1 
Number of all adverse live births 113 113 0 
Number of all adverse pregnancy outcomes 224 223 -1 
Expected cost per infant (£) 2,031.67   2,030.31  -1.37 
INFANT: AGE 15 
  Control Experimental Incremental 
Percentage of cohort alive 88.84 88.89 0.06 
Percentage of cohort with asthma 29.28 29.18 -0.11 
Expected cost per infant (£) £2,527.76 £2,525.06 -2.70 
Expected life years per infant 13.3332 13.3418 0.0086 
Expected QALYs per infant 10.1241 10.1311 0.0069 
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Table 10.6: Results of the deterministic analysis for combined mother and infant 
COMBINED  MOTHER AND INFANT: END OF PREGNANCY 
 Control Experimental Incremental 
Expected cost (£) 4,702.21 4,754.98 52.78 
Expected QALYs 0.6336 0.6343 0.0007 
Incremental cost per quitter (£) 2,932.10 
Incremental cost per QALY (£) 75,261.24 
COMBINED  MOTHER AND INFANT: POST-DELIEVERY 
  Control Experimental Incremental 
Expected cost (£) 12,271.47 12,314.33 42.86 
Expected life years 73.06 73.08 0.0204 
Expected QALYs 31.5449 31.5579 0.0130 
Incremental cost per quitter (£) 2,381.37 
Incremental cost per life year gained (£) 2,104.60 
Incremental cost per QALY (£) 3,286.75 
 
From the perspective of the mother, the SNAP intervention leads to a £54.14 increase in expected 
ĐŽƐƚ ƉĞƌ ŵŽƚŚĞƌ ǁŝƚŚŝŶ ƉƌĞŐŶĂŶĐǇ ? ǁŚŝĐŚ ĚĞĐƌĞĂƐĞƐ ƚŽ  ? ? ? ? ? ? ǁŚĞŶ ĐŽŶƐŝĚĞƌŝŶŐ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ
lifetime. QALYs also increase under the SNAP intervention by 0.0007 by the end of pregnancy and 
 ? ? ? ? ? ? ŽǀĞƌ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ůŝĨĞƚŝŵĞ ? ^/W ĂůƐŽsuggests that the SNAP intervention increases the 
number of women alive at age 100 by 0.02% and reduces the number of women with co-morbidities 
by 0.03%. Considering the number of quitters as our primary objective, as the deterministic model 
suggests that if the willingness to pay per quitter gained was £3,008.00, we could consider the SNAP 
intervention value for money by the end of pregnancy. However, if the primary outcome was QALY 
gained, then by the end of pregnancy the willingness to pay required for the SNAP intervention to be 
considered cost-effective is £77,209.47 per QALY gained. The implication of these results can be 
found in the discussion. 
 
For the infant, the SNAP intervention decreased the number of adverse pregnancy outcomes by one, 
due to a decrease in the number of infants being born with low birth weight. This suggested that by 
the end of pregnancy the SNAP intervention will have saved £1.37 per infant in healthcare costs 
compared to infants whose mothers only receive standard care. When considering the infants 
childhood up to the age of 15, the healthcare cost savings generated by the SNAP intervention are 
now £2.70 per infant. This is due to the 0.11% reduction in the number of children with asthma in 
the SNAP intervention group. Furthermore, more children are alive by age 15 in the SNAP 
intervention, and there is a 0.0069 gain in QALYs. No ICERs can be calculated for the infant results 
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because the cost of the intervention is not included within the infant model, and therefore the 
results are reproduced here for information. 
 
Once the results for the mother and her infant have been combined, the SNAP intervention 
increases expected costs by £52.78 per pregnancy at the end of pregnancy and £42.86 per 
ƉƌĞŐŶĂŶĐǇ ǁŚĞŶ ĐŽŶƐŝĚĞƌŝŶŐ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ůŝĨĞƚŝŵĞ ĂŶĚ ŝŶĨĂŶƚ ?Ɛ ĐŚŝůĚŚŽŽĚ ? ǆƉĞĐƚĞĚ Y>zƐ ĂůƐŽ
increased by 0.0007 per pregnancy within-pregnancy and by 0.0130 per pregnancy when including 
lifetime and childhood. ESIP estimated that the incremental cost per quitter was £2,932.10 within-
pregnancy and £2,381.37 when including lifetime and childhood, which suggests that if the 
willingness to pay for an additional quitter was £2,932.10, then the SNAP intervention could be 
considered value for money. However, the incremental cost per additional QALY is £75,261.24 when 
only considering pregnancy, and £3,286.75 when including the longer term. This would suggest that 
the willingness to pay for an additional QALY would have to be at least £75,261.24 before the SNAP 
intervention could be considered value for money. 
 
10.4.2 Sensitivity analyses 
 
The results of the sensitivity analysis for the incremental cost per quitter, combining costs associated 
with both the mother and infant can be found in Figure 10.1 and Figure 10.2, covering both within 
pregnancy and lifetime/childhood time horizons. 
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Figure 10.1: Tornado plot demonstrating the effect of sensitivity analyses on incremental cost per quitter combining 
costs associated with both the mother and her infant within pregnancy 
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Figure 10.2: Tornado plot demonstrating the effect of sensitivity analyses on incremental cost per quitter combing costs 
and outcomes associated for both the mother up to age 100 and her infant up to age 15 
 
 
The ICER per quitter seems to be highly sensitive to the cost of the SNAP intervention, as varying this 
in the sensitivity analysis appeared to have the greatest impact on the ICER, followed by the cost of 
usual care. This would suggest that the ICER is more sensitive to changes in cost than it is to changes 
in quit rates. However, it is worth noting that the SNAP intervention was considered dominated by 
usual care when the control quit rate was 15.2% and the experimental quit rate was 4.7%, both 
within-pregnancy and including longer term outcomes. Conversely, it was only considered dominant 
when considering impacts across the lifetime and childhood once the experimental intervention quit 
rate was 18.8%, when the experimental intervention cost was £51.70, and the control intervention 
cost £100.44. The SNAP intervention never gained dominance when considering costs and outcomes 
up to the end of pregnancy under the sensitivity analyses. The same behaviour in ICERs was 
observed when considering the impact of the sensitivity analyses on the ICER per additional QALY, 
but there was a greater degree in variability in the ICER reported by ESIP. These results can be found 
in Figure 10.3 and Figure 10.4. 
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Figure 10.3:Tornado plot demonstrating the effect of sensitivity analyses on incremental cost per additional QALY 
combining costs associated with both the mother and her infant within pregnancy 
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Figure 10.4: Tornado plot demonstrating the effect of sensitivity analyses on incremental cost per additional QALY 
combing costs and outcomes associated for both the mother up to age 100 and her infant up to age 15 
 
 
10.4.3 Results from the probabilistic sensitivity analysis 
 
To control for all parameter uncertainty within ESIP, a PSA was performed. Table 10.7 reports the 
results of this analysis for the mother both within-pregnancy and up to the age of 100 years, while 
Figure 10.5 and Figure 10.6 display the scatterplots for incremental costs versus incremental QALYs 
for up to the end of pregnancy and up to the age of 100 years.  
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Table 10.7: Results of the probabilistic sensitivity analysis for the mother both within-pregnancy and up to the age of 100 years 
Maternal : End of pregnancy 
 Control Experimental Incremental 
 Mean 95% confidence 
interval 
Mean 95% confidence interval Mean 95% confidence interval 
Number of quitters 80 35 141 99 47 163 19 -61 99 
Quit rate (%) 7.61 3.31 13.40 9.38 4.50 15.55 1.77 -5.83 9.43 
Expected cost per 
mother (£) 
2,674.28 1,685.27 3,948.78 2,728.85 1,743.73 4,002.67 54.57 -17.62 141.23 
Expected QALYs per 
mother 
.6334 .6158 .6482 .6341 .6165 .6489 .0007 -.0023 .0038 
ICER per QALY (£) 78,821.55 -499,122.85 653,852.19 
Probability cost-effective (WTP per QALY = £30,000) .2813   
ICER per quitter (£) 3,074.58 -19,334.68 25,232.53 
Maternal: Lifetime 
 Control Experimental Incremental 
 Mean 95% confidence 
interval 
Mean 95% confidence interval Mean 95% confidence interval 
Cohort alive (%) 19.34 15.79 23.08 19.36 15.79 23.10 .01 -.06 .11 
Cohort with morbidity 
(%) 
49.86 47.22 52.49 48.80 45.79 51.68 -1.07 -2.61 -.05 
Expected cost per 
mother (£) 
9,752.69 8,348.22 11,373.29 9,800.32 8,390.51 11,434.72 47.63 -34.01 139.58 
Expected life years 59.6992 58.9975 60.3852 59.7087 59.0029 60.3946 .0095 -.0392 .0709 
Expected QALYs 21.4124 20.5295 22.1350 21.4175 20.5322 22.1400 .0051 -.0197 .0356 
ICER per life year gained (£) 5,010.11 -99,503.73 113,788.51 
ICER per QALY (£) 9,333.42 -100,896.65 111,433.37 
Probability cost-effective (WTP per QALY = £30,000) .5933   
Incremental cost per quitter (£) 2,683.41 -19,650.37 24,794.48 
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Figure 10.5: Scatterplot for incremental costs and incremental QALYs for the mother within-pregnancy with 95% 
confidence ellipse for the ICER 
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Figure 10.6: Scatterplot of incremental costs versus incremental QALYs for the mother up to age 100, with 95% 
confidence ellipse for the ICER 
 
 
The results suggest that, assuming the primary outcome is the incremental cost per quitter, if we 
were willing to spend £3,074.58 to gain an additional quitter by the end of pregnancy, then the SNAP 
intervention could be assumed to be cost-effective. Extending this to the lifetime perspective 
reduces the ICER, demonstrating the impact of healthcare cost savings gained over the remaining life 
expectancy of the mother. However, the CIs cross zero, which suggests that there may be instances 
where the SNAP intervention is either dominated or dominant; unfortunately we cannot determine 
which from the ICER alone. 
 
Both within pregnancy and up to the age of 100 years old, there is a significant difference in 
expected cost per mother, with a mean increase in cost of £54.57 within-pregnancy and £47.63 by 
the age of 100 years. Although there was weak evidence of increased QALYs both at the end of 
pregnancy and up to age 100, this difference was non-significant. Within pregnancy, the ICER was 
£78,821.55 per QALY (95% CI -£499,122.85 to £653,852.19), with a 28% probability of being cost-
effective at a willingness to pay of £30,000 per incremental QALY. From the scatterplot in Figure 
10.5, it can be clearly seen that the majority of the iterations lie within the north east quadrant of 
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the cost-effectiveness plane, but the 95% confidence ellipse suggests that there are more iterations 
where the SNAP intervention is dominated by usual care rather than the SNAP intervention 
dominating usual care. When extending the time horizon to age 100 years, the ICER decreased to 
£9,33.42 (95% CI -£100,896.65 to £111,433.37) with a probability of being cost-effective at the same 
willingness to pay of 0.5933. From the scatterplot in Figure 10.6, the majority of the iterations still 
remain in the north east quadrant of the cost-effectiveness plane, but the 95% confidence ellipse for 
the ICER crosses all four quadrants, suggesting a large amount of uncertainty in the ICER. Compared 
to the ICER per quitter, there was a greater degree of uncertainty in the ICER per QALY.  
 
The cost-effectiveness acceptability curves can be found in Figure 10.7. The CEAC suggests that by 
the end of pregnancy, less than 10% of iterations save money. However, when extending it to the 
lifetime, this increased to approximately 15%. Nonetheless, the remaining the CEACs also suggest 
that by the end of pregnancy, even at a willingness to pay of £100,000, approximately 47% of 
iterations are not cost-effective, suggesting that around 47% of iterations do not offer any health 
benefit to the mother.  When considering the remaining life expectancy of the mother, this is 
reduced to approximately 35%, suggesting that 35% of iterations do not offer any health benefit in 
the long term. This is also clearly demonstrated in the scatter plots in Figure 10.5 and Figure 10.6. 
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Figure 10.7: Cost-effectiveness acceptability curves for the mother at the end of pregnancy and over her lifetime 
 
 
10.4.4 Probabilistic Sensitivity Analysis results for the infant 
 
Within pregnancy, there is evidence to suggest that the SNAP intervention reduced the number of 
pregnancies lost (e.g. ectopic, miscarried, still born) and the number of infants born with low birth 
weight; however, the model did not report any significant difference between the experimental and 
control groups. Conversely, the model did suggest there was a significant difference in both the 
number of live births with an adverse outcome and the number of all adverse pregnancy outcomes. 
The results of the PSA for the child can be found in Table 10.8. Although there was evidence that the 
SNAP intervention may have been cost-saving, there was no significant difference in healthcare costs 
between the experimental and control groups, both at the end of pregnancy and up to the age of 15 
years. There also appeared to be a non-significant difference for all within-pregnancy outcomes, and 
the number of infants alive, number of infants with asthma, expected life years per infant, and 
expected QALYs per infant by the age of 15 years, although there was weak evidence that the SNAP 
intervention improved the outcomes associated with these metrics.  
313 
 
Table 10.8: Results of the probabilistic sensitivity analysis for the infant for both within-pregnancy and up to the age of 15 years 
Infant: End of pregnancy 
 Control Experimental Incremental 
 Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Number of live births 939 930 947 939 931 948 1 -2 3 
Number of infants lost (ectopic, miscarried, 
stillborn) 111 98 125 111 98 124 -1 -3 2 
Number of premature births 77 68 88 77 68 87 0 -2 1 
Number of low birth weight 116 93 133 115 93 132 -1 -6 4 
Number of adverse live births 114 101 128 113 101 127 0 -3 2 
Number of all adverse pregnancy outcomes 225 209 242 224 209 241 -1 -6 4 
Expected cost per infant (£) 2,012.95 533.69 5,171.93 2,011.64 530.38 5,178.05 -1.31 -16.67 11.15 
Infant: Childhood (age 15 years) 
 Control Experimental Incremental 
 Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Cohort alive (%) 88.84 88.00 89.62 88.89 88.08 89.67 .06 -.19 .31 
Cohort with asthma (%) 22.53 17.32 28.31 22.47 17.40 28.10 -.06 -.55 .30 
Expected cost per infant(£) 2,517.99 739.73 6,016.97 2,515.25 740.02 6,028.29 -2.75 -27.32 15.44 
Expected life years per infant 13.3335 13.2086 13.4508 13.3421 13.2203 13.4584 .0085 -.0284 .0468 
Expected QALYs per infant 10.1271 9.4576 10.3169 10.1340 9.4691 10.3221 .0069 -.0230 .0382 
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10.4.5 Results of the PSA when combining both the mother and her infant 
 
Table 10.9 gives the results of the PSA when both mother and infant are combined, both up to the 
end of pregnancy and across lifetime/childhood, while Figures Figure 10.8 and Figure 10.9 give the 
scatter plots of incremental costs versus incremental QALYs.  
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Table 10.9: Results of the probabilistic analysis combining both the mother and infant for both within-pregnancy and lifetime/childhood 
Combined mother and infant: End of pregnancy 
 Control Experimental Incremental 
 Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Mean 95% confidence interval 
Expected cost per pregnancy (£) 4,687.23 2,744.03 8,016.65 4,740.50 2,796.12 8,072.77 53.27 -20.93 141.57 
Expected QALYs per pregnancy .6334 .6158 .6482 .6341 .6165 .6489 .0007 -.0023 .0038 
ICER per quitter (£) 3,001.14 -19,360.13 25,094.05 
ICER per QALY (£) 76,933.87 -503,395.10 652,204.67 
Probability cost-effective (WTP per QALY = £30,000) .2961   
Combined mother and infant: Lifetime and childhood 
 Control Experimental Incremental 
 Mean 95% confidence 
interval 
Mean 95% confidence 
interval 
Mean 95% confidence interval 
Expected cost per pregnancy (£) 12,270.68 9,836.44 16,005.78 12,315.26 9,866.23 16,038.76 44.88 -44.49 142.58 
Expected life years per 
pregnancy 73.0327 72.3121 73.7324 73.0508 72.3315 73.7465 .0180 -.0640 .1096 
Expected QALYs per pregnancy 31.5395 30.5222 32.3328 31.5515 30.5354 32.3426 .0120 -.0412 .0688 
ICER per quitter (£) 2,528.69 -19,835.35 24,554.82 
ICER per life year gained (£) 2,487.66 -22,262.49 26,323.59 
ICER per QALY (£) 3,746.22 -30,996.28 37,393.31 
Probability cost-effective (WTP per QALY = £30,000) .6525   
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Figure 10.8: Scatterplot of incremental costs versus incremental QALYs for combined mother and infant up to 
the end of pregnancy, with 95% confidence ellipse 
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Figure 10.9: Scatterplot of incremental costs versus incremental QALYs for combined mother and infant up to 
age 100 years for the mother and age 15 years for the infant, with 95% confidence ellipse for the ICER 
 
At the end of pregnancy, there was no significant difference in expected cost per pregnancy 
and expected QALYs per pregnancy between the control and experimental groups, 
although there was weak evidence of an increase in expected QALYs per pregnancy. When 
extended to include the lifetime for the mother and childhood for the infant, there was still 
no evidence of a significant difference in expected costs per pregnancy, expected life years 
per pregnancy, and expected QALYs per pregnancy. However, there was weak evidence of 
a decrease in expected costs per pregnancy and an increase in expected QALYs and life 
years per pregnancy, suggesting that the SNAP intervention was dominant, although the 
95% CIs crossed zero, suggesting that there may be instances where the SNAP intervention 
is not dominant. The probability of the SNAP intervention being cost-effective was 0.6525 
at a willingness to pay of £30,000 per incremental QALY. Within-pregnancy, the ICER per 
QALY was £76,933.87 (95% CI -£503,395.10 to £652,204.67); suggesting there was a great 
deal of uncertainty in the ICER at the end of pregnancy and that there may be instances 
where the SNAP intervention is dominant or dominated.  This can clearly be seen in Figure 
10.9 where the 95% confidence ellipse crosses all four quadrants along with the iterations 
from the PSA. The probability of the SNAP intervention being cost-effective at the end of 
pregnancy was 0.2961 at a willingness to pay of £30,000 per incremental QALY. Figure 10.8 
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suggests that the majority of the iterations are to the right hand side of the vertical axis, 
however the 95% confidence ellipse crosses all four quadrants suggesting there is a large 
amount of uncertainty in the ICER. 
 
The CEACs are represented in Figure 10.10 and suggest that at the end of pregnancy, just 
under 10% of iterations offered cost-savings, which increased to approximately 15% when 
extending to the lifetime and childhood time horizons. Furthermore, the CEACs suggest 
that approximately 50% of iterations by the end of pregnancy and approximately 32% of 
iterations when incorporating lifetime and childhood offered no health benefit to either 
the mother or infant, or both. This can also be seen in the scatter plots with several 
iterations being to the left of the vertical axis. 
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Figure 10.10: Cost-effectiveness acceptability curves for combined mother and infant up to end of pregnancy 
and age 100 years for the mother and age 15 years for the infant 
 
 
 Discussion 10.5
 
The ESIP model has been used to evaluate the SNAP intervention, performing both 
deterministic and probabilistic analyses. Our deterministic results suggest that for the 
mother, within pregnancy, the SNAP intervention may be seen as not value for money if 
there is only a willingness to pay £30,000 per incremental QALY. [36] However, when 
extending the time horizon to include the remaining lifetime of the mother, the SNAP 
intervention becomes cost-effective. The addition of healthcare costs and benefits 
associated with the infant decreases the ICERs in both time horizons, but does not change 
the overall decision. Our probabilistic results further support the deterministic analysis for 
the mother; however the probabilistic results suggest that, when including infant outcomes 
within pregnancy, the SNAP intervention becomes cost-effective, which is contrary to the 
deterministic results. However, the estimated 95% CIs for the ICER per QALYs were very 
wide at the within-pregnancy time horizon, and therefore demonstrate there is a great deal 
of uncertainty in these results. 
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10.5.1 Limitations of this analysis 
 
One difference between the SNAP trial and any analyses undertaken using ESIP is that the 
SNAP trial recruited women later in gestation, whereas the ESIP model considers the whole 
gestation period. This means that the SNAP trial may not include women who suffered an 
ectopic pregnancy or miscarried before they could be identified for recruitment; however 
they will be included within the ESIP model. Henceforth it could be argued that ESIP is 
modelling a slightly different pregnant population compared to the estimates generated by 
the SNAP trial. This can be seen in that the SNAP trial reported only 14 pregnancies which 
did not end in a live birth, due to miscarriage and still birth. However, ESIP suggests that 
there were 111 pregnancies lost. Furthermore, ESIP uses the risk of foetal loss (ectopic and 
miscarriage) from population estimates to calculate the number of mothers who 
experience these adverse events. These risks may be slightly different to the included 
women in the SNAP trial as they may include specific differences in characteristics 
compared to the population as a whole. Therefore, it is to be expected that there is going 
to be a difference in the number of foetal loss events between the SNAP and ESIP 
estimates. 
 
Furthermore, there appear to be differences in the number of reported adverse events in 
the trial and the number estimated by ESIP. This may cause ESIP to overestimate 
healthcare costs associated with within-pregnancy and potentially overinflate the possible 
healthcare cost savings generated by the SNAP intervention, which may lead to an ICER 
which suggests that the SNAP intervention offers more value for money than it does in 
reality. However, conducting a PSA aims to mitigate this issue by providing a summary 
measure of the level of confidence that the ICER generated by ESIP is the correct value.  
 
10.5.2 Strengths of this analysis 
 
The main strength of using ESIP for the SNAP intervention is that it has now been possible 
to fit QALY data to the increased quit rate generated by the intervention, giving some idea 
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of the benefits potentially gained both at the end of pregnancy and across the lifetime of 
the mother and childhood of the infant. This means that the SNAP intervention can now be 
compared with other healthcare interventions currently being utilised by the NHS, as the 
estimates for the ICER per QALY gives a generic summary measure, allowing comparability. 
Furthermore, whereas the SNAP trial was only able to follow up participants for up to two 
years after pregnancy, ESIP has extended the time horizon up to the age of 100 for the 
mother and age 15 years for the infant, giving long term estimates for the potential health 
benefits of the SNAP intervention. These estimates would be almost impossible to collect 
using trial data and hence using the ESIP model could be considered the next best 
approach. 
 
10.5.3 Comparison of SNAP trial and ESIP results 
 
The SNAP trial estimated that there was a £91 increase in expected costs in the 
experimental group compared to controls, with an ICER of £4,156 per additional quitter 
(95% CI -£65,994 to £82,059). These included both healthcare costs associated with the 
mother and those associated with the infant at the end of pregnancy.  For the deterministic 
analysis ESIP estimated that the incremental cost per quitter was £2,932.10, with an 
increase in expected costs for the experimental group of £52.79. If we assume that the 
SNAP estimates are the gold standard for estimates for costs and cost-effectiveness of NRT 
within-pregnancy, then this suggests that ESIP is underestimating the expected increase in 
costs between the two groups and hence this may explain why the ICER per quitter as 
determined by ESIP was smaller. However, the difference between the within-trial 
estimates and those generated in the deterministic analysis is small and therefore it could 
be considered that ESIP is producing valid within-pregnancy results. The probabilistic 
results were relatively similar, with a mean incremental cost of £53.27 per pregnancy. 
However, ESIP suggested that there was a relatively wide 95% CI, which stretched from -
£20.93 to £141.57, which the within-trial estimates also lie within. The ICER per quitter 
under the probabilistic analysis was slightly less, estimated to be £3,001.14, with a 
narrower 95% CI than that generated by the trial (95% CI -£19,360.13 to 25,094.05). Both 
the mean ICER per quitter and its associated CI generated by ESIP lie within the 95% CI as 
found by the within-trial analysis, and therefore it would seem sensible to assume that ESIP 
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is producing comparable results to that found in the SNAP trial and hence the estimated 
ICERs per QALYs and other outcomes generated by ESIP could be deemed valid. 
 
10.5.4 What policy makers can take from this analysis 
 
If the policy maker is only interested in within-pregnancy outcomes associated with the 
mother, both the deterministic and probabilistic results suggest that the SNAP intervention 
does not offer value for money, assuming that the maximum willingness to pay per 
incremental QALY is £30,000. [36] The results also suggest that the chance of the SNAP 
intervention being cost-effective is 0.2813 at that willingness to pay, which suggests that 
lack of confidence that the SNAP intervention is cost-effective within this time horizon. 
,ŽǁĞǀĞƌ ?ƚŚĞƉŽůŝĐǇŵĂŬĞƌŵĂǇǁŝƐŚƚŽŬŶŽǁƚŚĂƚĞǀĞŶŝĨƚŚĞǇǁĞƌĞŶ ?ƚǁŝůůŝŶŐƚŽƉĂǇĨŽƌ
any health benefits, there is an approximately 9% chance that the SNAP intervention will 
offer healthcare cost savings. However, the CIs associated with the ICERs per QALY are 
extremely large at the end of pregnancy, which suggests a great deal of uncertainty 
associated with these estimates. The decision maker would probably be sensible to request 
a value of information (VOI) analysis to determine where best to focus further resources to 
reduce this uncertainty; however, the deterministic one-way sensitivity analyses potentially 
suggest that some of this uncertainty is likely to be associated with the cost of the 
experimental and control group interventions rather than its effectiveness. 
 
Should the policy maker be interested in the lifetime perspective for the mother, both the 
deterministic and probabilistic results suggest that the SNAP intervention offers value for 
money, with mean estimated ICERs per QALY which are well within the assumed threshold 
of £30,000 per incremental QALY. Furthermore, the PSA suggests that there is greater 
confidence that the SNAP intervention offers value for money at that willingness to pay, 
with an estimated probability of being cost-effective of 0.5933. However, there is still a 
large degree of uncertainty associated with the ICER per QALY, and therefore it would seem 
pertinent to perform a VOI analysis. However, it would seem most likely, based on the 
results of the one-way sensitivity analyses, that the VOI is likely to suggest that further 
information is required around the costs associated with the experimental and control 
interventions. Furthermore, the policy maker may wish to be aware that if they are not 
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willing to pay for any health benefit, there is now an approximately 15% chance that the 
SNAP intervention offers healthcare cost savings. However, there is also an approximately 
35% chance that the intervention offers no health benefits for the mother across her 
lifetime. 
 
If the policy maker is interested in including outcomes associated with the infant, there is 
weak evidence to suggest that, both at the end of pregnancy and age up to 15 years, the 
SNAP intervention offers healthcare cost savings, as well as reducing some adverse birth 
outcomes and childhood morbidity. Both the deterministic and probabilistic results suggest 
that, considering just within- pregnancy, the SNAP intervention is not cost-effective, with a 
30% chance of being cost-effective at the assumed willingness to pay of £30,000 per QALY. 
When extending the time horizon to include the childhood of the infant, the SNAP 
intervention now becomes dominant, with a 65% chance of being cost-effective. 
Additionally, even if the policy maker was not willing to pay for any health benefit there is 
an approximately 10% chance that the SNAP interventions offers healthcare cost savings by 
the end of pregnancy, increasing to approximately 15% when considering the lifetime and 
childhood time horizons. However, there is still a 30% chance that the SNAP intervention 
ǁŽŶ ?ƚŽĨĨĞƌĂŶǇŚĞĂůƚŚďĞŶĞĨŝƚƐĨŽƌĞŝƚŚĞƌƚŚĞŵŽƚŚĞƌŽƌƚŚĞŝŶĨĂŶƚ ?ŽƌďŽƚŚ ?dŚĞƌĞŝƐƐƚŝůůĂ
high degree of uncertainty associated with our ICER estimates, which may require 
additional exploration. 
 
 Summary 10.6
 
This chapter demonstrates how ESIP can be used to evaluate a cessation intervention 
which was conducted as part of a clinical trial. In this scenario, ESIP suggests that from a 
within-pregnancy time horizon, the SNAP intervention is not cost-effective; however this 
decision is reversed when the longer time horizon, including lifetime and childhood for the 
mother and infant respectively, is included. ESIP also suggests that there is a small chance 
that the SNAP intervention will offer healthcare cost savings, but there is an even greater 
chance that it will offer no additional health benefit to the mother, her infant, or both. This 
chapter also provides some reassurance that ESIP produces results which, compared to the 
within-trial analysis conducted as part of the SNAP trial have some validity; it would appear 
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that ESIP produces similar estimates for the cost-effectiveness of the SNAP intervention 
and that in both cases the CIs between the within-trial and ESIP estimates overlap, which 
suggests there was no significant difference between the within-trial and model estimates. 
We can therefore conclude that ESIP is likely to be a valid model for estimating the cost-
effectiveness of cessation interventions in pregnancy. 
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 Chapter 11: Conclusions of this thesis 
 
 Introduction 11.1
 
This chapter summarises the work conducted throughout this thesis. In it, the author will 
highlight the limitations of the thesis work, its strengths and also its impact on the current 
literature. Finally, the author will discuss the possible impacts of ESIP in terms of policy, and 
suggests what future avenues of research may be appropriate.  
 
 The thesis in context of its aims and objectives 11.2
 
This thesis set out to develop a new economic model that would capture the impacts of 
smoking during pregnancy on the costs and health related quality of life of both the mother 
and her infant. The outcome is a complex economic model, which investigates the impacts 
of smoking on within-pregnancy complications and post-pregnancy smoking behaviour on 
the health of the mother and the infant. The steps that the author has taken to complete 
the main objective are as follows: 
1 A comprehensive scoping review, which identified the most relevant 
diseases associated with smoking during pregnancy. 
2 A systematic review of the previous economic literature highlighting 
the important deficiencies of those models, allowing the authors to 
focus on which aspects needed the most improvement 
3 A systematic review of abstinence in the postpartum period in order to 
better capture maternal smoking behaviour after pregnancy 
4 &ŽƵƌƐƚĂŶĚĂůŽŶĞŵŽĚĞůƐ ?ƌĞĨĞƌƌĞĚƚŽĂƐ ‘ĐŽŵƉŽŶĞŶƚƐ ? ?ǁŚŝĐŚŵŽĚĞůƚŚĞ
short- and long-term aspects of smoking during pregnancy associated 
with both the mother and the infant 
 
To the ĂƵƚŚŽƌ ?Ɛ ŬŶŽǁůĞĚŐĞ ? ŶŽ ƐƵĐŚ ĐŽŵƉƌĞŚĞŶƐŝǀĞ ĂŶĚ ƐǇƐƚĞŵĂƚŝĐ ĂƉƉƌŽĂĐŚ ŚĂƐ ďĞĞŶ
applied in this topic area before. This has led to a systematically developed new economic 
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model for cessation interventions within-pregnancy, and as such the author feels he has 
met the aims and objectives that he initially set out to undertake. The comprehensive 
scoping review of conditions (Chapter 2) systematically identified morbidities causally 
associated with smoking, thus meeting objective one. The author has critically assessed 
previous economic evaluations of cessation within-pregnancy, as detailed in Chapter 3, and 
thus meets objective two. Furthermore, the author has estimated the best estimates given 
the lack of available data for postpartum relapse utilised in ESIP, hence meeting objective 
three. How these estimates are generated is discussed in Chapter 4. Objectives four and 
five are met in Chapter 5 where the MWPC and IWPC components are described, which 
ĐĂƉƚƵƌĞƚŚĞŝŶĨůƵĞŶĐĞŽĨƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŶŽƚŽŶůǇŽŶŚĞƌŚĞĂůƚŚďƵƚĂůƐŽŽŶ
the health of her infant, with a direct link between the two models. In Chapter 6, the 
author describes the structure of the MLC, which captures the smoking behaviour of the 
mother post-pregnancy for her remaining lifetime, thus meeting objective six. Chapter 7 
describes the structure of the IC ?ĂŵŽĚĞůǁŚŝĐŚůŝŶŬƐƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŝŶ
the MLC and MWPC with the health of her infant, controlling for passive smoking and birth 
outcomes for the infant; hence the author feels that the thesis also meets objective seven.  
Finally, objective eight is met in Chapter 8 as the author describes how the four 
components of the final model, the MWPC, IWPC, MLC, and ICC, were combined into one 
model (ESIP), which can be utilised to evaluate within-pregnancy interventions, and how 
the model was constructed in Excel. Furthermore, the author has gone beyond the 
specified objectives by demonstrating how the deterministic model was adjusted to allow a 
PSA to be conducted (see section 8.5), as well demonstrating the how the ESIP model can 
be used to evaluate one such smoking cessation intervention (see Chapter 10). Therefore, it 
can be concluded that the aims and objectives set out at the start of this thesis have been 
met. 
 
 Brief summary of the chapters in this thesis. 11.3
 
This section briefly describes the content and main findings of each chapter. 
 
Chapter 2 describes a structured scoping review which was carried out to identify relevant 
conditions to be included in the economic model, as well as the incidence and utility 
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decrements/weights associated with these diseases. The review identified that smoking in 
pregnancy was causally associated with ectopic pregnancy, miscarriage, placenta 
abruption, placenta previa, pre-eclampsia, preterm premature rupture of the membranes 
(PPROM), premature birth, low birth weight, Sudden Infant Death Syndrome (SIDS), and 
childhood respiratory illnesses.  
 
Chapter 3 describes how the author performed a systematic review of previous economic 
evaluations to critically assess the previous literature and identify methodological issues 
which might be important for the improved economic model. Quality assessment of 
included studies was performed using the QHES checklist, and this identified that, out of 18 
included studies, only six could be considered high quality. The limitations of the literature 
identified were that few studies used health related quality of life as the primary outcome; 
most were focused on a within-pregnancy time horizon, with lifetime impacts excluded in 
all but four models; no studies included all the diseases the author identified in chapter 2; 
postpartum relapse was explored haphazardly; and only four studies used statistically 
robust techniques to control for uncertainty. These were identified as the major issues that 
a new improved economic model needed to address. 
 
Chapter 4 outlined another systematic review, completed to produce estimates of 
abstinence in the postpartum period. Focusing on studies of within-pregnancy 
interventions identified from two Cochrane systematic reviews [27, 28], 26 trials were 
included in the review. Data on postpartum abstinence was available for up to two years 
post-pregnancy; however, biochemically validated abstinence was only available for up to 
six months postpartum.  The review estimated that abstinence was 13% at the end of 
pregnancy, 7% at one year postpartum, and 5% at two years postpartum. The author found 
no significant difference in postpartum abstinence between control and intervention 
groups, and no significant difference in abstinence when using biochemically validated 
evidence only. 
 
Chapter 5 outlines the two within-pregnancy components of ESIP, the MWPC and IWPC. 
The two models were decision trees with linked parameters, allowing for a direct link 
ďĞƚǁĞĞŶ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ĂŶĚ ƌŝƐŬ ŽĨ Ă ĐŽŵƉůŝĐĂƚŝŽŶ ƚŽ ŝŵƉĂĐƚ ŽŶ ƚŚĞ
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health of the infant. Healthcare costs were calculated from NHS reference costs [298] in 
2011/12 prices. Utility values for smokers and quitters were taken from Maheswaran et al 
[295], with a utility loss associated with ectopic pregnancy and foetal loss. No utility values 
were placed on infants, but rather the measures of cost-effectiveness for the IWPC were 
the number of adverse live births (low birth weight and/or premature birth) avoided and 
adverse birth outcomes avoided. 
 
Chapter 6 ĚĞƐĐƌŝďĞƐ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ůŝĨĞƚŝŵĞ ĐŽŵƉŽŶĞŶƚ ŽĨ ^/W ? ǁŚŝĐŚ ŝƐ Ă DĂƌŬŽǀ ĐŽŚŽƌƚ
simulation with fiǀĞƐƚĂƚĞƐŵŽĚĞůůŝŶŐƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌƉŽƐƚ-pregnancy. The 
MLC includes four co-morbidities: Coronary Heart Disease, Chronic Obstructive Pulmonary 
Disorder, Lung Cancer, and Stroke. The number of women with these diseases are 
calculated in each cycle and costs are applied using 2011/12 prices and discounted at 3.5%. 
Utility values come from Maheswaran et al for healthy smokers/ quitters [295], while other 
literature sources are used for the utility values associated with co-morbidities (see Table 
6.11), calculating QALYs in each cycle, which are also discounted at 3.5%. 
 
Chapter 7 ŽƵƚůŝŶĞƐ ƚŚĞ ŝŶĨĂŶƚ ĐŚŝůĚŚŽŽĚ ĐŽŵƉŽŶĞŶƚ ? ǁŚŝĐŚ ůŝŶŬƐ ƚŚĞŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ
behaviour both within-pregnancy and postpartum with the health of the infant and its 
exposure to passive smoking, up to the age of 15 years. The ICC is a Markov model with 
ƐĞǀĞŶƐƚĂƚĞƐƌĞƉƌĞƐĞŶƚŝŶŐƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŝŶƚŚĞD> ?ĂŶĚĂƐƐƵĐŚƐŚĂƌĞƐ
parameters with the MLC. The ICC also controls for the increased mortality associated with 
LBW. Childhood asthma is the co-morbidity included in the ICC, controlling for within-
pregnancy smoking behaviour, passive smoking exposure, and birth weight, with the 
number of infants suffering from asthma estimated in each cycle. Healthcare costs 
associated with asthma as well as a 0.1 utility decrement are applied, and all costs and 
benefits are discounted at 3.5%. 
 
Chapter 8 describes how the four components were brought together into the ESIP model, 
ĚĞĨŝŶŝŶŐƚŚĞŝŶĨůƵĞŶĐĞůŝŶŬǁŚĞƌĞƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌŝŶĨůƵĞŶĐĞƐŽŶƚŚĞĐŚŝůĚ ?Ɛ
health, and the flow link which is the sequential nature of the ESIP components. 
Furthermore, the chapter describes how ESIP was parameterised to perform a probabilistic 
sensitivity analysis. 
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Chapter 9 demonstrates a validity exercise for the within-pregnancy components of ESIP 
compared to population values. The population estimates used in parameterising the 
MWPC and IWPC were bootstrapped 10,000 times to produce reasonable estimates for the 
confidence intervals and distributions for these parameters. ESIP was then programmed to 
perform a PSA to replicate the population values, using 10,000 Monte Carlo simulations. 
The MWPC was identified to produce valid results for within-pregnancy foetal loss, within-
pregnancy complications, and maternal death. Conversely, the IWPC was found to produce 
much lower mean estimates for infant birth outcomes, with distributions that were wider 
than the bootstrapped population estimates, which suggest that the IWPC is potentially 
invalid and its results should be treated with caution. 
 
Chapter 10 displays how the ESIP model can be programmed to perform an evaluation of a 
cessation intervention. Data from the SNAP trial evaluating NRT against placebo patches 
was programmed into ESIP [123], and the results of the deterministic and probabilistic 
analyses were displayed. Although the SNAP trial only produced an estimate of the 
incremental cost per quitter at the end of pregnancy, ESIP was demonstrated to produce 
valid results. When combining costs and outcomes for the mother and infant, ESIP 
estimated that the incremental cost per QALY at the end of pregnancy was £1,123.52 (95% 
CI -£649,654.26 - £463,317.24), but was dominant when considering the lifetime/childhood 
perspective. The probability of cost-effectiveness at a willingness to pay of £30,000 per 
QALY at the end of pregnancy was 0.54 and was 0.65 when considering the lifetime/ 
childhood perspective. 
 
 Limitations related to the chapters on the development of the model 11.4
 
This section briefly outlines the limitations associated with the first three chapters of this 
thesis, and discusses their impact. 
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There are several limitations associated with the scoping review in Chapter 2, which can be 
summarised as follows:  
x There was no quality assessment performed on included studies, and therefore it is 
impossible to tell whether the review results are based on high quality studies.  
x The search was limited to only a few search terms and one electronic database.  
x There has been no exploration of the impact of publication bias.  
Although these concerns have been highlighted, it is important to consider that performing 
a systematic narrative review on the amount of literature covered would have been 
impossible within the confines of this thesis. The review is comprehensive in that it covers 
evidence relating to 32 conditions, and appraises approximately 4,000 citations, making it, 
ƚŽ ƚŚĞ ĂƵƚŚŽƌ ?Ɛ ŬŶŽǁůĞĚŐĞ ? ƚŚĞ ŵŽƐƚ ĐŽŵƉƌĞŚĞŶƐŝǀĞ ƌĞǀŝĞǁŽĨ ĞǀŝĚĞŶĐĞ ŽĨ ĐŽŶĚŝƚŝŽŶƐ
relating to smoking in pregnancy to date.  Furthermore, although the included studies were 
not formally assessed, a  recognised standard for determining if smoking has a causal 
relationship was used, by particularly focusing on what is considered the gold standard of 
evidence; systematic review.  
 
The limitations for Chapter 3 revolve around the use of the QHES checklist as the quality 
assessment of included studies; namely that it is a subjective instrument, the scoring 
system is inflexible when only part of a question requirement is met, that the QHES itself 
could lead to potential bias and exclude high quality information, and finally that the 
additional specifications introduced to the QHES around statistically robust controls for 
uncertainty, inclusion of all the conditions identified in Chapter 2, and a time horizon 
covering both within-pregnancy and the lifetime of the mother, may also introduce bias in 
favour of this piece of work. However, it could be argued that this use of the QHES has 
allowed a systematic demonstration of the methodological shortcomings of the previous 
literature. Although the QHES scores are reported, the actual results of interest are the 
responses to the individual questions, as it is these which highlight the limitations in the 
previous literature of smoking cessation within-pregnancy. Furthermore, the broad search 
strategy utilised by the review has probably identified all the relevant studies in this topic 
area, making it the most comprehensive review to date. 
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For the review conducted in Chapter 4, the limitations identified were:  
x The review estimated patterns of abstinence rather than relapse curves, due to the 
lack of longitudinal data available, and hence it may be underestimating relapse;  
x Not all included studies reported data at all time points, and consequently several 
time points had very few studies to combine;  
x The primary and secondary analyses used both self-reported and biochemically 
validated abstinence, with self-reported abstinence only beyond six months 
postpartum, hence there may be some reporting bias inflating the abstinence at 
those time points;  
x Heterogeneity was high at most time points, suggesting that studies should not 
have been pooled together;  
x There was evidence of publication bias, with small studies appearing to be absent 
from the included studies.  
 
To counter this, it should be noted that point abstinence has been demonstrated to 
capture 74% of relapse, [362] and that therefore the review is not underestimating relapse 
significantly. Furthermore, there was a complete lack of longitudinal data, which made it 
impossible to determine any relapse estimates in the postpartum period. Although the 
review included self-reported abstinence, when performing a sensitivity analysis controlling 
for biochemically validated abstinence, the author found no statistically significant 
evidence of difference in abstinence between the analyses that included self-reported data 
ĂŶĚƚŚŽƐĞƚŚĂƚĚŝĚŶ ?ƚ ?ĚĚŝƚŝŽŶĂůůǇ ? ŝƚǁĂƐĞǆƉĞĐƚĞĚƚŚĂƚŚĞƚĞƌŽŐĞŶĞŝƚǇǁŽƵůĚďĞŚŝŐŚ ?ĂƐ
there is a great variety of cessation interventions included, but there are not enough 
studies to break the interventions down into separate categories; this may be possible in 
the future. Finally, it should be highlighted that all the included studies were trials, and as 
such could be thought of as the gold-standard in data quality. While other observational 
and cohort studies may be have been able to provide longer estimates of postpartum 
smoking behaviour, the quality of the data collected is likely to be lower, and hence would 
not add anything to the review. 
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 Limitations of individual model components 11.5
 
As has been mentioned, ESIP is formed of four components into a complex overall model. 
However, as each model can be considered an individual model in its own right, they each 
have their own individual limitations. What follows is a brief summary of the limitations for 
each component.  
 
11.5.1 Limitations with the MWPC 
 
A more detailed discussion of the limitations with the MWPC is given in Chapter 5; however 
they can be summarised as follows: 
x Are the risks of a quitting smoker the same as a never smoker? If this assumption is 
incorrect, then both the MWPC and IWPC will be overestimating the benefits of 
cessation since it will be reducing the risks of within-pregnancy complications and 
adverse birth outcomes too much for women who quit smoking in pregnancy. This 
would suggest the ICER estimates of the MWPC are too low. 
x Does the timing of cessation affect the risk of complications? The MWPC assumes 
that women who report being quit by the end of pregnancy have the same risks of 
within-pregnancy complications and foetal loss as women who were never 
smokers, irrespective of whether they quit early in pregnancy or just before they 
give birth. Similarly, women who report smoking at the end of pregnancy have 
been assumed to have smoked throughout pregnancy, even though they may have 
quit and relapsed just before birth. This suggests that the MWPC could be either 
over estimating the benefits from smoking if the former exists, or underestimating 
the benefits if the latter; however, the size of this potential problem is 
undetermined. 
x The costs associated with pregnancy, particularly with those estimated for a normal 
ďŝƌƚŚ ?ŵĂǇďĞ ŝŶĐŽƌƌĞĐƚ ?dŚŝƐ ŝƐďĞĐĂƵƐĞǁŚĂƚ ŝƐĐŽŶƐŝĚĞƌĚĂ  ‘ŶŽƌŵĂůďŝƌƚŚ ? ŝƐŶŽƚ
defined, and pregnancy can have many complications at delivery which affect how 
healthcare is delivered, e.g. a woman could have a perfectly healthy pregnancy but 
an extremely complicated birth. The potentially incorrect costs suggest that the 
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expected cost estimates generated by the MWPC are incorrect, however the 
ĂƵƚŚŽƌŝƐƵŶƐƵƌĞǁŚĂƚŝŵƉĂĐƚƚŚŝƐŚĂƐŽŶƚŚĞ/Z ?ƐŐĞŶĞƌĂƚĞĚďǇƚŚĞDtW ?ĂƐŝƚ
is dependent on whether the MWPC is under- or over estimating the costs 
associated with pregnancy. 
x The utility decrements used, generated by Maheswaran et al are only relevant to 
the population of England [295], and when compared to UK population Norms 
[306], they may be overestimating the utility associated with a non-smoking 
woman, thus suggesting the IWPC is over estimating the benefits associated with 
cessation within-pregnancy, and consequently the ICERs estimated could be too 
low. 
x No utility loss associated with within-pregnancy complications is applied. This was 
because the author was unable to identify suitable information for 
parameterisation. Their omission suggests that the MWPC could be 
underestimating the benefits of cessation, and thus the ICERs could be too high. 
x No utility loss associated with pregnancy was included, and hence we assume that 
a pregnant woman has the same utility as a non-pregnant woman. If a pregnant 
woman has a lower utility compared to a non-pregnant woman, then the MWPC 
may be overestimating the total utility at the end of pregnancy; however, it should 
not make a difference to the incremental difference in benefits at the end of 
pregnancy, as the utility loss associated with pregnancy would be applied to both 
groups, and thus should have no impact on the overall cost-effectiveness 
estimates. 
x The MWPC does not include PPROM, which was identified as having a causal 
association with smoking during pregnancy, due to being unable to differentiate 
the effect of smoking within-pregnancy on PPROM and PROM, the latter showing 
no link with smoking during pregnancy. Furthermore, PPROM is closely linked with 
premature birth, so it would have likewise have been difficult to distinguish the 
two.  
 
11.5.1.1 What are the potential implications of these limitations? 
 
 Although there is a concern with regard to the assumption that quitting smokers have the 
same chance of an adverse pregnancy event as never smokers, and also the assumption 
334 
 
regarding timing of cessation, the validity exercise performed in Chapter 9 should be 
considered. This chapter demonstrated that the MWPC produced slightly conservative, but 
very close, estimates for the number of ectopic pregnancies, miscarriages, placental 
abruptions, placenta previa, pre-eclampsia, and maternal death compared to population 
estimates. This would suggest that despite these shortcomings, the MWPC is still 
estimating the correct number of complications, and is therefore correctly specified and 
valid. Although there may be slightly conservative estimates of complications, the MWPC is 
likely to be therefore producing conservative estimates for the cost-effectiveness of the 
interventions, and therefore erring on the side of caution. Such conservative estimates are 
only likely to be an issue if the intervention is on the borderline of cost-effectiveness. 
 
With regards to the limitations of within-pregnancy costs, this could be a tricky issue, as it 
could be argued that the MWPC is inaccurately measuring the healthcare costs associated 
with pregnancy. However, the author has attempted a fairly detailed and systematic 
approach to the healthcare costs within-pregnancy, including consulting with a practising 
midwife to determine the most appropriate approach to attributing costs. Therefore, it is 
hoped that the model allayed this issue.  
 
The author does not believe the lack of a pregnancy specific utility for women or the lack of 
utility losses associated with within-pregnancy complications to be an issue. This is 
because: 1) a utility decrement associated with pregnancy itself would not impact on the 
results of the incremental analysis as all women in the cohort would have this value 
applied, and 2) as Chapter 2 highlighted, there was no evidence that any of these within-
pregnancy complications had an impact on the quality of life.   
 
Conversely, the utility values and decrements used from Maheswaran et al could prove to 
be of a concern, since they limit the generalisability of the MWPC to the English population 
only. [295] While this could be an issue for ESIP in its current state, the model in question is 
a flexible model, which allows for easy changes in parameterisation. Therefore, if future 
researchers/ policy makers from other countries/populations wish to use the model, it is 
simply a case of modifying the utility values to suit their population, and ESIP will produce 
valid results for them. 
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Finally, the omission of PPROM could also be a concern for the model. However, as 
discussed in Chapter 5, in most cases of PPROM/PROM the pregnancy results in a normal 
birth, suggesting that there is no additional healthcare costs, or that these additional costs 
are insignificant. Furthermore, in Chapter 2 the author found no evidence that these 
ĐŽŶĚŝƚŝŽŶƐŚĂĚĂŶǇŝŵƉĂĐƚŽŶƚŚĞŵŽƚŚĞƌ ?ƐƋƵĂůŝƚǇŽĨůŝĨĞ ?dŚĞƌĞĨŽƌĞ ?ŝƚŝƐƵŶůŝŬĞůǇƚŚĂƚƚŚĞŝƌ
omission will have any impact on the cost-effectiveness estimates generated by the MWPC. 
 
11.5.2 Limitations of the IWPC  
 
There are several limitations associated with the IWPC as highlighted in Chapters 5 and 9. 
These can be summarised as follows. 
x The IWPC does not include congenital anomalies and the associated costs and 
health impacts on the infant. Therefore, the IWPC could be underestimating the 
total healthcare costs for an infant, and the associated cost-savings generated by 
cessation, not to mention the health and quality of life gains to be had from 
preventing a congenital anomaly associated with smoking within-pregnancy. This 
would suggest that the ICER estimates generated by the IWPC are too high, 
underestimating the value for money of cessation interventions. 
x As highlighted in Chapter 9, the IWPC does not seem to produce close estimates of 
the number adverse birth outcomes, such as stillbirth, low birth weight, and 
premature birth. In all cases there appeared to be a large difference between the 
IWPC estimates and the population estimates, with the IWPC consistently 
underestimating the number of events. Furthermore, the distributions produced by 
the IWPC were much wider than those population estimates, suggesting that this 
issue with the IWPC is introducing a greater amount of decision uncertainty into 
the evaluation. 
 
11.5.2.1 What are the potential implications of these limitations? 
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Although the IWPC does not include congenital anomalies, the author does not think that 
this is an issue. As highlighted in Chapter 2, congenital anomalies are relatively rare, and 
very variable, with the high healthcare costs and high impacts of quality of life only really 
associated with those conditions which are very severe, which are even rarer. Therefore, if 
these conditions had been included, by the time the IWPC had taken them into account, 
the overall expected cost for these conditions would have been very low, and therefore 
would have had very little impact on the total healthcare costs calculated by the model. 
Furthermore, the cohort required to generate a change in the number of congenital 
anomalies averted would have to be exceedingly large, and then it is likely that cessation 
may only prevent one congenital anomaly. However, it would probably prevent hundreds 
of low birth weight infants, with which the majority of costs are associated. 
 
As discussed in Chapter 9, it is unclear how significant the concerns around validity of the 
IWPC are. The author suspects that the cause of the wide differences in the means 
between the IWPC output and the population estimates is the difference in the rates of 
premature birth in the HES data (which was based on one year), which are lower than the 
ONS estimates; this in turn impacts on the risk of LBW and stillbirth. Unfortunately, this 
cannot be addressed presently as the author does not have the available data, and 
therefore the estimates of the IWPC must be treated with caution until additional data is 
available. 
 
11.5.3 Limitations of the MLC 
 
A detailed discussion regarding the limitations associated with the MLC is given in Chapter 
6, however they can be summarised as follows: 
x There is no inclusion of subsequent pregnancies, which may impact smoking 
behaviour. This would suggest that the MLC might not accurately capture the 
smoking behaviour post-pregnancy, suggesting that the ICER estimates are too 
high, as more women should be estimated to have quit in later cycles.  
x Myocardial infarction is omitted from the MLC, unlike previous models [129, 139], 
and therefore the MLC is underestimating the benefits from smoking cessation and 
consequently the ICERs may be too high. 
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x The postpartum abstinence probabilities are based on self-reported abstinence and 
not from longitudinal continuous abstinence data. It may be that relapse is higher, 
and this is not being captured by the MLC, hence the MLC estimates of the ICER for 
cessation interventions are too low. 
x The MLC allows for numerous quit attempts to be made post pregnancy due to the 
Markov assumption, which may be considered unrealistic. As discussed in Chapter 
6, a woman may only require six or seven quit attempts before she finally succeeds 
in permanent cessation, but the MLC does not take this into account. Therefore, it 
could be argued that the MLC is overestimating the number of women who are 
smoking in later cycles, hence underestimating the benefits of the cessation 
intervention. This would suggest the ICER estimates generated by the MLC could be 
too high. 
x Related to quit attempts, the MLC includes a small probability for a long term 
quitter to relapse, which is applied to all cycles of the MLC. As is highlighted in 
Chapter 6, there is evidence to suggest that once a smoker has been quit for a long 
period of time, the risk of their relapsing is very small, and hence this assumption is 
incorrect. This would suggest that the MLC is overestimating the number of women 
smoking in later cycles, and hence underestimating the benefits of cessation, 
implying that the ICERs are too high.  
x The relative risks associated with the lifetime co-morbidities are from US data and 
not England/ UK data. Do these values really apply to these conditions in the 
population modelled by ESIP even though it is parameterised for the English 
population? 
 
11.5.3.1 What are the potential implications of these limitations? 
 
The author does not think the omission of subsequent pregnancies is a problem. Although 
any subsequent pregnancies are likely to lead to changes in smoking behaviour, pregnancy 
is a relatively short time (less than one year), and the mother may have already relapsed, 
having given up during her subsequent pregnancy. Furthermore, controlling for any 
subsequent pregnancies would be very difficult for a model to undertake, and would likely 
lead to a model too complex to construct.  
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The omission of myocardial infarction is also unlikely to be a concern. While there is 
significant mortality, healthcare costs, and quality of life issues associated with a heart 
attack, these are spread over relatively short periods, and hence a woman may regain her 
health within one cycle of the model. Furthermore, the inclusion of MI may risk double-
counting with the effects of CHD, as the two conditions are quite closely linked. Therefore, 
the author does not believe the omission of MI to be a major concern. 
 
Although the postpartum relapse probabilities are not from longitudinal data or 
biochemically validated data, it was concluded that this is the best data available regarding 
postpartum relapse should women have received a smoking cessation intervention within-
pregnancy. It has been demonstrated that self-reported data captures 74% of relapse 
compared to biochemical validated data [362], therefore even if the biochemically-
validated data was available, it is unlikely that the relapse rate would be significantly 
higher. Furthermore, the longitudinal data for postpartum relapse simply does not exist, 
although this may change in the future. Therefore, the author feels that this is not a major 
concern, but would like to highlight that the MLC has the flexibility to be adapted in the 
future should such information become available. 
 
With regards to the assumptions on the number of quit attempts and the long term relapse 
probability, the author would again argue that these are not major issues. The introduction 
of the required memory into the Markov to take into account the past smoking history of 
the mother would be exceedingly difficult, and produce a bushy Markov, as discussed in 
section 6.10.2. The author does not believe that the added complication such a Markov 
structure would bring would give much in the way of advantage over the current structure 
of the MLC. Furthermore, as highlighted in Chapter 6, there is evidence that individuals can 
relapse to smoking after a long time, and therefore it would seem reasonable to include 
this assumption. Thus the author does not believe this to be of concern. 
 
The final limitation, of the relative risks for the co-morbidities of the disease coming from 
US data rather than UK/ England data, is a possible problem. However, both the rates of 
CHD and COPD have been demonstrated to be similar in the US and the UK [363, 364], 
suggesting that using the same risks of developing the diseases are appropriate. However, 
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the rate of stroke in the UK is higher than the US [365], and the rate of lung cancer is higher 
in the US than the UK [366], so this would suggest that there is potential for the risks to be 
different in the English population compared to that of the US. However, the MLC is flexible 
in that should better parameters for the English population should be identified, then these 
could be programmed in to correct this issue. 
 
11.5.4 Limitations of the ICC 
 
There are several limitations associated with the ICC, as considered in Chapter 7. They can 
be summarised as follows. 
x The ICC does not include passive smoking associated ǁŝƚŚŵŽƚŚĞƌ ?Ɛ ƉĂƌƚŶĞƌ ?dŚŝƐ
can have an impact on the health of the child as well, and this exclusion could 
mean the ICC is underestimating the benefits of cessation (if the partner quits 
smoking as well), producing ICERs that are too high. 
x The ICC does not include other impacts outside of passive smoking, such as 
socioeconomic status, which is associated with smoking. As highlighted in Chapter 
7, people of lower socioeconomic status tend to have lower quality of life and 
higher rates of morbidity, but the ICC does not capture this. Smoking cessation 
could have lower rates of benefit amongst these individuals; hence the estimates 
of the ICERs generated by the ICC may be too high. 
x Only singleton pregnancies are taken into account, with multiple births excluded. 
The exclusion of multiple births suggests that the ICC is underestimating the 
benefits from cessation, and therefore the ICER estimates are too high. 
x No subsequent births are included, and these subsequent pregnancies are also 
ůŝŬĞůǇƚŽďĞĂĨĨĞĐƚĞĚďǇƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌ ?dŚŝƐƐƵŐŐĞƐƚƐƚŚĂƚƚŚĞ/
may be underestimating the benefits from smoking cessation, and that the ICER 
estimates are too high. 
x Sudden Infant Death Syndrome was excluded. This was identified as causally 
associated with smoking during pregnancy in Chapter 2, but was excluded from the 
model. This could suggest that the ICC is underestimating the benefits from 
smoking cessation and hence the ICER estimates for cessation interventions are too 
high. 
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x Only asthma was included in the ICC; other respiratory illnesses were excluded. 
This could suggest that the ICC is underestimating the benefits from cessation, and 
that the ICERs are too high. 
x No utility loss associated with a LBW infant was applied. If such a utility loss does 
exist, then the ICC would be underestimating the benefit of cessation within-
pregnancy, and hence the ICER estimates would be too high. 
 
11.5.4.1 What are the potential impacts of these limitations? 
 
/ƚ ŝƐ ŶŽƚ ďĞůŝĞǀĞĚ ƚŚĂƚ ƚŚĞ ĞǆĐůƵƐŝŽŶ ŽĨ ƉĂƐƐŝǀĞ ƐŵŽŬŝŶŐ ĨƌŽŵ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƉĂƌƚŶĞƌ ŝƐ ĂŶ
issue. This is because the cessation intervention is given to the smoking mother and not her 
partner (although the author is aware that interventions for both mother and partner do 
ĞǆŝƐƚ ? ? Ɛ ƐƵĐŚ ? ƚŚĞ ŽŶůǇ ƐŝŐŶŝĨŝĐĂŶƚ ĐŽŶƐŝĚĞƌĂƚŝŽŶ ŝƐ ǁŚĞƚ Ğƌ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ
behaviour changes, and what impact this has on the infant. Therefore, the author believes 
that passive smoking relating to the partner is exogenous to the model. 
 
With regard to other factors outside of passive smoking, such as socioeconomic status of 
the mother and her child, it should be highlighted that this model was constructed to 
represent the average mother in England, ensuring it is of most interest to a policy making 
body such as NICE. However, it would be possible to run a sub-group analysis focusing in on 
such women and infants, if suitable parameters for the ICC could be derived.  
 
Although the ICC excludes multiple pregnancies, it could be argued that this is not an issue. 
This is because if an intervention was to be cost-effective for a single infant, then it is likely 
that it will be cost-ĞĨĨĞĐƚŝǀĞĨŽƌŵƵůƚŝƉůĞŝŶĨĂŶƚƐ ?dŚƵƐƚŚĞ/ ?ƐĐƵƌƌĞŶƚĞƐƚŝŵĂƚĞƐĐŽƵůĚďĞ
considered the upper bound of cost-effectiveness. 
 
The author does not believe the exclusion of subsequent births to be an issue. This is 
because the model focuses on a cessation intervention given to a woman in a specific 
pregnancy, and therefore only interested in the impact of that cessation intervention on 
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that one child. Hence, it could be argued that subsequent pregnancies are exogenous to 
this evaluation. Furthermore, it could be contended that future lives are not improvements 
in health, and hence should not be included in the model. [145] 
 
Although SIDS has been causally linked with smoking, the author does not believe its 
exclusion to have significant effect on the outcomes produced by the ICC. As identified in 
Chapter 2, SIDS is a rare condition. Furthermore, the model already controls for SIDS in the 
mortality estimates from the ONS, but it cannot put a specific healthcare cost on this. 
Therefore, the author feels that the omission of SIDS from the ICC does not impact on the 
cost-effectiveness estimates because it is such a rare condition. 
 
The lack of inclusion of other respiratory illnesses may be a concern for the ICC. However, 
asthma is one of the most common childhood respiratory diseases, being chronic and with 
considerable healthcare costs. Other respiratory diseases may be acute attacks, and as such 
are short lived. The author would argue that the ICC is capturing the most important of the 
respiratory diseases, along with much of the expected costs associated across childhood. 
Therefore the omission of other respiratory diseases is not a problem. 
 
As discussed in Chapter 7, although there is evidence that children born with low birth 
weight may have a lower quality of life, it has also been highlighted that this effect is short 
lived and only really applies in the first few years of life. [341] While this could be a concern 
to the ICC, the fact that this only applies to first few years of life, means that its 
introduction might not have much impact on the overall estimates of the total benefit 
calculated. Although it is possible that there may still be changes in the incremental 
analysis due to the benefits gained from avoiding a LBW infant, the flexibility of the ICC 
means that it would be easy to incorporate such an impact if required.  
 
 Limitations of the overall model 11.6
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As well as the limitations associated with the separate components, there are several 
limitations associated with the overall ESIP model, as discussed in Chapter 8. These can be 
summarised as follows. 
x The influence link between the ICC and the MLC implies that in the PSA, the ICC 
could sample different values to the MLC, because the MLC uses Dirichlet 
distributions with three categories, while the ICC uses a Dirichelt with four 
ĐĂƚĞŐŽƌŝĞƐ ? dŚĞƌĞĨŽƌĞ ƚŚŝƐ ŵĂǇ ŶŽƚ ĂĐĐƵƌĂƚĞůǇ ƌĞĨůĞĐƚ ƚŚĞŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ
behaviour. 
x There was no adjustment in the PSA to take into account self-reported values. This 
is particularly in reference to the postpartum relapse probabilities, which are based 
on the pooled analysis in Chapter 4; this included self-reported abstinence, which 
could be biasing the relapse estimates to be lower than in reality. This suggests that 
the MLC/ICC may be underestimating the number of women who relapse post-
pregnancy and the number of infants exposed to passive smoking; therefore ESIP 
could be overestimating the benefits of within-pregnancy cessation, and hence the 
ICER estimates may be too low. 
x ESIP does not include any lasting health impacts of within-pregnancy 
complications. If the within-pregnancy complications have a lasting impact beyond 
pregnancy, then ESIP is currently not capturing these effects on the quality of life of 
the mother after pregnancy, underestimating the benefits to be gained from 
cessation, and suggesting that the ICERs may be too high. 
x ůƚŚŽƵŐŚ^/W ŝŶĐůƵĚĞƐƚŚĞ ŝŶĨĂŶƚ ?ƐŐĞŶĚĞƌ ŝŶƚŚĞ/CC, the IWPC does not. If there 
are different rates of adverse birth outcomes for different genders, then this would 
not be captured within the IWPC.  
x  The ESIP model uses parameters primarily from the English population, such as the 
prevalence of smoking within England, and the rates of within-pregnancy 
complications taken from English hospital episode data. This would suggest that 
ESIP is only generalizable to the English population, reducing its usefulness 
internationally. 
 
11.6.1 What are the potential implications of these limitations? 
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As discussed in Chapter 8, the author has attempted to mitigate for the break in the 
influence link in the way the Dirichlet distributions are calculated in the ICC, and in theory 
the approach used means that the ICC sampled parameters will always be slightly smaller 
than the respective parameter in the MLC. However, the impact of this on the output of 
ESIP is unclear, as is the extent of any potential bias on the results of the ESIP analysis.  
 
With regards to the lack of adjustment to the PSA and the self-reported data used in 
determining abstinence values, this is unlikely to be an issue since, as highlighted in 
Chapter 4, no statistically significant difference between biochemically validated 
abstinence and self-reported abstinence was found. This would suggest that no adjustment 
to the PSA to take into account self-reported data was required. 
 
As discussed in Chapter 2 of this thesis, there was no evidence of a lasting impact of within-
pregnancy complications. Furthermore, it appeared that one study recommended that pre-
eclampsia and other within-pregnancy complications were only acute conditions, and 
hence any quality of life loss was very short lived and that there were no further impacts on 
the mother. [157] This would suggest that the author was correct in his assumption to not 
include these conditions. Chapter 2 also demonstrated that there appeared to be no link 
between gender and adverse birth outcomes, which further suggests that the lack of 
gender in the IWPC is not problematic. 
 
As regards to generalisability, this is a practical limitation of the model, since data was 
readily available for England but not the whole UK, or other countries. This could restrict 
the usefulness of ESIP internationally. However, the author would suggest that this is a 
flexible model, which could be applied to any country, although it would require re-
parameterisation. However, this is a much simpler and faster task than constructing the 
model from scratch, and hence it is unlikely that the lack of generalisability is a particular 
limitation to the usefulness of ESIP. 
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 Strengths of ESIP and this thesis 11.7
 
There are several important strengths concerning the ESIP model and this thesis. These are: 
1) dŽ ƚŚĞĂƵƚŚŽƌ ?ƐŬŶŽǁůĞĚŐĞ ?^/W ŝƐ ƚŚĞ ĨŝƌƐƚŵŽĚĞůǁŚŝĐŚ ĂƐďĞĞŶƐǇƐƚĞŵĂƚŝĐĂůůǇ
constructed to specifically model cessation interventions within-pregnancy. When 
reviewing the previous economic models of smoking cessation within-pregnancy, it 
was unclear whether the authors of these models had performed such a 
comprehensive and systematic approach to producing their models, with several 
evaluations adapting models developed for cessation interventions in non-
pregnant populations [139, 196], which may not be correctly specified for 
estimating the benefits of cessation within-pregnancy.  
2) ESIP models a time horizon that covers both within-pregnancy and the lifetime for 
the mother and up to age 15 years for the infant. The majority of the previous 
economic evaluations do not include such a time horizon, with only one model 
including these conditions. [190] Furthermore, ESIP has included many of the 
within-pregnancy complications, adverse birth outcomes for the infant, and long 
term co-morbidities associated with the mother and the infant, which few other 
models have included, with only one study including these conditions. [190] 
3) The ESIP model is the first in the within-pregnancy literature which allows the 
ŵŽƚŚĞƌ ?Ɛ Ɛŵoking behaviour to directly impact on the health of the infant, both 
within- and post-pregnancy. No other model has included this link, with one study 
even stating that it was purposely excluded. [190] This link is a vital component 
since there are significant healthcare costs and quality of life impacts on the infant 
ĨƌŽŵƚŚĞŵŽƚŚĞƌ ?ƐƐŵŽŬŝŶŐďĞŚĂǀŝŽƵƌ ? 
4) Although a few previous evaluations included a PSA, the number is relatively small: 
only four did so. Two of these were within-trial analyses [123, 195], while the other 
two were both models. While Tappin et al fitted distributions to all included 
parameters [196], Mallender et al only put distributions on the effectiveness and 
costs associated with the evaluated interventions. [190] ESIP includes a PSA 
performed on all distributions included in the model, which means it is only the 
second model in the topic area to do so. 
5) The author has demonstrated that ESIP produces valid estimates of the cost-
effectiveness of within-pregnancy cessation interventions. In Chapter 9, the author 
demonstrated that the MWPC produces very similar estimates to the population 
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ones for within-pregnancy complications and maternal deaths. Furthermore, in 
Chapter 10, it is proved that ESIP can reproduce a within-trial analysis, estimating 
comparable within-pregnancy results to within-trial evaluations. Additionally, ESIP 
can be used to extend the results of the within-trial analyses to estimate the cost-
effectiveness of cessation interventions across the lifetime of the mother and the 
childhood of the infant, which could be very useful for both researchers and policy 
makers estimating the cost-effectiveness of cessation interventions within-
pregnancy. 
6) ESIP has a flexible structure, and could be easily parameterised to suit other 
populations/ countries. This means that in future, policy makers and researchers 
will have access to an easy-to-adapt model, one that could be considered high 
quality, meeting standards of good modelling practice, which may not have been 
true of previous evaluations. 
 
 Who can use ESIP? 11.8
 
ESIP has been developed so that anyone may use the model for evaluating cessation 
interventions within-pregnancy.  For this reason it was developed using a widely available 
software package, rather than one more specific for economic modelling. In the near 
future, it is hoped that ESIP will be hosted online on the UK Centre for Tobacco and Alcohol 
Studies website (see http://www.ukctas.ac.uk/), where researchers, policy makers, and 
other interested parties will be able to download the model and associated documentation 
(user guide, evidence of development) to use for their own purposes. It is hoped that by 
making ESIP widely available, the model will improve the quality of the literature on 
smoking cessation interventions within-pregnancy. 
 
 What impact will ESIP have on the research community? 11.9
 
It is anticipated that a wide range of researchers, including other health economists, will 
use the model. It is expected that the majority of researchers interested in ESIP will be 
those involved with tobacco and smoking cessation research, as these are the most likely to 
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be involved with evaluating smoking cessation interventions within-pregnancy. However, 
other researchers may be interested in the structure and programming of ESIP, as it may 
have relevance to their topic area, especially if they are investigating parental behaviour 
and its influence on the health of their offspring. One possible future use could be the 
evaluation of passive smoking interventions, including public health interventions, since the 
structures of the MLC and ICC lend themselves particularly well to these and could easily be 
adapted for their evaluation. 
 
Ultimately, the main objective for ESIP in terms of the research community is that through 
its use, researchers evaluating  within-pregnancy cessation interventions will be able to 
produce high quality economic evaluations which stand up to the scrutiny of the 
international academic community. Although ESIP in its current form is only generalizable 
to England, as that is where the parameters have been sought, it is hoped that other 
researchers will re-parameterise the model to suit their country, and hence ESIP will be a 
useful tool internationally. 
 
 What impact will ESIP have for policy makers? 11.10
 
ESIP has primarily been designed to meet the criteria as set out by the NICE reference case. 
[36] As such, the author hopes that ESIP could be utilised to inform NICE policy guidelines 
on the cost-effectiveness of cessation interventions within-pregnancy. Furthermore, any 
new within-pregnancy interventions being considered by NICE could be evaluated by ESIP, 
allowing the policy maker to make easy comparisons between new health technologies 
compared with those existing. It is hoped that ESIP will improve the decision-making 
process, allow accurate estimates of the cost-effectiveness of cessation to better inform 
the policy maker, and thus allow NICE to ration healthcare resources efficiently. Other 
policy makers from other countries may wish to use ESIP, and certainly its structure would 
apply to any within-pregnancy cessation intervention anywhere else in the world, given 
that smoking within-pregnancy has a causal effect on the included co-morbidities. 
However, policy makers outside of England would have to be careful of the generalisability 
given the current parameterisation of the model. Despite this, should they have available 
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data, the author would not hesitate to assist in re-parameterising the model to suit the 
ƉŽůŝĐǇŵĂŬĞƌ ?ƐĐŽƵŶƚƌǇ ?ƉŽƉƵůĂƚŝŽŶŽĨŝŶƚĞƌĞƐƚ ? 
 
As discussed in section 1.11, it has been highlighted that there is a lack of guidance on 
whether the benefits associated with the mother and her offspring should be included, 
with Goldhaber-Fiebert et al suggesting that there needs to be some international 
consensus. [146] As discussed in section 1.11 and later demonstrated in Chapter 8, the 
author decided to combine both healthcare costs and benefits for the mother and her 
offspring. While this may meet current NICE guidance, which is ambiguous on the subject 
[36] ?ƐŚŽƵůĚE/ĐŚĂŶŐĞƚŚŝƐ ŝŶ ƚŚĞ ĨƵƚƵƌĞ ?ĂŶĚŶŽ ůŽŶŐĞƌǁŝƐŚƚŽ ŝŶĐůƵĚĞƚŚĞŽĨĨƐƉƌŝŶŐ ?Ɛ
costs and QALYs, ESIP is already able to perform a cost-utility analysis for both the mother 
and the infant separately. This change would likely mean that the policy maker would be 
interested in a cost-consequence analysis, where the results of the mother and for the 
infant are presented independeŶƚůǇ ? ĂŶĚ ^/W ?Ɛ ŚŝŐŚ ĚĞŐƌĞĞ ŽĨ ĨůĞǆŝďŝůŝƚǇ ĞŶƐƵƌĞƐ ƚŚĂƚ ŝƚ
would continue to be of benefit in terms of the future decision-making process. 
 
Chapter 10 demonstrates how ESIP can be used to inform policy regarding cessation 
interventions within-pregnancy. The SNAP trial included an economic evaluation of the 
SNAP intervention, but only reported an incremental cost per quitter, since the EQ-5D data 
did not demonstrate any difference between the two groups, which could suggest to the 
policy maker that the SNAP intervention is dominated by usual care. However, by using 
ESIP, it was possible to demonstrate that, in reality, the SNAP intervention could be cost-
effective, especially when considering costs and benefits for not only the mother across her 
lifetime, but the infant and its childhood as well. This would suggest that by using ESIP, the 
policy maker could have prevented an incorrect decision being made with regards to the 
SNAP intervention. However, the results highlighted that there was a great degree of 
uncertainty in the analysis, which could be very important to the policy maker, who may 
conclude that the SNAP intervention requires more research to determine its true cost-
effectiveness. 
 
ESIP is already starting to inform public health policy. Recently, contact was made by Public 
Health England to request the author to estimate the potential cost-savings that could be 
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achieved for the 22 Clinical Commissioning Groups (CCGs) in the West Midlands of the UK. 
The author provided estimates of cost-savings that could be achieved by reducing smoking 
by 1%, 2.5%, 5%, and completely, for each individual CCG, controlling for their prevalence 
of smoking at delivery. Therefore, it is hoped that this demonstrates the potential 
usefulness that ESIP has for policy makers. 
 
 Future work and extensions to ESIP 11.11
 
A possible improvement is the improvement of estimates related to the healthcare costs of 
childhood associated with smoking. Petrou et al have demonstrated that infants born to 
smokers experience higher healthcare costs and more hospitalisations during the first five 
years of life. [142] The author is currently working with a research team to put together a 
research application to gain access to two large databases, The Clinical Practice Research 
Datalink and Hospital Episode Statistics, [272, 367] in order to extract data relating to 
women who report smoking and abstinence during pregnancy and the healthcare costs 
associated with their infants up to the age of 15. Once these values have been generated, 
the aim is to build these costs into the ICC. This would allow ESIP to calculate better 
estimates of the healthcare cost-savings generated by cessation. This is something that 
ESIP does not currently do, except for the healthcare costs associated with asthma. 
 
Another future extension is to construct a further component to represent the health of 
the child beyond the age of 15. Chapter 7 ƐƵŐŐĞƐƚĞĚ ƐŽŵĞ ĞǀŝĚĞŶĐĞ ƚŚĂƚ ƚŚĞ ŝŶĨĂŶƚ ?Ɛ
ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ŝƐ ĚŝƌĞĐƚůǇ ŝŶĨůƵĞŶĐĞĚ ďǇ ƚŚĞ ŵŽƚŚĞƌ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ĚƵƌŝŶŐ
childhood, with the risk of the child becoming a smoker by age 16 doubling if the mother 
smokes during his or her childhood. [25] Since maternal postpartum smoking behaviour can 
be somewhat influenced by their smoking behaviour during pregnancy, this implies that the 
ĐŚŝůĚ ?Ɛ ƐŵŽŬŝŶŐ ďĞŚĂǀŝŽƵƌ ŝƐ ƉŽƚĞŶƚŝĂůůǇ ĐŽŶƐĞƋƵĞŶƚŝĂů ŽĨ Ɛŵoking during pregnancy. 
Therefore, by persuading mothers to stop smoking during pregnancy and maintain that 
abstinence, the intervention may potentially prevent their child from becoming a smoker, 
saving the NHS money in terms of related healthcare costs attributable to smoking, as well 
ĂƐ ĂŶǇ ŚĞĂůƚŚ ůŽƐƚ ďǇ ƚŚĞ ĐŚŝůĚ ? dŚĞ ŽŵŝƐƐŝŽŶ ŽĨ ƚŚŝƐ  ‘ŽĨĨƐƉƌŝŶŐ ĂĚƵůƚ ĐŽŵƉŽŶĞŶƚ ?  ?K ?
suggests that ESIP is not capturing the healthcare costs and health losses attributed to this 
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particular problem, intimating that ESIP is conservatively estimating the differences in costs 
saved and health gains attributed to smoking related diseases for the child, and 
consequently the cost-effectiveness of interventions. Although the OAC is beyond the 
scope of this thesis, the user should be aware of this exclusion. 
 
The ESIP model also omits a value of information (VOI) analysis. A VOI analysis is a tool 
which focuses on the likelihood of making a wrong decision if a technology is adopted, and 
calculates the value of additional research based on the extent to which further 
information will reduce decision uncertainty. [39, 368] This allows a comparison between 
the costs of further research and the potential benefits of that information, which can be 
useful for prioritising future research recommendations. [368] A VOI analysis is performed 
by calculating the expected value of perfect information (EVPI), defined as the expected 
costs of uncertainty, since perfect information can eliminate the possibility of making the 
wrong decision. [368] To demonstrate, assume there are uncertainties in an evaluation, 
ĚĞĨŝŶĞĚ ĂƐ ɽ ? ĂŶĚ ƚǁŽ ŝŶƚĞƌǀĞŶƚŝŽŶƐ ? ƚA? ? ? ? ? /ƚ ĐĂŶ ďĞ ĂƐƐƵŵĞĚ ƚŚĂƚ ƚŚĞ ŵĂǆŝŵƵŵ ŶĞƚ
monetary benefit can be defined as ݉ܽݔ௧ܧఏܤሺݐǡ ߠሻ from the optimal decision under 
existing evidence. Under perfect information, the decision maker would know what values 
ɽǁŽƵůĚƚĂŬĞ ?ĂŶĚŚĞŶĐĞƚŚĞ expected net monetary benefit with perfect information can 
be defined as ݉ܽݔ௧ܤሺݐǡ ߠሻ.  
 
,ŽǁĞǀĞƌ ?ƐŝŶĐĞƚŚĞƚƌƵĞǀĂůƵĞƐŽĨɽĂƌĞƵŶŬŶŽǁŶ ?ƚŚĞĞǆpected value of a decision taken 
with perfect information can be found by averaging the maximum net benefit over the 
ĚŝƐƚƌŝďƵƚŝŽŶŽĨɽ ?ĚĞĨŝŶĞĚĂƐܧఏ݉ܽݔ௧ܤሺݐǡ ߠሻǤ [368] Therefore, the EVPI per patient can be 
defined by taking the difference between the expected value of the decision under perfect 
information and the decision based on existing evidence: ܧఏ݉ܽݔ௧ܤሺݐǡ ߠሻ െ ܧఏ݉ܽݔ௧ܤሺݐǡ ߠሻǤ [368] However, it is very important that the EVPI 
should be expressed as the total for all patients, as it can be used to demonstrate where 
future research could be beneficial. A VOI analysis can also work out the benefit of partial 
perfect information (EVPPI), where decision uncertainty and net monetary benefit is 
focused around a specific parameter in the model, thus helping to aid prioritisation within 
the topic area. [39, 368] VOI analyses are now considered as useful tools for prioritising 
future research, not only in terms of the research community [369], but also in terms of 
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prioritising research goals within health technology assessment and policy making 
decisions. [368] 
 
Performing a VOI analysis in ESIP would be useful as it would allow researchers and policy 
makers to determine whether 1) smoking cessation interventions within-pregnancy are an 
important area on which to prioritise funding, and 2) there are specific parameters in ESIP 
(e.g. postpartum relapse rates) which require further research. However, a VOI analysis in 
ESIP might demonstrate that there is little or no future gain to be had from further 
research, which would suggest that ESIP is a satisfactory model for performing evaluations 
of within-pregnancy cessation interventions. A VOI analysis has been performed before in 
this topic area. Tappin et al demonstrated that for maternal outcomes alone, there 
appeared to be a need for further information. [196] The authors estimated that further 
research was potentially worthwhile if it cost less than £3.3 million. This would suggest that 
including a VOI analysis might be a worthwhile extension.  
 
The structure of the ESIP is not necessarily restricted to smoking in pregnancy. Both the 
within-pregnancy and the lifetime and childhood components could be used to evaluate 
the impact of other harming behaviours within-pregnancy. For example, alcohol abuse 
within-pregnancy has been linked with similar adverse pregnancy events to smoking. [370-
372] It is likely that ESIP could easily be adapted to model alcohol interventions within-
pregnancy. Another situation where ESIP could be adapted is passive smoking 
interventions. The links between the MLC and ICC equally apply to interventions within-
pregnancy as well as interventions given to mothers post-pregnancy. Therefore, the author 
speculates that the structures of the MLC and ICC could be used to evaluate passive 
smoking interventions, including public health interventions. With future policy focusing on 
these public health interventions, such as the future ban in October 2015 of smoking in 
cars, the MLC and ICC are likely to be of particular use in the future.  
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 Practicalities for future similar economic evaluations 11.12
 
While ESIP could be considered the most thorough model of cessation within-pregnancy 
constructed to date, the author realises that such a model takes a long time to construct 
(ESIP took four years in a PhD setting), and requires large amounts of computing power. 
The time it took to construct ESIP may not be acceptable for policy makers who may wish 
to undertake rapid appraisals; hence they may not wish to fund such work. Undertaking 
such analyses requires a lot of resources, which were only possible in the PhD setting 
where the author was able to focus on ESIP for four years. This may not be practical in 
other settings, where a researcher might not be able to focus on developing a similar 
eǀĂůƵĂƚŝŽŶ ƚŽ ^/W Žƌ ĚŽĞƐŶ ?ƚ ŚĂǀĞ ƚŚĞ ŶĞĐĞƐƐĂƌǇ ƐŬŝůůƐ ŝŶŽƚŚĞƌ ĂƌĞĂƐ  ?Ğ ?Ő ? ƐǇƐƚĞŵĂƚŝĐ
reviewing). However, the process could be quicker if the author had been part of a larger 
team, with other team members undertaking other aspects (e.g. the systematic reviews). 
Conversely, additional team members would have led to additional expense which may 
have been unacceptable to the funder/policy maker. One final consideration is that ESIP is 
computationally intensive, requiring several hours to perform a PSA. While the author has 
access to a powerful computer, other researchers may not, preventing them from using 
ESIP. However, this may change as computers become more powerful in the future. 
 
 Concluding thoughts 11.13
 
The key message of this thesis is that previous economic evaluations are too simplistic and 
do not produce accurate estimates of the cost-effectiveness of smoking cessation 
interventions within-pregnancy, which could lead to incorrect policy decisions being made. 
The author has developed, through a systematic process, an improved economic model for 
performing economic evaluations on these interventions. Although ESIP is far from perfect, 
it is a far more comprehensive model of this topic area, with a novel approach of including 
the post-ƉƌĞŐŶĂŶĐǇ ŵŽƚŚĞƌ ?Ɛ ƐŵŽking behaviour, impacting on the health of the infant. 
,ŽǁĞǀĞƌ ? ƚŽ ƋƵŽƚĞ 'ĞŽƌŐĞ  W Žǆ ?  “ĞƐƐĞŶƚŝĂůůǇ ? Ăůů ŵŽĚĞůƐ ĂƌĞ ǁƌŽŶŐ ? ďƵƚ ƐŽŵĞ ĂƌĞ
ƵƐĞĨƵů ? ?[373]  It is anticipated that the outcome of this thesis, the ESIP model, can be 
ĚĞĞŵĞĚĂ “ƵƐĞĨƵů ?ŵŽĚĞů ? 
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 Chapter 12: Appendices 
 Search terms used for identifying utility values 12.1
Table 12.1 Electronic search terms used for identifying utility values using Medline 
Search 
number 
Search term Citations 
1 MESH exp Quality-Adjusted Life Years/ 7347 
2 MESH exp Placenta Previa/ 2252 
3 1 and 2 1 
4 MESH exp Pre-Eclampsia/ 23512 
5 1 and 4 2 
6 MESH exp Pregnancy, Ectopic/ 12806 
7 1 and 6 3 
8 MESH exp Abruptio Placentae/ 1782 
9 1 and 8 0 
10 MESH exp Fetal Membranes, Premature Rupture/ 5794 
11 1 and 10 1 
12 MESH exp Premature Birth 6621 
13 1 and 12 6 
14 MESH exp Asthma/ or MESH exp Lung Diseases/ or MESH exp 
Respiratory Tract Diseases/ or MESH exp Respiratory Tract 
Infections/ 
1087726 
15 1 and 14 484 
16 MESH exp Child/ 1561198 
17 MESH exp Infant/ 945317 
18 16 or 17 2030827 
19 15 and 18 79 
20 MESH exp Mental Disorders/ or MESH exp Child Behaviour 
Disorders/ 
963312 
21 MESH exp Conduct Disorder/ 2391 
22 MESH exp Attention Deficit Disorder with Hyperactivity/ 20459 
23 20 or 21 or 22 963312 
24 1 and 23 437 
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25 18 and 24 41 
26 MESH exp Congenital Abnormalities/ 462605 
27 MESH exp Limb Deformities, Congenital/ 17312 
28 26 or 27 462605 
29 1 and 28 40 
30 MESH exp Infant, Low Birth Weight/ 26706 
31 1 and 30 18 
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 Summaries of strength of evidence for smoking related morbidities 12.2
Table 12.2 Summary of strength of evidence found from both scoping reviews in Chapter 2 
Conditions 
associated with 
smoking 
Suggested link (Review 1) Summary of strength of evidence (Review 2) 
Pregnancy specific maternal conditions 
Placenta previa 7 studies reported a strong association. [1, 2, 4, 374-377] 
Increased risk of between 1.5 and 3 times [375], OR of 1.28 
to 7.42 [377] and 1.58. [2] RR between 1.28 and 4.4.[4] 
6 case-control studies, 5 cohort studies, and 1 meta-analysis identified a 
strong association. [2, 378-388] 
Placental 
abruption 
7 studies reported a strong association.[1, 2, 4, 374-377] 
1.4 to 2.4 fold increase in risk. [375] OR of 1.4 to 4.0 [377] 
and 1.62. [2] RR of 1.23 to 4.0. [4] 
11 cohort, 10 case-control, 1 systematic review, and 1 meta-analysis found 
a strong association. [2, 379, 380, 383, 388-406] 
Placenta 
accreta 
2 studies reported a strong association. [1, 377] 1 case control study reported a strong association. [407] 
Pregnancy 
bleeding of 
unknown origin 
2 studies reported an association. [1, 377] No evidence. 
Preterm 
Premature 
8 studies reported a strong association. [1, 2, 4, 142, 374-
377] Between two and three fold increase in risk. [375] OR 
7 case-control and 1 meta-analysis identified a strong association [2, 408-
414]. 
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rupture of 
membranes 
(PPROM) 
of 1.7 [2] and  1.7 - 2.25.[377] RR of between 1.6 and 
3.0.[4] 
Ectopic 
pregnancy 
7 studies reported a strong association.[2, 4, 142, 374-376, 
415] Between 1.5 and 2.5 increase in risk .[375] OR of 1.7 
[2] and 54. [376] RR of 2.2 [30] and 1.77-2.0.[4] 
8 case-control, 1 cross-sectional, 1 meta-analysis and 1 review identified a 
strong association. [2, 416-425] 
Pregnancy 
rhinitis 
1 study reported an association. OR of 1.7. [426] 1 survey reported an increase in incidence. [427] 
Deep vein 
thrombosis 
1 study reported an association. OR of 1.3. [376] 2 case-control studies reported a significant effect. [428, 429] 
Stroke 1 study reported an association. OR of 1.7. [376] No evidence. 
Pulmonary 
embolism 
1 study reported an association. OR of 2.5.[376] No evidence. 
Myocardial 
infarction 
1 study reported an association. OR of 4.6.[376] No evidence. 
Influenza 1 study reported an association. OR of 2.9.[376] No evidence. 
Bronchitis 1 study reported an association. OR of 15.2.[376] No evidence. 
Asthma 1 study reported an association. OR of 4.0.[376] 2 case-control and 1 cohort study identified a strong association. [430-432] 
Gastro 
intestinal ulcers 
1 study reported an association. OR of 3.7.[376] No evidence. 
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Gestational 
diabetes 
1 study reported a protective association. OR of 0.9. [376] 2 Systematic reviews found no association. [433, 434]. Two cohort studies 
found no association. [435, 436] 
1 cohort, 1 cross-sectional, and 1 randomized trial found an association. 
[437-439] 
Pre-eclampsia 7 studies reported a protective effect. [2, 4, 374-377, 415] 
OR between 0.7 and 0.8 [376], and 0.51.[2] 30-50% 
reduction in risk.[375] 
3 systematic reviews identified a protective effect.[2, 440, 441] 
15 cohort studies [388, 442-455] and 8 case-control [456-463] identified a 
protective effect. 
5 studies found no association.[461, 464-467] 
Uterine fibroids 1 study reported a protective effect with a RR of 0.7. [415] No evidence. 
Vomiting during 
pregnancy 
1 study reported a protective effect with a RR of 0.6. [415] 1 Cohort study reported no significant effect [468], while one survey 
identified a reduced risk. [469] 
Joint maternal and infant conditions 
Pre-term birth 9 studies reported a strong association. [1, 4, 142, 375-377, 
470-472] OR of 7.25 [472]. RR of between 1.1 and 1.7.[4] 
Risks between 1.5 and 2 times greater and passive smoking 
increased risk by 23%.[375] 
28 cohort studies, 12 case-control, 2 cross-sectional studies, and 5 review 
articles identified a significant association. [405, 411, 473-518] 
5 cohort studies, and 2 case-control found no significant association [372, 
519-524]. 1 systematic review identified no association with passive 
smoking. [525]   
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Early and late 
foetal loss 
8 studies reported a strong association. [1, 4, 374-377, 415, 
470] 10% of stillbirths attributable to smoking.[470]RR of 
1.28 [415] and 0.83 to 2.0 [4] for spontaneous abortion. RR 
of 1.2 to 1.6 for neonatal deaths.[4] Risk of miscarriage 
increased by 25% and risk of stillbirth by 40%.[375] 
1 systematic review [526], 30 cohort, 11 case-control and 12 reviews 
identified a strong association. [445, 527-579]. 
1 review, 6 cohort, and 4 case-control found no significant 
association.[524, 580-589].  
Infant conditions 
Lower quality of 
life for infant 
over lifetime. 
3 studies reported a tenuous link.[26, 142, 336] Infants 
born to smoking mothers stayed longer in neonatal 
intensive care units (NICU) and visited hospital more 
frequently in the first 2 years of life.[26, 142] Length of stay 
in NICU increased as dose increased: 6 days for non-
smoking mothers; 7 days for mothers who smoked 
between 1 and 9 cigarettes a day (OR 1.06); 7 days for 
mothers who smoked 10 to 19 cigarettes a day (OR 1.11); 8 
days for mothers smoked 20+ cigarettes a day (OR 1.21). 
[142] 
1 cohort study reported a strong association.[18] 
Sudden infant 
death 
syndrome 
(SIDS) 
7 studies reported a strong association. [4, 375, 377, 471, 
472, 590, 591] 3 studies identified a 2 fold increase in risk. 
[377, 471, 590] 40% increase in risk.[377] RR of between 
1.4 and 8.4.[4],One study identified a link with passive 
2 systematic reviews [3, 592], 5 reviews [593-597], 16 cohort [492, 598-
612], and 22 case-control studies [613-634] identified a significant 
association.  
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smoking.[375] Estimated 66% of mothers whose infants die 
reported smoking during pregnancy. [590]  
Low birth 
weight (LBW) / 
Small for 
gestational age 
/ Impaired 
growth 
10 studies reported a strong association with LBW/reduced 
birth weight. [1, 4, 142, 375, 377, 470-472, 635, 636] 
Babies born to smokers had a mean birth weight of 
3240g+/-566g versus 3516g+/-571g of babies born to non-
smokers.[472] /ŶĨĂŶƚ ?Ɛ ďŝƌƚŚ ǁĞŝŐŚƚ ƌĞĚƵĐĞĚ ďĞƚǁĞĞŶ  ? ?Ő
and 12g per cigarette a day. [377] 21% to 39% of LBW 
babies attributable to maternal smoking (OR 1.4 - 3.0). [4] 
Mothers who passive smoked more likely to have LBW 
infants. [375] 11 studies reported a fairly strong association 
with impaired growth and development of the infant.[1, 4, 
375, 415, 471, 472, 636-639] 4 studies reported an effect 
on growth restriction and limb reduction.[1, 4, 415, 471] 
RR of 2.1 [415], and 2.3  - 2.8. [4]  
6 reviews studies, 1 cross-sectional, 36 case-control, and 117 cohort 
studies found a significant association between smoking and LBW / small 
for gestation age/decrease in birth weight. [304, 405, 432, 443, 451, 473-
475, 478, 483, 484, 492, 494, 497, 501, 504, 509, 515, 516, 518, 520-524, 
528, 568, 640-772] One meta-analysis [3] found a significant link, while one 
systematic review found a link with passive smoking. [525] 
 
6 cohort, 4 case-control, and 1 cross-sectional study found no significant 
association. [479, 773-782] 
Congenital 
anomalies (limb 
malformation) 
5 studies reported a strong association. [1, 4, 415, 471, 
639] RR of 2.1 [415], and 2.3 - 2.8.[4] Greater risk of 
developing a physical disability after a musculoskeletal 
injury (RR 1.44 in young adults). [639] 
General abnormalities: 2 systematic reviews [783, 784], 6 cohort, 9 case-
control and 2 reviews identified a significant association [551, 597, 785-
799]; 7 cohort and 2 case  Wcontrol studies found no association. [800-808] 
 
Gastroschisis (intestine formed outside the body): 1 systematic review 
359 
 
[809] , 5 cohort and 5 case control studies identified a link [810-819]; 1 
cohort found no association. [820] 
 
Oral clefts: 3 systematic reviews[809, 821, 822], 6 cohort and 16 case-
control studies found a significant association [798, 814, 823-842]; 2 
cohort and 5 case-control studies found no association. [843-849] 
 
Neural tube defects: 4 case-control studies suggested an increase in risk 
[850-853]; 2 case-control and 1 cohort found a reduction in risk [840, 854, 
855]; 1 case-control and 1 cohort  found no association. [856, 857] 
 
Craniosynostosis (malformed skull): 1 systematic review [809], 2 case-
control and 1 cohort found evidence of an association [858-860]; 1 case-
control found no link. [861] 
 
Eye / retina: 2 cohort and 2 case-control reported an increase in risk. [862-
865] 
 
Congenital heart defects: 3 cohort and 8 case-control studies found an 
association [799, 839, 854, 866-873]; 2 cohort and 1 case-control found no 
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association. [874-876] 
 
Downs syndrome: 1 systematic review [877] and 1 case-control [878] 
identified a reduced risk; 1 case-control found an increase in risk [879]; 4 
case-control and 2 cohort studies found no association. [875, 880-884] 
 
Digit anomalies: 2 cohort and 1 case-control found an increased risk [814, 
885, 886]; 1 cohort found no association. [875]  
 
Hypospadias (malformation of the penis) / Cryptorchidism (undescended 
testicle): 4 studies found an increased risk [875, 887-890]; 2 cohort and 3 
case-control found no association [891-895]; 1 cohort study reported a 
decrease in risk. [896] 
 
Rectal / digestive: 3 case-control found an increase in risk [897-899]; 1 
study found a decrease in risk. [900] 
Cognitive 
development 
4 studies found a strong association. [375, 472, 636, 901], 
Development delay at 24 months (OR 2.36). [636]3 studies 
suggested that the infant had a lower IQ in adulthood. 
[375, 472, 901] Increased risk of an IQ of less than 80 
1 case-control and 2 cohort found an association.[902-904] 6 cohort found 
no association.  [905-911] 3 reviews found no association. [910, 912, 913] 
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[9].[901] 
Respiratory 
Illness 
11 studies reported a strong association. [1, 4, 142, 336, 
375, 376, 470, 472, 636, 914, 915] OR 1.72 for lower 
respiratory tract infection (LRI). [915] Risk of LRI in Children 
<5 years old was high (OR 2.5), and remained significant 
with children >5 (RR 1.63).[336] Increased hospitalisation 
and deaths caused by LRI (OR 2.41).[336] 8 studies 
identified an increased risk of asthma. [4, 336, 375, 470, 
472, 636, 914, 915] OR 1.46[336], and 11.6. [915] RR 1.3- 
2.0. [4] High risk even at age of 15 years (OR 1.8). [636]  
44 cohort, 9 reviews, 7 case-control, 2 cross-sectional, and 1 meta-analysis 
found a strong association. [216, 598, 916-974] 3 cohort found no 
association. [975-977] 
Behavioural 
Problems 
7 studies determined there was an association. [1, 142, 
375, 376, 636, 637, 978] 3 studies suggested link with 
ADHD [4, 17, 26].[1, 142, 978] 3 times more likely to have a 
clinical diagnosis of ADHD. [978] More likely to abuse other 
substances (drugs, alcohol). [1, 376, 978] 2 studies made a 
link between maternal smoking and criminality. [1, 978]  
7 reviews, 15 cross-sectional, 9 case-control 19 cohort, and 16 longitudinal 
identified a significant association. [637, 638, 901, 979-1041] One 
systematic review was identified. [1038] The authors concluded there was 
a link with ADHD; however, the meta-analysis reported no significant 
associations. 4 reviews, 2 cross-sectional, 2 case-control, 2 cohort, and 3 
longitudinal reported no association. [978, 1042-1053] 
Fertility 3 studies found evidence of a reduction in male fertility. 
[1054-1056] 
2 cohort and 1 clinical trial reported no significant effect. [1057-1059] 1 
cohort reported a small effect. [1060] 
Childhood 
Cancers 
3 studies identified an association. [375, 470, 636] RR of 
1.11 for childhood cancers and RR of 1.14 for 
2 reviews found no association. [1061, 1062] 13 case-control reported no 
association. [1063-1075] 6 case-control studies reported an association. 
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leukaemia.[375] [1076-1081] 
Otitis media 
(Middle Ear 
Disease) 
3 studies reported an association. [4, 336, 375] RR of 1.0 - 
3.0.[4] OR of 1.19.[336] 
2 observational studies reported an increase in the relative risk of Otitis 
Media. [1082, 1083]  1 Observational Study reported no association.[1084] 
Obesity 4 studies reported an association. [375, 376, 470, 1085] 3 
times more likely.[376]  
2 reviews reported a strong association. [1086, 1087] 1 review did not find 
any association. [1088] 8 Observational studies and 6 Cohort studies 
reported a strong association.[1089-1100] 
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 Characteristics of included studies of previous evaluations of cessation interventions during pregnancy. 12.3
Table 12.3 Characteristics of included studies: type of study, interventions and comparators, outcomes, and characteristics of costs
Author/ 
Year 
Type of study Intervention / comparator Primary / secondary 
outcomes 
Characteristics of cost 
data 
Ayadi 2006 
[201] 
Observational with 
hypothetical modelling 
5As intervention in three different settings; clinical 
trial, quit line, and rural managed care organisation / 
assumed baseline quit if 14% 
Assumed quit rate of 
intervention 30%  W 70% 
versus 14%  
Intervention micro-
costing in different 
settings; neonatal care 
costs for infants of 
mothers who smoke 
estimated from CDC 
software (SAMMEC) 
Cooper 
2014 [123] 
Within-trial analysis 
alongside RCT 
NRT with behavioural support / placebo patches with 
behavioural support 
Sustained biochemically 
validated abstinence between 
quit date and end of 
pregnancy / Self-reported 
abstinence at six months and 
two years after delivery; 
infant outcomes included 
stillbirth, miscarriage, birth 
Micro-costing of control 
and intervention groups, 
including salary, patches 
and biochemical 
validation costs; 
weighted average NHS 
reference costs used for 
HRG data; costs 
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weight, gestation age at birth; 
EQ-5D scores at six months 
postpartum 
reported for 2009/10 
financial year 
Dornelas 
2006 [202] 
Within-trial analysis 
alongside RCT 
90 minute psychotherapy session at clinic followed by 
bi-monthly telephone calls with mental health 
counsellor / Standard smoking cessation treatment 
guidelines 
Biochemically validated 
seven-day point prevalence at 
end of pregnancy and six 
months postpartum 
Cost of training, 
counselling time, 
telephone time, clerical 
staff 
Ershoff 
1983 [204] 
Within-trial analysis 
alongside non-
randomised trial 
Two 45 minute nutrition counselling sessions. Eight 
week program with home-correspondence. Three 
telephone calls with reinforcement message / 
Standard prenatal care from two sources  W random 
sample who attended in four months before program 
and random sample who attended maxi-care in 
different area 
Self-reported abstinence at 
two months postpartum / 
Nutrition behaviour; 
complications during 
pregnancy (toxaemia, 
infection, hypertension, 
weight gain); infant birth 
weight; Apgar scores; 
abnormalities 
In-patient claim forms,  
cost  of hospital stay, 
staff salaries, program 
development, 
implementation costs, 
overheads 
Ershoff 
1990 [203] 
Within-trial analysis 
alongside non-
randomised trial 
Self-help intervention,  series of booklets / usual care Biochemically validated point 
prevalence at end of 
pregnancy / birth weight and 
low birth categories; intra-
Overhead, time, 
materials, postage, 
health plans costs from 
computerized claims 
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uterine growth restriction; 
pre-term birth 
system, charges to 
health plan, charges 
from hospital based 
providers 
Hueston 
1994 [205] 
Decision analytic model Hypothetical intervention / hypothetical intervention 
with assumed level of effectiveness 
Intervention quit rate of 3% - 
29% at end of pregnancy 
versus. background quit rate 
of 6%, 15% and 37% / rates of 
LBW amongst smokers 
estimated from national 
cohort 
Costs of healthcare for 
LBW infants from 
literature, 
Mallender 
2013 [190] 
Decision analytic model Interventions come from established literature. 
Situations modelled were: 
High intensity versus low intensity behavioural support 
interventions 
High intensity behavioural support versus usual care 
Conditional incentives versus non-conditional 
incentives 
QALYs Costs for interventions 
taken from literature; 
literature based costs 
used for diseases / 
conditions; costs 
reported at 2011 prices 
Marks 
1990 [68] 
Decision analytic model Hypothetical smoking cessation programme / normal 
care with no cessation intervention 
LBW and prenatal deaths 
prevented 
Cost of intervention 
estimated from 2 
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previous studies in USD. 
Short and long-term 
costs averted taken from 
1986 office of 
technology cost 
assessment of neonatal 
intensive care for LBW 
infants. 
Parker 
2007 [206] 
Within-trial alongside 
observational (one arm 
of trial) 
Telephone calls providing motivational interviewing / 
those receiving no calls (either because they chose not 
to or because contact could not be made). All received 
a quit kit 
Biochemically validated  
abstinence at end of 
pregnancy and six months 
postpartum 
Costs of calls using unit 
price of staff and non-
staff  W personnel and 
training time 
Pollack 
2001 [71] 
Case-control with 
hypothetical modelling 
Hypothetical intervention using an average of reported 
success rates cessation programs across various 
settings / no intervention, no spontaneous quitting 
Abstinence rates at end of 
pregnancy / number of SIDs 
averted 
Cost of typical 
intervention per 
participant in 1998 USD 
Ruger 
2008 [137] 
Within-trial analysis 
alongside RCT 
Three 1 hour home visits using motivational 
interviewing (MI) and self-help manuals. MI targeted: 
1) impact of smoking on mothers, foetuses, and 
newborns; 2) evaluated smoking behaviour; 3) 
increasing self-efficacy for smoking cessation; 4) 
Abstinence and relapse 
prevention at six-months 
postpartum / birth weight; 
post-delivery status; LYs; 
QALYs 
Intervention costs 
collected within RCT.  
From literature: Cost 
savings for neonatal 
intensive care, chronic 
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setting goals to change smoking; 5) feedback about 
household nicotine levels / Standard prenatal care: 5-
minute intervention outlining the harmful effects of 
smoking during pregnancy and self-help materials 
medical conditions, and 
acute conditions during 
the first year of life, cost 
savings for maternal 
healthcare 
(cardiovascular and lung 
diseases) 
Shipp 1992 
[65] 
Decision analytic model Hypothetical intervention / no cessation program Abstinence at end of 
pregnancy / number of LBW, 
premature births, placental 
abruptions, haemorrhage, 
placenta previa, pre-
eclampsia cases avoided 
Direct medical charges 
for maternal care at 
delivery and hospital 
care for newborns. 
Tappin 
2014 [196] 
Within-trial analysis 
alongside RCT, extended 
using a decision analytic 
model [209] 
Standard care from NHS pregnancy stop smoking 
services plus financial incentives of vouchers up to 
£400 for women who quit and remained abstinent 
throughout pregnancy / standard care from NHS 
pregnancy stop smoking services which involves, face-
to-face appointments, support phone calls, and NRT 
for up to 12 weeks 
Biochemically validated 
abstinence at end of 
pregnancy, QALYs 
Micro-costing using 
resource use data 
within-trial, healthcare 
costs of birth weight and 
smoking related diseases 
from NHS Scotland 
reference costs and 
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established literature 
sources 
Taylor 
2009 [139] 
Decision analytic model Interventions identified by Cochrane review: cognitive 
behaviour strategies; stages of change; feedback; 
ƌĞǁĂƌĚƐ ?ƉŚĂƌŵĂĐŽƚŚĞƌĂƉŝĞƐ ? ‘ŽƚŚĞƌ ?ŝŶƚĞƌǀĞŶƚŝŽŶƐ ?
no intervention with spontaneous quit rate 
QALYs Lifetime costs from 
previously developed 
model; costs in first five 
years of life per infant 
admitted to hospital 
born to smoking and 
non-smoking mothers,  
taken from Oxford 
Record Linkage study 
Thorsen 
2004 [207] 
Within-trial alongside 
observational study 
dŚĞ ‘&ŝƌƐƚƌĞĂƚŚ ?ƐŵŽŬŝŶŐĐĞƐƐĂƚŝŽŶƉƌŽŐƌĂŵŵĞ ?
none given 
Abstinence rates at end of 
pregnancy 
Costs of: Maternal 
maternity admissions, 
inpatient neonatal care 
and medical costs for 
first month of life. 
Ussher 
2014 [195] 
Within-trial alongside 
RCT 
Intervention to encourage physical activity with 
behavioural support / standard behavioural support 
provided by NHS Stop Smoking Services 
Biochemically validated 
abstinence at end of 
pregnancy 
Micro-costing of 
intervention and control 
groups, including 
salaries, physical activity 
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equipment, biochemical 
validation equipment; 
weighted average NHS 
reference costs used for 
HRG data; costs 
reported for 2012/13 
financial year 
Windsor 
1988 [208] 
Within-trial alongside 
RCT 
Two intervention groups: Group 1 given standard 
information and "Freedom From Smoking in 20 Days"; 
'ƌŽƵƉ ?ŐŝǀĞŶƐƚĂŶĚĂƌĚŝŶĨŽƌŵĂƚŝŽŶƉůƵƐ “WƌĞŐŶĂŶƚ
Woman's Self-Help Guide to Quit Smoking". Both 
groups received "Because You Love Your Baby", and a 
10 minute presentation at the first prenatal visit / 
Control group received a non- focused interaction on 
smoking and pregnancy of 5 minutes during the first 
prenatal visit 
Abstinence at end of 
pregnancy  
Salary estimates in USD , 
cost of manuals 
Windsor 
1993 [69] 
Within-trial alongside 
RCT 
Three components: Self-help materials with brief 
counselling support with follow-up letters and a buddy 
system / Normal care  W not defined 
Abstinence at end of 
pregnancy / LBWs avoided 
Salaries of staff 
delivering intervention.  
Costs for the LBW infant 
at birth, in first year of 
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life and long-term costs 
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Table 12.4: Characteristics of included studies: type of evaluation, comparison, and results 
Author/ 
Year 
Type of 
analysis 
Units of 
comparison 
Perspective of analysis / time 
horizon / discounting (per annum) 
Sensitivity analyses Results 
Ayadi 2006 
[201] 
CBA Neonatal cost 
savings per 
quitter 
Provider / within-pregnancy / no 
discounting 
Effectiveness (30 to 
70%); intervention 
cost USD 24 to  USD 
34 
Neonatal cost savings of USD 881 per maternal 
smoker; net savings of up to USD 8 million based 
on intervention cost of USD 24 
Cooper 
2014 [123] 
CEA Incremental 
cost per quitter 
Societal / within-pregnancy / no 
discounting 
Uncertainty explored 
by using non-
parametric 
bootstrapping (1000 
iterations) on costs 
and effectiveness; 
exclusion of multiple 
births 
Mean cost of control £47.75 with a quit rate of 
7.6%; mean cost of intervention was £98.31 
with a quit rate of 9.4%; ICER £4,926 per quitter 
(95% CI -£114,128 to £126,747) 
Dornelas 
2006 [202] 
CEA Incremental 
cost per quitter 
Provider (implied) / within-
pregnancy and six months 
postpartum / no discounting 
None Intervention cost USD 56.37 per patient. 
Incremental quit rate 18.7 (28.3  W 9.6). 
Incremental cost per quitter USD 298.76 
Ershoff 
1983 [204] 
CBA Benefit-cost 
ratio 
Provider / within-pregnancy and 
two months postpartum / no 
None Intervention quit rate of 49.1% versus 37.5% of 
controls; mean birth weight greater in 
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discounting intervention group, 121.34 ounces versus 
113.64; hospital treatment cost differential of 
USD 183 per delivery; intervention cost USD 93 
per patient; benefit cost ratio of 2:1 
Ershoff 
1990 [203] 
CBA Benefit-cost 
ratio 
Provider / within-pregnancy / no 
discounting 
None Intervention quit rate of 22.2% versus 8.6% for 
and controls; intervention infants weighed 
average 57g more; intervention cost per 
delivery USD 1028 versus USD 1074 in controls; 
cost savings of USD 5,428; total intervention 
cost of USD 1,939; benefit: cost ratio of 2.8:1 
Hueston 
1994 [205] 
CBA Intervention 
cost versus 
neonatal costs 
averted 
Provider (implied) / within-
pregnancy / no discounting 
Intervention quit 
rate between 3% and 
29%; spontaneous 
quit rate of 6%, 15% 
and 37% 
Cessation programmes in pregnancy cost 
effective for preventing LBW births if they cost 
$80 or less per participant and achieve quit 
rates of at least 18% with a spontaneous  quit 
rate of 37% 
Mallender 
2013 [190] 
CUA Incremental 
cost per QALY 
Societal (implied) / up to three 
years after intervention; lifetime 
for mother and infant / costs and 
QALYs at 3.5% 
Intervention cost 
and effectiveness 
varied in PSA 
analysis (1000 
iterations) 
High vs low intensity behavioural: 
Short term (three years): £5,445, £1,331 
Lifetime (mother): £563, £136 
Lifetime (mother and infant): £183, £51 
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High intensity behavioural vs usual care: 
Short term (three years): £17,827, £157,696, 
£2,344 
Lifetime (mother): £1,864, £16,515, £244 
Lifetime (mother and infant): £528, £4,594, £72 
 
Conditional incentives vs non conditional: 
Short term (three years): £41,088, £60,409, 
£43,161 
Lifetime (mother): £4,331, £6,441, £4,589 
Lifetime (mother and infant): £1,124, £1,488, 
£1,091 
 
Note: Also ICERs including productivity 
estimates, not reproduced here 
Marks 
1990 [68] 
CBA Cost per LBW 
averted; cost 
per prenatal 
death averted; 
benefit-cost 
Provider (implied) / lifetime / cost 
of LBW at 4% 
Cessation rates from 
5% through to 25%; 
costs programmes 
varied USD 5-100; 
percentage of LBW 
Cost per LBW birth prevented USD 4000; cost 
per prenatal death prevented USD 695,452; 
costs averted in terms of short term 
hospitalization USD 3.31 for every USD 1 spent 
on cessation; long-term costs averted USD 3.26 
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ratios for short 
and long-term 
hospitalisation 
costs 
needing neonatal 
special care 33%-
67%; relative risk of 
LBW 1.5  W 2.5; 
relative risk of 
prenatal death 1.1 to 
1.4 
per every USD 1 cessation 
Parker 
2007 [206] 
CEA Cost per quitter Provider / within-pregnancy / no 
discounting 
Varied costs of 
intervention per 
patient from USD 20 
to USD 30 
Quit rate for no calls 9.6% and 3 calls 23%; 
effectiveness to cost ratio of 1: USD 84 based on 
3 calls 
Pollack 
2001 [71] 
CEA Cost per SIDS 
averted 
Provider (implied) / within-
pregnancy / 5% per cost of life year 
None Assumed quit rate of 15%; intervention cost 
USD 45; averts 108 SIDS deaths annually at an 
estimated cost of USD 210,500 per life saved 
Ruger 2008 
[137] 
CUA Incremental 
cost per LY; 
incremental 
cost per QALY 
Societal / lifetime for the mother; 
first year of life for the infant / 
costs and QALYs at 3% 
Lifetime cost savings 
due to maternal 
illness and cost 
savings due to infant 
illness in first year of 
life; varying smoking 
For smoking cessation, MI cost more but 
provided no additional benefit compared to UC, 
therefore MI was dominated by UC; MI 
intervention did prevent relapse more 
effectively than UC with an estimated ICER of 
USD 628/QALY 
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status data; varying 
intervention costs; 
varying QALY 
weights 
Shipp 1992 
[65] 
CBA Break even cost Provider / within-pregnancy / no 
discounting 
Prevalence of 
smoking; 
intervention quit 
rate; spontaneous 
quit rate; probability 
of LBW; probability 
of maternal 
outcomes 
Break even cost of USD 32 per pregnant woman; 
varying between USD 10 and USD 237 in 
sensitivity analyses 
Tappin 
2014 [196] 
CEA, CUA Incremental 
cost per quitter, 
incremental 
cost per QALY 
Societal / within-pregnancy and 
lifetime / discounting costs and 
QALYs at 3.5% 
Inclusion of smoking 
related disease 
costs; discount rate 
of 0%; risk of relapse 
at three months 
postpartum varied 
between 30% and 
80% 
Intervention quit rate of 23% vs 9% for controls; 
ICER of £1,127 per quitter; ICER of £482 per 
QALY for lifetime; 70% of cost-effective at 
£20,000-£30,000 WTP; additional research cost-
effective if less than £3.3 million at £30,000 
WTP  
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Taylor 
2009 [139] 
CUA Incremental 
cost per QALY 
Societal (implied) / lifetime / 
discounting costs and QALYs at 
3.5% 
Varying costs of each 
intervention 
between £0 and 
£1,000 
For both mother and infant (per QALY), 
cognitive behaviour therapy ICER £4,005; stages 
of change ICER £3,033; feedback ICER £1,992; 
pharmacotherapies ICER £2,253; rewards and 
other interventions were dominant over control 
Thorsen 
2004 [207] 
CBA Cost of 
intervention 
versus cost 
saved 
Provider (implied) / pregnancy and 
six months postpartum / no 
discounting 
None If the intervention costs USD 15,366 it would 
achieve savings of USD 137,592 
Ussher 
2014 [195] 
CEA Incremental 
cost per quitter 
Societal / within-pregnancy / no 
discounting 
Uncertainty explored 
by using non-
parametric 
bootstrapping on 
costs and effects; 
halving and doubling 
the number of 
participants per fixed 
cost; sub-group 
analysis on age and 
cigarette 
Intervention quit rate of 7.7% versus 6.4% for 
controls; intervention cost £35 less per patient 
than control therefore dominant; high degree of 
uncertainty with CEAC suggesting that the 
probability of intervention being cost-effective 
was 0.8 at £50,000 WTP 
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dependence 
Windsor 
1988 [208] 
CBA Incremental 
cost per quitter 
Provider / within-pregnancy / no 
discounting 
Varying effectiveness 
of guide; varying cost 
of staff time; varying 
of intervention cost 
Standard information cost per person USD 2.08; 
quit rate of 2%; ICER USD 104.00; ALA manual 
cost per person USD 7.13; quit rate of 6%; ICER 
USD 118.83; pregnant woman's guide cost per 
person USD 7.13; quit rate of 14%; ICER USD 
50.93 
Windsor 
1993 [69] 
CBA Benefit-cost 
ratio 
Provider (implied) / lifetime / no 
discounting 
Cost of intervention 
varied USD 4.5 - USD 
9.0; smoking 
attributable risk of 
LBW varied from 0.2 
to 0.15; low and high 
estimate of smoking 
attributable LBWs 
LBW costs USD 9,000 to USD 23,000; cost-
benefit ratio low estimate is USD 1:17.93 and 
high estimate is USD 1:45.83; net benefit minus 
cost difference is USD 365,728 (low estimate) 
and USD 968,320 (high estimate) 
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 Risk of bias assessment tool as used in Chapter 4 to grade quality of 12.4
included studies 
 
This risk of bias tool was adapted from the Cochrane Handbook of Systematic Reviews. 
[236] 
Domain Method  and 
statement of 
clear / 
unclear etc 
1. Selection Bias 
Random sequence generation 
Describe the method used to generate the allocation sequence in 
sufficient detail to allow an assessment of whether it should 
produce comparable groups. 
 
Allocation concealment 
Describe the method used to conceal the allocation sequence in 
sufficient detail to determine whether intervention allocations 
could have been foreseen in advance of, or during, enrolment. 
 
Patients taking part 
Is there a large/significant difference in the proportion of possible 
participants and those that took part in the trial/were 
randomised? 
 
Was there any potential bias caused by major differences 
between treatment arms? 
 
Was there anything about the individuals taking part which could 
have led to bias in the overall estimate of relapse?  
 
2. Performance Bias  
Blinding of participants and personnel 
Assessments should be made for each main outcome (or class of 
outcomes).  
Describe all measures used, if any, to blind study participants and 
personnel from knowledge of which intervention a participant 
received. Provide any information relating to whether the 
intended blinding was effective. 
 
3. Detection Bias 
Blinding of outcome assessment 
Assessments should be made for each main outcome (or class of 
outcomes). 
Describe all measures used, if any, to blind outcome assessors 
from knowledge of which intervention a participant received. 
Provide any information relating to whether the intended blinding 
was effective. 
 
4. Attrition Bias 
Incomplete outcome data 
Assessments should be made for each main outcome (or class of 
outcomes).  
Describe the completeness of outcome data for each main 
outcome, including attrition and exclusions from the analysis. 
State whether attrition and exclusions were reported, the 
numbers in each intervention group (compared with total 
randomized participants), reasons for attrition/exclusions where 
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reported, and any re-inclusions in analyses performed by the 
review authors.  
Has an intention to treat analysis been conducted, and if yes, has 
it been conducted correctly/appropriately? 
Were patients lost to follow up treated as smokers? 
5. Reporting Bias 
Selective reporting 
State how the possibility of selective outcome reporting was 
examined by the review authors, and what was found. 
 
6. Other Bias 
 
Was biochemical validation undertaken? If yes, was biochemical 
validation undertaken post childbirth? 
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 Summaries of trials referred to in Chapter 4: Smoking abstinence in the postpartum period after receiving a smoking 12.5
cessation intervention 
Table 12.5: Table of excluded studies 
Author/ 
year 
Method Participants Interventions Outcomes Reasons for exclusion 
Albrecht 
2006 
[1101] 
RCT Pregnant teens aged 14 
to 19 years; within 12 to 
28 weeks gestation, 
literate in English; 
smoking at least one 
cigarette per day; single 
marital status; no 
previous live births; 
access to telephone. 
Recruited from five 
hospital- and two 
community-based 
prenatal clinics. 
Control group: advice at clinic to stop 
smoking and educational materials. 
Meeting lasted 45 to 60 minutes, and 
received an incentive for attending. 
Intervention group one: TFS 
intervention, an eight week program 
using cognitive behavioural therapy 
techniques to promote and maintain 
abstinence. Also included a peer 
support program, whereby a peer 
was chosen from the same year as 
the teen to provide support and 
sanctions. Intervention group two: 
same TFS intervention; however the 
Biochemically 
validated smoking 
using either salivary 
cotinine (cut off 
A? ? ?ŶŐ ?ŽƌƵƌŝŶĂƌǇ
ĐŽƚŝŶŝŶĞ ?ĐƵƚŽĨĨA? ? ?
ng/mU) at baseline; 
eight weeks post 
randomisation, and 
one year following 
study entry. 
Data presented in an 
unusable format and no 
contact with the author 
established. No end of 
pregnancy time point. 
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teen chose a non-smoking peer to aid 
their cessation. 
Britton 
2006 
[1102] 
Quasi-experimental 
design, control 
recruited first 15 
months, 
experimental in 
next 17 months 
Women were less than 16 
weeks gestation, self-
reported smoker at onset 
(includes recent quitters), 
recruited from seven 
obstetric offices and one 
medical centre in western 
New York, USA 
Control: received standard prenatal 
care, may have included cessation 
information and tobacco use 
assessment. Intervention: enrolled in 
 ‘^ŵŽŬĞ&ƌĞĞĂďǇĂŶĚDĞ ?ƉƌŽŐƌĂŵ ?
ŶƵƌƐĞƐƵƐĞĚ ‘DĂŬĞǇŽƵƌƐĂ&ƌĞƐŚ
^ƚĂƌƚ&ĂŵŝůǇ ?ƉƌŽŐƌĂŵ ?ŝŶǀŽůǀŝŶŐ
tailored health message, readiness to 
quit assessment, kit (including 
calendar, booklets and distractors), 
action plan and quitting advice 
following visits. 
Urinary cotinine (cut-
off 200ng/ml) at first 
visit, 16 weeks and 28 
weeks gestation and 
postpartum. Self-
reporting at 16 and 
28 weeks and 
postpartum visits. 
No details on when 
postpartum visit 
undertaken; data 
presented in an unusable 
manner 
Byrd 1993 
[1103] 
RCT Pregnant women 
currently smoking, English 
speaking and reading, 
able to give free consent, 
expecting to live in 
Milwaukee following 
All received usual care, involving a 
discussion of impacts of smoking on 
mother and child, plus a booklet or 
videotape taking around 11 minutes 
to read/watch. 
Intervention: PƌŽǀŝĚĞĚǁŝƚŚŶƵƌƐĞƐ ?
Self-reported status 
at one month post 
intervention, end of 
pregnancy and one 
month postpartum. 
Abstainers were 
Intervention and control 
group results grouped 
together. 
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delivery; recruited from 
community based 
obstetrics/gynaecology 
clinics in Milwaukee 
counselling based on the Four A 
model: Ask, Advise, Assist, Arrange 
asked to provide CO 
samples, but less 
than 20% did, results 
were excluded. 
Cinciripini 
2000 
[1104] 
RCT tŽŵĞŶĂŐĞĚA? ? ?ǇĞĂƌƐ ?
more than three 
cigarettes a day; less than 
30 weeks gestation; 
working video cassette 
player; willing to set a 
cessation date within two 
weeks of screening; not 
involved with any other 
cessation program. 
Recruited from Houston 
and surrounding 
metropolitan area, USA. 
Both control and intervention groups 
received a Quit Calendar and Tip 
Guide. Quit Calendar showed name, 
quit date, and various health risk 
information and cessation tips. Tip 
Guide contained six, one page 
sections, outlining the major points 
included in the intervention video 
tapes. Intervention consisted of six 
25-30 minute videos, covering topics 
ranging from initial quitting to 
relapse prevention and featured 
vignettes, peer commentary, and 
professional experts. 
Biochemically 
validated abstinence 
using salivary cotinine 
 ?ĐƵƚŽĨĨA? ? ?ŶŐ ?ŵů ?Ăƚ
quit date (two weeks 
after recruitment), 
end of treatment 
(four to five weeks 
after quit date), and 
one month 
postpartum. 
No data reported at end 
of pregnancy. 
Cinciripini 
2010 
RCT Women aged more than 
16 years, less than 32 
All received 10 individual counselling 
sessions, lasting 60 minutes: 
Abstinence data 
collected at in-clinic 
Abstinence not reported 
for end of pregnancy.  
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[1105]  weeks pregnant, and 
smoked at least a puff or 
more during the past 7 
days; Texas, USA. 
 
consisting of 15 minutes of standard 
behavioural and motivational 
cessation counselling, plus 45 
minutes of either the Health and 
Wellness intervention (control) or 
Cognitive Behavioural Analysis 
System of Psychotherapy 
(intervention). Health and Wellness 
intervention aimed to educate 
women on ways to decrease stress, 
respond to stressful events, and take 
care of themselves physically during 
pregnancy. Modules on stress 
management, pregnancy symptoms, 
postpartum depression, relaxation, 
optional topics including sleep, 
exercise, yoga, time management, 
parenting tips, and dealing with 
anger, negative thoughts and 
feelings. Cognitive Behavioural 
visits (Visits 1-10, 
three and six months 
postpartum), and by 
telephone at two 
weeks postpartum 
and two, four and six 
weeks post end of 
treatment. 
Abstinence measured 
as seven day point 
prevalence, 
continuous (end of 
treatment to future 
time point), and 
prolonged abstinence 
(end of treatment to 
three month and six 
month postpartum), 
Seven day point 
prevalence 
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Analysis System of Psychotherapy: a 
problem-solving exercise creating 
awareness of the relationship 
between their behaviour and 
outcomes in stressful interpersonal 
situations. Participants identified a 
recent, distressing situation, and 
whether their desired outcome was 
ĂĐŚŝĞǀĞĚ ?ǁŝƚŚƚŚĞƚŚĞƌĂƉŝƐƚ ?ƐĂŝĚ ?
participants then modified their 
interpretation, their behaviour 
and/or desired outcome, increasing 
the likelihood of achieving their 
desired outcome. 
biochemically 
validated by expired 
carbon monoxide 
(<4ppm) or cotinine 
(<15 ng/ml) at visits 
1-10, three and six 
months postpartum. 
 
Culp 2007 
[1106] 
Quasi-experimental 
 W cluster (assigned 
control/intervention 
by site) 
Women less than 28 
weeks gestation, smokers 
and non-smokers, 
recruited from 12 rural 
counties health 
departments 
Control: not defined. Intervention: 
Community-Based Family Resource 
and Support (CBFRS) Program 
involves curriculum on maternal 
health, infant health and safety and 
child development and parenting, 
Self-reported 
abstinence collected 
at baseline, 6 months 
postpartum and 12 
months postpartum. 
Non-smoking women 
included, no cessation 
intervention, no end of 
pregnancy data 
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including advice on smoking, 
delivered in a series of home visits. 
De Vries 
2006 
[1107] 
Cluster RCT of four 
provinces, 
Netherlands. 
 
Women not pregnant 
more than twice, able to 
speak and understand 
Dutch, smoked at least 
one cigarette a day, 
approximately 12 weeks 
gestation. 
Control group received usual care 
(not defined) and a folder from the 
Dutch Smoking and Health 
Foundation. Intervention consisted of 
a video, self-help manual, partner 
booklet on non-smoking, and health 
counselling by midwives. Self-help 
guide was stage matched, focusing 
on pregnancy specific material and 
the dangers of relapsing after 
pregnancy. Partner's booklet focused 
on health impacts of the father's 
smoking on the child. 
Self-reported seven 
day abstinence and 
continuous 
abstinence at six 
weeks post 
intervention and six 
weeks postpartum. 
 
No end of pregnancy data 
 
El-
Mohandes 
2011 
[220] 
RCT tŽŵĞŶĂŐĞĚA? ? ?ǇĞĂƌƐ ?
English speaking, less 
than 29 weeks gestation, 
and of an ethnic minority, 
recruited from 
Control group: usual care, not 
defined. Intervention: consisted of 10 
sessions (eight delivered prenatal 
and two postpartum) on a stages of 
change technique. Each session was 
Biochemically 
validated abstinence 
using salivary cotinine 
(cut off A? ? ?ŶŐ ?ŵů ?Ăƚ
baseline, 22-26 
Trial results were 
unreported. 
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Washington DC, USA. approximately 35 minutes long. 
Women encouraged to avoid 
triggers, use alternative coping 
strategies, address active and passive 
smoking. 
weeks gestation, 30-
34 weeks gestation, 
and eight to ten 
weeks postpartum. 
Emmons 
2000 
[1108] 
Quasi-experimental, 
12 months control 
followed by 12 
months 
intervention 
Smokers or non-smokers, 
pregnant or up to three 
months postpartum, at 
risk of poor pregnancy 
outcome, low birth 
weight or complications 
All: usual care of standard cessation 
 ‘,ĞĂůƚŚǇĂďǇƉƌŽŐƌĂŵ ?,W ? ? ?ƐƚƌŽŶŐ
recommendation to quit. 
Intervention: incorporated into 
regular home visits; MVI approach 
including nicotine level feedback, 
strategy for smoke reduction, 
feedback on nicotine levels and 
smoking discussed at all further visits. 
Biochemically 
validated seven day 
point prevalence at 
six week prenatal visit 
and one month 
postpartum. 
Household nicotine 
levels and maternal 
salivary cotinine 
collected at each 
assessment. 
No end of pregnancy data 
Ershoff 
1983 
[204] 
Quasi-experimental; 
control recruited 
then intervention 
group 
Women included if less 
than 24 weeks gestation, 
elementary English 
speakers, smokers or 
Control: standard prenatal care from 
Maxicare, but could choose the 
intervention; Intervention: group-
based eight week home 
Telephone interviews 
conducted 
approximately 2 
months postpartum, 
No end of pregnancy data, 
control groups also 
received intervention, 
data reported in non-
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recent-quitters (quit on 
learning of pregnancy), 
recruited from Maxicare, 
Southern California 
correspondence smoking cessation 
program adapted from American 
Cancer Society, involved booklets on 
preparing to quit, quitting and 
maintaining abstinence, and 
motivational telephone answerphone 
system  
self-reported only usable format. 
Haug 
1994 
[1109] 
RCT Women aged 18-34 years, 
daily smoker; recruited 
from GPs in Norway, half 
pregnant and half non-
pregnant 
Control group received usual care; 
details not given. 
Invention: told to stop smoking, 
received one session by GP up to 15 
minutes and two booklets. 
Blood test for serum 
thiocyanate at first 
visit and 12 months 
post-intervention, 
questionnaire at 18 
months; point 
prevalence data at 
six, 12, 15 and 18 
months post-
intervention 
No end of pregnancy data 
Hotham 
2006 
[1110] 
RCT Women smoking at least 
15 cigarettes daily 
(biochemically confirmed 
Control: counselling via QUITR 
organisation involving brochures, 
quit date negotiation, discussion of 
CO measurement at 
start of intervention 
(over 8 p.p.m) and at 
No postpartum data. 
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by CO measurement), 
between 12 and 28 weeks 
gestation, interest in 
quitting, recruited in 
tŽŵĞŶĂŶĚŚŝůĚƌĞŶ ?Ɛ
Hospital, Adelaide, 
Australia 
smoking habits and support options, 
including healthy eating. 
Intervention: Offered nicotine 
patches (15mg/16h) for maximum of 
12 weeks, optional weaning to lower 
strength 
last antenatal visit; 
telephone contact at 
six weeks and three 
months, self-reported 
only 
Hughes 
2000 
[1111] 
RCT Infertile and pregnant 
women who smoked 
three or more cigarettes 
in last six months; 
recruited from University 
of Michigan Centre, 
Henderson Hospital, and 
^ƚ:ĂŵĞƐ ?,ŽƐƉŝƚĂů ?
Hamilton, Ontario, 
Canada 
Control: standard information 
available at clinics on impacts of 
smoking. Intervention: scripted five 
point stages-of-change intervention: 
1) pre-contemplation, 2) considering 
quitting, 3) preparing to quit 4) 
quitting 5) maintaining cessation. 
Booklets given out at each session 
along with further encouragement. 
CO breath monitoring 
conducted at 
enrolment, six and 12 
months after 
enrolment. Cut-off 
not reported; 
questionnaire 
conducted at 12 
months after follow-
up 
No end of pregnancy data, 
postpartum data in 
unusable format 
Kientz 
2005 
[1112] 
N/A Women aged 18 or older, 
stopped smoking by 36 
weeks gestation. 
Control: not defined. Intervention: 
received the Kientz Interventions for 
Continued Cessation of Smoking, 
Self-reported 
smoking at 7-14, 14-
28, and 28-42 days 
Relapse prevention 
intervention, delivered in 
the postpartum period. 
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consisting of personalised, stage-
matched interventions delivered 
from the 36th week of pregnancy to 
sixth week postpartum, including 
reading materials, hard candy, and 
follow up phone call. 
postpartum, and six 
weeks postpartum. 
Langford 
1983 
[1113] 
RCT Women attending pre-
natal classes, 
approximately seven 
months pregnant and 
current smokers 
All received regular antenatal classes. 
Intervention 1: received a 30 minute 
presentation and pamphlet on 
smoking during pregnancy. 
Intervention 2: Received intervention 
1 plus a home visit by nurse to 
reinforce presentation. 
Self-report only. 
Collected 
immediately before 
intervention, four 
months and one year 
after delivery. 
No end of pregnancy data. 
Mayer 
1990 
[1114] 
RCT Currently smoking 
pregnant women; 
recruited in Grand Rapids, 
USA 
Control: received printed information 
on risks of smoking in pregnancy and 
usual care (not defined). Intervention 
1: Multiple Component group  W 
received 20 minute one-to-one 
session including risk information and 
behaviour change, adapted from 
Biochemical 
validation (saliva 
thiocyanate) only 
conducted on last 
third of trial. 
No fixed time point for 
postpartum data. 
Attempted contact with 
author but no response. 
390 
 
 ‘ĞĐĂƵƐĞ/ >ŽǀĞŵǇĂďǇ ?ŵĂƚĞƌŝĂůƐ ?
which involved agreeing an individual 
behavioural contract and self-
monitoring charts with action plan. 
Intervention 2: Risk information 
group: received face-to-face session 
of approximately 10 minutes, 
provided with factual brochures but 
no self-help or behavioural change 
information. 
McBride 
1999 
[1115] 
RCT Women less than 20 
weeks gestation, current 
smoker or recent quitter 
(within 30 days prior to 
recruitment). 
All groups received self-help booklet 
ĞŶƚŝƚůĞĚ ‘^ƚŽƉEŽǁĨŽƌǇŽƵƌĂďǇ ? ?
Contained information about health 
effects of smoking during pregnancy, 
suggestions for quitting, stress 
reduction techniques, and 
behavioural alternatives. Both 
intervention groups received 
personalised letters and relapse 
prevention kits, consisting of a 
Biochemically 
validated smoking 
using salivary cotinine 
(cut ŽĨĨA? ? ?ŶŐ ?ŵů ?Ăƚ
28th week gestation, 
six and 12 months 
postpartum. 
Unable to separate 
women who had smoked 
during pregnancy from 
those that had quit before 
pregnancy. 
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ďŽŽŬůĞƚĞŶƚŝƚůĞĚ ‘ĂůĂŶĐŝŶŐĐƚ ? ?ǁŝƚŚ
introductory letter. Booklet discussed 
transition from pregnancy to 
postpartum and related factors. This 
was mailed after completing 28th 
week follow up. Intervention group 
one: prenatal telephone counselling 
consisting of three calls, first 
approximately two weeks after self-
help booklet mailed, and the 
remaining at monthly intervals. 
Telephone calls delivered by trained 
counsellors, and followed a 
standardised protocol using 
motivational interviewing and stages 
of change techniques. Calls lasted 
approximately 8.5 minutes. 
Intervention group two: an additional 
three calls within the first four 
months postpartum. Calls reinforced 
392 
 
themes from relapse prevention 
booklet; first call scheduled within 
four weeks after delivery; the rest 
following at four to six week 
intervals. Calls lasted on average 7.7 
minutes. Also received series of 
postpartum newsletters at two, six 
and 12 weeks postpartum. 
McBride 
2004 
[1116] 
RCT Women less than 20 
weeks gestation, current 
smokers or recent 
quitters (within 30 days 
prior to pregnancy but 
not smoking at intake), 
living with an intimate 
partner, willing for 
partner to be contacted 
for study. Women 
recruited from the 
Womack Army Medical 
All groups received usual care, 
consisting of self-ŚĞůƉďŽŽŬůĞƚ ‘DĂŬĞƐ
zŽƵƌƐĂ&ƌĞƐŚ^ƚĂƌƚ&ĂŵŝůǇ ? ?ǁƌŝƚƚĞŶĂƚ
a fifth grade reading level by the 
American Cancer Society. 
Intervention one: late pregnancy 
relapse prevention kit consisting of a 
booklet and gift items, and six 
counselling calls. Calls delivered by a 
health advisor using motivational 
interviewing techniques. Three 
conducted during pregnancy and 
Self-reported 
abstinence at the 28th 
week gestation, 
three, six and 12 
months postpartum. 
Biochemically 
validated abstinence 
at 28 weeks gestation 
and six months 
postpartum, method 
and cut off not 
stated. 
Women who had quit 
before pregnancy 
included; unable to 
separate from women 
who had smoked up to 
and during pregnancy. 
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Centre, Fort Bragg, 
Fayetteville, North 
Caroline, USA. 
three postpartum, last one no later 
than four months postpartum. Calls 
at monthly intervals. Intervention 
two: partner expected to assist. 
ZĞĐĞŝǀĞĚ ‘/ƚƚĂŬĞƐƚǁŽ ?ďŽŽŬůĞƚĂŶĚ
companion video. Partners received 
ƐŝǆĐĂůůƐĨƌŽŵƚŚĞǁŽŵĂŶ ?ƐŚĞĂůƚŚ
advisor, using a similar motivational 
interviewing technique. Three 
delivered during pregnancy and three 
postpartum. Smoking partners given 
self-help guides, free nicotine 
patches, and stage appropriate 
counselling. 
Parker 
2007 
[206] 
RCT Smoked one puff in last 
30 days, no more than 26 
weeks pregnant, access to 
a telephone, spoke 
English or Spanish. 
Recruited from urban 
All received self-help materials which 
included a quit kit and a video. Both 
intervention groups: enrolled on a 
quit and win monetary incentive 
lottery program. Eligibility for prize of 
USD 100 restricted to smokers who 
Biochemically 
validated abstinence 
using urinary cotinine 
 ?ĐƵƚŽĨĨA? ? ?ŶŐ ?ŵů ?Ăƚ
32 weeks gestation 
and six months 
Data from only one arm of 
the second intervention 
arm of the trial reported. 
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prenatal clinics in Rhode 
Island, Connecticut, and 
Massachusetts, USA. 
reported abstinence for at least 30 
days, confirmed by urinary cotinine. 
Intervention two: up to three 
motivational interview calls; to 
discuss smoking habits, maternal and 
foetal health risks, readiness to 
change, and encourage use of 
intervention materials. 
postpartum. 
Patten 
2010 
[1117] 
RCT Women aged 18 years or 
older, less than 24 weeks 
gestation, self-reported 
smoking in last seven 
days, planning to quit 
within next 30 days, 
access to telephone and a 
video/DVD player. 
Women were recruited 
from Yukon WKuskokwim 
Delta in Western Alaska, 
USA. 
Control group received a counselling 
based intervention utilising the 5 As; 
Ask, Advise, Assess, Assist, and 
Arrange. Session conducted at first 
visit and lasted five minutes. All 
received four pregnancy brochures. 
Intervention participants received 
the cessation guide, and 15-25 
minute counselling session based 
upon the 5 As. Also privately shown a 
video, followed by 10-15 minute 
discussion with the counsellor. Video 
Biochemically 
validated abstinence 
using salivary cotinine 
 ?ĐƵƚŽĨĨA? ? ?ŶŐ ?ŵů ?Ăƚ
baseline and end of 
pregnancy. 
No postpartum outcomes. 
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provided for home use. Also 
scheduled four 10-15 minute 
telephone sessions at weeks one, 
two, four, and six. Women 
encouraged to set a quit date at each 
session. 
Pbert 
2004 
[1118] 
Cluster RCT  W health 
centres were 
randomised. 
Women who spoke 
English or Spanish, at 
least two months before 
due date, current smoker 
or spontaneous quitter 
(quit after learning of 
pregnancy), planning to 
remain in the area for at 
least six months following 
delivery. Women 
recruited from six 
community Health 
Centres in the greater 
Boston area, 
Control group received usual care, 
not defined. Intervention: to change 
delivery of cessations services at 
community health centres. Consisted 
of training to deliver an intervention 
using national best practice 
guidelines and stages of change 
techniques; an office based 
management system to routinely 
screen smoking status, prompts to 
intervene, document encounters, 
distribute materials, and arrange 
follow ups. Establishment of program 
boards to coordinate transfer of 
Biochemically 
validated abstinence 
using salivary cotinine 
 ?ĐƵƚŽĨĨA? ? ?ŶŐ ?ŵů ?Ăƚ
baseline, nine month 
of pregnancy/before 
delivery, one month, 
three months, and six 
months postpartum. 
Women who had quit 
before pregnancy 
included; unable to 
separate from women 
who had smoked up to 
and during pregnancy. 
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Massachusetts, USA. documentation among clinics and 
conduct periodic meetings with all 
clinic representatives. 
Peden 
2008 
[1119] 
Quasi-experimental  Pregnant women who 
ǁĞƌĞA? ? ?ǁĞĞŬƐ
gestation, 18 years old or 
over, current smokers or 
recent quitters within the 
last nine months, access 
to a telephone 
Control: no intervention. 
Intervention: Received four 90 
minute group sessions targeting 
negativity and making affirmations to 
quit with post-session reinforcement. 
Received six postpartum telephone 
calls once a week, starting at one 
week postpartum. 
Urinary cotinine at 
baseline (cut-off 
100ng/ml). Self-
reported data 
collected at one 
month post-
intervention, two and 
four months 
postpartum. 
Results for controls and 
interventions combined; 
no end of pregnancy data 
Peterson 
1992 
[1120] 
Part RCT and part 
cluster: Three sites 
randomised 
between control 
and intervention 
group one; one site 
allocated to 
intervention group 
Pregnant women who 
were literate and English 
speaking  
 
 
All participants received pregnancy 
related health education materials. 
Control group: received routine 
obstetric care and mailed a list of 
community-based cessation 
resources. Intervention group one: 
mailed the pregnancy specific self-
help manual and audiocassette tape. 
Biochemically 
validated abstinence 
(cut off 80 ng/mL 
using urinary 
cotinine) at six 
months gestation. 
Self-reported 
smoking status at 
No end of pregnancy data. 
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two. 
 
Intervention group two: same 
materials as group one, obstetricians 
and practice nurses attended a 
session reviewing current research 
and guidelines, a progress sheet 
ŝŶĐůƵĚĞĚŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂů
records, patients reinforcement 
letters signed by their physicians 
during eighth month gestation and 
one month postpartum. 
eight weeks 
postpartum. 
 
Polanska 
2004 
[1121] 
Cluster RCT Pregnant women who 
were either smokers or 
spontaneous quitters. 
Public maternity centres 
ŝŶ<ŽĚǍ ?WŽůĂŶĚ ? 
Control group: standard written 
information about the health risks 
from smoking during pregnancy and 
the benefits of quitting. Intervention: 
ĨŽƵƌǀŝƐŝƚƐďǇŵŝĚǁŝĨĞƚŽƉĂƌƚŝĐŝƉĂŶƚ ?Ɛ
home. Women received translated 
written materials prepared by the 
Community Health Research Unit in 
Ottawa. A further five visits were 
offered to those still smoking at the 
Self-reported 
abstinence at end of 
pregnancy and one 
year postpartum. 
Could not split women 
who had quit before 
pregnancy from those 
smoking during pregnancy 
in the control group. 
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fourth visit. Spontaneous quitters 
received information on how to avoid 
smoking and relapse. 
Reitzel 
2010 
[1122] 
RCT English speaking, aged 18 
years or older, who 
stopped smoking either 
during their pregnancy or 
within two months prior 
to pregnancy. 
All participants received self-help 
materials and five to 10 minutes of 
relapse prevention advice. 
Intervention one ( MAPS 
intervention): six telephone 
counselling sessions delivered at 
weeks 34 and 36 gestation, and two, 
four, seven, and 16 weeks 
postpartum. Intervention two 
(MAPS+): identical to MAPS, with two 
additional calls at baseline and eight 
weeks postpartum. 
Biochemically 
validated abstinence 
using either carbon 
monoxide (cut off 
A? ? ?ƉƉŵ ?ŽƌƐĂůŝǀĂƌǇ
ĐŽƚŝŶŝŶĞ ?ĐƵƚŽĨĨA? ? ?
ng/ml) at eight weeks 
and 26 weeks 
postpartum. 
Women who had quit 
before pregnancy unable 
to separate from those 
that smoked during 
pregnancy; no end of 
pregnancy data; relapse 
prevention intervention. 
Ruger 
2008 
[137] 
RCT Less than 28 weeks 
gestation, receiving 
prenatal care, current 
smoker or not smoking 
within 3 months of 
Control: standard prenatal care 
including five minute interview and 
self-help materials. Intervention: MVI 
in home visit format, three one hour 
visits on average tailored to stage of 
Biochemically 
validated abstinence 
at baseline, one 
month after 
intervention and six 
No end of pregnancy data 
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baseline, English or 
Spanish speaker, no 
inpatient drug treatment; 
recruited from hospital 
and health clinics in 
Boston area, USA 
readiness. Involved impact of 
smoking education, smoking 
behaviour evaluation, self-efficacy 
improvement, goal setting and 
household nicotine feedback. Also 
received self-help materials 
months postpartum 
(salivary cotinine 
level, cut-off not 
reported). 
Strecher 
2000 
[1123] 
RCT Women smoked 100 
cigarettes or more in 
lifetime, current smokers 
or quit since becoming 
pregnant, recruited from 
obstetrics and 
gynaecology clinics at 
Universities of Michigan 
and North Carolina, USA 
ŽŶƚƌŽů PZĞĐĞŝǀĞĚ ‘ƉƌĞŐŶĂŶƚ
ǁŽŵĂŶ ?ƐŐƵŝĚĞƚŽƋƵŝƚƐŵŽŬŝŶŐ ?ĂĨƚĞƌ
first visit. Intervention: tailored 
cessation messages after each 
prenatal visit, personalised guide and 
quit plan based on responses to 
questionnaires after each visit. 
Updated guide sent out each time 
new interview completed. 
Urine samples 
collected at prenatal 
visit, 24th week of 
pregnancy and six 
weeks postpartum. 
Self-reported 
abstinence at three 
months postpartum. 
No end of pregnancy data; 
smokers and recent 
quitters grouped together 
Tuten 
2012 
[1124] 
RCT Over 18 years old, less 
than 30 weeks gestation, 
smoked more than 10 
cigarettes daily, capable 
of informed consent; 
Control: information on adverse 
effects of smoking, educational 
materials, routinely asked about 
status at follow-up, compensated for 
urine and breath samples. Incentive 
Biochemical 
validation at baseline 
using exhaled CO and 
urinary cotinine (cut-
off 200 ng/ml). Self-
No end of pregnancy data 
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recruited from Center for 
Addiction and Pregnancy, 
Hopkins Bayview Medical 
Campus, Baltimore, USA 
1: increasing financial incentives 
based on meeting abstinence targets, 
from USD 7.50 to a maximum of USD 
41.50, reset to base level if target not 
met, returned to previous level if met 
five times consecutively. Intervention 
2: pre-determined incentive schedule 
not dependent on individual smoking 
status, patients required to submit 
samples for eligibility; received 
incentives for up to 12 weeks or until 
delivery  
reported at one and 
three months after 
enrolment and six 
months postpartum. 
 
Valanis 
2001 
[1125] 
Quasi-experimental 
 W historical 
comparison, interim 
controls and 
intervention group 
Smokers (at least one 
cigarette in the last seven 
days before prenatal 
visit), or recent quitters 
(smoked in the month 
before conception but 
not in last seven days); 
recruited from six 
Control: discussed smoking and its 
impacts with expectant mothers. 
Interim: usual care but may have 
received some intervention 
Intervention: At first prenatal visit, 
used MVI based on FRAMES model:  
Feedback, Responsibility of patient, 
Advice, Menu of strategies, Empathy, 
Data obtained via 
questionnaire one 
year postpartum 
Smokers and recent 
quitters not separated 
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prenatal clinics, two 
hospitals, and seven 
paediatric clinics in 
Portland, Oregan, USA 
Self-efficacy in quitting. Action plans 
created and updated in subsequent 
visits. Relapse prevention messages 
delivered in hospital or at 3-day 
postpartum visit, nurses continued to 
work with smoking mums 
postpartum at well-baby clinics. 
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Table 12.6: Table of included studies 
Author/ 
year 
Method Participants Interventions Outcomes Notes 
Bullock 2009 
[248] 
RCT Women attending 21 
rural Women Infant 
and Children 
Nutritional 
Supplement clinics in a 
Midwest state. 
Usual care group: Quit Smoking for Good 
pamphlet from the American Heart 
Association. Intervention group one: social 
support (baby BEEP) plus booklets, a 
scheduled weekly telephone call and 24 hour 
access to the nurse for additional social 
support. The eight booklets comprised a 
ƉƌŽŐƌĂŵĐĂůůĞĚ ‘ ‘^ƚŽƉ^ŵŽŬŝŶg! A Special 
WƌŽŐƌĂŵĨŽƌWƌĞŐŶĂŶƚtŽŵĞŶ ? ?ĂĚĂƉƚĞĚƚŽĂ
7th grade reading level. Intervention group 
two: social support alone. Intervention group 
three: the booklets alone. 
Primary outcomes: point 
prevalence abstinence 
(cut off cotinine <30 
ng/ml) in late pregnancy 
and 6 weeks post-
delivery. 
 
 
Cooper 2014 
[123] 
RCT Women aged 16 to 50 
years, between 12 and 
14 weeks pregnant, 
smoking at least 10 
cigarettes daily before 
All participants: midwife delivered 
behavioural support counselling for one 
hour, involving advice and tips for cessation, 
requirement ƚŽƐĞƚĂƋƵŝƚĚĂƚĞŝŶƚǁŽǁĞĞŬƐ ?
time. Midwives provided three further 
Primary outcomes: 
biochemically validated 
sustained abstinence 
(carbon mŽŶŽǆŝĚĞA? ?
ppm) at one month after 
One woman 
removed from the 
placebo group after 
being recruited to 
the study twice. 
403 
 
pregnancy and 
currently smoking at 
least five per day; 
exhaled carbon 
monoxide 
concentration of at 
least eight p.p.m. 
Women excluded if 
they had diseases 
which could be 
affected by NRT 
(cardiovascular 
disease, unstable 
angina, cardiac 
arrhythmias, skin 
disorders, known 
sensitivity to NRT), 
known drug or alcohol 
dependence, known 
major foetal 
support sessions after quit date. Telephone 
support conducted on the quit date, three 
days, and one month afterwards. Could also 
contact NHS Stop Smoking Services for 
additional support. 
The intervention group received a four week 
supply of 15mg/ 16 hour nicotine 
replacement therapy transdermal patches. 
The control group received visually identical 
placebo patches. Women told to start using 
the patches on their quit dates. One month 
after quitting, those biochemically identified 
as not smoking were issued with another 
four week supply of NRT/placebo patches if 
requested. 
quit date and delivery. 
 
Secondary outcomes: 
biochemically validated 
point prevalence 
abstinence at one 
month after quit date, 
and at delivery. Self-
reported point 
prevalence and 
sustained abstinence at 
one month after 
randomisation, at 
delivery, six months, 
one year, and two years 
postpartum.  
404 
 
abnormalities, or 
unable to give 
informed consent. 
Donatelle 
2000 [249] 
RCT 
 
Women aged 15 years 
or older, 28 weeks 
gestation or less, and 
self-reported smoker, 
Oregon, USA. 
 
 
All participants: verbal and written 
information on the importance of cessation, 
and received self-help kit "A Pregnant 
Woman's guide to Quit Smoking". 
Intervention group: three pronged program 
involving positive incentives, social support, 
and community participation. Included 
financial incentive vouchers of USD 50 a 
month for confirmed quitters, and financial 
incentive vouchers (USD 50 in first and last 
months of the trial, USD 25 for the month in-
between) for the social supporter. 
Biochemically validated 
status (salivary 
thiocyanate (<100 
ug/ml)) at end of 
pregnancy and two 
months postpartum. 
 
 
Dornelas 
2006 [202] 
RCT Women aged 18 or 
over, 30 weeks 
gestation or less, 
access to telephone, 
no recent history of 
All participants: standard cessation 
treatment comprising: an educational 
booklet and chart prompt reminding 
providers to give personalised quit message 
at each visit, with cessation advice from an. 
Biochemically validated 
status using carbon 
monoxide (<4ppm) at 
end of pregnancy and 6 
months postpartum 
33 women who had 
quit before 
baseline along with 
two people with 
missing data 
405 
 
alcohol, substance 
abuse, or psychiatric 
illness, recruited from 
prenatal tertiary care 
clinic, Hartford, 
Connecticut, USA 
obstetrician, gynaecologist or nurse. 
Intervention: One 90 minute psychotherapy 
session, plus bi-monthly calls during 
pregnancy and monthly calls post-delivery by 
trained mental health counsellors. 
excluded. 
 
Dunkley 
1997 [244] 
RCT WŽŵĞŶA? ? ?ǁĞĞŬƐ
gestation, smoking one 
or more cigarettes 
daily, maternity units 
in teaching hospitals, 
UK 
Control: No intervention 
Intervention: midwives trained in and 
delivered five stages of change intervention: 
pre-contemplation, contemplation, ready for 
action, action and maintenance 
Self-reported data; end 
of pregnancy and one 
month postpartum 
 
Gielen 1997 
[245] 
RCT Women who had 
smoked a puff within 
seven days, 27 or less 
weeks gestation, 
African-American or 
white, large prenatal 
clinic, Baltimore, USA 
All received advice from nurse pre-and 
postpartum on risks of smoking and 
recommended to quit, plus pamphlets. 
/ŶƚĞƌǀĞŶƚŝŽŶ PƌĞĐĞŝǀĞĚ ‘ƉƌĞŐŶĂŶƚǁŽŵĂŶ ?Ɛ
ŐƵŝĚĞƚŽƋƵŝƚƐŵŽŬŝŶŐ ?ǁŝƚŚƐŝǆƚŚŐƌĂĚĞ
reading level, 15 minute one-to-one 
counselling session on the guide and 
educational materials, clinic reinforcement 
Saliva Cotinine (cut off 
not reported) only on 
self-reported quitters at 
first prenatal visit, over 
28 weeks gestation, end 
of pregnancy, three and 
six months postpartum. 
76 women 
excluded due to 
miscarriage, 
abortion or 
withdrawal 
406 
 
including verbal support, written prescription 
given at each prenatal visit; two letters of 
encouragement mailed 1-2 weeks after first 
visit. 
Hajek 2001 
[259] 
Cluster RCT  W 
individual 
midwives 
randomised 
Women who were 
current smokers or 
recent ex-smokers 
(within last 3 months), 
nine hospital and 
community trusts, UK 
Control: access to standard smoking leaflets. 
Interventions: those not planning to change 
ƌĞĐĞŝǀĞĚ ‘ŚŽŝĐĞŝƐǇŽƵƌƐ ?ďŽŽŬůĞƚ ?^ŵŽŬĞƌƐ
aiming to quit and recent ex-smokers also 
given advice including CO analysis and 
ďŽŽŬůĞƚ ‘,ŽǁƚŽƐƚŽƉƐŵŽŬŝŶŐĨŽƌŐŽŽĚ ? ? ?,Žǁ
ƚŽƐƚĂǇŽĨĨƐŵŽŬŝŶŐĨŽƌŐŽŽĚ ?ƌĞƐƉĞĐƚŝǀĞůǇ ?
followed by quiz, interview, and commitment 
ƐƚĂƚĞŵĞŶƚ ? ‘ƵĚĚǇ ?Ɛupport system pairing 
with other pregnant smokers encouraged. 
Midwives received additional training: one 
hour for control, two hours for intervention. 
Biochemically validated 
(Carbon Monoxide A?10 
p.p.m) continuous 
abstinence at end of 
pregnancy and six 
months postpartum  
167 women were 
excluded due to 
adverse pregnancy 
outcomes or 
moved away. 
Heil 2008 
[250] 
RCT 
 
Women who self-
reported smoking in 
last 7 days, were 20 
weeks or less 
All participants: usual care involving 
discussing the advantages of quitting during 
pregnancy, and two pamphlets designed 
specifically for pregnant women, distributed 
Biochemically validated 
point prevalence and 
continuous abstinence 
at end of pregnancy, 12 
 
407 
 
gestation, English 
speaking, residing in 
the greater Burlington 
area, US. 
 
during pregnancy and after delivery. Control 
group received non-contingent vouchers 
which were independent of smoking status. 
Voucher values were USD 15 per visit 
antepartum and USD 20 postpartum. 
Intervention group received vouchers based 
upon biochemical validation results, 
reporting breath CO specimens <6ppm or 
urine cotinine levels <80 ng/ml. Vouchers 
began at USD 6.25, and increased by USD 
1.25 per consecutive negative specimen, to a 
maximum of USD 45. A positive or missed 
report reset the voucher to the beginning, 
though it was restored if the next two 
samples were negative. 
weeks, and 24 weeks 
postpartum. 
Hennrikus 
2010 [251] 
RCT 
 
Women in the first or 
second trimester, 
current smoker, at 
least 18 years old, 
All participants: in-person session designed 
to increase motivation to quit and provide 
information about community cessation 
resources. Intervention group received 
additional monthly telephone sessions and 
Biochemically validated 
seven day point 
prevalence (urinary 
cotinine (<100 ng/ml)).  
 
408 
 
Minnesota, USA. 
 
 
their supporter also contacted. 
Hjalmarson 
1991 [264] 
Quasi 
randomised -
allocated by 
days born in 
month, 1-10 of 
every month 
allocated to 
controls and 11-
31 allocated to 
treatment. 
 
 
Self-reported daily 
smoking pregnant 
women, less than 12 
weeks gestation, 13 
public health clinics, 
Gothenburg, Sweden. 
 
Control group received an information sheet 
which included basic facts about smoking and 
pregnancy and recommended to quit. 
Intervention group: self-help manual written 
for pregnant women, which included a task 
based upon behavioural therapy, information 
and advice on how to keep abstinent, and 
basic facts about smoking and pregnancy. 
Biochemically validated 
(blood thiocyanate 
A? ? ? ?ŶŐ ?ŵů ?Ɖoint 
ƉƌĞǀĂůĞŶĐĞĂƚǁĞĞŬ ?Ɛ ? ?-
34 gestation, at hospital, 
and eight weeks after 
delivery. 
 
Lawrence 
2003 [262] 
Cluster RCT, 
randomised by 
antenatal clinics. 
Women aged 16 or 
over, current smoker, 
English speaking, West 
Control group: standard smoking cessation 
advice currently given by midwives. All 
participants received the booklet "Thinking 
Biochemically validated 
(urinary cotinine <1.5 
ug/l) point prevalence 
 
409 
 
 Midlands, UK. 
 
about stopping". Midwives in control group 
ƌĞĐĞŝǀĞĚŚĂůĨĂĚĂǇ ?ƐƚƌĂŝŶŝŶŐŽŶƚŚĞƌĞƐĞĂƌĐŚ
protocol only. Midwives in intervention 
group A received two and a half days 
training, with two days on the theory of the 
transtheoretical model, aimed to aid 
midwives deliver the stages of change model. 
Also received the same training on the 
research protocol as the control group. 
Participants received a set of six, 30 page 
stage based self-help manuals, entitled "Pro-
change programme for a healthy pregnancy". 
At three points during pregnancy, midwives 
assessed a participant's stage of change, 
highlighted the appropriate manual in the 
stage series, and spent no longer than 15 
minutes ensuring the participant was familiar 
with how to use the materials. Midwives in 
intervention group B received the same 
training as group C, and the participants 
abstinence at 30 weeks 
pregnancy, and 10 days 
after pregnancy. 18 
months point 
prevalence and 18 
months continuous 
abstinence from self-
reported data only.  
410 
 
received the same self-help manuals as group 
B. Additionally, participants used a computer 
programme on a laptop for each intervention 
in the manual. Women worked alone, and 
feedback was printed and sent to the 
participant within one week of each 
intervention. 
Lillington 
1995 [260] 
Cluster RCT  W 
site of program 
randomised 
Women 18 years old 
or more, current and 
ex-smokers; Los 
Angeles, USA 
Control: usual care including printed 
information on risks of pregnancy and group 
quit messages as part of initial visit. 
/ŶƚĞƌǀĞŶƚŝŽŶ P ‘dŝŵĞĨŽƌŚĂŶŐĞ ?ǁŝƚŚĨŽƵƌ
components: 1) one-to-one counselling 
session, 2) self-help guide, 3) reinforcement 
booster cards (mailed one month after study 
entry), 4) incentive contest (weekly draw of 
USD 100 worth of baby items). Available in 
English and Spanish at third grade reading 
level. 
End of pregnancy self-
report only. Salivary 
cotinine (A?20ng/ml) at 
six weeks postpartum. 
Participant with 
missing data 
excluded from 
analyses 
McLeod 
2004 [263] 
Cluster RCT - 
midwives 
Midwives eligible if 
they planned to 
Control group: usual care from the midwives, 
which consisted of anything from just asking 
Point prevalence was 
self-reported at six 
 
411 
 
stratified by 
geographical 
location. 
 
continue practising for 
the next 12 months. 
Eligible women 
reported smoking 
when registering with 
the midwife for 
maternity care. North 
Island of New Zealand. 
 
to providing more detailed cessation advice. 
Intervention group A: a programme of 
education and support for cessation or 
reduction, which involved using brief 
intervention and motivational interviewing. 
Training consisted of a four hour session, 
training videotape, and follow up problem 
solving sessions with a smoking counsellor. 
Intervention group B: a programme of 
education and support for breast feeding for 
smoking women, aimed to increase the 
duration of full breast feeding, with 
information about the effects of smoking. 
Training consisted of provision of information 
about breast feeding, discussion with a 
qualified lactation consultant, introduction of 
an information booklet, additional refresher, 
and problem solving sessions with a lactation 
consultant and/or midwife. Intervention 
group C: received both the smoking 
weeks and four months 
postpartum. 
Biochemical validation 
was undertaken at 28 
weeks gestation, using 
cotinine in serum  ?A?15 
ng/ml). 
 
412 
 
education and breast feeding programme, 
with an additional session combining the two 
interventions training content. 
Messimer 
1989 [261] 
Cluster RCT  W 
individual 
practices were 
randomised 
Women smoking at 
ĨŝƌƐƚƉƌĞŶĂƚĂůǀŝƐŝƚA? ? ?
weeks gestation; 
Michigan and upper 
Wisconsin, USA 
All: Counselling by physician on three 
occasions, suggestion to quit after each one. 
Discussion on nicotine effects, smoking-
related complications and effect on foetus; 
ashtrays removed from waiting area, staff 
not allowed to smoke in view of patients. 
/ŶƚĞƌǀĞŶƚŝŽŶ PƵƐĞŽĨ ‘ĞĐĂƵƐĞǇŽƵǇŽƵ ?ƌĞǇŽƵƌ
ďĂďǇ ?ĨůŝƉĐŚĂƌƚ ?ƉĂĐŬĞƚƐĂŶĚƉŽƐƚĞƌ ?
monitoring of smoking at each visit with 
encouragement to quit, presentation at first 
visit. 
Self-reported data at 
end of pregnancy and 
six weeks postpartum 
Women with 
adverse pregnancy 
event (abortion, 
miscarriage), 
moved away, or 
incomplete data 
excluded. 
K ?ŽŶŶŽƌ
1992 [265] 
Quasi-
randomised 
using an 
alternate day 
strategy. 
Women reporting 
smoking daily and less 
than 31 weeks 
gestation; Canada.  
 
All participants received usual care: three to 
five minute verbal explanation of the hazards 
of smoking during pregnancy, invitation to a 
two hour group cessation class using a self-
help guide. Classes were conducted in the 
evening by a public health nurse, in English or 
Biochemical validated 
(A?64 ng/mL urinary 
cotinine) status at 36 
weeks gestation and six 
weeks postpartum. 
 
413 
 
 French, and a nurse was available for one 
follow up contact. Intervention group also 
received the option of Windsor's self-help 
smoking cessation program during the visit to 
the clinic. A 20 minute intervention was 
provided on an individual basis, in English or 
French, by a public health nurse, with the 
offer a telephone follow up contact at a 
mutually agreed upon time. 
 
Oncken 2008 
[252] 
RCT 
 
English or Spanish 
speaking women, 26 
weeks gestation or 
less, currently smoking 
at least one cigarette 
per day, aged 16 years 
or over, intending to 
carry the pregnancy to 
term. Hartford 
Hospital, Connecticut, 
New Britain, 
All participants: two 35-minute counselling 
sessions using a motivational interviewing to 
aid cessation. Counselling sessions delivered 
at baseline and at the first visit, focusing on 
benefits of quitting during pregnancy, 
assessing the stage of change, motivating the 
participant to quit, and setting a quit date or 
reduction target within the next week. The 
second session occurred one week after the 
quit/reduction date; focused on dealing with 
withdrawal symptoms and urges. Also 
Biochemically validated 
status (carbon monoxide 
< 8ppm) at 6 weeks 
post-intervention, 32-34 
weeks gestation, 6-12 
weeks postpartum. 
 
The Data and 
Safety and 
Monitoring Board 
decided to stop 
enrolment at 147 
patients after 
reviewing efficacy 
data at six weeks 
due to a larger 
study would be 
required to detect 
414 
 
Connecticut, and 
Springfield 
Massachusetts. 
 
received printed educational materials 
tailored for pregnancy and bi-monthly 
telephone calls until delivery. Control group: 
placebo gum. Intervention group: gum 
containing 2mg of nicotine. Both groups were 
instructed to chew one piece of gum for 
every cigarette per day, up to 20 pieces. 
Participants received six weeks of treatment 
followed by a six week taper period. 
the anticipated 
difference. 
 
Panjari 1999 
[247] 
RCT 
 
Women less than 20 
weeks gestation, 
either smokers or 
recent quitters, 
singleton pregnancy, 
the ability to speak 
and read English, no 
drug dependency. 
Royal Women's 
Hospital, Melbourne, 
Control group: standard antenatal care, 
including distribution of a Quit Victoria 
ƉĂŵƉŚůĞƚ ‘^ŵŽŬŝŶŐĂŶĚWƌĞŐŶĂŶĐǇ ? ?
Intervention group: four counselling sessions 
by a midwife trained in smoking cessation 
techniques. The first session lasted for 25 
minutes, and included distribution of 
literature, viewing the Baby Breathing video 
followed by discussion of its contents, 
delivery of a strong verbal message about the 
risks of smoking during pregnancy, and 
Biochemically validated 
status (urinary cotinine 
<115 ng/mL) at 30-34 
weeks gestation. Self-
reported smoking status 
at six weeks and six 
months postpartum.  
 
 
415 
 
Victoria, Australia. 
 
advice to quit. Subsequent sessions usually 
lasted five to ten minutes, and focused on 
the patient's progress. Sessions delivered at 
16-20, 24, and 28 weeks gestation. 
Pollak 2007 
[253] 
RCT 
 
Women aged 18 or 
older, between 13 and 
25 weeks gestation, 
five or more cigarettes 
a day and over 100 
cigarettes in their 
lifetime, planning to 
continue prenatal care 
in a participating clinic, 
English speaking. 14 
clinical sites in 
Durham, Raleigh, and 
Fayetteville, North 
Carolina, USA. 
 
All participants: six counselling sessions (five 
face to face prenatal visits and one via 
telephone) designed to enhance motivation 
and develop skills needed to quit, a quit kit: a 
booklet designed for pregnant smoker:, 
water bottle, straws, hard candy, an exercise 
band, and a stress management tape. 
Intervention group: At first session, women 
were informed of advantages and 
disadvantages of the three types of NRT 
therapy (patch, gum, and lozenge), and aided 
in deciding which type to choose, with no 
NRT an option. Enough NRT given to last until 
the next session. Use of NRT recommended 
for up to six weeks, but women could choose 
to use it for longer. Women allowed to 
Biochemical validated 
status (salivary cotinine ) 
at 7 weeks post 
randomisation, 38 
ǁĞĞŬ ?ƐŐĞƐƚĂƚŝŽŶ ?ĂŶĚ ?
months postpartum, 
however only self-report 
results were reported.  
 
Recruitment 
suspended early by 
Independent Data 
and Safety 
Monitoring Board 
when the interim 
analysis found a 
higher rate of 
negative birth 
outcomes in the 
intervention group. 
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 change between NRT modalities. Women 
who wore patches were instructed to only 
use them during waking hours (16 hours). 
The dosage was: less than 10 cigarettes a 
day, 7mg/day; 10 to 14 cigarettes a day, 
14mg, and more than 15 cigarettes a day, 
21mg/day. Those who choose the gum or 
lozenge instructed to use one 2mg piece for 
every cigarette. 
Rigotti 2006 
[254] 
RCT 
 
Women, smoking at 
least one cigarette in 
the past seven days, 
18 years or older, 26 
weeks gestation or 
less, willing to consider 
altering their smoking 
habits, access to 
telephone, English 
speaking. Tufts Health 
At enrolment, all subjects mailed a validated 
pregnancy specific smoking cessation 
booklet. WĂƌƚŝĐŝƉĂŶƚƐ ?ƉƌĞŶĂƚĂůĐĂƌĞƉƌŽǀŝĚĞƌƐ
were sent the American College of 
Obstetricians and Gynaecologists smoking 
cessation practice guideline and a reminder 
to address smoking at the subjects' visits. 
Control participants: standardised 
counselling intervention of up to five minutes 
at the enrolment session. Smokers 
requesting further assistance referred to the 
Biochemically validated 
seven day point 
prevalence and 
sustained abstinence 
(salivary cotinine < 20 
ng/mL) at end of 
pregnancy and three 
months postpartum. 
 
 
417 
 
Plan, Massachusetts. 
 
Massachusetts telephone quit line. 
Intervention subjects: each subject had a 
dedicated counsellor offering up to 90 
minutes of counselling during pregnancy and 
15 minutes over two months postpartum. 
Calls scheduled to subject's needs. 
Intervention consistent with the five step 
cessation counselling guidelines, targeting 
pregnancy related issues, working towards 
goals, plans for cessation or reduction, and 
relapse prevention techniques. After initial 
call, subjects mailed a personalised 
worksheet and a summary letter and 
targeted written materials after each 
subsequent call. 
Secker-
Walker 1994 
[243] 
RCT 
 
Women less than 25 
weeks gestation, 
smoking one or more 
cigarette a day. 
Control group: usual advice about smoking 
provided by obstetrician or midwife. 
Intervention group: usual care and 
individualised cessation intervention, 
consisting of a series of counselling sessions, 
Biochemical validated 
status (urinary cotinine 
<80 ng/mL) at 36 weeks 
gestation. Self-reported 
smoking at 8-15 months, 
 
418 
 
Vermont, USA. 
 
delivered by trained counsellor at first, 
second, and third prenatal visits, at 36 weeks 
gestation and six weeks postpartum. Sessions 
consisted of setting up a quit plan, health 
benefits of cessation, and a specially 
prepared booklet about quitting. Postnatal 
sessions focused on the influence of the 
parent on the child and its future. 
16-24 months, and 24-
54 months postpartum. 
 
Secker-
Walker 1998 
[246] 
RCT Not stated; assumed 
12 years old. Maternal 
infant care clinic, 
Vermont, USA 
Control: physicians prompted by sheet on 
chart to provide advice, strong 
recommendation to stop and cessation 
booklet for pregnant women at first visit. 
Intervention: at first visit physicians gave 
structured advice including exhaled CO 
analysis, strong recommendation to quit and 
commitment statement, combined with 
referral to trained nurse for individual 
counselling on behaviour change. Repeated 
at second, third, fifth visits and 36th week 
visit. Quitters praised and counselled for 
Biochemically validated 
status (carbon monoxide 
A?6 p.p.m and urinary 
ĐŽƚŝŶŝŶĞA? ? ? ?ŶŐ ?ŵů ?) 
status at first, second 
and 36th week visits. 
Self-reported status at 
one year postpartum. 
24 women 
excluded due to 
adverse pregnancy 
conditions. 
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remaining quit. 
Stotts 2002 
[255] 
RCT 
 
English speaking 
women aged 18 years 
or older, smoked more 
than 5 cigarettes a 
week, less than 20 
weeks gestation. 
Houston and Dallas 
metropolitan area. 
 
Control group unclear. Intervention group: 
one-to-one intervention consisting of a 20-30 
minute telephone counselling session using 
motivational interviewing strategies, 
conducted at 28-30 weeks gestation, focusing 
on commitment to change smoking 
behaviour. A personalised, stages of change 
based feedback letter mailed within a week 
of first call. Letters computer generated 
based upon responses to first call, including 
individualised messages about effects of 
smoking on others, pros and cons of smoking, 
temptation to smoke, and confidence to 
abstain. A final motivational interview based 
counselling call four to five days after the 
feedback letter. Included discussing the 
letter, reassessing commitment to change, 
building motivation, and evaluating the 
change plan. 
Biochemically validated 
status (urinary cotinine 
<80 ng/mL) at the 34th 
week gestation 
conducted on a sub 
sample of 175 out of 
269 randomised. Self-
reported smoking at six 
weeks, three months, 
and six months 
postpartum. 
 
Unclear whether 
the control group 
received no 
intervention or 
counselling and 
self-help booklets 
before 
randomisation. 
420 
 
Thornton 
1997 [256] 
RCT 
 
Women had to be 
currently smoking or 
spontaneously quit 
prior to entering 
prenatal care. Public 
antenatal clinic at 
Rotunda Hospital, 
Dublin.  
 
 
All participants: routine prenatal advice on a 
wide range of health issues, including 
smoking, from the midwifery staff and 
obstetricians. Intervention group: face-to-
face 10 to 15 minute counselling session by 
the stop smoking facilitator at first visit. 
Further counselling sessions for both the 
woman and her partner offered at 
subsequent visits. Also received an 
information pack consisting of a leaflet 
outlining the health effects of smoking on the 
woman and baby, an invitation to join a 
quitting group in the hospital, a letter to the 
partner to support her attempts to quit with 
an invitation to join the quit support groups, 
a self-help booklet dealing with preparing to 
stop and strategies to cope with withdrawal 
and maintaining abstinence, prompt cards 
 ‘ZĞĂƐŽŶƐĨŽƌƋƵŝƚƚŝŶŐŵǇƐĞůĨ ?ĂŶĚ ‘ZĞĂƐŽŶƐĨŽƌ
ƋƵŝƚƚŝŶŐĨŽƌŵǇďĂďǇ ? ?ĂŶĚĂĐĂƌďŽŶŵŽŶŽǆŝĚĞ
Self-reported smoking at 
delivery and three 
months postpartum. 
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monitor to quantify smoking habits. 
Ussher 2014 
[192] 
RCT Women aged 16  W 50 
years old, 10-24 weeks 
gestation, currently 
smoking one cigarette 
or more daily, 
prepared to quit one 
week after enrolment, 
English speakers and 
able to walk 
continuously for 15 
minutes or more, not 
dependent on alcohol 
or drugs. 13 hospital 
antenatal clinics in 
England 
All patients: behavioural support comprising 
six weekly 20 minute sessions starting one 
week before quit date and finishing four 
weeks afterwards. All sessions one-to-one 
and face-to-face. Continuing support offered 
to non-quitters or relapsed smokers. 
Intervention: physical activity (PA), 
combining consultation and supervised 
exercise. Total of nine 20 minute consultation 
sessions prior to supervision, working 
through booklet retained by patient; 
encouraged to view PA as self-control 
strategy. Total of 14 supervised exercise 
sessions, twice a week for six weeks then 
weekly for two weeks, patients advised to 
aim for minimum 30 minutes continuous 
treadmill walking per session. Asked to log 
daily steps, 10% weekly increment calculated, 
gradually aiming for 10,000 steps. 
Biochemically validated 
status (carbon monoxide 
<8 p.p.m) assessed 
weekly up to four weeks 
after quit date and at 
end of pregnancy; 
salivary cotinine 
(<10ng/ml) measured at 
four weeks post quit 
date and at end of 
pregnancy. Self-
reported status at six 
months postpartum. 
Two excluded due 
to sequential 
pregnancies and 
two erroneously 
enrolled 
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Walsh 1997 
[257] 
RCT 
 
Smoking women. 
Antenatal clinic of an 
urban teaching 
hospital, Australia. 
 
Control group: at first visit, patients informed 
by doctor and midwife that smoking was an 
important health issue and that they should 
stop. Also received a sticker, risk pamphlet 
for women, and two-page cessation guide.  
Intervention group: three minute advice 
session from doctor highlighting risks from 
smoking during pregnancy, followed by 15 
minute video on risks, barriers to quitting, 
and cessation tips. Also received a 10 minute 
counselling session with midwife using the 
same format, setting a quit date. Received a 
self-help manual with four packets of gum. 
Social support came from an accompanying 
adult invited to participate. Chart reminder 
placed on medical record. Letter signed by 
midwife sent at 10 days. At the second visit 
and 34th to 36th visits, midwives provided 
five further minutes of counselling and 
doctors gave approximately two minutes of 
Biochemically validated 
status (urinary cotinine 
<500 nmol/L) at four 
weeks post intervention, 
end of pregnancy, and 
six to 12 weeks 
postpartum. 
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risk advice. Those still smoking at the last visit 
were advised to attend an external cessation 
course. 
Wisborg 
2000 [258] 
RCT 
 
Women less than 22 
weeks gestation who 
smoked 10 or more 
cigarettes per day. 
Denmark. 
 
All received a 45-60 minute counselling 
session informing women about the 
pharmacologic and psychological aspects of 
smoking, consequences of smoking during 
pregnancy, and advice to quit. Also received 
a pamphlet on smoking and pregnancy. 
Further counselling at eight weeks and 11 
weeks after first visit, and four weeks before 
due date, lasting 15-20 minutes. Control 
group received 11 weeks of placebo patches 
at first visit. Intervention group received NRT 
consisting of 15 mg patches for 16 hours per 
day for eight weeks, and 10 mg patches for 
16 hours per day for three weeks. 
Biochemically validated 
status (salivary cotinine 
<26 ng/mL) at fourth 
prenatal visit. Self-
reported smoking status 
at second and third 
prenatal visit, three 
months and one year 
postpartum. 
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 Results of meta-analysis of patterns of abstinence in the postpartum 12.6
period 
Figure 12.1: Primary analysis, pooled estimates of abstinence using combined data on all participants 
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Figure 12.2: Secondary analysis, pooled abstinence using combined data for control participants 
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Figure 12.3: Secondary analysis, pooled abstinence using combined data for intervention participants 
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Figure 12.4: Sensitivity analysis, pooled estimates using combined biochemically validated data only 
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  UK data on the prevalence of smoking related diseases amongst 12.7
ǯ
model. 
 
The prevalence data in this chapter is for all women in the UK, including smokers, former 
smokers, and never smokers. Due to thesis constraints, calculated smoking contingent 
prevalences can be found in the ^/WƐƉƌĞĂĚƐŚĞĞƚŽŶƚŚĞ “>ŝĨĞƚŝŵĞĚŝƐĞĂƐĞƉƌĞǀĂůĞŶĐĞ ?ƚĂď ? 
 
12.7.1 Coronary heart disease 
 
Table 12.7: Prevalence of CHD by age among women in England, 2006 
Age Prevalence (%) 
0-15 0 
16-24 0.1 
25-34 0.1 
35-44 0.3 
45-54 1.3 
55-64 3.5 
65-74 10 
75+ 19.3 
Source: Table 2.13, Compendium of CHD Statistics 2012 [1126] 
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12.7.2 Chronic obstructive pulmonary disorder 
 
Table 12.8: Prevalence of COPD by age among women in the UK in 2008 
Age Prevalence (%) 
0-4 0.01 
5-9 0.01 
10-14 0.02 
15-19 0.03 
20-24 0.01 
25-29 0.02 
30-34 0.04 
35-39 0.09 
40-44 0.23 
45-49 0.53 
50-54 1.13 
55-59 1.99 
60-64 3.14 
65-69 4.71 
70-74 5.74 
75-79 6.81 
80-84 6.78 
85+ 5.30 
Source: Chronic disease prevalence by age, sex, SHA, and UK country 2008 [333] 
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12.7.3 Lung cancer 
 
Table 12.9: Prevalence of LC by age among women in the UK 
Age Prevalence (%) 
0-44 0.00 
45-64 0.07 
65+ 0.23 
Source:  Table 3, Forman et al, EUROPREVAL study [1127]  
 
12.7.4 Stroke 
 
Table 12.10: Prevalence of stroke by age among women in England, 2006 
Age Prevalence (%) 
0-15 0 
16-24 0.2 
25-34 0.1 
35-44 0.4 
45-54 0.9 
55-64 2.3 
65-74 4.2 
75+ 10.7 
Source: Table 2.13, Compendium of CHD statistics 2012 [1126] 
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 Determining the required parameters to fit the Gamma distribution 12.8
when information on the inter-quartile range was available but not 
the standard error 
 
The next two pages form the information given to the author to enable the fitting of the 
Gamma distribution to the NHS Reference costs as these only report the inter-quartile 
range rather than the standard error. These parameter values were estimated by Professor 
Murray Smith on behalf of the author as it required the use of Mathematica to which the 
author did not have access. [1128] The file was sent as a pdf and as such cannot be edited. 
It is reproduced here as a set of images for information as to how the values were 
computed. 
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 Full size trees illustrating maternal and infant within-pregnancy components  12.9
Figure 12.5: Maternal within-pregnancy component (decision tree) 
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Infant stillborn
Premature birth < 37 weeks Infant born with low birth weight Infant liveborn
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Mother dead
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Infant born with normal birth weight Infant stillborn
Pregnancy ends in delivery Infant liveborn
Mother dead
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Premature birth < 37 weeks Infant born with low birth weight Infant liveborn
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Infant born with normal birth weight Infant stillborn
Pre-eclampsia Infant liveborn
Mother dead
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Infant liveborn
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Figure 12.6: Infant within-pregnancy component (decision tree)  W part one: mother quits during pregnancy 
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Figure 12.7: Infant within-pregnancy component (decision tree)  W part two: mother smokes throughout pregnancy 
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 Training and presentations. 12.10
Table 12.11: Masters of public health modules 
Code Module Semester / Year Credits 
A34587 Epidemiology of 
Tobacco Use and the 
Role of the Tobacco 
Industry 
Spring / 2011 15 
A34589 Health Economics Spring / 2011 10 
  Total 25 
 
Table 12.12: Graduate school short courses 
Course name Course date Booking reference Credits 
Nature of the 
doctorate and the 
supervision process
  
November 2010 7661 1 
Introduction to 
quantitative research 
December 2010 7671 4 
Essential information 
skills for new 
researchers in 
medicine and health 
sciences 
December 2010 11217 1 
Basic Statistics December 2010 7673 1 
Introduction to Stata 
for epidemiological 
analyses (M&HS 
Faculty) 
April 2011 7664 3 
  Total 10 
  
438 
 
Table 12.13: External courses 
Course name Course date Course vendor 
Advanced Modelling Methods for Health 
Economic Evaluation Course 
March / April 
2011 
Centre for Health 
Economics, University of 
York 
The Nottingham Systematic Review 
Course 
June 2011 Cochrane Schizophrenia 
Group, University of 
Nottingham 
 
Table 12.14: Presentations 
Conference Date Title Type of presentation 
Population Health 
Methods and 
Challenges 
Conference, 
Birmingham 
April 
2012 
Developing an Economic Model 
to represent Foetal and 
Maternal Costs and Benefits of 
Maternal Smoking Cessation 
During Pregnancy 
Oral 
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